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ABSTRACT 
Predicting adherence to antiretroviral therapy and retention to HIV care: 
Effects of baseline biopsychosocial status and neuropsychological 
functioning 
Daniella Mark, BSocSc(hons), MA 
 
 
 
Introduction: The introduction and scale-up of antiretroviral therapy has dramatically 
improved the clinical outcomes of HIV infection. These drugs have demonstrated 
efficacy in improving immune function and reducing HIV-related morbidity and mortality, 
and while a cure is not available, patients on treatment may live longer, healthier lives. 
However, early optimism has been tempered by the growing recognition that meticulous 
adherence is a prerequisite for optimal clinical response and prevention of drug 
resistance. In this context, it is critical that systematic research be conducted to identify 
valid and reliable correlates of nonadherence and loss to follow-up in clinical settings in 
sub-Saharan Africa, so that solutions to these challenges can be implemented in the 
most affected region.   
Methods: Patients were recruited from a community clinic in a peri-urban settlement 
near Cape Town, South Africa. Demographic and biopsychosocial data were collected 
through file reviews, interviews and neuropsychological testing at treatment initiation. Pill 
count adherence was measured across the first 16 weeks of treatment and retention and 
virological suppression assessed at 96 weeks. Bivariate and multiple logistic regression 
analyses were used to investigate the association of each factor with adherence 
outcomes.  
Results: 150 patients were recruited. Sixty-three percent were female and 73% 
unemployed. 39% showed depressive symtomatology and 41% hazardous or harmful 
alcohol consumption. 75% achieved !90% pill count adherence across 16 weeks, and 
71% were retained in care and 77% of those retained achieved virological suppression 
at 96 weeks. Factors associated with nonadherence, nonsuppression and/ or loss to 
follow-up were younger age, unemployment, holding/ having applied for a disability 
grant, lower CD4+ cell count, heamatological or ophthalmic but not dermatological or 
urological symptoms, able to name just some of the medications in the prescribed 
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regimen, alcohol abuse, poor neurocognitive performance, unmarried or in non-
cohabiting relationship, disclosure to broader family or friends, less people known on 
antiretrovirals, living in households of three or more, no planned use of cell phone alarm 
as adherence aid and greater length of time spent traveling to the clinic. 
Conclusion: High depression and alcohol abuse rates call for early identification and 
treatment of mental health disorders in this population. Special attention should be paid 
to younger and unemployed patient groups in adherence counseling. HIV 
symtomatology should be assessed and symptoms treated aggressively. Adaptation of 
treatment guidelines for earlier treatment initiation would minimize cognitive compromise 
in initiating populations. Mechanical reminders like cell phone alarms have proven 
successful in this sample and may be especially beneficial to those with cognitive 
dysfunction. Patients should be counseled to choose appropriate confidantes for 
disclosure and supportive relationships should be encouraged. Clinic visit burden should 
be minimized through home visits, flexible clinic hours and discounted transportation.    
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CHAPTER 1 
Medication adherence and loss to follow-up in the HIV era 
 
 
 
The HIV/AIDS pandemic 
Global 
Human immuno-deficiency virus (HIV) infection is one of the biggest health challenges 
facing humanity today. While there have been steps towards preventing new infections 
and decreasing the number of acquired immune deficiency syndrome (AIDS)- related 
deaths, the number of people living with the virus continues to increase. There are now 
an estimated 32.8 million people living with HIV worldwide: 30.3 million adults and 2.5 
million children. Each day, an estimated 7,100 people become infected, amounting to 
2.6 million new infections per year. AIDS-related illnesses remains one of the leading 
causes of mortality worldwide; annually, there are 1.8 million AIDS-related deaths (Joint 
United Nations Programme on HIV/AIDS [UNAIDS], 2010b).      
 
Sub-Saharan Africa  
With an adult HIV prevalence of 5% and accounting for 22.5 million persons infected 
with HIV (up from 20.3 million in 2001), sub-Saharan Africa is home to the majority 
(68%) of the global total. In 2009, 1.8 million adults and children were newly infected 
with HIV in the region, accounting for 67% of all new infections. In the same year, there 
were 1.3 million deaths due to AIDS in sub-Saharan Africa, comprising 72% of the 
world’s AIDS-related deaths (UNAIDS, 2010b). The impact on households and 
communities is staggering; just over 14.1 million children in sub-Saharan Africa have lost 
one or both parents to AIDS-related illnesses (UNAIDS & World Health Organization 
[WHO], 2009).  
 
The scale and trends of the HIV/AIDS pandemic in the sub-Saharan region vary widely, 
with Southern Africa most seriously affected. The nine countries with the world’s highest 
HIV prevalence (all over 10%) are located in Southern Africa (UNAIDS & WHO, 2009). 
In 2009, this sub-region accounted for just over a third (34%) of the world’s HIV 
infections and the same percentage of its AIDS deaths (UNAIDS, 2010b).  
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South Africa 
As the country with the largest number of infected individuals in the world, South Africa 
is at the epicentre of the pandemic. In 2009, there were 5.6 million people living with HIV 
in South Africa, accounting for 17% of the global total, i.e. one in six people living with 
HIV in the world today lives in South Africa (UNAIDS, 2010b). This is in contrast to South 
Africa’s population size, which is just 0.7% of the world’s total population (UNAIDS, 
2010a).  
 
The most recent national population-based household survey found the national HIV 
prevalence across all age groups to be 10.6%. General adult age 15–49 years HIV 
prevalence was estimated at 16.9%, increasing from 16.2% in 2005. One in three 
women (32.7%) age 25–29 years is HIV-positive, and one in four men (25.8%) age 30–
34 years is infected (Shisana et al., 2009). The most recent National Antenatal Sentinel 
HIV and Syphilis Prevalence Survey conducted in 2008 in all nine provinces showed the 
overall national HIV prevalence among pregnant women aged 15–49 years to be 29.3%, 
similar to the rates of 29.1%, 29.4% and 29.3% seen in the previous three years. This 
data suggests that the prevalence rate amongst pregnant woman has stabilized, albeit at 
a very high level (Department of Health, 2009).  
 
The numbers continue to grow. In 2009, there were an estimated 1,500 new infections 
daily, and 409,000 new infections throughout the year (UNAIDS, 2010a). The 
predominant mode of HIV transmission in the country is heterosexual sex, followed by 
mother-to-child transmission, with drivers including intergenerational sex, multiple 
concurrent partners, low condom use, high alcohol use and low rates of male 
circumcision (Department of Health, 2010c).  
 
In 2009, more than 270,000 South Africans died of HIV-related causes, representing 
42% of all national deaths. Recent reports show that between 1.4 and 2.1 million 
children have lost one or both parents to the disease (Department of Health, 2009; 
Statistics South Africa, 2010). As of mid-2010, life expectancy at birth was estimated at 
just 53.3 years for males and 55.2 years for females (Statistics South Africa, 2010). 
South Africa is one of the few countries in the world whose child mortality rates have 
worsened since the 1990’s (UNAIDS, 2010b), and are currently estimated at 46.9 per 
1,000 lives births (Statistics South Africa, 2010)   
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Western Cape  
In 2008, there were approximately 241,000 persons living with HIV/AIDS in the Western 
Cape (Department of Health, 2009). General adult age 15–49 years HIV prevalence is 
5.3% in the province (Shisana et al., 2009). While the Western Cape has the lowest 
antenatal prevalence in South Africa at 16.1%, it is one of the five provinces that has 
shown an (in this case slight) increase in prevalence, while the other provinces 
decreased or remained static in 2008; the overall antenatal HIV prevalence had 
increased from 15.1% in 2006 to 16.1% in 2008 (see Figure 1). A close analysis of the 
2008 Western Cape data confirms the difference in HIV prevalence by race. The HIV 
results in this province show that 29.4% of Africans are infected compared with 3% of 
Coloureds (Department of Health, 2009).  
 
 
Figure 1.  HIV prevalence among pregnant women curve, Western Cape, 1990 to 2008 (Department of 
Health, 2009).  
 
According to the ASSA2003 AIDS and Demographic model, which uses several data 
sources, including the antenatal clinic survey results and deaths from the population 
register, it was estimated that in the Western Cape in 2010, there would be 318,115 
people living with HIV, 31,338 people with AIDS-defining conditions, cumulative AIDS-
related deaths since 1990 of 109,803 and 59,926 maternal orphans due to AIDS 
(Dorrington, Johnson, Bradshaw, & Daniel, 2006.)  
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Antiretroviral therapy (ART) 
Since the first AIDS cases of 1979 until the late 1990’s, a diagnosis was considered the 
first step in a steady downward progression leading to certain death as a result of 
opportunistic infections. Medications were available to treat opportunistic infections, and 
later, antiretroviral (ARV) medications like Zidovudine (AZT) could temporarily suppress 
HIV levels until the virus’ rapid replication cycle allowed it to develop resistance to the 
single antiretroviral medication. In 1996, a significant shift in HIV medical care and 
disease prognosis occurred, with the development and roll-out of a new type of 
antiretroviral drug class called protease inhibitors that were to be used in combination 
with existing reverse transcriptase inhibitors (Catz, Kelly, Bogart, Benotsch & McAuliffe, 
2000).  
 
The development of multi-drug combination therapy has been heralded as one of the 
greatest success stories of modern medicine (Delaney, 2006). The introduction and 
scale-up of highly active antiretroviral therapy (HAART) has dramatically improved the 
clinical outcomes of HIV infection. HAART consists of the use of at least three ARV 
drugs to suppress the virus and halt disease progression. HAART has demonstrated 
efficacy in suppressing HIV viral load levels (the amount of virus circulating in the blood), 
improving immune system functioning (Autran et al., 1997; Lederman et al, 1998), and 
reducing HIV-related morbidity and mortality (Palella et al., 1998; Jacobson & French, 
1998; Murphy et al., 2001), and while a cure for HIV has not been found, patients on 
HAART may go on to live longer, healthier lives. Thanks to the scientific advances that 
include HAART and HIV disease monitoring, for the first time since the start of the 
pandemic, clinicians can now effectively treat HIV disease. When ARV’s are taken 
correctly, HIV viral load may be reduced to a level that is below the limits of detection 
(less than 50 copies/mL or less than 400 copies/mL, depending on the test) of 
commercially available assays. The ASSA2003 model projected that approximately 
100,000 AIDS deaths could be prevented in 2010 alone in South Africa due to ART 
(Dorrington et al., 2006).  
 
HAART is now being rapidly scaled up across the globe, particularly in resource-limited 
settings with high HIV prevalence and previous low access like Africa, Asia, South 
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America, Central America and the Caribbean. The Group of Eight countries and the 
United Nations member states all sanctioned the global goal of universal access by 2010 
(United Nations Development Programme [UNDP], 2010). While this goal has not yet 
been reached, major strides have been undertaken. In 2009, 1.2 million people began 
antiretroviral therapy, a 30% increase in the number of people on treatment in just one 
year (UNAIDS, 2010b). An estimated 2.9 million lives have been saved because of 
antiretroviral therapy, 1.2 million of these from sub-Saharan Africa. Approximately 11.7 
million life-years were added globally between 1996 and 2008 due to antiretroviral 
therapy (UNAIDS & WHO, 2009). The WHO, UNAIDS, the Global Fund to Fight AIDS, 
Tuberculosis and Malaria and the United States President’s Emergency Plan for AIDS 
Relief (PEPFAR) have all committed to supporting ART expansion. Despite this 
progress, global antiretroviral coverage remains relatively low as new infections outpace 
the response rate; with 10 million people who need ART not receiving such services and 
just over 5 million on treatment, only a third in need are covered (UNAIDS, 2010b).   
 
ART scale-up in developing countries is based on WHO guidelines (modified by country) 
and consists of one first-line regimen consisting of one non-nucleoside reverse 
transcriptase inhibitor (NNRTI) supported by two nucleoside/ nucleotide reverse 
transcriptase inhibitors (NRTI’s). The use f three ARV medications is currently the 
standard treatment for HIV disease, in order to achieve best possible clinical outcomes. 
An alternative regimen, involving a different NNRTI, and/ or a different NRTI, can be 
substituted if required because of factors like drug interactions, toxicity or other health 
conditions. A second-line regimen, consisting of a protease inhibitor (PI), ideally boosted 
by Ritonavir, and two NRTI’s is used when the first regimen fails. In resource-limited 
countries, selection of drugs is based largely on availability and affordability (in addition 
to criteria like efficacy, durability and tolerability that are also used in resource-rich 
countries).     
 
Barriers to antiretroviral success 
Treatment access  
Despite the dramatic benefits of ART, there remain some major obstacles to overcome. 
Initially, the biggest challenge facing optimization of ART and the fulfillment of its 
benefits for HIV-positive individuals was structural; treatment access in many developing 
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countries, including South Africa, has and continues to be a major issue. South Africa’s 
slow response to curbing the growth of the pandemic and delays in implementing 
antiretrovirals meant that deaths in the country doubled between 1997 and 2005. 
According to a 2008 Harvard University study, approximately 330,000 AIDS-related 
deaths could have been prevented had the government acted sooner in providing ART 
to those with HIV-related illness and pregnant women (UNAIDS, 2010a). Senior 
government officials questioned the link between HIV and AIDS and expressed mistrust 
in antiretroviral efficacy. The South African Department of Health’s HIV/AIDS/sexually 
transmitted disease (STD) strategic plan for South Africa 2000–2005 (Department of 
Health, 2000) did not include the provision of ART to HIV-positive persons, inciting a 
national movement and legal proceedings initiated by the Treatment Action Campaign 
(TAC). Ultimately, the Constitutional Court ordered that the strategic plan be adapted to 
include ART provision to all HIV-infected pregnant women. In 2003, the South African 
Department of Health announced the National Comprehensive HIV and AIDS Care, 
Management and Treatment Plan (Department of Health, 2003), a strategy for HIV care 
that included ART, and in 2004, two ART regimens became available free of cost in the 
South African public health sector.  
 
Since then, ART provision has seen a large national scale-up. This has coincided with 
increasing affordability of the medications, largely due to global efforts towards 
expanding access and availability. South Africa now has the largest antiretroviral therapy 
programme in the world. By the end of 2009, there were approximately one million 
people receiving treatment at public health facilities (n = 919,923, including eight 
provinces and excluding all deaths, losses to follow-up and transfers out) and an 
additional 51,633 individuals receiving treatment through the private and non-
governmental organisational (NGO) sectors. In early 2010, antiretrovirals were being 
dispensed through approximately 500 accredited public sector health facilities, primarily 
hospitals but also community health centers and clinics (Department of Health, 2010c).  
 
In the Western Cape, the most recent estimate of antiretroviral coverage (the number of 
patients receiving ART divided by the number needing treatment) was 71.7% in 2008 
(Adam & Johnson, 2009), but numbers on treatment in the province have increased 
significantly since that report. As of July 2010, there were a total of 76,345 adults and 
6,026 children (total 82,371) on ART in the Western Cape. In July alone, 2,445 adults 
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and 87 children (total 2,532) initiated ART in the province (unpublished Department of 
Health internal report dated July 2010: Western Cape ART Monthly Summary for July 
2010).  
 
While scale-up has been ongoing, the need remains great. In 2009, it is estimated that 
1.5 million adults and 106,000 children actually needed treatment in South Africa 
(UNAIDS, 2010a), meaning that antiretroviral coverage for those who were in need was 
at approximately 56% (Department of Health, 2010c). Depending on the definition used 
for required treatment initiation, the year before, coverage was at 40.2% (using the 
Department of Health treatment criteria at the time of WHO stage IV or CD4+ cell count 
<200 cells/!L) (Department of Health, 2004) or just 22.2% (using the Southern African 
HIV Clinicians Society guidelines of WHO stage IV or CD4+ cell count <350 cells/!L), 
with 430,000–1.79 million people awaiting treatment. These figures are a substantial 
improvement from coverage in 2004, which was at just 4.9% (Adam & Johnson, 2009), 
but remain fairly low, with approximately half of those who need treatment actually 
receiving ART.   
 
In 2010, the estimate of those in need moved up to 1.6 million (Statistics South Africa, 
2010). By this year, it is estimated that 2.75 million South Africans with HIV need 
antiretroviral therapy. On 24 April 2010, President Zuma launched a national campaign 
that aims to scale up treatment to 1.5 million people by June 2011, reaching 80% 
coverage of those who need treatment. This would represent a dramatic 50% increase in 
the country’s current antiretroviral patient base (UNAIDS, 2010a). The plan is to further 
decentralize care to primary health care (PHC) facilities, move to a largely nurse-driven 
model and increase the number of health care centers providing ART approximately 
tenfold to 4,000 (Department of Health, 2010c, 2010b). In April 2010 alone, over 500 
new health centers began dispensing ARV’s (UNAIDS, 2010a).  
 
Limited resources 
Obstacles to ART access are being dismantled and ARV medicines are becoming 
increasingly available and affordable – ART is being scaled up rapidly and treatment is 
reaching more and more patients in the country. Despite the absolute necessity for and 
obvious benefits of these developments, they too are a structural challenge: the 
expansion is taxing given the region’s inadequate health infrastructure and facilities, lack 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
Predicting adherence to antiretroviral therapy and retention to HIV care 
 
 
8 
of appropriately trained health care workers and related personnel, and insufficient 
laboratory capacity (Department of Health, 2010c). In 2009, several of South Africa’s 
nine provinces exceeded their health care budgets, and there were reports of 
antiretroviral drug stock short supplies in seven. South African Health Minister, Aaron 
Matsoaledi has said, ‘We are aware that the health system is not working well, we can’t 
hide it... Some call it a collapse, others call it a crisis’, listing ‘human resource capacity, 
and supply and logistical problems’ as key challenges (UNAIDS, 2010a, p.76).         
 
The fundamental question that has emerged is how to ensure programme effectiveness 
with a rapid scale-up, and a growing patient base, in the context of a resource-limited 
setting.  
 
Medication adherence   
Aside from the structural challenges of treatment access and resource limitations, in the 
past few years, early optimism about HAART has been tempered by the growing 
recognition that a fairly substantial proportion of patients does not achieve or sustain 
virological suppression, and significant rates of HIV-related morbidity and mortality have 
persisted (Bisson et al., 2006; Deeks, Beatty, Cohen, Grant & Volberding, 1998; 
Djomand et al., 2003; Karcher, Omondi, Odera, Kunz & Harms, 2007; Parruti et al., 
2006; Seyler et al., 2003; Weidle et al., 2002). This is true of both developed (Paredes et 
al., 2000; Parruti et al., 2006) and developing (Bisson et al., 2006; Djomand et al., 2003; 
Karcher et al., 2007; Seyler et al., 2003; Weidle et al., 2002) contexts, including settings 
where access to HIV treatment is available free of charge (Karcher et al., 2007; Sterling, 
Chaisson, Keruly & Moore, 2003). Whilst certain biomedical factors like varying potency 
of regimens, ARV history and disease stage do impact patients’ physical response to 
treatment (Altice & Friedland, 1998; Deeks, 2000), by far the most critical determinant of 
ART success is patients’ adherence to the medication regimen (Altice & Friedland, 1998; 
Bangsberg et al., 2000; Paterson et al., 2000; Raboud et al, 2002). 
 
The classic definitions of adherence and its alternate term compliance can be found in 
an oft cited text by Haynes, Taylor & Sackett (1979, p.1–2):  
‘Compliance… is defined simply as the extent to which a person’s behaviour (in 
terms of taking medications, following diets, or executing lifestyle changes) 
coincides with medical or health advice. The term adherence may be used 
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interchangeably with compliance. The definition is intended to be non-
judgmental… the term compliance is troublesome to many people because it 
conjures up images of patient or client sin and serfdom.’   
Thus, while the term compliance may contain a value judgment (Chesney, Morin & 
Sherr, 2000), adherence is generally preferred for its recognition of the patient as an 
active partner in selecting and maintaining a medical regimen (Altice & Friedland, 1998; 
Lerner, Gulick & Dubler, 1998).   
 
It has been said that many health care providers now consider adherence as important 
as regimen potency (Stone, Jordan, Tolsen, Miller & Pilon, 2004). What we are being 
confronted with is the distinction between efficacy and effectiveness: what works in 
randomized controlled trials in highly adherent patients (Chesney et al, 2000) might not 
work (or not work as well) in the real world of diverse patient populations with competing 
challenges. Sometimes referred to as the Achilles’ heel of antiretroviral therapy (Simoni, 
Frick, Pantalone & Turner, 2003), adherence to medication is an issue across all 
diseases (Wright, 2000). For instance, it was shown in the 1950’s that patients with 
streptococcal pharyngitis seldom complete 10-day courses of penicillin (Mohler, Wallin & 
Dreyfus, 1955). Adherence in the context of chronic, life-long medication is particularly 
challenging as evidenced by observational cohorts reporting decreases in adherence 
rates with time (Carrieri et al., 2003; Parruti et al., 2006; Roco, Gomez & Arnedo, 1999).  
 
ART literature reports highly variable adherence rates; among HIV-positive individuals, 
estimates of mean adherence levels range from 71% to 100% (Lima et al., 2009; Weidle 
et al., 2006). In one Ugandan study, 99% of patients were found to be adherent to 
HAART (Weidle et al., 2006); a similarly high rate of adherence was noted in a study in 
Malawi, where 84% of participants were adherent (van Oosterhout et al., 2005). This 
contrasts with a Canadian study in which only 129 of the 278 patients participating in the 
study (46%) were shown to be adherent (Palepu et al., 2006).  
 
As outlined earlier, HAART involves the simultaneous administration of multiple ARV 
medications, including PI’s, NRTI’s and NNRTI’s. Typically, patients are prescribed two 
or three ARV medications, each of which is dosed once or twice daily; at each dose, 
between one and four pills is consumed, adding up to as many as twelve pills per day. 
Moreover, each drug has specific, often compound administration instructions. For 
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instance, Didanosine (ddI) must be taken on an empty stomach (at least an hour before, 
or at least two hours after, a meal), should not be taken with other ARV medications, and 
should be dissolved in at least 30ml of water or clear apple juice (no other juice may be 
used). The magnitude of effort required to sustain adherence to regimens with such high 
dose burdens and complexities is considerable and should not be underestimated. Of 
course, many patients also receive treatments for various conditions, side effects and 
comorbidities that relate to their HIV status (e.g. antiemetics for drugs that commonly 
cause vomiting) and others that do not (e.g. anti-hypertensives or insulin), each of which 
comes with its own set of dosing and administration instructions.  
 
Helping patients to optimize antiretroviral adherence in clinical settings is crucial for 
several reasons related to the patient’s own welfare and to public health. First, for the 
potential of antiretroviral treatment to be optimized, meticulous adherence is necessary. 
Without good adherence, antiretroviral medications are not maintained at sufficient 
concentrations to suppress HIV viral replication and to lower HIV plasma viral load. 
Historically, in most chronic diseases (such as hypertension), sufficient and even optimal 
adherence has been defined as 80% or more of prescribed doses taken (Christensen et 
al., 1997; Gebo, Keruly & Moore, 2003; Sackett et al., 1975; Sherr, 2000) and in early 
antiretroviral work, the 80% threshold was used (Roco, Gomez & Arnedo, 1999).  
 
However, subsequent findings indicated that antiretrovirals are less ‘forgiving’ than other 
chronic medications, and do not provide sufficient coverage at the 80% level. Near-
perfect adherence is required to facilitate the best possible short- and long-term 
treatment outcomes, including maximum and durable reduction of viral load, reduced 
destruction of CD4+ cells, promotion of immune reconstitution, and slowed disease 
progression, certainly for PI therapy. For instance, Paterson et al.’s (2000) pioneer study 
showed that in order for virological outcomes of patients to be optimized, adherence of 
at least 95% is necessary. This is the equivalent of missing only one pill per month for a 
once-daily regimen, and three pills per month for a twice-daily regimen. In their 
prospective observational study of 81 patients, a dose-response effect was clearly 
evident: as adherence decreased, HIV ribonucleic acid (RNA) levels increased sharply. 
The virological failure rate was just 22% for patients with adherence of 95% or greater, a 
dramatic increase to 61% for patients with adherence between 80% and 94% (an 
adherence rate that would have led to treatment success in many medical conditions), 
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and 80% for patients with adherence less than 80%. In addition, no opportunistic 
infections or deaths occurred in patients with 95% or greater adherence. The authors 
concluded that 95% or greater was the required level of adherence necessary to 
optimize treatment outcome. Comparable findings are available elsewhere (Orrell, 
Bangsberg, Badri & Wood, 2003; Tuldra et al., 2000).  
 
Recently however, Bangsberg (2006) reported that while "95% adherence is indeed 
necessary for viral suppression on unboosted PI therapy, more potent NNRTI regimens 
may lead to viral suppression at more moderate levels of adherence. Thus, while the 
precise minimum threshold of adherence for clinical effectiveness of HAART has been a 
point of discussion and seems to be dependent on the regimen concerned, experts 
agree that excellent adherence is crucial to the success of ARV treatment, and findings 
continue to show the predictable and dramatic relationship between ART adherence and 
HIV outcomes (Bangsberg, Moss & Deeks, 2004; Hogg et al., 2006; Spire et al., 2002; 
Wood et al., 2004). Thus, at an individual level, antiretroviral therapy – compared with 
therapy for most other medical conditions – requires an unprecedented high level of 
adherence to be maintained for an indefinite time period in order for optimum outcome to 
be achieved.    
 
Second, treatment is in itself an important prevention modality. Evidence from studies in 
serodiscordant couples shows that virological suppression (as achieved by good 
antiretroviral adherence) can significantly reduce infectiousness and thereby decrease 
the risk of HIV transmission to sexual partners (Padian, Buve, Balkus, Serwadda & 
Cates, 2008). A meta-analysis published in 2009 showed that the transmission rate 
drops from 5.6 per 100 person-years in patients not on ART to just 0.5 per 100 person-
years for patients on ART (Attia, Egger, Muller, Zwahlen & Low, 2009). In a recent 
prospective cohort study of 3381 serodiscordant couples across seven African countries 
(South Africa, Botswana, Kenya, Rwanda, Tanzania, Uganda and Zambia), Donnell et 
al. (2010) found a transmission rate of 0.37 (95% CI 0.09–2.04) per hundred person-
years in those who had initiated ARV treatment, compared with a transmission rate of 
2.24 (95% CI 1.84–2.72) in those who had not, a 92% reduction (adjusted incidence rate 
ratio 0.08, 95% CI 0.00–0.57, p=.004). Hence, good antiretroviral adherence is 
necessary to prevent transmission of the virus to sexual partners.        
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Third, the consequences of poor adherence include not only reduced efficacy, but also 
the development of resistance. HIV is highly adaptive; it evolves and mutates rapidly in 
the human body. The success of HAART is contingent upon the constant and invariable 
suppression of HIV viral load to such low levels that the virus cannot replicate rapidly 
enough to develop resistance to the medication (Catz et al., 2000). The only way this 
can occur is through daily or bi-daily dosing of multiple ARV medications to maintain 
optimal plasma drug levels. Any variation, however modest or occasional, from this 
frequent and regular consumption can not only greatly diminish treatment efficacy, but 
lead to viral replication and resistance. Poor adherence leads to suboptimal drug levels, 
treatment failure and ultimately drug resistance. During ART, HIV strains containing 
mutations associated with resistance can emerge within days if treatment is interrupted 
and sufficient drug levels are not maintained. Once resistant strains emerge, they begin 
to replicate, and will persist indefinitely. A study by Sethi (2004) set out to determine the 
adherence cut-off point for minimizing the risk of drug resistance, and found that while 
no resistance was noted in patients who were less than 60% adherent (no plasma drug 
levels), the greatest risk occurred in those patients who were 70–89% adherent 
(inadequate plasma drug levels). Thus, while very poor adherence may lead to 
virological failure, in terms of resistance, at highest risk is the reasonably but not 
perfectly adherent patient.      
 
Moreover, mutations conferring resistance to one drug often confer cross-resistance to 
other drugs within the same class that are not yet prescribed; patients become resistant 
to entire classes of antiretroviral agents, thereby rendering those classes ineffective 
(Temesgen, Warnke & Kasten, 2006). There is a particularly high degree of cross-
resistance between NNRTI’s, which form the basis of the South African Department of 
Health’s antiretroviral treatment protocol (Department of Health, 2010b), and providing a 
second NNRTI after resistance has developed would be unlikely to provide any clinical 
benefit (Max & Sherer, 2000). The world has seen this occur in tuberculosis (TB) care; 
poor adherence has led to the emergence of multi-drug resistant strains of the disease 
(Lerner et al., 1998). In a resource-constrained setting like South Africa, with its limited 
treatment options, minimizing antiretroviral resistance is especially important. The goal is 
for treatment programmes to successfully keep patients on uninterrupted first-line 
therapy for as long as possible, which is simpler to administer, associated with higher 
adherence levels, and less costly than second-line therapy. Patients who fail first-line 
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therapy must move on to second-line, with its more complex pill-taking requirements and 
higher cost.  
 
At present, if patients then fail their second-line therapy, there are no further standard 
treatment options in the public sector (Department of Health, 2010b). What usually 
occurs in South Africa is that second-line therapy is continued until there is no longer 
clinical benefit to its use, or the patient and provider choose to switch to palliative care. 
The latest Department of Health clinical guidelines for HIV/AIDS management stipulate 
the following for cases of second-line treatment failure: ‘…If viral load remains high, refer 
where possible, but maintain [sic] on failing regimen’ (Department of Health, 2010b, p.9). 
Salvage ART regimens (for use in those cases of second-line regimen failure) are rare in 
most low- and middle-income countries and are unlikely to become available in 
resource-limited countries within the next few years largely due to cost (Bennet, 
Bertagnolio, Sutherland & Gilks, 2008) as even second-line regimens costs three times 
more than first-line regimens (Orrell et al., 2007) and require more complex monitoring 
systems and challenging supply chain management. Thus, non-adherence must be 
minimized in order to maintain virological suppression on first-line therapy, especially in 
resource-limited settings like South Africa.  
 
Fourth and finally, the prospect of resistance is not just relevant at an individual level, but 
is a public health threat. Resistant strains of the virus may actually be transmitted to 
others through high risk activities, leading to new infections which are unresponsive to 
currently available treatments and the further spread of resistant strains of HIV across 
society. Widespread HIV drug resistance (HIVDR) is a real fear, and its prevention an 
international priority. One longitudinal study conducted in North America among newly-
infected patients who had not yet received treatment, found that the frequency of high-
level resistance to one or more drugs had increased from 3.4 percent during the period 
from 1995 to 1998 to 12.4 percent during the period from 1999 to 2000 (p=.002) (Little et 
al., 2002). The prevalence of transmitted HIVDR in a society is a function of the extent of 
ART coverage, length of use/ availability and the prevalence of primary resistance 
(Bennet et al., 2008).  
 
In South Africa, as coverage expands and length of use/ availability increases, primary 
resistance must be kept at the absolute minimum possible so as to avert the emergence 
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of widespread transmitted HIVDR. Facilitating ART adherence is one of the most 
important strategies for suspending emergence of resistant strains of the virus and 
ensuring durability of the currently available regimens. Hence, adherence to ARV drugs 
is crucial to both individual and public health. The WHO’s recommended strategy for 
prevention and assessment of HIVDR in resource-limited countries suggests targets of 
>90% of ART patients taking >90% of each of their prescribed drugs at each clinic visit 
and >70% of patients, who, at 12 months, have an HIV RNA level of less than the 
detection limit of the test used (Bennet et al., 2008). 
 
Retention to HIV care 
Retention in ART programmes is a precursor to medication adherence and essential for 
programme success, but has received far less attention (Cornell et al., 2010; Rosen, Fox 
& Gill, 2007). Studies to date have tended to focus on describing adherence, laboratory 
and clinical outcomes of those patients who are retained in care, sidestepping the often 
substantial proportion of the patient base who are lost to care, with many reporting on-
treatment rather than intention-to-treat analyses (Carrieri et al., 2001; Golin et al., 2002; 
Spire et al., 2002; Tesoriero et al., 2003). This may be a result of the significant costs 
associated with tracking missing patients, and also that while adherence research can 
examine very short pill-taking periods (with some recall surveys spanning as little as a 
few days) (Spire et al., 2002; Tesoriero et al., 2003; Wagner, 2002; Wagner, Iguchi, 
Schneider, Scott & Anderson, 2002), retention research requires longer-term monitoring 
periods. 
 
Antiretroviral treatment requires frequent clinic visits, long-term counseling, regular 
clinical and immunological staging and ongoing monitoring, all of which are resource-
intensive for both the health care system and the patient (Dalal et al., 2008). Loss to 
follow-up (LTFU) from ART programmes raises many of the same issues as described 
with regard to ART adherence; it is a potential source of patient illness and death, HIV 
transmission, and single- and multi-drug resistance for similar reasons. Keeping rates of 
LTFU in ART programmes to a minimum is key to ensuring continuity of treatment so 
that patients reap the survival benefits of ART, halt disease transmission and minimize 
both their own and society-wide resistance. LTFU rates, like adherence levels, vary 
widely across studies, contexts and patient groups. Studies in Uganda (Kabugo et al., 
2005) and Cameroon (Guiard-Schmid et al., 2004) report LTFU rates as high as 39.3% 
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and 38.5%, while a study from Khayelitsha, South Africa (Coetzee et al., 2004) reported 
an extremely low rate of 0.3%.  
 
In a meta-analysis of 74,289 ART patients across 33 cohorts in 13 sub-Saharan 
countries (Rosen, Fox & Gill, 2007), at 24 months retention was at just 60%, largely due 
to LTFU. A recent cohort analysis of 44,177 ART patients from eight public sector 
programmes across South Africa reported a higher retention rate of 71% at 24 months 
(Cornell et al., 2010). Of note was the finding that LTFU increased with expansion of the 
ART programme (from just 1% at 12 months in 2002/ 2003 to 13% at 12 months in 
2006), and that with each additional year on ART, failure to retain patients in the 
programme was increasingly attributable to LTFU compared with mortality (at 6 months, 
5% had died and 9% were LTFU; at 36 months, 10% had died and 30% were LTFU). 
The authors concluded that LTFU is playing an increasing role in the South African 
national ART programme, presenting a major threat to its effectiveness, and attributed 
the observed LTFU rates to the size and pace of ART scale-up. The WHO’s 
recommended strategy for prevention and assessment of HIVDR in resource-limited 
countries suggests a target of <20% LTFU in first year of ART (Bennet et al., 2008).  
 
Consequently, with as many as one million patients currently on ART and approximately 
500,000 new patients due to start by June 2011, South Africa now faces the dual 
challenges of ensuring medication adherence and retention to care in the context of a 
massive programme scale-up. We are entering a new phase of the HIV pandemic, one 
termed by Altice and Friedland (1998), the ‘era of adherence’.  
 
Next steps 
In the face of the supremely difficult task of maintaining near-perfect adherence 
indefinitely to a daily medication regimen and frequent clinic visits, some of the early 
optimism around ART has decreased. The considerable variability in domestic and 
international antiretroviral adherence and loss to follow-up rates show an overwhelming 
potential for individual and public health to be compromised. If ‘real world’ patients are to 
truly benefit from the medical advances of HAART, and a sub-pandemic of treatment-
resistant HIV is to be averted, it is critical that we conduct systematic research to identify 
valid and reliable correlates of antiretroviral medication nonadherence and LTFU in 
clinical settings in sub-Saharan Africa, so that solutions to these challenges can be put 
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forward and implemented in the most affected region. These correlates are likely to be a 
complex interaction of disease, health system, social and individual patient 
characteristics, and are poorly understood.  
 
The purpose of this research is to identify baseline demographic, biomedical and 
psychosocial factors that may predict adherence to ART and retention to care in a cohort 
of adult HIV-infected patients in South Africa in order to provide data for planning, 
monitoring and evaluation of response activities. The results will be available for use in 
three important ways to help lessen the impact of HIV on individuals and communities: 
 
1) To develop effective treatment readiness/ preparation programmes  
The latest Department of Health clinical guidelines for HIV/AIDS management 
(Department of Health, 2010a, p.12) stipulate the conduct of ‘a basic psychological 
assessment to document social issues and current psychological state, focusing on 
factors that impact adherence’ at the first visit, before treatment initiation. The guidelines 
are based on the assumption that baseline psychosocial factors impact subsequent 
adherence, but do not specify how these factors should be determined, who should 
conduct the assessment, or which measures should be used. The document goes on to 
recommend ‘evaluat(ing) psychosocial support’ and the conduct of an ‘information and 
education session’ at subsequent pre-treatment visits; this time the underlying 
assumption is that baseline social support and knowledge impact adherence, and 
specifics like how social support should be defined or measured or what information is 
most important to convey in the education session are not described. Finally, at the ART 
commencement visit, the guidelines suggest that ‘the multidisciplinary team should 
reassess ART readiness criteria’, including ‘patient’s understanding of their HIV status, 
the need for ART, importance of adherence and the link to treatment outcomes, 
specifically virological suppression, and commitment to scheduled visits.’ The focus of 
this final assessment is therefore levels of knowledge, with the underlying assumption 
again that increased knowledge would lead to better adherence behaviour.  
 
In certain settings, treatment readiness programmes have included other forms of 
knowledge transfer, such as possible side effects to be expected and their management 
(Highstein, Willey & Mundy, 2006), ‘mock’ adherence trials using co-trimoxazole, 
multivitamins or jelly beans (Balfour et al., 2006; Bekker, Myer, Orrell, Lawn & Wood, 
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2006), home visits to assess and promote social support (Coetzee et al., 2004; Koenig, 
Leandre & Farmer, 2004), encouragement of disclosure and even a ‘treatment buddy’ or 
‘treatment assistant’ (Coetzee et al., 2004), identification of reminder strategies like 
alarms and medication diaries (Andrade et al., 2005), and diagnosis and treatment of 
depression (Balfour et al., 2006). While on-ART adherence intervention research is 
scarce, pre-initiation adherence interventions are even less available (Balfour et al., 
2006).  
 
Since providing interventions once patients are already on treatment may be too late to 
prevent early resistance or to modify already set behaviour patterns, for the benefits of 
HAART to be realized and resistance averted, the field needs theory-based strategies to 
prepare patients before their antiretroviral initiation and for these strategies to be 
incorporated into the national guidelines. For this to occur, valid and reliable baseline 
predictors of adherence behaviour are needed for the South African context.        
 
2) To develop effective adherence and retention support programs 
The latest Department of Health guidelines (Department of Health, 2010a, p.17) advise a 
large number of on-treatment adherence interventions: ‘explaining the link between 
virological suppression and clinical outcome, and adherence’, ‘provide ongoing 
education to patients on their disease, including any new diagnoses, unexplained 
symptoms or opportunistic infections’, ‘reassure on the transient nature of nausea and 
vomiting, if a patient experiences that at treatment initiation’, ‘address adverse events, 
interim illness, issues around stigma and disclosure’, ‘treat depression and substance 
abuse’, ‘identify food insecurity and actively address this through government support 
programmes’, ‘ensure communication between clinic visits and referral points’, ‘enlist 
support of family/ friends/ partners/ support group members/ community adherence 
support workers’, ‘home visits’, ‘use reminders and reinforce with adherence tools’, 
‘spend time with the patient and explain the disease, the goals of therapy and why the 
need for adherence’, ‘consider monitoring of medications such as co-trimoxazole prior to 
ART initiation’, ‘negotiate a treatment plan that the patient can understand and to which 
he/ she commits’, ‘explain to patients how to avoid adverse drug reactions’, ‘encourage 
attendance and participating in a support group – these should ideally be run by 
community members but might need to be supported by the clinic staff or adherence/ 
therapeutic counselors or social workers’, ‘arrange home visits… to facilitate access to 
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drug and alcohol counseling, social welfare for grant access, emergency relief for 
nutritional support and support with disclosure’, ‘reinforce the use of adherence tools e.g. 
pill boxes and/ or daily dosing diary’, consider using a ‘treatment buddy’ or even directly 
observed therapy for an agreed period’. Given the overburdened and under-resourced 
health care system, and the country’s rapidly growing ART patient base, this intervention 
list is unfeasible to action in the South African context. Instead of over-recommending a 
litany of interventions that may or may not prove effective in this context, the guidelines 
should be adapted to include only a few interventions that target valid and reliable 
predictors of nonadherence and loss to follow-up.      
 
A small number of on-ART adherence interventions have been investigated and 
implemented globally with varying success, such as motivational interviewing (MI), 
cognitive behavioural therapy (CBT) and other counseling types (Bekker et al., 2003; 
Dilorio et al., 2003; Martin et al., 2001; Safren, Otto & Worth, 1999; Safren et al., 2001), 
education sessions of varying lengths and formats (Goujard et al., 2003; Remien et al., 
2005); use of electronic devises such as beepers, pagers, wrist watches and cellular 
phone alarms (Dunbar et al., 2003; Bamberger et al., 2000; Holzemer, Henry, Portillo & 
Miramontes, 2000), reminder phone calls (McCance-Katz et al., 2002), pill boxes 
(Holzemer et al., 2000), treatment of conc mitant mental health and substance abuse 
(Murphy, Lu, Hoffman & Marelich, 2002) and even cash reinforcement (Bamberger et al., 
2000; Rigsby et al., 2000).  Each of these interventions has a different focus, intending 
to modify either knowledge levels, attitudes, mental health, substance abuse, or social 
relationships, with the eventual aim of impacting medication adherence and/ or retention 
to care. This final aim will only be realized if the target of change is actually a significant 
correlate of adherence behaviour, something which has not been reliably determined. 
Thus, efforts to support adherence and retention are hampered by the current lack of 
knowledge of the predictors of adherence and retention, and what helps to sustain them 
over time.  
     
The costs associated with interventions to increase ART adherence are minimal 
compared with the costs of the treatment itself (Altice & Friedland, 1998). Moreover, 
given the high costs of HIV-associated morbidity and mortality, the implementation of 
effective adherence programs would prove highly cost-effective. Using a simulation 
model to perform a cost analysis of various adherence support programmes, Goldie et 
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al. (2003) found that even intensive interventions (such as home- or clinic-based 
supervised medication administration, including all medical, personnel and transportation 
costs) proved cost-effective. This was particularly true of the model’s advanced disease 
(mean CD4+ cell count 87 cells/!L) patients, who were the most representative within 
the model of South Africa’s HIV population initiating treatment. For these patients, 
providing an intervention that even modestly improved HIV RNA suppression (e.g. from 
60% to 78% of the cohort) meant quality-adjusted life expectancy gains of 5.5 months to 
more than 42.7 months at cost effectiveness ratios below $50,000 per quality-adjusted 
life-year (QALY), which is the commonly suggested threshold. Given this, the 
development and implementation of effective evidence-based national, population-
specific adherence and retention interventions should be a priority; the first step of which 
will be to identify the biomedical, psychological or social factors that they should target.      
 
3) To offer stratified adherence and retention support dependent on who will benefit 
most  
South Africa’s urgent need for rapid scale-up and context of low health system resources 
makes impractical the ART provision model seen in resource-rich countries, which 
involves intensive and personalized patient management through highly specialized 
staff, extensive treatment options and expensive laboratory monitoring. Locally, patients 
are provided basic HIV care at PHC level, and referred on to hospital centers if 
necessary. While HIV has meant increased patients numbers and responsibilities, in 
many cases this has not translated into increased personnel. At PHC level, health care 
practitioners are faced with heavy workloads, competing tasks and priorities, lack of 
sufficient human resources and training, and major time constraints (Ruud, Toverud, 
Radloff & Srinivas, 2010). In South Africa, as treatment scales up and the patient base 
increases, the goal is a system that can cope with high patient numbers while 
maintaining quality of care at the lowest cost possible. In seeking to make maximum use 
of limited resources and human capital, it is pertinent to consider a model of stratified 
retention and adherence support, wherein, instead of all patients receiving low to 
moderate levels of adherence and retention support, patients who would benefit most 
from intensified and targeted support would receive it. In the absence of such profiling, 
clinics are forced to use limited resources to offer uniform low- or moderate-level support 
– insufficient for those in need, and a misuse of resources for those that are not.   
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For such a model to be actualized, patients would need to be screened and accurately 
identified as at high or low risk for nonadherence and/ or loss to follow-up so that they 
could be positioned in the appropriate adherence support stream. In order for this 
screening to be both effective and feasible in a low-resource, high volume context, it 
would need to have the following features and properties: 
• Administered at first clinic presentation  
Unlike many of the adherence interventions designed to date (Bamberger et al., 2000; 
Dilorio et al., 2003; Dunbar et al., 2003; Goujard et al., 2003; Holzemer et al., 2000; 
Martin et al., 2001; McCance-Katz et al., 2002; Murphy et al., 2002; Remien et al., 2005; 
Rigsby et al., 2000; Safren et al., 1999; Safren et al., 2001), the screening and 
stratification should occur as patients enter the treatment system (i.e. at the first clinic 
visit), rather than once they are already on-treatment. At present, what usually occurs is 
that all patients receive the same (if any) adherence/ retention support, until the first 
elevated viral load or low-intake pill count result suggests nonadherence or the patient is 
LTFU, at which point intensified formal or informal adherence/ retention support kicks in. 
The benefit of screening and stratification at the first clinic visit would be to flag high-risk 
patients and provide timely treatment support before treatment onset, without delay and 
time for resistance to emerge or early patient fall-off.  
• Evidence-based 
The focus of the screening would need to be the assessment of those factors that have 
been observed – in systematic, methodologically-sound and rigorous observational 
research – to reliably predict adherence behaviour in the South African context.   
• Reliable  
The screening would ideally have high sensitivity (true positive rate [TPR] or the 
probability that an at-risk patient will be identified as at risk) and high specificity (true 
negative rate (true negative rate [TNR] or the probability that a patient not at risk will be 
identified as not at risk), but since its primary function is screening rather than 
confirmation, and given the over-arching aim of providing increased support to all of 
those that need it, high sensitivity should be prioritized.    
• Standardized 
The screening would need to be standardized for three reasons. First, in scaling up ART 
to the maximum number of persons in need, and decentralizing care to non-specialized 
clinic level, it is necessary to have clear, standardized protocols and guidelines for each 
aspect of patient management in order to maintain quality of care. Second, with South 
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Africa’s current (and growing) ART patient load, health care workers should not be 
further burdened with the additional task of making individualized support-profiling 
assessments. Third and finally, it has been repeatedly shown that health care providers 
typically are poor predictors of patient medication adherence (Gerbert, Bronstone, 
Clanon, Abercrombie & Bangsberg, 2000; Miller et al., 2002; Paterson et al., 2000; 
Weiser et al., 2003), tending to overestimate adherence (in the Miller et al. [2002] study, 
in 60% of cases and by 8.9% on average) and insufficiently detect poor adherence. For 
example, in a prospective observational study of 88 patients, physicians predicted 
adherence incorrectly for 41% of patients, and nurses predicted incorrectly for 30% of 
patients (Paterson et al., 2000). This may be a function of the nature of the predictors of 
adherence. As the following chapter will show, while some literature has confirmed the 
validity of certain demographic and biomedical factors as predictors of medical 
adherence in certain contexts (Ammassari et al., 2004; Cornell et al., 2010; Gordillo, del 
Amo, Soriano & Gonzalez-Lahoz, 1999; Hill et al., 2010), much of the research has 
pointed to psychological and/ or social constructs, attribut s that do not fall within the 
traditional domain of medical assessments in practice. This further points to the need for 
an objective measure; without standardized assessment, clinicians are unlikely to 
accurately identify patients at risk of suboptimal adherence, missing the opportunity for 
targeted interventions. 
• Designed for use in routine ART clinics and primary care facilities in resource-
constrained environments: suitable for use by lay counselors or personnel, user-
friendly for staff and patients, quick to administer, and inexpensive to set up and 
maintain 
The South African Department of Health’s most recent UNGASS report (Department of 
Health, 2010c, p.65) outlined the department’s plan to ‘formally adopt, and invest 
sufficient resources in, task-shifting and down-referral policies so that patients on ART 
can be seen at the lowest appropriate level in the health system.’ The aim is to enable 
healthcare workers with non-specialized training to deliver HIV care to considerable 
numbers of patients. It is estimated that there are just 26 medical practitioners for every 
100,000 South Africans (Day & Gray, 2008), meaning that approaches to minimize 
dependence on highly skilled providers is critical. At many PHC facilities, doctors and 
pharmacists are not permanently on staff, so delegation to various auxiliary health care 
workers is key where possible. Due to limited health care resources, it must be assumed 
that no clinical psychological, psychiatric or neuropsychological services will be available 
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to conduct the assessment at PHC level. Lay counselors are one of the primary health 
care system’s greatest resources, significantly outnumbering other personnel types. Any 
intervention intended for routine widespread use in public facilities in this country would 
have the best chance of being utilized if targeted at lay counselors. This means the 
screening needs to be simple and easy to administer as many lay counselors are 
appointed to work without prior medical or professional standardized training (Ruud et 
al., 2010). With such high patient numbers, the screening should also be streamlined 
and quick to administer, with the level of effort required for administration possible 
between routine activities in a busy clinic. This is also necessary to minimize the burden 
on patients, who often spend much time waiting at busy clinics, losing casual wages and 
delegating childcare responsibilities. Finally, the screening should be inexpensive to set 
up and utilize, meaning that in addition to lay administration (reducing burden on high-
cost medical personnel), it should be paper-based and involve no additional laboratory 
or other high assessment costs.     
 
For all of these features to be realized, the most useful form would be a an evidence-
based, highly sensitive, paper Rapid Assessment Tool (RAT), administered at first clinic 
presentation, in order to identify patients at highest risk for non-adherence and LTFU, 
and utilized to trigger adherence support measures from the onset. This is one of the 
primary goals of this project.  
 
 
Summation, aim and objectives 
In sum, while HAART has the potential to dramatically improve HIV outcomes at an 
individual and population level, turning the tide of HIV in this country, significant barriers 
to its effectiveness still exist. One of the primary barriers is patient adherence and LTFU, 
and effective treatment readiness and on-treatment support programmes are sorely 
needed. For such interventions to be designed and implemented, there is an urgent 
need for systematic data collection and analysis to identify valid and reliable predictors 
of nonadherence and LTFU in the South African population. The goal of this project is 
twofold: to determine these predictors through systematic and rigorous methodology, in 
order to provide evidence-based recommendations for the development of effective 
treatment readiness and adherence support programmes; and to develop an effective 
RAT for patient risk profiling and stratification of such programmes.   
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Study aim 
The aim of this study is to identify baseline demographic, biomedical and psycho-social 
factors that may predict adherence to ART and retention to care in a cohort of adult HIV-
infected patients in South Africa, in order to provide data for planning, monitoring and 
evaluation of response endeavors. 
 
Specific objectives 
• To describe the demographic and biopsychosocial profile of adult patients 
accessing ART in a primary health care clinic in South Africa 
• To determine the prevalence of nonadherence to HAART and loss to follow-up in 
the sample  
• To examine the effects of various demographic, biomedical, psychological and 
social factors on key laboratory (virological suppression) and behavioural (pill 
count, retention to care) endpoints indicative of adh rence, and to make this 
information available for guideline-development, advocacy and the development of 
focused strategic treatment readiness, adherence and retention programmes 
• To develop a treatment success prediction rapid assessment tool (RAT), based on 
the findings above, suitable for routine clinical use by lay counselors in resource-
limited settings, in order to facilitate the detection of patients at high risk for 
nonadherence and loss to follow-up and in need of increased adherence support 
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CHAPTER 2 
Predictors of antiretroviral adherence and retention to HIV care: State of 
the science  
 
 
 
Across diseases, medication adherence and retention to care are complex and dynamic 
human behaviours, resulting not only from individual attitudes, thoughts and behaviors, 
but also relevant health systems, socioeconomic conditions, disease- and drug-related 
factors. The goal of this review chapter is to describe the state of the science in 
emerging predictors of medication adherence and retention to care, focusing on HIV 
treatment antiretroviral adherence and retention to HIV care in particular. Using search 
and extraction methodology, information from literature across the field has been 
collected and synthesized for presentation here.    
 
Theoretical framework 
The biopsychosocial model is derived from an established body of psychological and 
behavioural research and theory and posits that psychological and social processes 
must be considered alongside biomedical symptoms, conditions and treatments in our 
attempts to understand health-related behaviours. Unlike the biomedical model (which is 
reductionist in its perception of illness and treatment as low-level processes, focusing 
only on such as aspects as bacteria and surgical interventions) (Edelmann, 2000), the 
biopsychosocial model recognizes the role played by individual habits, emotions and 
motivations as well as social context and circumstance in addition to biomedical 
processes in determining disease course and treatment efficacy.       
 
It is the premise of this research that health-related actions and treatment adherence 
can only be understood by examining individual psychological factors like attitudes or 
affective state and broader social relationships and realities like marital and employment 
status alongside biological signs and symptoms.  
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Studies reviewed 
This review covers a number of complex subject areas and themes. Space limitations 
preclude full and complete presentations of each topic, but representative articles are 
drawn together and cited, with a focus on recent literature.  
 
 
Methodology of published studies  
Because the study of antiretroviral adherence and its predictors is fairly new, study 
methodologies, methods of adherence measurement, durations of follow-up and 
endpoints vary widely, making comparisons of results challenging.  
 
Most studies are conducted in developed nations, particularly the United States and 
Europe, with relatively few conducted in developing countries (Bisson et al., 2006; 
Byakika-Tusiiime et al., 2005; Caluwaerts et al., 2009; Cornell et al., 2010; Dalal et al., 
2008; Do et al., 2010; Karcher et al., 2007; Laniece et al., 2003; Lubega et al., 2010; 
Maskew, Macphail, Menezes & Rubel, 2007; Nam et al., 2008; Ncama et al., 2008; 
Richard, Simon, Joseph, Fred & Violet, 2009; van Oosterhout et al., 2005; Weidle et al., 
2006; Weiser et al., 2003; Wools-Kaloustian et al., 2006; Zachariah et al., 2008). As a 
result, little is known about predictors of adherence in Africa and particularly sub-
Saharan Africa, which is sadly paradoxical as this is where the HIV pandemic continues 
to have its most devastating impact.  
 
Most research is done with patients already on HAART, with just a few studies 
conducted among those initiating treatment (Bisson et al., 2006; Caluwaerts et al., 2009; 
Carrieri et al., 2006; Cornell et al., 2010; Dalal et al., 2008; Golin et al., 2002; Laniece et 
al., 2003; Lime et al., 2009; Parruti et al., 2006; Roco et al., 1999; Spire et al., 2002; 
Weidle et al., 2006; Zachariah et al., 2008), limiting their ability to identity at-risk patients 
before they have already begun treatment. While most studies are conducted in general 
adult populations made up of various transmission groups, some studies are conducted 
in special populations like injection drug users (IDU’s) (Arnsten et al., 2007; Kerr et al., 
2005; Turner & Hecht, 2003) or the incarcerated (Roberson, White & Fogel, 2009), and it 
is unclear how applicable each set of findings is to other population groups.  
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Some studies assess only self-reported reasons for poor adherence or loss to follow-up 
(Abel & Painter, 2003; Lubega et al., 2010; Maskew et al., 2007; Morse, Simon, Besch & 
Walker, 1995; Murphy, Roberts, Martin, Marelich & Hoffman, 2000; Nam et al., 2008; 
Roberson et al., 2009; Vervoort et al., 2010), rather than testing for associations 
between these factors and observed adherence. Of those studies that do test for 
associations, most do not use objective methods of assessing adherence (such as pill 
counts, HIV RNA level tests, electronic monitoring devices, pharmacy records or 
therapeutic drug monitoring); the most common form of assessing adherence across the 
literature is self-report  (Ammassari et al., 2004; Arnsten et al., 2007; Byakika-Tusiime et 
al., 2005; Carrieri et al., 2006; Catz et al., 2000; Chesney et al., 2000; Corless, Nicholas, 
Davis, Dolan & McGibbon, 2005; Do et al., 2000; Gebo et al., 2003; Golin et al., 2002; 
Gordillo et al., 1999; Laniece et al., 2003; Malcolm, Ng, Rosen & Stone, 2003; Murphy et 
al., 2000; Murphy et al., 2010; Ncama et al., 2008; Parruti et al., 2006; Roco et al., 1999; 
Spire et al., 2002; van Oosterhout et al., 2005; Wagner, 2002; Weiser et al., 2003; 
Wools-Kaloustian et al., 2006), which is prone to bias. 
 
Most studies are cross-sectional (Ammassari et al., 2004; Arnsten et al., 2007; Byakika-
Tusiime et al., 2005; Catz et al., 2000; Chesney et al., 2000; Corless et al., 2005; Do et 
al., 2010; Gebo et al., 2003; Gordillo et al., 1999; Hinkin et al., 2002; Malcolm et al., 
2003; Murphy et al., 2010; Ncama et al., 2008; Richard et al., 2009; van Oosterhout et 
al., 2005; Weiser et al., 2003); comparatively few studies incorporate a follow-up 
assessment period of adherence and/ or retention outcomes. Of those that do, most 
durations of follow-up are shorter than two years (Bisson et al., 2006; Caluwaerts et al., 
2009; Dalal et al., 2008; Golin et al., 2002; Hinkin et al., 2004; Karcher et al., 2007; Roco 
et al., 1999; Spire et al., 2002; Wagner, 2002; Weidle et al., 2006; Wools-Kaloustian et 
al., 2006; Zachariah et al., 2008). While operationally simpler, cross-sectional designs 
are limited in their inability to evaluate cause-effect associations, which must be 
longitudinally tested. As such, some of the factors identified as ‘determinants’ of non-
adherence may actually be outcomes of non-adherence. For instance, high rates of 
depression in poor adherers in cross-sectional studies may instead indicate the impact 
of non-consumption of ART and associated progressing illness on mood states. 
Likewise, correlations between adherence self-efficacy (i.e. patients’ belief in their ability 
to take their medication as prescribed) and adherence behaviour may, instead of 
underscoring the significance of self-confidence and beliefs in determining adherence 
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patterns, reflect the impact of past adherence behaviour on self-perceived ability to 
adhere. Authors of cross-sectional studies agree that longitudinal designs are needed to 
more definitively establish the direction of these relationships (Ammassari et al., 2004; 
Catz et al., 2000; Corless et al., 2005; Hinkin et al., 2002) and call for the conduct of 
longitudinal investigations.      
 
Few studies (Corless et al., 2005; Malcolm et al., 2003) use a theoretical framework to 
guide their choice of factors to investigate. Many assess only demographic, clinical, 
immunological and virological data (Bisson et al., 2006; Byakika-Tusiime et al., 2005; 
Caluwaerts et al., 2009; Cornell et al., 2010; Dalal et al., 2008; Hill et al., 2010; Karcher 
et al., 2007; Laniece et al., 2003; van Oosterhout et al., 2005; Weidle et al., 2006; 
Wools-Kaloustian et al., 2006; Zachariah et al., 2008), with no psychological or social 
evaluations. This is likely due to the fact that demographic, clinical and laboratory data 
are routinely collected in ART programmes, whereas the time and costs associated with 
collecting psychosocial data would necessitate special provisions. Only a handful of 
studies include cognitive testing (Albert et al., 1999; Ammassari et al., 2004; Avants, 
Margolin, Warburton, Hawkins & Shi, 2001; Hinkin et al., 2002; Hinkin et al., 2004; 
Levine et al., 2005; Wagner, 2002; Waldrop-Valverde et al., 2006); of those that do, 
most have sample sizes of less than 150 participants (Albert et al., 1999; Ammassari et 
al., 2004; Avants et al., 2001; Hinkin et al., 2002; Hinkin et al., 2004; Waldrop-Valverde 
et al., 2006) and are conducted in the United States (Albert et al., 1999; Avants et al., 
2001; Hinkin et al., 2002; Hinkin et al., 2004; Levine et al., 2005; Wagner, 2002; 
Waldrop-Valverde et al., 2006), likely a function of the level of expertise, training and 
time required to perform such testing.  
 
 
Biopsychosocial predictors of antiretroviral adherence and retention to HIV care 
While medication adherence has been the focus of research for many years, interest in 
adherence has intensified in the era of ART. The seriousness and implications of non-
adherence to ART has sparked increased attention; however, rigorous empiric 
investigations are sorely lacking. This emerging body of literature links certain 
demographic, biomedical, psychological and social constructs with adherence to ART 
and retention to care. These constructs include factors related to the patient (including 
demographics like age, gender, ethnicity, education and employment; levels of 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
Predicting adherence to antiretroviral therapy and retention to HIV care 
 
 
28 
understanding about, attitudes towards and concerns about HIV and ART; mental 
illness, which may or may not predate HIV-infection; concomitant substance abuse; 
comorbid conditions; adherence self-efficacy), factors related to HIV (primarily perceived 
HIV symtomatology) and its treatment (regimen complexity and perceived treatment side 
effects), and factors related to the patient’s environment (disclosure; family and other 
social support; professional support and relationship with health care provider), but an 
almost equal literature set refutes each association.  
 
Differences in reported results are likely a function of two factors: significant 
methodological variations, and differences in study populations. As outlined earlier, the 
literature uses various study designs (cross-sectional versus longitudinal; quantitative 
versus qualitative; reported versus observed behaviour), measures (subjective versus 
objective assessment of adherence, various viral load assays with different limits of 
detection), definitions (percentage of pill to be consumed for adherence to be considered 
acceptable, length of time absent to be considered lost to follow-up, viral load level to be 
considered suppressed). These methodological differences are likely to significantly 
impact study results. For certain constructs, the conflicting findings and variability of 
identified predictors of adherence by study may result from differences in study 
populations and settings, with studies conducted in both developed and developing 
countries, each with its own culture, circumstances and clinical settings (e.g. ART 
requiring payment or available free of charge), focusing on different population groups 
(general adult populations versus special subpopulations), and clinical settings (prisons, 
inpatient, outpatient). For instance, Hinkin et al. (2002) found older age to be associated 
with better adherence in a broad sample of HIV-infected patients, while Avants et al. 
(2001) found no association between age and adherence in a sample of HIV-infected 
injection drug users. Findings from Gebo et al.’s (2003) cross-sectional study of ART 
patients at an urban hospital clinic in the United States illustrate this point: in multivariate 
analyses, social pressures outside of the clinic were a significant predictor of 
nonadherence only in patients without a history of injection drug use. Even those studies 
that focus on general adult populations have significantly different sample 
characteristics, due to country and setting differences (for instance, men who have sex 
with men [MSM] populations in the United States versus heterosexual populations in 
Africa). Other differences may be explained by a time span across studies of 
approximately fifteen years, with divergent results reflecting changing patient 
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populations, ART regimens, clinical guidelines and social norms. This further justifies the 
need for methodologically-sound, locally-relevant, current antiretroviral adherence 
research. 
 
Demographic predictors  
Demographic features were some of the earliest variables to be examined as potential 
characteristic indicators of risk for nonadherence or loss to follow-up (Chesney et al., 
2000) (see Table 1), although the data has generally found inconsistent and context-
dependent associations. Female gender has been identified as a determinant of good 
ART adherence in some previous research (Wagner, 2002), as has male gender 
(Turner, Laine, Cosler & Hauck, 2003). Wagner (2002) noted better adherence in 
women than men according to medication diary, and Turner et al. (2003) showed that 
women were less adherent than men according to pharmacy refill records. Spire et al. 
(2002) however, found no relationship between gender and medication adherence in a 
cohort of HAART-initiating patients in France; nor did Catz et al. (2000), Do et al. (2010), 
Gebo et al. (2003), Golin et al. (2002); Parruti et al. (2006) or Weiser et al. (2003) in 
various observational studies.  
 
The same inconsistencies exist in retention research. In a cohort study of 435 
adolescents and adults (age 13 and older) initiating ART at a district hospital in Kenya, 
Zachariah et al. (2008) found a significantly higher proportion of females to have been 
lost to care. However, Hill et al. (2010) found that potential loss to follow-up (defined as 
12 months without CD4+ cell count, the equivalent of 2–4 missed clinic appointments) 
was independently associated with male sex. Maskew et al. (2007), Mocroft et al. (2008) 
and Wools-Kaloustian et al. (2006) also found males to be significantly more likely to be 
lost to follow-up than females. However, Caluwaerts et al. (2009), Dalal et al. (2008), 
Karcher et al. (2007) and Kerr et al. (2005) found no relationship between gender and 
retention to care. Those that have found relationships between gender and adherence 
behaviour have attributed them to differences in attitudes to health and health-seeking 
behaviour, socio-cultural beliefs and patterns, and differences in employment levels and 
the associated impact on ability to attend clinic visits.   
 
While some studies investigating the relationship between age and medication 
adherence (Bisson et al., 2006; Catz et al., 2000; Do et al., 2010; Gebo et al., 2003; 
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Parruti et al., 2006; Turner et al., 2003; Weiser et al., 2003) or loss to follow-up (Dalal et 
al., 2008; Maskew et al., 2007; Zachariah et al., 2008) have reported no association, 
each study that has seen a relationship has reported that younger patients are 
significantly less likely to adhere (Carrieri et al., 2006; Golin et al., 2002; Gordillio et al., 
1999; Hinkin et al., 2002; Hinkin et al., 2004; Spire et al., 2002; Wagner, 2002) or be lost 
to follow-up (Caluwaerts et al., 2009; Cornell et al., 2010; Hill et al., 2010; Karcher et al., 
2007; Kerr et al., 2005; Lanoy et al., 2006; Mocroft et al., 2008) than older patients. In 
Hinkin et al.’s (2002) cross-sectional investigation of 137 HAART patients in the United 
States, younger age was associated with a 4.6 times greater risk of adherence failure. 
The authors concluded that younger patients may have less prior experience adhering to 
daily medications, and that the lifestyle changes necessary for managing a high-burden 
medication regimen may be more challenging for younger individuals. In Hinkin et al.’s 
(2004) subsequent longitudinal study, wherein 148 patients were followed with electronic 
adherence monitoring for one month, younger patients again adhered more poorly 
(78.3% versus 87.5%), and were three times less likely to be adherent. Caluwaerts et al. 
(2009) found that young adult ARV patients age 16–35 years were at greater risk of 
being lost to follow-up than those older than 35 years, and Hill et al. (2010) found that 
patients age 25 and younger had a markedly higher risk of permanent loss to follow-up.  
 
However, studies examining the impact of age on adherence underscore the importance 
of conducting locally-relevant research as opposed to applying international findings to 
the South African population: the definition used by Hinkin et al. (2002) and Hinkin et al. 
(2004) in their United States studies for ‘younger’ was <50 years. In a recent meta-
analysis of 74,289 ART patients across 33 cohorts in 13 sub-Saharan countries (Rosen 
et al., 2007) the weighted mean age of the sample was 35.5 years (range 31–41 years).  
 
There are a few studies that have addressed the association between education and 
adherence (Arnsten et al., 2007; Catz et al., 2000; Do et al., 2010; Golin et al., 2002; 
Gordillio et al., 1999; Karcher et al., 2007; Spire et al., 2002; Wagner, 2002; Weiser et 
al., 2003). Higher level of education has been reported to both positively influence 
adherence (Arnsten et al., 2007; Golin et al., 2002; Gordillo et al., 1999; Wagner, 2002) 
and negatively influence adherence (Weiser et al., 2003). For instance, in Wagner’s 
(2002) investigation of 180 HAART patients in the United States, having at least some 
college education was associated with greater electronic-monitored adherence, whereas 
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in Weiser et al.’s (2003) cross-sectional study of 109 patients in Botswana, patients who 
did not complete secondary school were 3.87 times more likely to adhere than those 
with higher levels of education. However, according to Spire et al. (2002), level of 
education (defined in their cohort as ! a high school certificate) had no bearing on 
HAART adherence. Similar nonsignificant results are available elsewhere for medication 
adherence (Catz et al., 2000; Do et al., 2010) and retention (Karcher et al., 2007) 
research.   
 
Past research has linked unemployment with poor antiretroviral adherence (Chesney et 
al., 2000; Gordillo et al., 1999; Morse et al., 1995). In a series of interviews conducted 
with 18 clinicians at various community centers conducting ARV drug trials, the most 
frequently mentioned barrier to patient recruitment, retention and adherence was 
unemployment (endorsed by 45% of clinicians) (Morse et al., 1995). Gordillo et al. 
(1999) concur; in their cross-sectional study of 366 patients on HAART in Spain, having 
a job was associated with better adherence (OR, 2.24; 95% CI, 1.27–2.73). Interestingly, 
one study of 75 HAART patients in the United States showed the opposite: less 
adherent patients were more likely to be employed outside the home for pay than 
adherent patients (Chesney et al., 2000). The authors hypothesized that employed 
patients may be too busy or forget to carry medications with them to their place of work. 
Results of other observational studies show no association between unemployment and 
adherence (Do et al., 2010; Golin et al., 2002; Parruti et al., 2006; Wagner, 2002) or 
retention to care (Karcher et al., 2007).    
 
Economic barriers like low income (Byakika-Tusiime et al., 2005; Golin et al., 2002; 
Richard et al., 2009) and poor material living conditions (Gebo et al., 2003; Parruti et al., 
2006; Spire et al., 2002) have been associated with poor adherence to ART. One study 
in France showed that patients with poor housing conditions were more likely to be non-
adherent (p < .01) (Spire et al., 2002), underscoring the negative influence of low socio-
economic status. Another in Italy associated homelessness with a 1.95 times higher 
likelihood of adherence failure (p < .05) (Parruti et al., 2006). Gebo et al. (2003) noted 
that patients who reported running out of money in the past ninety days for life essentials 
were 2.21 times more likely to be nonadherent. Low socio-economic status may prevent 
patients from being able to afford transportation to clinics or preoccupy them with more 
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immediate concerns (Mehta, Moore & Graham, 1997). One study however saw no link 
between socio-economic status and ART adherence (Weiser et al., 2003).  
  
Factor Significant result Non-significant result 
Gender Hill et al., 2010 
Maskew et al., 2007 
Mocroft et al., 2008 
Turner et al., 2003 
Wagner, 2002 
Wools-Kaloustian et al., 2006 
Zachariah et al., 2008 
Caluwaerts et al., 2009 
Catz et al., 2000 
Dalal et al., 2008 
Do et al., 2010 
Gebo et al., 2003 
Golin et al., 2002 
Karcher et al., 2007 
Kerr et al., 2005 
Parruti et al., 2006 
Spire et al., 2002 
Weiser et al., 2003 
Age Caluwaerts et al., 2009 
Carrieri et al., 2006 
Cornell et al., 2010 
Golin et al., 2002 
Gordillo et al., 1999 
Hill et al., 2010 
Hinkin et al., 2002 
Hinkin et al., 2002 
Karcher et al., 2007 
Kerr et al., 2005 
Lanoy et al., 2006 
Mocroft et al., 2008 
Spire et al., 2002 
Wagner, 2002 
Bisson et al., 2006 
Catz et al., 2000 
Dalal et al., 2008 
Do et al., 2010 
Gebo et al., 2003 
Maskew et al., 2007 
Parruti et al., 2006 
Turner et al., 2003 
Wesier et al., 2003 
Zachariah et al., 2008 
Education Arnsten et al., 2007 
Golin et al., 2002 
Gordillo et al., 1999 
Wagner, 2002 
Wesier et al., 2003 
Catz et al., 2000 
Do et al., 2010 
Karcher et al., 2007 
Spire et al., 2002 
Employment Chesney et al., 2000 
Gordillo et al., 1999 
Morse et al., 1995 
Do et al., 2010 
Golin et al., 2002 
Karcher et al., 2007 
Parruti et al., 2006 
Wagner, 2002 
Socio-economic status and 
living conditions 
Byakika-Tusiime et al., 2006 
Gebo et al., 2003 
Golin et al., 2002 
Parruti et al., 2006 
Spire et al., 2002 
Weiser et al., 2003 
 
Table 1. Demographic factors assessed for impact on adherence behaviour in literature.  
 
Biomedical predictors 
Several biomedical factors have been identified as having the potential to impede 
adherence (see Table 2). More advanced immunological stage of HIV disease, as 
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measured by CD4+ cell count, has been associated with decreased adherence to 
HAART treatments (Ammassari et al., 2004; Gordillo et al., 1999; Weidle et al., 2006). 
CD4 cells (white blood cells) are a key measure of strength of the immune system; 
because HIV targets CD4 cells specifically, the lower the CD4+ cell count, the greater 
the damage HIV has done. The relationship between CD4+ cell count and adherence 
has been observed using CD4+ cell count cut-off of 100 cells/"L (Weidle et al., 2006) 
and 200 cells/"L (Gordillo et al., 1999) for advanced immunological disease. Contrarily, 
other cohorts (Bisson et al., 2006; Spire et al., 2002; Wagner, 2002) and cross-sectional 
studies (Catz et al., 2000; Gebo et al., 2003; Hinkin et al., 2002) have shown no 
relationship between CD4+ cell count and medication adherence.  
 
Some previous literature has linked CD4+ cell count with retention to care (Caluwaerts et 
al., 2008; Cornell et al., 2010; Hill et al., 2010; Lanoy et al., 2006; Mocroft et al., 2008; 
Zachariah et al., 2008). Lanoy et al. (2006) and Zachariah et al. (2008) reported a 
significantly higher proportion of patients with CD4+ cell counts under 200 cells/"L to be 
lost to follow-up than those with better immune functioning, as did Caluwaerts et al. 
(2008) and Mocroft et al. (2008) for patients with CD4+ cell counts less than 50 cells/"L. 
Hill et al. (2010) and Cornell et al. (2010) found the opposite – patients with CD4+ cell 
counts 50–499 cells/"L were at lower risk f potential loss to follow-up (defined earlier) 
than those with CD4+ cell counts greater than 500 cells/"L in the Hill et al. (2010) study, 
and patients with CD4+ cell counts 50–199 cells/"L were less likely to be lost to follow-
up than those with CD4+ cell counts greater than or equal to 200 cells/"L in the Cornell 
et al. (2010) study. Finally, Karcher et al. (2007) found no association between CD4+ cell 
count and loss to follow-up.  
 
Viral load (the amount of virus in the blood) may also play a role in medication 
adherence and/ or retention to HIV care (Hill et al., 2010; Lanoy et al., 2006; Mocroft et 
al., 2008; Weidle et al., 2006). Weidle et al. (2006) reported that a viral load level at 
baseline of 100,000 copies/mL or more was significantly associated with non-
suppression at six and 12 months, and Mocroft et al. (2008) noted that a 1 
log10copies/mL higher viral load level was associated with a 19% increased incidence of 
loss to follow-up in a large European cohort. Conversely, Hill et al. (2010) observed that 
a viral load of 50 copies/mL or less meant a lower risk of potential loss to follow-up 
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(definition earlier). Finally, Bisson et al. (2006), Gordillo et al. (1999), Spire et al. (2002) 
and Wagner (2002) reported no association between viral load and adherence.  
  
WHO stage has been associated with adherence to ARV’s (Lima et al., 2009). In 1993, 
the WHO developed a system which characterized and staged HIV disease based on 
clinical symptoms (WHO International Collaborating Group for the study of the WHO 
Staging System, 1993). While the first two stages are largely asymptomatic, stage III 
includes symptoms like weight loss and oral infections, and stage IV more severe 
conditions like pneumonia, TB and wasting (Dorrington et al., 2006). The system is still 
in use today, and is used as a guide for medical decision-making and reporting. Lima et 
al. (2009) showed that a significantly higher proportion of those with an AIDS diagnosis 
at baseline were adherent to therapy. However, others have shown that WHO/CDC 
stage is not related to HAART adherence (Parruti et al., 2006; Spire et al., 2002; 
Wagner, 2002) or retention to care (Caluwaerts et al., 2009; Karcher et al., 2007).  
 
The length of time between HIV diagnosis and ART initiation may be related to 
adherence and loss to follow-up (Lanoy et al., 2006; Vervoort et al., 2010). In a 
qualitative study using individual interviews and focus groups to explore nurse 
consultants’ strategies to promote adherence among their HIV-positive patients, one of 
the themes that emerged was the belief that adherence was most likely to be 
compromised when patients needed to start treatment soon after hearing the HIV 
diagnosis (Vervoort et al., 2010). However, Spire et al. (2002) observed no difference 
between self-reported adherence rates at four months on HAART between those who 
had been diagnosed more than a year before initiation and those less than a year. 
Similarly, Catz et al. (2000) found no relationship between length of time since HIV 
diagnosis and self-reported adherence in a cohort of HAART patients with a mean length 
of time on treatment of 15 months.  
 
Poor health and HIV symptoms at the time of ARV initiation can either act a strong 
motivator for adherence, or make clinic visits and medication routine following 
challenging. Conversely, feeling well and healthy may either lead to complacency, 
making antiretroviral medications or clinic visits feel unnecessary, or allow patients the 
strength to attend the clinic and take the necessary actions to ensure adherence. For 
instance, in the same recent study, 43% of the sample listed feeling sick as a reason for 
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missing medication, whilst 35% of the sample mentioned feeling good as a reason for 
nonadherence (Gardenier et al., 2010). Supporting the association between HIV 
symptomatology and difficulty with adherence, in Wagner’s (2002) study of 180 patients 
on HAART in the United States, patients who reported a greater number of symptoms 
and patients who reported higher symptom severity were less likely to adhere well, as 
evidenced by scores on electronic monitoring, self-report and medication diaries. 
Severity of certain symptoms in particular – insomnia, headaches, poor concentration, 
anxiety and diarrhea – was associated with lower adherence levels. Similarly, in a study 
by Corless et al. (2005), the degree to which patients were bothered by symptoms 
(‘bothersomeness’) was significantly associated with forgetting to take ARV medications 
(p=.003), difficulty taking the medications (p=.04) and discontinuing medications when 
feeling better (p=.007); symptom intensity was also associated with discontinuing 
medications when feeling better (p=.047). Other studies have documented the 
relationship between good health and nonadherence (Murphy et al., 2000). A patient in 
Murphy et al.’s (2000, p.52) investigation of common barri rs to antiretroviral adherence 
explained, ‘I think a lot of this probably has to do with how good a person feels. If a 
person feels like they’re healthy and they [miss], they’re like, “Well, if I missed my dose, 
that’s okay, as long as I feel good or as long as I get a good report on my health.”’ 
However, in a small pilot study assessing a motivational interviewing ART adherence 
intervention, Dilorio et al. (2003) found that only 6% of these on-treatment participants 
reported ‘feeling good’ as a reason for missing doses.   
 
Cohort studies have examined the impact of transmission group (heterosexual, MSM or 
IDU’s on adherence rates, and some have found significant relationships (Ammassari et 
al., 2004; Gebo et al., 2003; Gordillio et al., 1999; Hill et al., 2010; Lanoy et al., 2006). 
For example, route of HIV transmission was associated with antiretroviral adherence in 
studies by Ammassari et al. (2004) and Gordillo et al. (1999), with suboptimal adherence 
found in patients with IDU as their mode of HIV acquisition. Hill et al. (2010) found that 
potential loss to follow-up (defined earlier) was less frequent among MSM as compared 
with the heterosexual group and those with nonsexual risks for infection (comprising 
66% IDU’s). Gebo et al. (2003) also reported positive results for MSM, who were more 
likely to adhere to their antiretroviral regimen than patients with an HIV risk factor of 
high-risk heterosexual activity. The authors hypothesized that MSM had more social 
support to take ART as prescribed and felt less social stigma attached to taking the 
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medication in public. However, Spire et al. (2002) investigated a cohort of 445 adult 
patients initiating HAART in France and found that transmission group (heterosexual 
exposure, MSM exposure, IDU or other) did not predict ARV adherence at four months 
follow-up. Similar nonsignificant results are available elsewhere (Parruti et al., 2006).  
 
Previous studies have found that patients with comorbid conditions like TB (Caluwaerts 
et al., 2009), Kaposi’s sarcoma (Caluwaerts et al., 2009) and pneumonia (Turner et al., 
2003) have higher nonadherence and lost to follow-up rates than others. Other studies 
have found no relationship between various chronic conditions like hepatitis and ART 
adherence (Parruti et al., 2006).  
 
Patients who have already experienced difficulty adhering to previous ART might 
logically be more likely to adhere poorly to newly-prescribed regimens, and this has 
been confirmed in a number of investigations (Carrieri et al., 2006; Spire et al., 2002). 
Interestingly, while Spire et al. (2002) observed no difference in adherence rates at four 
months on HAART between patients who had been ex osed to previous ART before 
HAART initiation and those that had not (p=.70), the authors found that those who self-
reported adherence difficulties with the previous regimens were more often non-
adherent with HAART at month four than those who had also been exposed to previous 
ART but who did not report such difficulties (p=.001).  
 
Complex ART regimens, high pill burden and high dose frequency are inconvenient and 
can lead to patient difficulty incorporating the medication into daily life or schedule (Abel 
& Painter, 2003; Mehta et al., 1997; Murphy et al., 2000). Unfortunately, considering the 
relatively short half-lives of the NNRTI’s and PI’s, reduction of dosing frequency is 
unlikely to occur in the short-term (Chesney, 2000). Patients may also be more unlikely 
to take prescribed medications with inconvenient requirements, such as the need to take 
a medication on an empty stomach (Murphy et al., 2000). The taste and size of specific 
pills may also play a role (Murphy et al., 2000). There have been some study results that 
correlate prescribed regimen with antiretroviral adherence (Ammassari et al., 2004; 
Carrieri et al., 2006; Golin et al., 2002; Hinkin et al., 2002; Laniece et al., 2003; Lima et 
al., 2009). Lima et al. (2009) found that among adult patients initiating ARV treatment in 
Canada, those first prescribed non-boosted PI’s were at significantly greater risk of non-
adherence than those prescribed NNRTI’s or boosted PI’s. A study from Senegal found 
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that adherence tended to be better with efavirenz than with indinavir (Laniece et al., 
2003). Contrarily, Spire et al. (2002) investigated various dimensions of regimen 
prescription and their relationship with adherence, including whether a PI was included 
in the regimen, the mean daily number of prescribed pills and whether the regimen was 
to be taken on an empty stomach, and found none of these factors to be significant. 
Others (Gebo et al., 2003; Parruti et al., 2006; Wagner, 2002; Weiser et al., 2003) have 
also found no association between regimen, pill burden or dosing schedule and ART 
adherence.       
 
   
Factor 
 
Significant result Non-significant result 
CD4+ cell count Ammassari et al., 2004 
Caluwaerts et al., 2009 
Cornell et al., 2010 
Gordillo et al., 1999 
Hill et al., 2010 
Lanoy et al., 2006 
Mocroft et al., 2008 
Weidle et al., 2006 
Zachariah et al., 2008 
Bisson et al., 2006 
Catz et al., 2000 
Gebo et al., 2003 
Hinkin et al., 2002 
Karcher et al., 2007 
Spire et al., 2002 
Wagner, 2002 
 
Viral load Hill et al., 2010 
Lanoy et al., 2006 
Mocroft et al., 2008 
Weidle et al., 2006 
Bisson et al., 2006 
Gordillo et al., 1999 
Spire et al., 2002 
Wagner, 2002 
WHO stage Lima et al., 2009 Caluwaerts et al., 2009 
Karcher et al., 2007 
Parruti et al., 2006 
Spire et al., 2002 
Wagner, 2002 
Time since HIV diagnosis Lanoy et al., 2006 
Vervoort et al., 2010 
Catz et al., 2000 
Spire et al., 2002 
HIV symptomatology Corless et al., 2005 
Gardenier et al., 2010 
Murphy et al., 2000 
Wagner, 2002 
 
Dilorio et al., 2003 
Gardenier et al, 2010 
Transmission group Ammassari et al., 2004 
Gebo et al., 2003 
Gordillo et al., 1999 
Hill et al., 2010 
Lanoy et al., 2006 
 
Spire et al., 2002 
Parruti et al., 2006 
 
Comorbid conditions Caluwaerts et al., 2009 
Turner et al., 2003 
 
Parruti et al., 2006 
 
Treatment experience Carrieri et al., 2006 
Spire et al., 2002 
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Regimen/ regimen complexity Abel & Painter, 2003 
Ammassari et al., 2004 
Carrieri et al., 2006 
Golin et al., 2002 
Hinkin et al., 2002 
Laniece et al., 2003 
Lima et al., 2009 
Mehta et al., 1997 
Murphy et al., 2000 
Gebo et al., 2003 
Parruti et al., 2006 
Spire et al., 2002 
Wagner, 2002 
Weiser et al., 2003 
 
Table 2. Biomedical factors assessed for impact on adherence behaviour in literature. WHO, World Health 
Organisation.   
   
 
Psychological predictors 
Several psychological barriers have been linked to nonadherence to antiretroviral 
regimens (see Table 3). Low levels of knowledge and understanding of HIV illness, the 
benefits and risks of ARV treatment, and the need for strict adherence may be an 
individual-level risk factor for ART adherence problems (Chesney et al., 2000; Malcolm 
et al., 2003; Spire et al., 2002; Wagner, 2002). Spire et al. (2002) reported results of a 
longitudinal observational study in which patients who believed at baseline that taking 
less than the prescribed doses of medications in general was not risky, were more often 
non-adherent to HAART at follow-up than those who thought it was (p=.03). Wagner 
(2002) had similar findings, with greater knowledge of HIV treatment and adherence 
positively correlated with electronically-monitored adherence. Patients who understood 
the meaning of drug resistance were more adherent according to both electronic 
monitoring and medication diaries. In Chesney et al.’s (2000) investigation, nonadherent 
patients were less sure about the statement that ‘if I do not take the medications exactly 
as directed, the HIV in my body could become resistant to HIV medications’ (19% versus 
53% were ‘very sure’, p=.009). However, some studies have contradictory findings. 
Among HIV-positive adolescents (age 16–24 years) in the United Sates, health literacy 
(the degree to which they were found to have the ‘capacity to obtain, process and 
understand basic health information’) was not associated with antiretroviral adherence 
(Murphy et al., 2010, p.25). Similarly, levels of HIV knowledge were found to have no 
association with ART adherence levels in cross-sectional studies in Botswana (Weiser et 
al., 2003) and Spain (Gordillo et al., 1999).  
 
Logically, several studies (Abel & Painter, 2003; Arnsten et al., 2007; Catz et al., 2000; 
Gebo et al., 2003; Kerr et al., 2005; Malcolm et al., 2003; Murphy et al., 2000) have 
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linked belief in or skepticism about ART drug efficacy and ART adherence. Catz et al. 
(2000) found that a checklist item ‘I do not think treatments will help anyway’ was cited 
as a barrier to adherence more often by nonadherent patients. In their cross-sectional 
study of 196 HIV-infected patients prescribed at least one antiretroviral medication, 
Gebo et al. (2003) found that strongly holding any of the following beliefs positively 
impacted antiretroviral adherence: the medication would increase longevity, sickness 
would result if medications were not taken, medications prevented hospitalization, and 
medication prevented HIV symptoms. A patient in Murphy et al.’s (2000, p.53) focus 
group discussions on factors impacting ART adherence stated, ‘I find [taking ART] very 
easy because what motivates me to take it is that I want to live. And that alone helps me 
to remember to take my medication.’ Surprisingly, others (Golin et al., 2002; Spire et al., 
2002; Wagner, 2002) have noted no relationship between beliefs about antiretrovirals 
and antiretroviral adherence.   
 
Patients might choose not to take prescribed ARV regimens because of concerns about 
anticipated side effects, or to control unwanted experienced side effects, whether or not 
the reported symptoms are truly established as medical and related to HAART. 
Qualitative and quantitative studies using interview, focus group and survey 
methodologies to elicit reasons for non-adherence and LTFU have confirmed this (Abel 
& Painter, 2003; Gardenier et al., 2010; Kerr et al., 2005; Murphy et al., 2000; Spire et 
al., 2002; Weiser et al., 2003), as have cross-sectional (Ammassari et al., 2004; Simon 
et al., 2009; Catz et al., 2000) and longitudinal (Carrieri et al., 2006; Parruti et al., 2006; 
Roco et al., 1999; Wagner, 2002) observational studies. A HAART patient in Abel & 
Painter’s (2003) qualitative study explained, ‘The medication makes me so sick till I say 
“God, it’s not worth it”’ (p.65).   
 
Concerns about side effects are justified. Fellay et al. (2001) assessed the prevalence of 
adverse events in 1160 patients who were receiving ART, and found 70% of the sample 
to have experienced a clinical adverse event that was possibly (23%), probably (31%) or 
certainly (16%) attributable to ART, and 78% of the sample to have experienced a 
laboratory adverse event that was possibly (51%), probably (23%) or certainly (4%) due 
to ART. Applicable to this sample was the finding that the use of stavudine was 
independently associated with headache, lipodystrophy and a rise in serum 
concentrations of urate, creatine phosphokinase, lactate, cholesterol and triglyceride, 
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lamivudine with mood disorders and lipodystrophy, efavirenz with mood and sleep 
disorders, nevirapine with a rise in serum transaminase concentrations, didanosine with 
an increase in urate and lactate concentrations and zidovudine a trend towards an 
association with anaemia. Similarly, Spire et al. (2002) reported that 89.1% of their 
sample of 445 patients initiating HAART reported experiencing at least one symptom in 
the four weeks prior to the 4-month follow-up visit after initial HAART prescription, and 
39.7% declared five symptoms or more. The majority (63.4% of the total sample) 
reported that these symptoms had been ‘quite’ or ‘a lot’ disturbing for them. Similar 
results showing high levels of treatment-related side effects are available elsewhere (van 
Oosterhout et al., 2005). Despite the prevalence of side effects associated with 
antiretrovirals, some investigations have found no relationship between either pre-
initiation anticipation of and concern about side effects (Spire et al., 2002) or on-
treatment perceived bad experience of side effects (Maskew et al., 2007) and adherence 
to medication or care.        
 
In those patients who have not accepted their HIV status, medication-taking may act as 
an unwanted reminder of that status, and thus be intentionally or unconsciously avoided. 
In a number of qualitative investigations eliciting barriers to adherence, acceptance or 
denial of HIV status has emerged as a major factor (Abel & Painter, 2003; Catz et al., 
2000; Murphy et al., 2000; Nam et al., 2008; Roberson et al., 2009; Vervoort et al., 
2010). When Catz et al. (2000) elicited barriers to treatment adherence from a sample of 
72 HAART patients, treatment as a reminder of HIV status was cited by 89% of 
participants as an adherence barrier. In Murphy et al.’s (2000) analysis of barriers to 
HAART adherence, 32% of patients listed ‘want(ing) to forget the whole thing’ as an 
adherence barrier. One patient in Abel & Painter’s (2003) qualitative study with women 
on ART explained, ‘When you take the medicine it’s reminding [you] that you’re sick’ 
(p.65). Nam and colleagues (2008) had similar results; in their series of 32 interviews 
with patients on HAART for six months or more, the key concept described by 
participants as associated with good or excellent adherence was acceptance of HIV 
status. Participants explained how those who had accepted their status were able to 
develop a new perception of themselves as living with the virus, saying HIV was ‘within 
me, so how can I forget?’ (p.303), as compared with those who had not fully adapted to 
their HIV status or denied it in some way and therefore could not develop a positive and 
proactive relationship towards it or its treatment. One participant explained: ‘The break 
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[in medication-taking] was caused by not accepting myself… I was just, like, curious on 
myself, asking to myself, why did it happen to me? Is it true that it’s there?’, and another 
‘They were looking for me at work… I was staying [away] because I was sort of 
embarrassed by my own things. I was embarrassed by my own fate (p.303)’. Health care 
practitioners agree; in the qualitative analysis of nurse consultants outlined earlier 
(Vervoort et al., 2010), nurses expressed that they were convinced that non-acceptance 
of HIV status was a risk factor for nonadherence, in that treatment could act as a 
confrontation of the diagnosis.  
 
Patients’ confidence or doubt in their ability to adhere, as measured by adherence self-
efficacy self-rating scales, has been identified as a determinant of their antiretroviral 
treatment adherence in previous research (Arnsten et al., 2007; Catz et al., 2000; 
Chesney et al., 2000; Kerr et al., 2005). For example, a cross-sectional investigation of 
antiretroviral adherence found that treatment-adherent patients had higher levels of 
treatment adherence self-efficacy than patients who reported missing a HAART dose 
once per week or more during the past three months (Catz et al., 2000). Chesney et al. 
(2000) also found low adherence self-efficacy to be associated with nonadherence: 
nonadherent patients were less sure (56% versus 85%) that they would be able to take 
all or most of the medications as directed. Other research has not confirmed the 
association between medication self-efficacy and antiretroviral adherence (Golin et al., 
2002; Wagner, 2002).  
 
A major factor in treatment with HAART medication that has also been explored in 
several studies is depressed mood, as measured by self-report rating scales. Studies 
have generally found a predictive relationship, with depressive symptoms acting as a 
challenging barrier to achieving adherence (Ammassari et al., 2004; Arnsten et al., 2007; 
Carrieri et al., 2006; Catz et al., 2000; Do et al., 2010; Gordillo et al., 1999; Wagner, 
2002); although this has not always been the case (Spire et al., 2002). In a study by 
Ammassari et al. (2004) among 135 HAART patients in Italy, patients who showed 
depressive symptoms were three times as likely as persons without depressive 
symptoms to be nonadherent to their regime. Wagner (2002) found that those patients 
with a current major depressive disorder had significantly lower adherence compared to 
others (86% versus 95%) although depressive symptomatology as measured by the 
Beck Depression Inventory (BDI) was not related to adherence. Studies assessing 
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patient-reported barriers to antiretroviral adherence have also linked depression to 
nonadherence (Gardenier et al., 2010; Malcolm et al., 2003; Murphy et al., 2000).  
  
Depression is common among persons living with HIV/AIDS. In an assessment of 395 
HIV-positive patients naïve to HAART, Starace et al. (2002) found the prevalence of 
prominent depressive symptomatology to be 15.5% across the sample, and 35.2% in 
those with full-blown AIDS. Ammassari et al. (2004) found depressive symtomatology in 
24% of their sample of on-HAART patients. HAART (or its associated medical 
improvements) has been shown to curb HIV-associated depression (Low-Beer et al., 
2000; Judd et al., 2000; Brechtl, Breitbart, Galietta, Krivo & Rosenfeld, 2001; Starace et 
al., 2002). For instance, Starace et al. (2002) observed a significant difference in the 
prevalence of depressive symptomatology between patients on HAART (14%) and those 
not on HAART (23.8%, p=0.05). 
 
Perhaps unsurprisingly, various studies among ART-initiating (Spire et al, 2002) and on-
treatment patients (Chesney et al., 2000; Do et al., 2010; Golin et al., 2002) have shown 
a strong association between alcohol use and/ or abuse and ability to adherence to the 
medication. Considering that substance abuse is a major risk factor for HIV acquisition, 
and the high rates of alcohol abuse in HIV-positive populations, this is a matter of 
concern. Golin and colleagues (2002) conducted a 48-week prospective cohort study 
with 140 HAART patients at a hospital HIV clinic and observed that patients who drank 
no alcohol in the last three days took 74.6% of their antiretroviral doses, while those who 
had drunk alcohol took 65.5% of theirs (p=.008). In Chesney et al.’s (2000) assessment 
of 75 HAART patients enrolled in clinical trials, nonadherent patients had a higher 
median consumption of alcoholic drinks over the past month (9 versus 2, p=.03). Patient-
reported barriers to ART medication adherence concur (Malcolm et al., 2003; Ncama et 
al., 2008). One patients from Malcolm et al.’s (2003) qualitative interviews with patients 
on HAART for three months or more stated, ‘When I’m drinking, I won’t take the 
medications… they’re not going to work’ (p.258). On the other hand, some observational 
studies have found no distinctions in adherence with regard to alcohol abuse (Catz et al., 
2000; Gebo et al., 2003; Hinkin et al., 2004; Parruti et al., 2006; Turner et al., 2003). 
 
The importance of illicit drug use as a predictor of adherence behaviour has been 
highlighted in studies as well in Canada (Kerr et al., 2005; Lima et al., 2009), Italy 
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(Ammassari et al., 2004), France (Lanoy et al., 2006), Spain (Roco et al., 1999) and the 
United States (Gebo et al., 2003; Golin et al., 2002; Hinkin et al., 2004; Malcolm et al., 
2003; Turner et al., 2003). Injection and other illicit drug users have – barring a few 
exceptions (Spire et al., 2002) – consistently poorer ART adherence and clinic 
attendance patterns than non-drug users (Ammassari et al., 2004; Gebo et al., 2003; 
Golin et al., 2002; Hinkin et al., 2004; Lanoy et al., 2006; Lima et al., 2009; Malcolm et 
al., 2003; Roco et al., 1999; Turner et al., 2003). Roco et al. (1999) compared 
medication adherence, clinic attendance and clinical outcomes in IDU’s versus non-
IDU’s and noted a significant difference between the two groups at six months follow-up. 
In Golin and colleagues’ (2002) prospective study of 140 ART patients at a public 
hospital-affiliated clinic, patients actively using drugs took 59% of their ART doses 
compared with the adherence rate of 72% for nonusers. These findings were 
corroborated by Gebo et al. (2003) who found that while IDU as the mode of HIV 
transmission was not associated with nonadherence, active illicit drug use in the past six 
months conferred a 2.75 times greater risk of nonadherence, heroin use a 4.46 times 
greater risk and binge drug use a 3.92 times greater risk.   
 
A number of investigations have examined the impact of HIV-associated neurocognitive 
dysfunction on ART adherence (Albert et al., 1999; Ammassari et al., 2004; Avants et 
al., 2001, Hinkin et al., 2002; Hinkin et al., 2004; Levine et al., 2005; Wagner, 2002; 
Waldrop-Valverde et al., 2006) through objective neuropsychological testing. Not 
surprisingly, all but one (Ammassari et al., 2004) of these investigations report an 
association between neurocognitive performance and ARV adherence. The specific 
cognitive domains implicated are attention (Hinkin et al., 2002), speed of information 
processing (Albert et al., 1999; Hinkin et al., 2004; Wagner, 2002; Waldrop-Valverde et 
al., 2006), executive functioning (Albert et al., 1999; Avants et al., 2001; Hinkin et al., 
2002; Hinkin et al., 2004; Wagner, 2002) and verbal memory (Albert et al., 1999; Hinkin 
et al., 2002; Hinkin et al., 2004; Wagner, 2002). Hinkin and colleagues (2002) found a 
mean adherence rate of 73% in their globally cognitively impaired group compared with 
84% in their cognitively intact group. The study showed that global neuropsychological 
compromise was associated with a 2.3 times greater risk and memory dysfunction a 
2.25 greater risk of adherence failure. Results of Wagner’s (2002) assessment of 180 
HAART patients showed that those patients with cognitive impairment indicated by at 
least one of the administered neuropsychological tests (California Verbal Learning Test 
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[CVLT], the Trail Making Test [TRAILS A and B] and the Digit Symbol subscale of the 
Wechsler Adult Intelligence Scale-Revised [WAIS-R]) were more likely to have lower 
adherence levels according to electronic monitoring, with a mean adherence of 82% as 
compared with 91% in those who were unimpaired.     
 
As outlined in the previous chapter, recommended ART regimens are often complex, 
including two or three different drugs at specific dosages and with specific administration 
instructions. This excludes the often significant number of additional medications 
patients are also required to take, both related and unrelated to their HIV status. This 
complex and demanding pharmacologic regimen places high demands on cognitive and 
motivational factors, and thus may be particularly challenging for patients with cognitive 
dysfunction. Hinkin and colleagues’ (2002) assessment of neurocognitive functioning 
and medication adherence found a significant interaction effect between cognitive 
impairment and regimen complexity, with cognitively impaired patients on more complex 
dosing schedules (defined as three doses daily as opposed to one or two) evidencing 
the lowest adherence rates. This was true of global cognitive impairment (across all of 
the cognitive domains assessed) as well as executive dysfunction and higher order 
attentional compromise in isolation. Typically, the simplest regimens are first line 
treatment. With treatment failure – which is generally due to poor adherence – regimens 
are switched to second and third line treatment. The upshot is therefore that those 
patients with a history of poor adherence are ultimately placed on the most complex 
regimens (Murphy et al., 2000).  
 
Patients’ own perceptions of their barriers to medication adherence also underscore the 
importance of cognitive functioning as a predictor of medication adherence. By far the 
most common reason cited by patients for nonadherence across the interviews, focus 
groups and surveys conducted with HIV-positive patients to elicit perceived facilitators 
of, and barriers to adherence is ‘forgetting’ to take the medications (Brigado et al., 2001; 
Chesney et al., 2000; Do et al., 2010; Golin et al., 2002; Murphy et al., 2000; Pienaar et 
al., 2006; Roberts, 2000; Spire et al., 2002; Weidle et al., 2006). For instance, Brigado et 
al. (2001) used surveys to elicit the main reasons for missing doses in 182 HIV-1-
infected patients, and found ‘forgetfulness’ to be the most frequent response (48% of the 
sample). Murphy et al. (2000) conducted focus groups with 39 HIV-infected patients and 
reported that 40% of patients said they ‘simply forgot’ to take their medication, and a 
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further 21% said that while they remembered that they were required to self-medicate, 
they forgot how many pills they had already taken. Also using qualitative methodology, 
Roberts (2000) conducted a series of interviews with 28 patients on multi-drug regimens, 
and identified common themes expressed by participants in discussions around barriers 
to adherence. ‘Forgetfulness’ was the most frequently mentioned obstacle. Other studies 
have reported cognitive barriers to treatment adherence other than forgetfulness, 
including confusion over how many pills of each kind to take (Catz et al., 2000; Murphy 
et al., 2000), confusion about the appearance of the different medications and difficulty 
understanding complex medication instructions (Catz et al., 2000).     
 
These findings are expected. HIV affects almost all organ systems, including the central 
nervous system (CNS). It is estimated that between 75% and 90% of patients will have 
some CNS involvement before they die, either due to the primary HIV infection (i.e. the 
direct effects of HIV-1 disease on the CNS that is not due to infections, tumours, 
cerebrovascular complications or metabolic disorders), th  effects of CNS infections or 
neoplasms secondary to HIV-related immunocompromise, or both. In the later stages of 
HIV, the most common neurological condition is a chronic encephalitis. Cerebral 
changes tend to show on MRI as multiple small diffuse or larger bilateral subcortical – 
mostly white matter, but also deep gray matter – lesions and general atrophy (Lezak, 
1995; Victor & Ropper, 2001). This encephalitis presents as a type of frontal-subcortical 
dementia, most frequently termed HIV-1-associated dementia (HAD) or AIDS dementia 
complex (ADC).  
 
A considerable body of literature has documented the adverse neuropsychological 
consequences of HIV disease, the spectrum of presentation ranging from subtle 
neurocognitive complaints to frank dementia (Baldewicz et al., 2004; Castellon, Hinkin & 
Myers, 2000; Hinkin, Castellon, Atkinson & Goodkin, 2001; Krikorian & Wrobel, 1991; 
Maruff et al., 1994; Navia & Rostasy, 2005; McArthur et al., 2003; Paul, Cohen & Stern, 
2002; Portegies et al., 1992; Reger, Welsh, Razani, Martin & Boone, 2002; Starace et 
al., 2002). Consistent with damage to subcortical regions, HIV-infected patients may 
present with decreased curiosity and spontaneity, disturbances of attention, and slowed 
mental processing (Baldewicz et al., 2004; Maruff et al., 1994; Paul et al., 2002; Reger et 
al., 2002;). In addition, executive dysfunction has been reported (Castellon et al., 2000; 
Krikorian & Wrobel, 1991), likely due to disruption of frontal-subcortical pathways. By 
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contrast, cortical processes like language, praxis and gnosis remain intact (Krikorian & 
Wrobel, 1991). Verbal memory deficits have also been shown to be associated with HIV 
disease. The pattern of memory deficits seen in HIV-positive patients is typical of 
subcortical dysfunction – evidenced on free recall tests due to poor retrieval, but 
improved with cueing. It has been estimated that neurocognitive impairment may be 
detectable in as many as 28% of asymptomatic individuals (Villa et al., 1996) and up to 
40–50% of symptomatic individuals (Heaton et al., 1995).   
 
The prevalence and severity of cognitive dysfunction due to HIV/AIDS increase as a 
function of disease progression (Reger et al., 2002; Starace et al., 2002; Baldewicz et 
al., 2004). While a few studies have noted observable cognitive disturbances in early 
disease (Villa et al., 1996; White, Heaton & Monsch, 1995), most report the early stages 
of HIV to be notably asymptomatic (Damos, John, Parker & Levin, 1997; Grassi et al., 
1999; Miller et al., 1990; Selnes et al., 1995). While the conflicting findings on early 
disease may be difficult to reconcile, studies across the board agree that patients with 
later disease perform significantly worse on global and specific-domain 
neuropsychological testing than individuals in earlier stages. As the disease progresses, 
patients present with increased cognitive dysfunction. For instance, in their assessment 
mentioned earlier of 395 HIV-positive patients naïve to HAART, Starace et al. (2002) 
found the global prevalence of neurocognitive impairment (defined as an impaired 
performance on at least two neuropsychological tests) to be 18% across the sample, 
and 35% in those with full-blown AIDS.  
 
HAART is able to achieve enduring suppression of HIV replication, resulting in dramatic 
improvements in HIV-related diseases (Paredes et al., 2000). However, many of the 
antiretroviral agents currently available do not penetrate the blood-brain-barrier (Gartner, 
2000). While ziduvodine, stavudine and lamivudine have relatively high levels of CNS 
penetration, PI’s are highly protein bound and have been shown to have poor CNS 
penetration (Dore et al., 1999). Some literature suggests that since HAART decreases 
systemic HIV viral load, the CNS may serve as a sanctuary for the virus and neurological 
dysfunction (such as HIV dementia) may result when the CNS serves as a reservoir for 
virological escape (Anderson, 1996; Melton, Kirkwood & Ghaemi, 1997; Portegies, 
1997).  
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The literature on the impact of HAART on improving HIV-associated cognitive 
dysfunction has yielded some contradictory findings. Some studies have shown that 
cognitive dysfunction persists, despite HAART initiation (Starace et al., 2002). 
Consequently, patients on HAART may remain susceptible to HIV-associated cognitive 
impairment despite viral suppression in other tissues (Deutsch et al., 2001), meaning 
that should HIV-associated cognitive dysfunction impact upon capacity to adhere, there 
is good reason to anticipate that this relationship would persist beyond the initiation of 
ARV treatment. In their evaluation of HIV-positive patients naïve to HAART as 
mentioned earlier, Starace et al. (2002) found that patients on HAART did no better on 
neuropsychological testing than those not on HAART. In fact, and surprisingly, cognitive 
dysfunction was more prevalent in those on HAART, although the authors suggested the 
plausible explanation that those patients presenting with neuropsychological symptoms 
may have been initiated sooner onto HAART than their cognitively intact counterparts, 
making the two groups within the observational cohort (on and off HAART) qualitatively 
different to begin with.      
 
Factor Significant result 
 
Non-significant result 
HIV/ ART knowledge and 
health literacy 
Chesney et al., 2000 
Malcolm et al., 2003 
Spire et al., 2002 
Wagner, 2002 
 
Gordillo et al., 1999 
Murphy et al., 2010 
Weiser et al., 2003 
Attitudes towards HIV/ ART Abel & Painter, 2003 
Arnsten et al., 2007 
Catz et al., 2000 
Gebo et al., 2003 
Kerr et al., 2005 
Malcolm et al., 2003 
Murphy et al., 2000 
 
Golin et al., 2002 
Spire et al., 2002 
Wagner., 2002 
Concerns about/ perceived 
side effects 
Ammassari et al., 2004 
Abel & Painter, 2003 
Carrieri et al., 2006 
Catz et al., 2000 
Gardenier et al., 2010 
Kerr et al., 2005 
Murphy et al., 2000 
Parruti et al., 2006 
Roco et al., 1999 
Simon et al., 2009 
Spire et al., 2002 
Wagner, 2002 
Weiser et al., 2003 
 
Maskew et al., 2007 
Spire et al., 2002 
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Denial/ acceptance of HIV 
status 
Abel & Painter, 2003 
Catz et al., 2000 
Murphy et al., 2000 
Nam et al., 2008 
Roberson et al., 2009 
Vervoort et al., 2010 
- 
Self-efficacy Arnsten et al., 2007 
Catz et al., 2000 
Chesney et al., 2000 
Kerr et al., 2005 
Golin et al., 2002 
Wagner, 2002 
Depression Ammassari et al., 2004 
Arnsten et al., 2007 
Carrieri et al., 2006 
Catz et al., 2000 
Do et al., 2010 
Gardenier et al., 2010 
Gordillo et al., 1999 
Malcolm et al., 2003 
Murphy et al., 2000 
Wagner, 2002 
Spire et al., 2002 
Alcohol use Chesney et al., 2000 
Do et al., 2010 
Golin et al., 2002 
Malcolm et al., 2003 
Ncama et al., 2008 
Spire et al., 2002 
Catz et al, 2000 
Gebo, Keruly & Moore, 2003 
Hinkin et al, 2004 
Parruti et al, 2006 
Turner et al, 2003 
Illicit drug use Ammassari et al., 2004 
Gebo et al., 2003 
Golin et al., 2002 
Hinkin et al., 2004 
Kerr et al., 2005 
Lanoy et al., 2006 
Lima e  al., 2009 
Malcolm et al., 2003 
Roco et al., 1999 
Turner et al., 2003 
Spire et al, 2002 
Neurocognitive functioning Albert et al., 1999 
Avants et al., 2001 
Brigado et al., 2001 
Catz et al., 2000 
Chesney et al., 2000 
Do et al., 2010 
Golin et al., 2002 
Hinkin et al., 2002 
Hinkin et al., 2004 
Levin et al., 2005 
Murphy et al., 2000 
Pienaar et al., 2006 
Roberts et al., 2000 
Spire et al., 2002 
Wagner, 2002 
Waldrop-Valverde et al., 2006 
Weidle et al., 2006 
Ammassari et al, 2004 
 
Table 3. Psychological factors assessed for impact on adherence behaviour in literature.  
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Social predictors 
Various social factors have been linked with adherence behaviour (see Table 4). Some 
investigations have shown that people who are not married have more difficulty adhering 
to antiretroviral regimens (Parruti et al., 2006; Spire et al., 2002), whereas others have 
observed higher adherence rates in those who are single (Wagner, 2002). Using patient 
self-report and pharmacy records as adherence outcomes, Parruti et al. (2006) followed 
171 patients in Italy for a minimum of 24 weeks and up to eight years to assess the 
impact of various potential predictors on adherence rates, and showed that those 
patients who were married were two times less likely to experience adherence failure 
(p=.03). By contrast, some studies have reported no association between marital or 
relationship status and ART adherence (Golin et al., 2002; Weiser et al., 2003) or loss to 
follow-up (Zacariah et al., 2008). Clearly, this is an area requiring further investigation.  
 
Lack of disclosure has also been reported as a barrier to adherence (Abel & Painter, 
2003; Catz et al., 2000; Do et al., 2010; Malcolm et al., 2003; Maskew et al., 2007; 
Murphy et al., 2000; Nam et al., 2008; Ncama et al., 2008; Richard et al., 2009; Weiser 
et al., 2003). Non-disclosure can lead to circumstances and situations in which taking 
the prescribed antiretrovirals or attending clinic visits is difficult. Patients may need to 
avoid taking medications in public spaces – including communal areas of the home or 
workplace – in order to avoid inadvertent exposure (Abel & Painter, 2003; Maskew et al., 
2007; Murphy et al., 2000; Weiser et al., 2003); where avoidance is impossible, doses 
may be missed or delayed. Patients may also feel uncomfortable going to HIV clinic 
visits due to confidentiality concerns (Weiser at al., 2003). Nondisclosure not only leads 
directly to avoidance of medication-taking or clinic attendance in certain circumstances, 
but prevents patients from accessing social support. Barriers to disclosure tend to 
include fear of stigmatization and social rejection (Do et al., 2010). Despite the country’s 
high HIV prevalence rates and efforts to destigmatize the disease, stigma and 
discrimination surrounding HIV is sadly still rife in South Africa (Ncama et al., 2008). 
Stigma continues to result in rejection by family and partners, ostracism from community 
and even loss of employment. To avoid such unwanted consequences, patients may 
avoid disclosure, thereby impacting their ability to adhere. Using a checklist to elicit 
barriers to treatment adherence in HAART patients, Catz et al. (2000) found that 71% of 
their sample cited not wanting other people to know their HIV status as a barrier to 
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medication adherence. A patient in Murphy et al.’s (2000, p.53) focus group discussions 
on barriers to ART adherence in a United States sample, a patient explained, ‘During 
May and June and July, I may go home to Memphis and stay anywhere from two to four 
months. So, the biggest problem I was having there was ducking and dodging my nieces 
and nephews and sister-in-law, in taking my medication.’ Other investigations into the 
impact of disclosure on adherence behaviour have found that disclosure has no bearing 
on adherence rates (Spire et al., 2002).  
 
Patients may be more likely to miss ART doses if they do not have sufficient social 
support (Carrieri et al., 2006; Catz et al., 2000; Gardenier et al., 2010; Gordillo et al., 
1999; Spire et al., 2002). Gardenier et al. (2010) conducted a recent study that 
addressed social support and adherence in a sample of HAART patients with comorbid 
medical or psychiatric conditions, and found significant differences between levels of 
social support reported by adherent versus nonadherent patients. These differences 
were observed on the overall social support score of the social support scale used, both 
of its two indices (emotional support and instrumental support), and four of its six 
component subscales (guidance, attachment, social integration and reassurance of 
worth). In Gordillo et al.’s (1999) earlier cross-sectional study of HAART patients 
assessing the role of various socio-demographic and psychosocial variables on self-
reported and pill count adherence, having good self-perceived social support meant the 
likelihood of achieving adherence success doubled.  
 
Qualitative data on patient-reported adherence barriers concurs (Malcolm et al., 2003; 
Murphy et al., 2000; Nam et al., 2008). Participants in Nam et al.’s (2008) one-to-one in-
depth interviews examining barriers to and facilitators of antiretroviral adherence 
explained that finding a confidante who could both share their disease burden and 
encourage hope and a will to live positively for the future was beneficial. One participant 
explained, ‘She told me you have to… “eat well, sleep well. You are going to live a 
normal life better than somebody who is negative if you just take care of yourself and 
you just take the medicines”’ (p.305). Significant others may even take on the role of 
reminding the patient to take the medication (Malcolm et al., 2003; Murphy et al., 2000). 
A patient in Murphy et al.’s (2000, p.53) analysis of facilitators of and barriers to HAART 
adherence said, ‘My wife keeps me on schedule… Regardless of what I’m doing, if I’m 
awake, if I’m sick over the toilet or something like that [laughs], she gives them to me.’ 
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The social support may be further strengthened if the supportive other is also HIV-
positive or even on antiretrovirals themselves, facilitating the development of informal 
‘buddy systems’. Another of Murphy et al’s participants explained, ‘We call each other… 
“Take the pills and have you taken yours?” If you have somebody who’s on the same 
schedule as you, it’s easier because then you can… keep up with each other. It helps.’ 
Beneficial and supportive social networks may be informal as just described, but do 
include formal structures such as church networks, sports clubs and support groups 
(Malcolm et al., 2003; Nam et al., 2008). Other assessments of the relationship between 
levels of social support and ART adherence have noted no relationship (Golin et al., 
2002; Kerr et al., 2005; Ncama et al., 2008).  
 
Household size and composition has also been studied for its impact on ART patient 
adherence (Do et al., 2010; Gebo et al.,2003; Wagner, 2002). Living with more people 
may lead to more possibilities for social support, or greater risk of exposure if no 
disclosure has taken place. Larger household size may also be a marker of low socio-
economic status. In an assessment of 180 patients who had been on HAART for one 
month or more, Wagner (2002) observed that living alone was associated with greater 
adherence as measured by both electronic monitoring and self-report, and a large 
household with lower adherence as measured by self-report and medication diaries. 
Some studies have seen no relationship between number of people sleeping in the 
home and adherence (Do et al., 2010; Gebo et al., 2003).   
 
Studies assessing patients on ARV’s indicate the importance of the patient-health care 
provider relationship in determining a patient’s adherence rates (Abel & Painter, 2003; 
Gardenier et al., 2010; Golin et al., 2002; Malcolm et al., 2003; Murphy et al., 2000; Nam 
et al., 2008; Roberson et al., 2009; Spire et al., 2002). Poor communication quality and 
clarity (Murphy et al., 2000; Roberson et al., 2009; Spire et al., 2002), difficult 
interactions, breaches in confidentiality and lack of provider respect for patients 
(Roberson et al., 2009) and low patient trust in provider competence (Malcolm et al., 
2003; Spire et al., 2002) have all been observed or reported to negatively impact 
adherence behaviour. One ART patient in Roberson et al.’s (2009) exploration of female 
prison inmates’ facilitators of and barriers to adherence explained, ‘It hurts [being treated 
like you] don’t matter’ (p.56), and another from Malcolm et al.’s (2003) qualitative 
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assessment said, ‘All [the doctor’s] going to do is what a drug company tells him’ 
(p.257).   
 
Conversely, a positive relationship and supportive health care provider can enhance 
patients’ adherence (Abel & Painter, 2003; Gardenier et al., 2010; Golin et al., 2002; 
Malcolm et al., 2003; Nam et al., 2008; Roberson et al., 2009). A qualitative study of 32 
adults on ART aimed to deepen understanding of the predictors of adherent behaviour 
(Nam et al., 2008) and found that some patients considered clinicians confidantes in 
their disease process (‘like a sister or mother’, p.304) and transmitters or messages of 
hope, which they said contributed to their self-respect, sense of hope and good 
adherence. In Golin et al.’s (2002) cohort of HAART patients, while the number of 
specific provider counseling behaviours (things the provider had done to increase 
adherence), overall patient satisfaction with the health care at the clinic, and the extent 
of the continuity of care (whether or not they saw the same doctor at each visit) were not 
predictive of adherence, patients who reported high levels of trust in their health care 
providers were significantly more likely to adhere well subsequently (p=.03). Results 
from other investigations show no relationship between patient-provider relationship and 
medication adherence (Gordillo et al., 1999).       
 
Factor Significant result Non-significant result 
Relationship status Parruti et al., 2006 
Spire et al., 2002 
Wagner, 2002 
Golin et al., 2002 
Weiser et al., 2003 
Zachariah et al., 2008 
Disclosure Abel & Painter, 2003 
Catz et al., 2000 
Do et al., 2010 
Malcolm et al., 2003 
Maskew et al., 2007 
Murphy et al., 2000 
Nam et al., 2008 
Ncama et al., 2008 
Richard et al., 2009 
Weiser et al., 2003 
Spire et al., 2002 
Social support Carrieri et al., 2006 
Catz et al., 2000 
Gardenier et al., 2010 
Gordillo et al., 1999 
Malcolm et al., 2003 
Murphy et al., 2000 
Nam et al., 2008 
Spire et al., 2002 
Golin et al., 2002 
Kerr et al., 2005 
Ncama et al., 2008 
 
Household size and 
composition 
Wagner, 2002 Do et al., 2010 
Gebo et al., 2003 
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Patient-provider relationship Abel & Painter, 2003 
Gardenier et al., 2010 
Golin et al., 2002 
Malcolm et al., 2003 
Murphy et al., 2000 
Nam et al., 2008 
Roberson et al., 2009 
Spire et al., 2002 
Gordillo et al., 1999 
 
Table 4. Social factors assessed for impact on adherence behaviour in literature.  
 
Miscellaneous predictors 
Making use of certain reminder tools has been reported to enhance ART adherence 
(Abel & Painter, 2003; Golin et al., 2002). After a follow-up of 12 months, Golin et al. 
(2002) showed that ART patients who used the most (upper quartile) adherence aids 
took on average 76% of their ARV doses, while patient who used no adherence aids 
took 68%. In a pilot study exploring factors that influence adherence among women in 
the United States, participants explained that using strategies like alarm clocks, having 
family members remind them and writing reminder notes were central maintaining their 
adherence (Abel & Painter, 2003).     
 
Research has also highlighted the importance of costs and time associated with clinic 
visits for HAART adherence. In developing countries, the economic burden of HIV/AIDS 
on households has been shown to be cumulative and catastrophic. Studies have 
consistently shown that patients who are required to pay for their antiretroviral drugs 
adhere more poorly (Bisson et al., 2006; Braitstein et al., 2006; Ivers, Kendrick & 
Doucette, 2005; Laniece et al., 2003; Weiser et al., 2003; Zachariah et al., 2008). 
Although the costs of antiretrovirals and medical care are oftentimes covered by 
universal healthcare systems, and this is true of the South African situation, indirect 
user-end costs, including cost of travel and loss of casual labour work due to clinic 
appointments, can pose significant barriers to treatment success. Studies have shown 
that ART patients experience difficulty leaving work to make clinic appointments 
(Maskew et al., 2007; Weiser et al., 2003), sometimes risking exposure and job loss, and 
for the contract worker, missing a day’s wages (Maskew et al., 2007). Those who live far 
from ARV facilities struggle to travel long distances to ART clinics (Catz et al., 2000; 
Morse et al., 1995; Weiser et al., 2003) and incur the associated travel costs (Lubega et 
al., 2010; Maskew et al., 2007).  
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One recent study described the results of interviews and focus groups with clinic 
managers, patients currently in pre-ARV care, patients who had dropped out of pre-ARV 
care and families and friends of people living with HIV/AIDS on the reasons for drop-out 
from pre-ARV care in eastern Uganda (Lubega et al., 2010). The study found that 
difficulty affording transport costs was mentioned often as a barrier to clinic attendance. 
Catz et al. (2000) found that difficulty traveling to clinic appointments was a barrier to 
medication adherence significantly more often cited by nonadherent patients than 
adherent patients. Patients also mentioned long waiting lines as a deterrent. One female 
who had dropped out of pre-ARV care remarked: ‘Why should I waste money on 
transport to get nothing I rather spend it on food and fees for my children.’ (p.156). In 
Morse et al.’s (1995) series of interviews conducted with 18 clinicians at various 
community centers conducting ARV trials, one of the most frequently mentioned patient 
barriers to recruitment, retention and adherence was transportation (endorsed by 21% of 
clinicians). There are exceptions however. Some observational studies have however 
found no association between travel time from home to ART clinic and medication 
adherence (Do et al., 2010), virological failure (van Oosterhout et al., 2005) or 
adherence to care (Karcher et al., 2007).     
 
Factor Significant result Non-significant result 
Use of reminder tools Abel & Painter, 2003 
Golin et al., 2002 
- 
Costs and time associated 
with medication-taking and 
clinic visits 
Bisson et al., 2006 
Braistein et al., 2006 
Catz et al., 2000 
Ivers et al., 2005 
Laniece et al., 2003 
Lubega et al., 2010 
Maskew et al., 2007 
Morse et al., 1995 
Weiser et al., 2003 
Zachariah et al., 2008 
Do et al., 2010 
Karcher et al., 2007 
van Oosterhout et al., 2007  
 
Table 5. Miscellaneous factors assessed for impact on adherence behaviour in literature.  
 
 
Summation and next steps 
The above review has shown that the literature suggests a diverse array of 
demographic, biomedical, psychological and social factors that may impact ART 
adherence and/ or adherence to HIV care. The studies outlined have been conducted 
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using various methodologies, many of which – likely due to resource constraints – have 
been less than ideal. Most studies have used self-report as a means of assessing 
adherence, rather than objective measures like pill count, HIV RNA level tests, electronic 
monitoring devices, pharmacy records or therapeutic drug monitoring. Almost all have 
been conducted with participants already on ART, meaning we have little knowledge of 
baseline predictive factors. Most studies are cross-sectional, limiting our understanding 
of causality. Few have included psychological or social assessments, and even fewer 
neuropsychological testing. Most literature stems from developed settings, oftentimes 
IDU, MSM or prison populations, and it is not known how applicable these results are to 
the general South African ART-initiating population.   
 
Partly due to conflicting methodologies and partly due to differing patient populations, 
results across most constructs have been inconsistent and are in need of further 
investigation. There is an urgent need to conduct methodologically-sound population-
specific research in a low-resource sub-Saharan African population to investigate the 
predictors of adherence behaviour in this context. This study sets out to do that, using an 
objective measure of adherence, assessing psychological, social and 
neuropsychological assessments, within an ART-initiating population, using a 
longitudinal study design.  
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CHAPTER 3 
Methods 
 
 
 
Design 
Longitudinal cohort study.  
 
Although much of the previously work in this area has been conducted using cross-
sectional designs, it was determined that a longitudinal cohort study would be the most 
effective design to evaluate the causative role that demographic and biopsychosocial 
factors have on adherence outcomes.  
 
Population and sampling  
Study setting 
The study was conducted in the Nyanga district, a peri-urban settlement close to Cape 
Town (geographical location in Figure 2a), South Africa. The district has an estimated 
population of 350,000 (City of Cape Town, 2003) and an HIV prevalence of 29% 
(Western Cape Provincial Department of Health, 2007). According to the last census, the 
population of the suburb of Guguletu within the Nyanga district was 99% Black African 
and 95% Xhosa-speaking. Thirty-nine percent of the population live in shacks/ informal 
dwellings, 71% of adults age 20 years and over have not completed Grade 12, and 51% 
of the ‘economically-active’ population (age 15–65 years) is unemployed. Sixty-seven 
percent of earners receive less than R1,600 per month (Statistics South Africa, 2001). 
The geographical location of the district is shown in Figure 2b.  
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Figure 2a. Geographical location of Cape Town, South Africa (©2009 Google – Map data).  
 
  
 
Figure 2b. Geographical location of Nyanga district, Western Cape (©2009 Google – Map data).  
 
Patients were recruited from the well-established Hannan Crusaid Treatment Centre 
(HCTC). The clinic was set up in 2002 as a result of a pilot programme predating the 
national roll-out of ART, by the Desmond Tutu HIV Centre (DTHC) – a not-for-profit HIV 
research and academic centre affiliated with the University of Cape Town – and a UK-
based charity fund, Crusaid. The clinic is one of the longest-running public-sector 
community-based ART programmes in sub-Saharan Africa (Bekker et al., 2006). It has 
subsequently been integrated into the Provincial Administration Western Cape’s (PAWC) 
ART roll-out programme. Today, the clinic is managed as a public sector facility offering 
comprehensive outpatient primary HIV/AIDS care by PAWC in collaboration with the 
DTHC. The clinic is a free-standing structure within the grounds of the local PHC clinic, 
the Guguletu Community Health Centre. A secure supply of drug is maintained at all 
times, and as part of the national Department of Health programme, there are no direct 
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user fees incurred for patients accessing any of the medications or clinical services. 
Patients enter the clinic through voluntary counseling and testing (VCT), inpatient and 
outpatient referrals. Patients requiring inpatient care are referred on to a nearby 200-bed 
secondary hospital, GF Jooste Hospital. The clinic had initiated 3,162 HIV-infected 
patients on antiretroviral therapy between 2002 and the start of the study, primarily 
drawn from the local community.  
 
Patients’ first clinic visit (–4 weeks) is followed by a screening visit two weeks later (–2 
weeks), where CD4 + cell count, viral load, liver function test (LFT) and full blood count 
(FBC) are performed, followed by a treatment initiation visit (0 weeks). This pre-
treatment visit schedule is truncated for women presenting in the later stages of 
pregnancy. After ART initiation, standard medical follow-up occurs at +4, +8 and +16 
weeks, and at 16-week intervals thereafter (those initiated on nevirapine [NVP] are seen 
at +2 weeks as well in order to assess for potential hepatoxicity). Pharmacy visits – 
where a supply of medications is provided and pill counts are performed – are conducted 
at the standard medical follow-ups as just described, as well as at +12 weeks and at the 
midpoint between the 16-week intervals between medical follow-ups (i.e. 8-weekly after 
the first 16 weeks). Viral load, CD4+ cell count, LFT and FBC measurements are 
performed at 16-week intervals during treatment. Patients may visit the clinic outside of 
the visit schedule for medical problems that arise. Duration of visits excluding waiting 
time varies between 15 and 45 minutes, with highest durations at early ART initiation. 
Patients are asked to bring their pill bottles to each clinic visit, where pill counts are 
routinely performed. Virological failure is defined as two consecutive viral load levels 
above 1,000 copies/mL, and an indication for initiating second line therapy. 
 
Antiretroviral treatment was available at the time of the study according to the 
Department of Health (2004) guidelines, in accordance with the WHO’s 2002 
recommendations for scaling up ART in resource-limited settings. Patients were 
medically eligible for HAART if they had a CD4+ cell count of less than 200 cells/!L or a 
WHO stage IV disease condition. (The national guidelines have since been updated to 
include pregnant women at CD4+ cell counts of less than 350 cells/!L and all patients 
co-infected with TB, regardless of CD4+ cell count [Department of Health, 2010b]). 
Treatment was also prescribed according to Department of Health (2004) guidelines and 
WHO (2002) recommendations, with first-line triple therapy combinations of two NRTI’s 
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(stavudine [d4T] and lamivudine [3TC]) combined with an NNRTI (either efavirenz [EFV] 
or NVP, with NVP substituted for EFV in women of child-bearing potential, and EFV 
preferred in those with TB co-infection). (The updated national guidelines reduce the use 
of d4T due to associated peripheral neuropathy, lipodystrophy and hyperlactataemia, 
replacing it with tenofovir [TDF], Department of Health, 2010b). If patients failed first-line 
therapy, they moved on to a PI-based second-line treatment including combinations of 
lopinavir/ritonavir (LPV/r), AZT and ddI (see Table 6). Individual drugs were substituted 
in the event of severe toxicity. All medications were registered with the Medicines 
Control Council of South Africa, and sourced from a single pharmaceutical supplier.  
 
Medication Type Dosing Possible side effects 
First-line ART 
d4T (stavudine) 
 
 
NRTI 1 x 30mg (<60kg); 
1 x 40mg (>60kg)  
12-hourly 
Peripheral neuropathy, 
gastrointestinal, headache, 
elevated AST and ALT levels 
3TC (lamivudine) 
 
NRTI 1 x 150mg  
12-hourly 
Nausea, headache, fatigue, 
insomnia 
EFV (efavirenz) NNRTI 2 x 200mg (<40kg)  
1 x 600mg (>40kg) 
once daily at night 
CNS effects, rash, elevated 
AST and ALT levels, 
contraindicated in pregnancy 
NVP (nevirapine) NNRTI 1 x 200mg once 
daily for 14 days, 
thereafter  
1 x 200mg 12-
hourly  
Rash, Stevens-Johnson 
syndrome, fever, elevated 
AST and ALT levels, nausea, 
headache 
Second-line ART 
LPV/r (lopinovir/ritonavir)   PI 3 x 133/33mg 12-
hourly 
[refrigerated] 
Nausea, diarrhea, taste 
perversion, elevated AST and 
ALT levels, asthenia, 
headache, vomiting, 
anorexia, perioral 
dysesthesia, 
hypertriglyceridemia, 
hypercholesterolemia 
AZT (zidovudine) NRTI 1 x 300mg 12-
hourly 
Headache, fatigue, 
neutropenia, nausea, anemia, 
insomnia, vomiting, myalgia, 
myopathy  
ddI (didanosine) NRTI 4 x 100mg (>60kg) 
2 x 100mg + 1 x 
50mg (<60kg) once 
daily 
[on empty stomach; 
dissolved in water] 
Pancreatitis, diarrhea, 
peripheral neuropathy, 
elevated AST and ALT levels  
Table 6. ART drugs available at Hannan Crusaid Treatment Centre (Department of Health, 2004; Max & 
Sherer, 2000; WHO, 2002). NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse 
transcriptase inhibitor; PI, protease inhibitor; AST, aspartate amino transferase; ALT, amino alanine 
transferase; CNS, central nervous system. 
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The clinic’s adherence model consists of a treatment readiness programme prior to ARV 
initiation and a system of both in-clinic and outreach counseling once treatment begins. 
Both the treatment readiness programme and the on-treatment counseling are 
administered by a team of approximately thirty counselors. The counselors are lay 
persons who have been trained in HIV/AIDS and ART and who themselves are HIV-
infected. Many of them are on ART. At the first clinic visit (–4 weeks), each new patient 
is assigned to a particular counselor for ongoing counseling support for the duration of 
his or her retention in care at the clinic. The assignment is based in part on geographical 
location; patients are matched with counselors who live in close proximity to them in 
order to facilitate home visits. The treatment readiness programme is compulsory, and 
comprises three education sessions and a home visit every two weeks pre-treatment. 
The education sessions are run by the lay counselors and administered to a group of 
patients at the HCTC. The treatment readiness decision is made at –1 week at a weekly 
interdisciplinary case review team meeting, attended by clinic doctors, nurses and 
adherence counselors, and is based on –2-week blood results and psychosocial 
treatment readiness (as determined by attendance at the three treatment readiness 
sessions, and the counselor’s impressions of the home visits). Despite the advantages 
of this facility – extensive experience, academic expertise and additional donor support – 
the strain of rapid programme expansion is evident. Since 2006, the number of 
employed lay counselors has remained constant at 30, despite the significant increase in 
patient numbers from 2,503 to 3,162. The ratio of patients to counselor has increased 
from 13:1 in 2002/2003 to 98:1 in 2007/2008.    
 
Once patients are on treatment, the generalized adherence programme involves a home 
visit each month until viral suppression is achieved, and every three to four months 
thereafter. Where the attending clinician identifies an adherence concern (a pill count 
adherence of less than 85% or a viral load greater than 1,000 copies/mL at any follow-up 
visit during ART), the patient is moved to the clinic’s ‘Red Alert’ group, and a targeted 
adherence intervention is commenced. Patients who move onto Red Alert are required 
to re-attend the three treatment readiness education sessions, and are issued with a pill 
box and a dosing diary. From that point on until their adherence increases to over 85% 
and/ or their HIV RNA load becomes undetectable again (<50 copies/mL) (a repeat viral 
load measurement is taken six to eight weeks after identification as Red Alert), patients 
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are marked for attention with a red sticker on their clinic folder, the frequency of their 
clinic visits (and the associated pill counts) increases to monthly, and the frequency of 
their home visits increases to weekly. A second viral load measurement >1,000 
copies/mL is defined as virological failure and triggers a switch to second-line therapy.  
 
The HCTC facility was chosen as an ideal setting for this research for a number of 
reasons. First, the study set out to enroll patients at HAART initiation so as to ensure 
that any biopsychosocial differences between adherent and nonadherent patients were 
pre-existing, as opposed to a consequence of adherent or nonadherent behaviour; in the 
12 months preceding the data collection period of this study, 685 patients initiated 
treatment at the center, suggesting a large potential participant base for the upcoming 
12 months. Second, in order to assess medication adherence in a methodologically-
rigorous way (see review of various adherence methodologies later in this chapter), a 
combination of two objective measures of adherence behaviour was chosen: pill counts 
and viral load tests. Pill counts are performed routinely at HCTC at each pharmacy visit, 
despite the fact that they are not mandated in the national (Department of Health, 2004; 
2010b) or provincial (PAWC, 2004) protocols and rarely occur in the public sector, likely 
because they are particularly labour-intensive. HIV viral load measurement is also 
performed routinely at HCTC at 16-week intervals on treatment, even though it is only 
recommended in the national and provincial protocols to be performed 6-monthly, due to 
high cost and insufficient laboratory facilities. Finally, the allocation of each patient to a 
lay counselor is not just an effective adherence intervention, but a valuable means of 
determining true patient outcomes; those patients who fail to attend scheduled clinic 
visits are traced, and so the determination of patients as LTFU in the programme is likely 
to be true LTFU, as opposed to hidden mortality or clinic transfer.    
 
Eligibility and recruitment 
Patients initiating HAART between April 2007 and January 2008 were invited to 
participate. Participation in the study was voluntary. For the purpose of the study, 
HAART was defined as any combination of three or more ARV agents that included at 
least one NNRTI or PI. Inclusion criteria for the study were: adults aged 18 years and 
older, scheduled for self-administered HAART, and able and willing to provide informed 
consent. Inclusion criteria were deliberately broad as the study intended to enroll the 
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wide range of patients presenting to the clinic, so that any results, outcomes and 
conclusions were applicable to the heterogeneous patient base.  
 
A total of 150 patients initiating treatment were recruited via staff referrals and assessed 
for eligibility.  
 
Procedures  
Data collection 
Across the study, five types of data were collected: 
1. Psychological and social information was elicited through face-to-face interviews 
conducted within seven days of HAART initiation (Week 0)  
2. Demographic and clinical data were extracted from clinic files at the time of the 
interview (Week 0) 
3. Pill count adherence was measured across the first 16 weeks of HAART through 
routine pill counts at the clinic and subsequent calculations by the researcher 
(Week 16) 
4. Virological suppression was measured at the 96-week visit through routine viral 
load monitoring at the clinic (Week 96) 
5. LTFU was assessed at 96 weeks through assessment of clinic files and 
discussions with the lay counselor to whom the patient had been assigned (Week 
96)      
See Figure 3 for the data collection timeline.   
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Figure 3. Data collection timeline.   
 
 
Study visit 
The study visit took place in a private room in an outbuilding of the HCTC, on its 
premises. This outbuilding was chosen in order to facilitate ease of participation due to 
proximity to the clinic, whilst also presenting the interview as separate from standard 
clinical care, and therefore decrease the likelihood of participants responding according 
to perceived social desirability. The visit lasted approximately two hours. A short break 
was offered to participants between the first and second hours. In a few cases, 
participants completed the second hour the following day. At the study visit, each 
participant was evaluated in a face-to-face interview, using a structured Biopsychosocial 
Questionnaire (Appendix A), a validated depression scale (Appendix B), a validated 
alcohol abuse scale (Appendix C), and a validated neuropsychological test battery (list of 
tests to follow in chapter). A translator was available to assist where necessary, and was 
used in 49 (33%) of the interviews. The study visit was scheduled to take place as close 
as possible to, but a maximum of seven days from, the clinic visit at which patients were 
initiated on ART. Twenty-one (14%) of the interviews were conducted on the day of the 
clinic visit, and a further 53 (35%) on the day before or the day after the visit. One 
Week 0 Week 16 Week 96 
Pill count 
analysis: 
Adherence 
data  
Viral load 
analysis: 
Adherence 
data  
Clinic file 
review/ 
counselor: 
LTFU data  
Clinic file 
review: 
Demographic 
and clinical data  
 
Study 
visit/ 
interview:  
Psycho- 
logical and 
social data  
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hundred and thirteen (75%) of the interviews took place within three days of the clinic 
visit. Participants received a R50 stipend for study participation and attendance at the 
study visit, and signed a Receipt of Reimbursement Form (Appendix D).    
 
For components of the interview that may have elicited social desirability bias or 
performance anxiety – specifically, the alcohol abuse scale, depression scale, and 
neuropsychological test battery – an introductory statement was used that normalized 
the ‘undesirable’ behaviour or poor performance, and acknowledged the associated 
challenges.      
 
Clinic file review 
At the time of the study visit, patient clinic files were reviewed, and relevant medical 
information extracted, including retrospective data about the patient’s history: date of 
testing HIV positive and reason for test, previous prescriptions of antiretroviral regimens 
and clinical episodes, history of mental illness, history of neurological deficits, and 
comorbid and chronic health conditions. Standardized clinical and biomedical data was 
also extracted, including: WHO HIV disease stage, most recent HIV-1 RNA level, most 
recent CD4+ cell count and prescribed ARV schedule.  
 
 
Measures 
Biopsychosocial Questionnaire 
The Biopsychosocial Questionnaire was developed for the purposes of the present 
study, based on the literature outlined in the previous chapter which links certain 
demographic, biomedical, psychological and social constructs with antiretroviral 
medication adherence and retention to care, and after consultation with several experts 
in the field of antiretroviral treatment and adherence. The questionnaire was informed by 
cognitive theories like the Health Belief Model (Rosenstock, 1974) and the Theory of 
Reasoned Action (Terry, Gallois & McCamish, 1993) in their recognition of ‘subjective’ 
factors like perceived disease severity and self-efficacy for adherence to the regimen. 
The questionnaire was piloted with five HAART-initiating patients from a similar 
population prior to data collection and modified accordingly.  
 
The questionnaire comprised 40 primary and 12 supplementary questions and explored 
10 domains: demographics (7 items); perceived HIV symtomatology (2 items), 
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understanding of HIV illness, information about own biomedical status, such awareness 
of latest CD4+ cell count and viral load test results, the implications of nonadherence, 
understanding of resistance and the names of each medication in the prescribed ART 
regimen (6 items), attitudes towards and concerns about HIV and ART, including belief 
in ART efficacy and concern about anticipated side effects (7 items), confidence in own 
ability to adhere to ARV regimen (adherence self-efficacy) (1 item), illicit drug use (2 
items), perceived social support and disclosure (15 items); perceived quality of 
relationship with health care provider, including level of trust and the extent to which able 
to communicate problems and challenges to the provider during the consultations (6 
items), planned use of adherence aids (1 item), and proximity to clinic and associated 
time and travel costs (5 items).  The Biopsychosocial Questionnaire is reproduced in the 
appendix (Appendix A).  
 
Depression scale 
Depressive symptomatology was assessed with the Centr  for Epidemiological Studies 
in Depression Scale (CES-D) (Radloff, 1977). The CES-D is a 20-item self-rating scale 
that assesses symptoms associated with depression. Respondents report on a 4-point 
scale, using response anchors ranging from 0 (rarely or none of the time) to 3 (most or 
all of the time) for how often during the past week they had experienced each symptom. 
Sample items include ‘I was bothered by things that usually don’t bother me’ and ‘I had 
crying spells’. A higher score indicates greater levels of depressive symtomatology. 
Standard clinical cut-offs were used to define severity of depressive symptoms: a score 
of 15 or below indicated none or low depressive symptomatology, a score in the range of 
16–21 indicated symptoms associated with mild to moderate depression, and a cut-off 
point of 22 or higher indicated symptoms associated with a major depressive episode. 
This measure has been validated for use in community settings to detect the presence of 
depressive symptoms (Boyd, Weissman, Thompson & Meyers, 1982; Meyers & 
Weissman, 1980; Roberts & Vernon, 1983; Weissman, Sholomskas, Pottenger, Prusoff 
& Locke, 1977) and has been validated in many cross-cultural samples (Ghubash, 
Daradkeh, Al Naseri, Al Bloushi & Al Daheri, 2000; Iwata & Buka, 2002; Munet-Villaro, 
Folkman & Gregorich, 1999), ethnic groups (Guarnaccia, Angel & Worobey, 1989; 
Roberts, 1980; Roberts, Rhoades & Vernon, 1990) and used extensively in persons with 
HIV infection (Burrack et al., 1993; Catz et al., 2000; Cook et al., 2004; Duran et al., 
2001; Himelhoch, Medloff & Oyeniyi, 2007; Ickovics et al., 2001; Lyketsos et al., 1996; 
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McClure, Catz, Prejean, Brantley & Jones, 1996). It has also previously been used in 
South Africa with sufficient reliability and validity (Jewkes et al., 2006; Simbayi et al., 
2007). The CES-D is reproduced in the appendix (Appendix B). 
 
Alcohol abuse scale 
Alcohol abuse was measured with the Alcohol Use Disorders Identification Test (AUDIT) 
(WHO, 1992). The AUDIT is a 10-item self-rating scale that assesses hazardous 
drinking. Most of its items are scored on a 5-point scale, ranging from 0 (never) to 4 
(daily or almost daily) and a summary score of 8 or more indicates a presence of 
hazardous or harmful drinking. Sample items include ‘How often do you have six or more 
drinks on one occasion?’ and ‘How often during the last year have you had a feeling of 
guilt or remorse after drinking?’ The AUDIT was developed and validated by the WHO in 
a cross-national study that included six different countries (Saunders, Aasland, Babor, 
de la Fuente, & Grant, 1988). It has been validated in a variety of community and 
primary health care settings (Bohn, Babor & Kranzler, 1995; Cherpitel & Borges, 2000; 
Cherpitel & Clark, 1995) and cultures, including Mexico (Medina-Mora, Carreno & de la 
Fuente, 1998), Venezuala (Seale, Seale, Alvarado, Vogel & Terry, 2002), Hong Kong 
(Leung & Arthur, 2000) and Zimbabwe (Chinyadza et al., 1993). In all of these studies it 
outperformed other self-report measures in the identification of hazardous drinking. The 
scale has been used extensively in South Africa (Dunkle, 2006; Jewkes et al., 2006; 
Kalichman et al., 2007; Myer et al., 2008; Peltzer, 2006; Simbayi et al., 2004), and 
among persons with HIV infection (Conigliaro, Gordon, McGinnis, Rabeneck & Justice, 
2003; Cook et al., 2001; Justice, 2004; Palepu et al., 2003; Shaffer, Njeri, Justice, Odero 
& Tierney, 2004). The AUDIT is reproduced in the appendix (Appendix C). 
 
Neuropsychological assessment 
A battery of neuropsychological tests was administered by the researcher, a trained 
neuropsychologist. The neuropsychological assessment was designed to focus on the 
areas of cognition sensitive to HIV-associated cognitive dysfunction: attention, 
motivation, speed of mental processing and executive functions. Verbal memory tests 
were also conducted due to their relevance to adherence behaviour. The Delis-Kaplan 
Executive Function System (D-KEFS) (Delis, Kaplan & Kramer, 2001) and the Wechsler 
Memory Scale – Third Edition (WMS-III) (Wechsler, 1997) served as comprehensive 
standardized executive functions and memory batteries, from which individual subtests 
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were selected. The batteries are the gold standards of executive functions and memory 
testing for both neuropsychological research and clinical utility. Both have been 
established as reliable and valid in the United States, and the WMS-III in the United 
Kingdom as well. Because the present study’s sample does not match the populations in 
which the batteries have been validated, two precautions were taken. The first was to 
adapt the administration to the local population, and the second was to adapt the scoring 
to the local population. For the first, all of the stimulus information was thoroughly 
reviewed for applicability to the South African culture. This was approached 
conservatively so as to make only minor, necessary word substitutions so as to increase 
applicability of the items without compromising their level of difficulty. Of the six tests 
used across the two batteries, only one test – WMS-III Logical Memory – required word 
substitutions. Table 7 lists the four word substitutions applied to this test. For the second 
precaution, participant test results were not converted into scaled scores or percentile 
ranks based upon United States or United Kingdom norms. Instead, raw test scores 
were used for the statistical analyses.  
 
Original wording on US/ UK versions SA modifications 
Story A 
South Boston/ South London East London 
the High Street the Main Road 
dollars/ pounds Rand  
Story B 
San Francisco/ Liverpool Durban 
 
Table 7. Word substitutions applied to WMS-III Logical Memory test.   
 
The D-KEFS is a set of nine standardized tests focusing on higher order cognitive 
functions or executive functions. The tests measure functioning in either verbal or non-
verbal domains. Each test is designed to function as either a stand-alone instrument or 
to be utilized in conjunction with the rest of the battery, depending on the pathology and 
the context. Several of the tests are comprised of multiple conditions, with earlier 
conditions measuring fundamental cognitive skills upon which the higher executive 
functions measured in the later conditions depend. Earlier conditions may be 
administered individually without moving on to administration of the later conditions, but 
the reverse is not true. The tests generally have high ceilings and low floors, meaning 
that they can detect both subtle cognitive deficits in those with high baseline functioning 
and distinctions in performance between those with severe functional impairment. The 
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administration manual provides detailed and clear instructions on test administration and 
scoring. Each test has standardized discontinue rules and time-limits to minimize 
examinee and examiner burden. Instructions and prompts are also prescribed and 
standardized. Each test has a primary score to characterize overall performance on the 
test (e.g. time taken to complete the task), as well as various process scores which 
characterize performance on key components or specific aspects of the task. The D-
KEFS standardization sample consisted of 1750 individuals age 8–89 years, and 
stratification of age, gender, race, ethnicity was matched to the latest United States 
census data. Because of the variability of tests within the battery, each D-KEFS test has 
separately calculated internal consistency and test-retest reliability. With just a few 
exceptions, the tests show moderately good internal consistency coefficients and good 
test-retest reliability (Swanson, 2005).  
 
The following D-KEFS subtests were administered: 
• D-KEFS Verbal Fluency Test – verbal domain (Condition 1 – Letter Fluency; 
Condition 2 – Category Fluency; Condition 3 – Category Switching):  
In the first condition, the examinee is required to generate as many words as possible 
that begin with a series of designated letters (F, A, S) in three trials of 60 seconds each. 
In the second condition, the examinee is required to generate as many words as 
possible that belong to designated semantic categories (‘animals’ and ‘boy’s names’), in 
two trials of 60 seconds each. The third condition requires participants to use designated 
semantic categories again (‘fruit’ and ‘furniture’), this time alternating between them, in 
one trial of 60 seconds. For this test, four types of process measures are recorded: 1) 
number of correct responses in each of the three conditions, and the number of correct 
switches in the third condition, 2) contrast in performance between generating words in 
the first and second conditions, and contrast in performance between the second and 
third conditions, 3) errors of repetition (same response generated more than once within 
a trial) and errors of set-loss (response generated that does not follow the phonemic or 
semantic rule of the trial), and 4) time-interval analyses (i.e. the number of correct words 
generated during each of the four 15-second intervals making up a trial). The test 
provides a measure of the examinee’s ability to generate words fluently in both a 
restricted phonemic format (letter fluency) and a restricted semantic format (category 
fluency), providing a good indication of generativity, motivation and spontaneity. The 
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switching condition requires rapid shifting from one cognitive set to another, assessing 
cognitive flexibility and the ability to undertake and manage conflicting demands.  
•  D-KEFS Design Fluency Test – nonverbal domain (Condition 1 – Filled Dots; 
Condition 2 – Empty Dots Only; Condition 3 – Switching):  
This test is a non-verbal variation of the D-KEFS Verbal Fluency test. In the first 
condition, the examinee is required to generate as many designs as possible by 
connecting filled circles in a single trial of 60 seconds. In the second condition, the 
examinee is required to do the same, this time with empty circles. For the third condition, 
the examinee is again required to produce as many designs as possible, this time 
shifting between connecting filled and open circles. For this test, four types of measures 
are recorded: 1) number of correct responses in each of the three conditions, across the 
first two conditions and across all three conditions, 2) total number of designs attempted 
across all three conditions, 3) contrast in performance between the first and second 
conditions compared with the third condition, and 4) errors of repetition and errors of set-
loss. Like the D-KEFS Letter Fluency Test, the test provid s a measure of generativity, 
motivation, spontaneity and cognitive flexibility, this time in the non-verbal domain.  
• D-KEFS Colour-Word Interference Test – verbal domain (Condition 1 – Colour 
Naming; Condition 2 – Word Reading; Condition 3 – Inhibition): 
The first condition requires examinees to name coloured patches and the second 
condition requires examinees to read colour-words (e.g. ‘red’) printed in black ink. The 
third condition requires examinees to name the ink colour of colour-words where the ink 
colour differs from the colour-word (e.g. the word ‘blue’ printed in red ink). For these 
conditions, three types of measures are recorded: 1) number of seconds the examinee 
takes to complete each condition, and the combined number of seconds the examinee 
takes to complete the first two conditions, 2) contrast in performance between seconds 
to complete the third condition versus the first condition, and 3) self-corrected errors and 
uncorrected errors. The test assesses the examinee’s ability to inhibit a learned 
response (e.g. reading printed words) in order to generate a required and conflicting 
response (e.g. naming the dissonant ink colour in which the words are printed).  
• D-KEFS Tower Test – nonverbal domain (single condition):  
This test requires the examinee to move discs varying in size across three pegs, in the 
fewest number of moves possible within set time limits, to build a series of nine towers 
that match the target pictures shown by the examiner. In constructing the towers, the 
examinee is required to move only a single disc at a time and never place a larger disc 
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over a smaller disc. For this test, two types of measures were recorded: 1) number of 
moves used to build a correct tower within the time limit, and 2) mean number of rule 
violations made across the nine trials. The test evaluates the examinee’s ability to initiate 
and maintain planning and problem-solving behaviour, as well as follow rules and inhibit 
unplanned, impulsive responses in the pursuit of an established goal.  
 
The WMS-III comprises eleven standardized tests which assess learning, memory and 
working memory. Like the D-KEFS, WMS-III tests measure functioning in either verbal or 
non-verbal domains. Many of the tests are separated into two conditions: an immediate 
condition, and a delayed condition which is administered 25–35 minutes after the 
immediate condition. The administration manual provides instructions on administration 
and scoring, and there are standardized discontinue rules but no time-limits. Each test 
has a primary score to characterize overall test performance, and several tests have 
supplemental scores as well which document performance on specific aspects of 
performance. The WMS-III was developed using a stratified standardization sample of 
1,250 adults in the United States and was adapted for use in the United Kingdom in a 
sample of 332 adults.  
 
The following WMS-III subtests were utilized: 
• WMS Logical Memory – verbal domain (Condition 1 – Immediate; Condition 2 – 
Delayed) 
In the first condition, two short stories are presented orally to the examinee; the first 
story is presented once and the second story twice. The examinee is then required to 
retell the stories from memory. In the second condition, after a 25–35 minute delay, the 
examinee is required to retell both stories. Then, the examinee is required to answer a 
series of 30 yes/ no questions, 15 about each story. For this test, four types of measures 
are recorded: 1) number of correctly recalled story units for each of the two stories and 
across both stories, and for each of the conditions and across both conditions, 2) the 
number of correctly recalled story themes from each story and across both stories, and 
for each of the conditions and across both conditions, 3) the improvement in recall after 
the second presentation of the second story (learning slope), and 4) number of correct 
responses to yes/ no questions. The test assesses auditory immediate and auditory 
delayed recall as well as auditory delayed recognition.  
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• WMS Digit Span – verbal domain (Condition 1 – Digit Span Forwards; Condition 
2 – Digit Span Backwards)   
This test requires the examinee to recall a series of digits, increasing in length, and to 
repeat them back to the examiner. The test consists of 30 items, starting at two digits in 
the series for both conditions, and increasing up to nine digits in the first condition, and 
eight digits in the second condition. In the first condition, examinees are required to 
repeat each series as it was presented (forwards); in the second condition, examinees 
are required to repeat each series in the reverse order (backwards). For this test, two 
measures were recorded: 1) number of correctly recalled items in each condition and 
across both conditions, and 2) number of correctly recalled digits in each condition. The 
test evaluates auditory working memory. 
 
 
Adherence and LTFU monitoring 
Methods of assessing adherence and their challenges 
Diverse strategies have been used to measure and document adherence in antiretroviral 
research. These methods differ in meaningful ways; each has theoretical, empirical and 
practical advantages and disadvantages and a certain level of systematic measurement 
error. Utilization of these different methods within adherence research is likely to account 
for some of the variations in findings in the predictor literature described in the previous 
chapter. Assessment of adherence remains an imperfect science and no universally 
accepted method exists (Berg & Arnsten, 2006; Chesney et al., 2000; Wutoh et al., 
2003). The methods may reasonably be divided into subjective (recall survey and visual 
analogue scale, pill identification test, medication diary, and clinician estimate) and 
objective (pharmacy records, electronic monitoring devices, therapeutic drug monitoring, 
directly observed therapy, pill counts and HIV RNA level tests).  
       
The most widely used (Chesney, 2000) measure of adherence is the self-report recall 
survey. These assessments are based on patients’ retrospective recall of past 
adherence, ranging in the literature from three days (Wagner, 2002) to one year (Weiser 
et al., 2003). Its widespread use is a function of its many administrative advantages: it is 
inexpensive, easily implemented and has a low patient burden (Chesney et al., 2000; 
Chesney, 2000). One common permutation of the recall survey is the Visual Analogue 
Scale (VAS), that positions a line with one end representing the minimum possible 
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adherence (e.g. 0%) or the lowest possible adherence score (e.g. 0), and the other end 
representing the maximum possible adherence or the highest possible adherence score. 
Patients are asked to position their adherence somewhere along the line.  
 
Subjective recall does have several distinct disadvantages and was therefore not 
selected as an adherence measurement methodology for the present study. First, in 
order to minimize recall errors, self-report usually examines the shortest time period of 
all the adherence measures, making the data less representative (Chesney, 2000; 
Wutoh et al., 2003). Second, self-report is known to over-estimate adherence, probably 
because of social desirability bias, wherein patients misrepresent the degree of their 
compliance in order to avoid judgment on the part of the clinician or researcher 
(Chesney, 2000; Chesney et al., 2000; Wagner, 2002). Because of this tendency for 
self-report data to be positively skewed, it is predisposed to the ‘ceiling effect’ and its 
associated analytic challenges (Wagner, 2002). Third, the recall survey relies heavily on 
cognitive functions such as attention, motivation, insight and memory (Chesney, 2000). 
As discussed in the previous chapter, these are the very functions associated with HIV-
associated cognitive dysfunction, making self-report an unlikely choice for this patient 
group with high rates of cognitive compromise. Fourth, the significant variability in survey 
types and characteristics – time-frame monitored, Likert versus visual analogue scale, 
closed- versus open-ended questions, single-item versus scale – has led to poor 
agreement between different self-report adherence measurements (Berg & Arnsten, 
2006), which decreases comparability between studies.   
 
Other subjective methods of assessing adherence include the medication diary, the Pill 
Identification Test (PIT), and the clinician estimate. Medication diaries require patients to 
complete a diary form each day, indicating the time they took each ARV medication and 
how many pills they took at each dose time. Because the medication diary is also a self-
report measure, adherence rates reported in medication diaries are often biased 
upwards, once again likely because of perceived desirability of responses (Wagner, 
2002), and the diary also relies heavily on cognitive functions such as attention, 
motivation and memory. It is also important to consider that patients who complete 
diaries are also likely by definition to be adherent (Matsui et al., 1994). It is for these 
reasons that the diary was also not selected for use in this study. In the PIT, the clinician 
asks the patient to inspect each medication container and its contents, or a photograph 
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thereof, and then name the medication, outline the number of pills per dose, dosing 
frequency, and any additional administration instructions. Although used as a measure 
of adherence, the PIT is a knowledge index rather than a marker of behaviour, and as 
presented in the previous chapter, knowledge levels are not necessarily associated with 
adherence behaviour (Gordillo et al., 1999; Weiser et al., 2003). The clinician estimate 
measure asks health care providers to assign each patient an adherence score, based 
upon the provider’s subjective impression of the patient’s conduct. However, as 
described in the first chapter, research shows that clinicians are poor predictors of 
patient adherence (Gerbert et al., 2000; Miller et al., 2002; Paterson et al., 2000; Weiser 
et al., 2003) tending to overestimate medication adherence and insufficiently detect poor 
adherence. Miller et al. (2002) analyzed the accuracy of clinician estimates by 
calculating the difference between estimated adherence and measured adherence for 
the same period, and found mean clinician estimated adherence t  be 86.2% compared 
with a mean measured adherence of 77.3%, a 9% difference. he sensitivity of clinician 
estimates to detect nonadherent patients was poor (24% to 62%), and the difference 
between clinician estimate and measured adherence was between +5% and –5% in 
36% of cases.  
 
Pharmacy records have been used as an bjective measure of adherence, the premise 
being that patients who do not collect their refills timeously are missing doses, to the 
extent of the time lag between expected collection and actual collection. There are two 
major limitations to this measure. First, pharmacy records provide a crude score 
compared with pill counts and are therefore less amenable to statistical analysis. 
Second, pharmacy records provide only an approximation of adherence, since what they 
measure is a step removed from the action of pill-taking itself. Using pharmacy refill data 
assumes that patients who collect their medication on time ingest all of it correctly and 
timeously, which is logically not the case.  
 
Electronic monitoring devices (EMD) such as the Medication Events Monitoring System 
(MEMS) are relatively new to adherence research as compared with other measures 
(Wagner, 2002). One such EMD, The MEMS, developed by the Aardex Company in 
2005, employs a pressure-activated microprocessor in the medication bottle cap that 
records the date, time and duration of each bottle opening. At the clinic visit, patients are 
required to return the bottle cap, which is then scanned for retrieval of adherence data, 
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and the information transferred to a MEMS database. While MEMS adherence data is 
closely correlated with HIV RNA levels (Liu et al., 2001; Arnsten et al., 2001) and is able 
to detect more detailed aspects of pill-taking behaviour like dosing intervals (McNabb, 
Nicolau, Stoner & Ross, 2003), it does have several significant limitations. The first is the 
expense (Chesney et al., 2000) and therefore inaccessibility of MEMS technology (in 
terms of the computerized medication bottles, the computer software to scan and 
analyze the caps, and the specialized staff to manage it). This is obviously pertinent in 
resource-poor settings like South Africa, and all but prohibitive for local research. Even 
in those developed settings where electronic drug monitoring technology has been 
afforded, usually only one of the three or more antiretroviral medications is fitted with a 
MEMS cap due to cost constraints (Bova et al., 2005; Hinkin et al., 2004; Wagner, 2002) 
so the data is less representative of the complete regimen. Second, although the MEMS 
technology is seen as an objective measure, the objective record is of bottle opening 
(each cap opening is assumed to reflect a single medication-taking event) rather than 
pill-taking behaviour itself, and these are not always indistinguishable. For instance, 
some patients tend to remove more than one dose at a time (for example, taking out an 
extra ‘pocket dose’ in the morning for later ingestion before going out for the day), which 
leads to underestimates of adherence (Bova et al., 2005; Bangsberg et al., 2000; 
Chesney, 2000; Chesney et al., 2000; Hinkin et al., 2004), while others may open the 
device to show it to friends or check medication supply without actually ingesting 
medication. In an exploratory study of EMD use among HIV-infected adults enrolled in a 
randomized clinical trial, Bova et al. (2005) found that 41% of the sample reported 
having taken out more than one dose at a time (pocket dosing), and 26% reported 
having opened the device without taking out a dose of medication. So, while EMD data 
tends to reflect lower adherence levels than self-report measures or pill count, it is not 
clear whether EMD data are really more accurate or simply provide an inaccurately 
lower estimate of adherence.  
 
Third, assigning patients to MEMS cap monitoring might actually act as an adherence-
improving intervention (Wagner & Ghosh-Dastidar, 2002), in accordance with the 
‘Hawthorne effect’, rendering MEMS data incomparable to retrospective adherence 
evaluations like self-report. Finally, MEMS caps are large and bulky; they tend not to fit 
commercially available bottles, meaning clinics or patients need to transfer and re-label 
their medications; they are not conducive to travel (Bova et al., 2005), and their uptake 
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precludes the use of medication organizers like pill boxes (Golin et al., 2002; Wagner, 
2002), a cheap and common method many patients use as an adherence aid. These 
features have lead to high refusal rates (Turner & Hecht, 2003), possibly introducing a 
selection bias, and may in themselves adversely affect adherence rates.  
 
Therapeutic drug monitoring (TDM), wherein serum drug levels are assessed, has also 
been used as an objective adherence measure. However, TDM relies on laboratory use, 
and the expense related to performing therapeutic drug measurements is prohibitive 
(Chesney, 2000). It is also the most invasive of all the adherence measures. Also, serum 
drug levels only reflect adherence over the past 24 hours, just a recent snapshot of a 
chronic behaviour (Chesney, 2000). Finally, serum drug levels are affected by factors 
other than adherence, including diet and drug interactions, and also individual 
pharmacokinetic variation.  
 
The directly observed therapy (DOT) method, wherein patients are required to visit the 
clinic for each pill ingestion for observation by the health care provider, has been used 
extensively in chronic diseases like tuberculosis. While DOT is the only adherence 
assessment that assesses the behaviour itself rather than a proxy (e.g. number of times 
the medication container was opened), several major criticisms of the method exist. 
First, DOT requires extensive operational costs, which makes its use as both a research 
methodology and adherence intervention impractical in resource-constrained settings. 
Second, DOT has been labeled paternalistic, and threatening to the clinician-patient 
relationship, the bedrock upon which successful research and retention in clinical care 
are founded. Finally, the assessment itself is the most obviously impactful as an 
intervention, and so not an ideal observational research methodology.   
 
The most widely-used (Golin et al., 2002; Gordillo et al., 1999; Laniece et al., 2003; 
Weidle et al., 2006) objective measure of patient adherence is the pill count, whereby 
patients are asked to return their medication bottles to clinic visits for the clinician to 
empty and count. While pill counts are time-consuming and computationally complex for 
resource-limited clinics, the HCTC includes routine pill counts at every pharmacy visit, 
which was one of the primary reasons that the center was chosen as the research 
setting. The concept of measuring returned medicine as a proxy for consumed medicine 
does pose a particular challenge through the phenomenon of ‘pill dumping’, where 
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patients dispose of surplus medication without ingesting the medication before the clinic 
visit (Chesney, 2000). While this phenomenon cannot be excluded, the significant 
association between pill count adherence and EDM and virological suppression (Liu et 
al., 2001; Bangsberg et al., 2000) suggests that pill count correlates well with actual 
adherence. For this study in particular, because it was conducted in a clinical setting with 
a high emphasis on adherence at treatment readiness sessions, on-treatment lay 
counseling, and routine pill counts, it was especially important to utilize an objective 
measure of adherence because of the potential for social desirability bias. Also, because 
one of the premises of the study is that HIV-associated cognitive dysfunction impacts 
behavioural ability, self-report measures of adherence such as the recall survey, which 
rely heavily on memory, motivation, attention and executive functions, were not used. 
For these reasons, pill counts were chosen as an objective behavioural marker of 
medication adherence for the present study.  
 
Biological endpoint measures like HIV RNA level have also been used as objective 
measures of adherence (Bisson et al., 2006; Roco et al., 1999; van Oosterhout et al., 
2005; Weidle et al., 2006). Although factors like viral resistance and fitness, drug 
pharmacokinetics, and cellular metabolism may also come into play (Brigado et al., 
2001), adherence plays a central role in determining clinical outcome, especially in 
patients naïve to previous ART early on treatment, which is the case in the present 
study. For this study, viral load level was used as an objective clinical marker of 
medication adherence.  
 
Finally, some studies have used a combination of some or all of the above approaches, 
either replacing one measure with another if the first was missing or unavailable or 
setting out to formulate a composite adherence score (Golin et al., 2002; Gordillo et al., 
1999; Laniece et al., 2003; Parruti et al., 2006; Roco et al., 1999; van Oosterhout et al., 
2005; Wagner, 2002). In an editorial on measuring adherence, Turner and Hecht (2003) 
concluded that while self-report is likely the most practical approach for clinical patient 
care, a combination of measures is best for research purposes. Similarly, after reviews 
of the literature on predictors of adherence, Chesney (2000) and Wutoh et al. (2003) 
both advocated the use of simultaneous multiple methods to assess adherence 
adequately.   
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Adherence outcome variables in the present study 
In order to best capture the complex variations in adherence from different angles, and 
in accordance with the recommendations to use a combination of adherence measures 
for research purposes (Chesney, 2000; Turner & Hecht, 2001; Wutoh et al., 2003), 
medication adherence was measured and evaluated according to four indices: i) early 
behavioural marker of medication adherence (‘early pill count adherence’), ii) late clinical 
marker of medication adherence (‘late virological suppression’), iii) late behavioural 
marker of clinical care adherence (‘retention to care’), and iv) a composite measure of all 
three (‘composite adherence success’).    
 
i) Early behavioural marker of medication adherence – ‘early pill count adherence’  
As discussed earlier, although pill counts are not mandated in either the national 
(Department of Health, 2004; 2010b) or provincial (PAWC, 2004) protocols and rarely 
occur in the public health sector, likely because they are time-consuming and 
computationally complex, they are performed routinely at HCTC at each pharmacy visit. 
Pharmacy visits occur at standard medical follow-up (+4, +8 and +16 weeks, and at 16-
week intervals thereafter, with those initiated on NVP also are seen at +2 weeks) and at 
+12 weeks and at the midpoint between the 16-week intervals between medical follow-
up. This means that pill count data is available in 4-week intervals for the first 16 weeks 
of treatment, and 8-week intervals thereafter. Patients are asked to bring their pill bottles 
to each clinic visit, where a lay counselor performs the pill count. The counselor counts 
and records the number of pills remaining in the bottle and subtracts those numbers 
from the pharmacy record of the number of pills dispensed, in order to determine the 
number of pills consumed. This number is then divided by a multiplication of the required 
daily consumption and the number of days since the last pharmacy visit. The adherence 
computation is presented in Figure 4. This calculation is performed for each prescribed 
ARV medication.  
 
Metric                          Derivation 
Percent adherence  
                 DISPENSED – RETURNED                               
 
REQUIRED DAILY CONSUMPTION X NUMBER OF DAYS 
 
 
Figure 4. Pill count computation.  
X 100 
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Although these computations are completed at the clinic by the lay counselor, for the 
purposes of this study, these calculations were re-performed by the researcher to ensure 
accuracy and completeness. The pharmacy record of the number of pills dispensed and 
the counselor’s documentation of the number of pills remaining in the bottle were drawn 
from the clinic folder and entered into a Microsoft Excel database for calculations.  
 
Pill count data was extracted and computed for each of the four 4-week time intervals in 
the first 16 weeks after HAART initiation. The choice of four months to define ‘early’ 
treatment has been used elsewhere (Carrieri et al., 2006; Cornell, Myer, Kaplan, Bekker 
& Wood, 2009; Lawn et al., 2006), with this period previously shown to require the 
highest adherence rates in order to achieve long-term immuno-virological success 
(Carrieri et al., 2003). For the purposes of this study, and in line with the WHO’s 
recommended strategy for prevention and assessment of HIVDR in resource-limited 
countries (Bennet et al., 2008), and Harries, Nyangulu, Hargreaves, Kaluwa and 
Salaniponi’s (2001) recommended framework for an effective antiretroviral programme in 
sub-Saharan Africa, patients were defined as adherent if they had taken 90% or more of 
their prescribed drugs across the 16 weeks. This is also in accordance with many other 
studies which have also used the 90% cut-off for good adherence (Arnsten et al., 2007; 
Gebo et al., 2003; Gordillo et al., 1999; Murphy et al., 2010; Parruti et al., 2006). Pill 
count calculations were performed for each medication in the prescribed regimen as 
opposed to just one. Selective adherence to certain but not all medications prescribed in 
combination therapy would mean that the anticipated benefits of combination therapy 
(pharmacological synergy) would not be realized. Thus, for each participant, either eight 
or twelve pill count calculations were performed: one calculation for each of the four 
time-intervals per ARV medication.    
 
ii) Late clinical marker of medication adherence – ‘late virological suppression’   
As outlined earlier, while viral load measurement is only recommended in the national 
(Department of Health, 2004; 2010b) and provincial (PAWC, 2004) protocols to be 
performed 6-monthly due to high cost and insufficient laboratory facilities, viral load 
testing is performed routinely at HCTC at 16-week intervals on treatment. Laboratory 
work is performed on site in a stand-alone laboratory (a modified shipping container) on 
the premises. Viral load is measured with the Versant HIV-1 RNA 3.0 assay performed 
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on a 340 bDNA analyzer (Bayer Diagnostics, Tarrytown, NY, USA), which is sensitive for 
detecting 50 copies or more of HIV-1 RNA per milliliter of blood plasma. Internal and 
interlab quality assurance (QA) is performed routinely for viral load measurements. HIV 
RNA levels are expressed in log10 and reported in copies/mL.   
 
For the purposes of this study, viral load levels were accordingly classified as either 
detectable "50 copies/mL (log<1.49) or undetectable <50 copies/mL at the 96 week 
clinic visit as a clinical marker of medication adherence. This assay-detection threshold 
is lower than the commonly-used 500 copies/mL or 400 copies/mL marks of some years 
ago, and has been used by many studies as the cut-off point for suppression of viraemia 
in recent years (Cooper et al., 2008; Lehrman et al., 2005; Steigbigel et al., 2008; Trkola 
et al., 2005; van Oosterhout et al., 2005). Individuals who achieved an HIV RNA level of 
less than 50 copies/mL were classified as achieving virological suppression according to 
this clinical marker.  
 
The use of a single elevated viral load result was necessary because while the assay 
used had a detection threshold of 50 copies/mL, allowing for increased sensitivity in a 
population with proven high suppression rates (Bekker et al., 2003; Bekker et al., 2006; 
Orrell et al., 2007), the clinic’s targeted adherence intervention (with increased viral load 
monitoring) was only triggered at the 1,000 copies/mL threshold, meaning that for all 
patients with viral load’s between 50 copies/mL and 1,000 copies/mL, the follow-up viral 
load measurement occurred only 16 weeks later. The use of a single elevated viral load 
result is however justified because studies have shown that a single elevated viral load 
is associated with a higher risk of subsequent virological failure (Easterbrook et al., 
2002; Masquelier et al., 2005; Moore et al., 2002). Moreover, studies have also shown 
that one elevated viral load result (termed ‘initial’ or ‘primary’ virological failure [Orrell et 
al, 2007]) is more suggestive of lack of adherence than viral resistance at the time of the 
single elevated viral load (Masquelier et al., 2005), and therefore most closely 
represented the study’s focus on adherence.  
 
iii) Late behavioural marker of clinical care attendance – ‘retention to care’  
Patients are lost to care due to death, transfer to an alternate service or loss to follow-
up. As discussed, the HCTC has 30 lay counsellors on staff, with each new patient 
allocated to one of these counsellors based on geographic location to facilitate home 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
Predicting adherence to antiretroviral therapy and retention to HIV care 
 
 
80 
visits. This allocation is intended as an adherence/ retention intervention, but also 
facilitates the determination of true patient outcomes; patients who fail to attend their 
scheduled clinic visits are traced through home visits by the counselors, and so the 
identification of patients as LTFU in the programme is an indication of true LTFU, as 
opposed to hidden mortality or clinic transfer. All participant clinic files were reviewed at 
96 weeks to evaluate loss to follow-up and possible causes thereof. For the purposes of 
this study, and in accordance with the WHO’s recommended strategy for prevention and 
assessment of HIVDR in resource-limited countries (Bennet et al., 2008), patients were 
defined as lost to follow-up if at the end of the monitoring period (in this study, 96 weeks 
post treatment initiation), they had not returned to the clinic for 90 days or more since 
their last appointment and were not known to have died or transferred out to another 
treatment facility. This is in accordance with the 90-day definition used in other retention 
studies (Cornell et al., 2009; Laurent et al., 2005; Lawn et al., 2006; van Oosterhout et 
al., 2005). Patients who did not return to the clinic for 90 days or more after a clinic 
appointment but subsequently returned to the clinic during the 96-week monitoring 
period were not defined as LTFU. The date of LTFU was recorded as the date of the last 
visit to the clinic.  
 
iv) Composite measure – ‘composite adherence success’ 
Development of a composite measure is in accordance with several adherence reviews 
(Chesney, 2000; Turner & Hecht, 2001; Wutoh et al., 2003) that have advocated for a 
combination of measures to properly assess adherence in a research context. A 
composite measure of overall adherence success was developed, comprising the three 
adherence indicators just described: i) early behavioural marker of medication 
adherence (‘early pill count adherence’), ii) late clinical marker of medication adherence 
(‘late virological suppression’), and iii) late behavioural marker of clinical care adherence 
(‘retention to care’). Patients were defined as achieving adherence success if their mean 
pill count adherence across the first 16 weeks of treatment was greater than or equal to 
90%, they achieved an HIV RNA level of less than 50 copies/mL at the 96 week visit, 
and they were retained in care at 96 weeks. A similar method of adherence appraisal 
(utilizing medication adherence, viral load suppression and adherence to care) has been 
utilized previously (Roco et al., 1999).  
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Data management 
Raw data – including all psychological and social information, demographic and clinical 
data, pill count records, viral load results and retention data – were captured using 
Microsoft Excel. Data cleaning was performed by running all frequencies, identifying 
missing records and entering or replacing them. 
 
A set of principles to guide interpretation of missing and inconsistent data was 
established in advance and used throughout. Pill count adherence was calculated using 
an intention-to-treat analysis: patients who were LTFU during the 16-week pill count 
monitoring period were included in the pill count analysis and assigned an adherence 
value of 0% from the date of their first missed scheduled pharmacy visit, at which point 
they would have run out of drug. This principle has been used in other cohort studies 
(Karcher et al., 2007). Similarly, patients who interrupted treatment (did not return to the 
clinic for >1 day after a scheduled pharmacy visit, but returned before the end of the 16-
week monitoring period) were also assigned an adherenc  value of 0% from the date of 
their missed scheduled pharmacy visit until the date of their return, i.e. for the period that 
they were without drug.  
 
Patients who died on treatment during the early pill count adherence monitoring period 
were included in the analysis so as not to positively bias the adherence outcomes. In this 
case however, rather than being assigned an adherence value of 0% for the remainder 
of the 16-week monitoring period, they were considered only until their death. This is 
because there are a number of potential causes of early mortality in ART programmes 
other than nonadherence, including: delayed initial presentation for treatment and 
therefore advanced HIV disease, opportunistic infections, and severe HIV-related 
complications such as bacteraemia and tuberculosis (Antiretroviral Therapy in Lower 
Income Countries [ART-LINC] Collaboration & ART Cohort Collaboration [ART-CC] 
Groups, 2006). Importantly also, death records include death for any reason while on 
ART, including reasons unrelated to HIV. Patients who notified the clinic that they were 
transferring to another HIV treatment facility to continue ART during the pill count 
monitoring period were classified as transferred out (TFO) and only considered until the 
time of their transfer. 
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Periods of missing pill count data due to prescribed non-use (such as doctor-initiated 
treatment gaps due to side effects), hospitalizations and incarcerations were 
distinguished from poor adherence through extensive file reviews and the preceding 4-
week interval’s pill count adherence value was brought forward. In those cases where 
medication was dispensed from a different facility (e.g. an unplanned trip) without the 
patient transferring out and that facility also performed routine pill counts, efforts were 
made to obtain pharmacy record and pill count data from the facility. Where this was 
impossible, the preceding 4-week interval’s pill count adherence value was brought 
forward. If patients notified the clinic at a scheduled pharmacy visit that they would be 
unavailable to attend the following scheduled pharmacy visit and were thus dispensed 
medications for eight weeks of use, pill count adherence was calculated for the 8-week 
interval and applied to each of the two 4-week intervals. Where patients visited the clinic 
between scheduled pharmacy visits (i.e. within a 4-week interval) to report lost 
medication and request a new pill set, pill count adherence was calculated based only 
on the remaining time between the new pill set and the next scheduled pharmacy visit 
and applied to the entire 4-week interval. If patients failed to bring their pill bottles to a 
certain pharmacy visit so that remaining pills could not be counted, the preceding 4-
week interval’s pill count adherence value was brought forward. In those cases where 
medication changes (such as a switch from NVP to EFV due to side effects) were made 
between scheduled pharmacy visits, the pill count calculation was performed for each of 
the two periods, weighted according to time on each regime and applied to the entire 4-
week period.     
 
Pill count adherence scores greater than 100% reflected consumption of more than the 
prescribed dose during the measurement period. So as not to reward patients for over-
consumption in calculations of mean scores across multiple time periods or drugs (for 
instance, if a patient took 120% of prescribed dose for 8 weeks and 80% of prescribed 
doses for the remaining 8 weeks, or 120% of certain drug and 80% of another drug), and 
because – unlike poor adherence – data on the clinical implications of over-consumption 
are limited, pill count adherence scores greater than 100% were truncated at 100%.  
  
Patients who died on treatment and TFO before the 96 week visit were excluded from 
the late virological suppression analysis. As in pill count analysis, patients who were 
LTFU before the 96 week visit were included in the virological suppression analysis, and 
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assigned as unsuppressed. For those patients who had not died on treatment, TFO or 
LTFU, where a viral load test result was unavailable for the 96 week visit, the closest 
preceding viral load measurement by date was used.  
 
 
Statistical analysis 
All statistical analyses were carried out using the SAS package (SAS Institute, Inc., 
Cary, North Carolina). Conventional significance levels were adopted for all tests (p # 
0.05) and 95% confidence intervals used throughout.   
 
Baseline predictor and follow-up outcome variables were described using means and 
standard deviations for normally distributed continuous variables, medians and 
interquartile ranges (IQR’s) for continuous variables that were not normally distributed, 
and counts and percentages for categorical data.  
 
Within the interview data, a composite knowledge score was developed, and calculated 
as the number of correct answers to the six items pertaining to basic HIV illness, own 
biomedical status, implications of nonadherence, understanding of resistance and the 
names of each medication in the prescribed ART regimen; a higher knowledge score 
indicated greater knowledge levels. For all knowledge questions, participants who 
answered ‘unsure’ were grouped with those who answered incorrectly for that item. For 
the single open-ended knowledge question (understanding of resistance), participants 
were graded as 0 (no/ poor understanding) or 1 (good understanding) according to the a 
priori scoring system. A score of 1 was recorded if the participant mentioned that 
incomplete adherence may lead to medication not working/ not working as well. A 
composite antiretroviral therapy attitude score was also developed, calculated as the 
number of positive responses to the five items pertaining to the efficacy, benefits and 
drawbacks of the medication; a higher score indicated a more positive attitude. Finally, a 
composite patient-clinic relationship score was developed, calculated as the number of 
positive responses to the four items pertaining to communication, trust, respect and 
satisfaction with clinic staff; a higher score indicated a greater level of satisfaction with 
the relationship.  
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Pill count adherence was analyzed as a continuous measure to determine mean, 
median and range during the monitoring period and for other descriptive purposes, and 
as a dichotomous measure (<90% versus "90%) for bivariate analyses and the 
statistical model. Pill count adherence rates were calculated for each 4-week time 
interval first, to facilitate comparisons between adherence rates across time. Thereafter, 
mean adherence across the full 16-week measurement period was computed by 
weighting each between-visit measurement period (usually four weeks, but variable due 
to patient, clinic and environmental factors) appropriately. Similarly, adherence for each 
antiretroviral drug was calculated first, to facilitate comparisons between drug-specific 
adherence rates. Thereafter, mean adherence across all prescribed antiretroviral drugs 
was computed by averaging drug-specific adherence values. Pill count adherence 
scores ranged from 0% to 100%, with 0% indicating complete nonadherence and 100% 
indicating perfect adherence.  
 
Bivariate analyses were used to investigate the association of each demographic, 
biomedical, psychological and social factor with the four adherence outcomes: early pill 
count adherence (mean "90% across first 16 weeks of treatment), late viral load 
adherence (<50 copies/mL at the 96 week visit), late adherence to clinical care (retained 
in care at the 96 week visit) and the combined adherence success measure (mean pill 
count adherence "90% across first 16 weeks of treatment, viral load <50 copies/mL at 
the 96 week visit, and retained in care at the 96 week visit). Differences in the 
prevalence of each adherence outcome according to each potential predictor were 
examined using chi-square tests with 95% confidence intervals (95% CI).  
 
Finally, multiple logistic regression analysis was performed, with the combined 
adherence success measure as the dependent variable. This analysis allows each 
predictor variable to be assessed for its capacity to enhance the prediction of the 
outcomes variable over and above all of the other predictor variables. 
 
For those baseline predictor variables that contained one response set that made up 
95% or more of responses, only counts and percentages are presented descriptively; 
bivariate analyses were unable to be performed and they were excluded from the 
statistical model. Variables that were highly correlated with other variables (meaning that 
they provide the same information as another variable) were excluded from the model so 
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that the model was not influenced by the effect of multicolinearity. Because of the large 
number of bivariate analyses undertaken, all significant associations were assessed for 
plausibility and discarded from the regression model where appropriate. All variables 
excluded from the model and the reasons for exclusion are listed in Appendix E. For risk 
factors identified in the multivariate analysis, odds ratios (OR) are presented.         
 
Supplementary exploratory analyses were performed where appropriate to investigate 
alternative interpretations of primary results.   
 
 
Ethical considerations 
Approval  
The study protocol was approved by the University of Cape Town’s Research Ethics 
Committee, the Institute of Infectious Disease and Molecular Medicine’s Internal Review, 
and the University of Cape Town’s Department of Psychology’s Ethical Review. 
 
Consent process  
Informed consent was obtained prior to conducting any study procedures. Prior to 
consenting, written information in the form of an information sheet with attached consent 
form, available in both English (Appendix F) and Xhosa (Appendix G), was given to the 
patient to read. The researcher went through each paragraph of the information sheet with 
the patient and answered any questions as they arose. If the patient decided to participate, 
he or she signed two copies of the consent form, witnessed by the researcher. The 
participant kept one copy, and the other was kept secure by the researcher. If the 
participant elected not to keep a copy (e.g. for confidentiality reasons, in the case of non-
disclosure), the researcher documented this and kept both copies.  
 
Participant withdrawal 
Patients were informed prior to consenting and in the information sheet that they were free 
to withdraw from the study at any time without any penalty or loss of benefits that they 
would otherwise have been entitled to receive. This included, but was not limited to, social 
and medical benefits, and future care at the study site or clinic.  
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Privacy and confidentiality protection 
Confidentiality was strictly maintained. All study procedures were conducted in private, 
to the extent possible. A unique participant identity number was allocated to each 
participant and it is this number that was recorded on all study records – such as the 
questionnaire, administrative forms and other study-related reports and databases – in 
order to maintain participant confidentiality. All records that contained names or other 
personal identifiers, such as the participant log and the informed consent documents, 
were stored separately from the study records identified by the unique participant identity 
number. Hard copies of the records that contained names were stored in a separate, 
locked cabinet with limited access. Electronic copies of the records that contained 
names were secured with password-protected access systems. 
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CHAPTER 4 
Biomedical, psychological and social characteristics of the sample 
 
 
 
This chapter sets out to describe, in detail, the demographic, biomedical, psychological 
and social characteristics of the sample. The reason for the allocation of an entire 
chapter to this description is that, as will be outlined in this and the following chapters, 
the sample is broadly demographically and clinically representative of patients initiating 
ART at this particular clinic (Chapters 4 and 5) as well as broadly demographically and 
clinically representative of public-sector patients accessing ART in South Africa (Cornell 
et al., 2010) and even public-sector patients accessing ART in sub-Saharan Africa 
(Rosen et al., 2007) (Chapter 6). The psychological and social characteristics of ART 
patients seen in routine clinical practice are largely unknown in this under-researched 
population. The extensiveness and diversity of material covered in the interviews 
provided a unique opportunity for the detailed description of a demographically and 
clinically representative ARV patient base, which may be of use to public health 
professionals and clinicians in policy, planning and approaches to patient interactions. 
After this description, Chapter 5 will go on to explore the implications of the 
demographic, biomedical, psychological and social characteristics described in this 
chapter on treatment outcomes.           
 
Demographic characteristics of the sample  
A total of 150 patients initiating treatment were recruited into the study. Participants were 
predominantly female (n=95, 63%). The median age of the sample at enrolment was 34 
years (IQR, 29–40 years). Ninety-seven percent (n=145) spoke Xhosa as their home 
language. Only 32 (21%) had completed school; across the sample, the median level of 
education attained was Grade 10 (IQR, Grades 8–11). The mean number of years of 
education was 9.47 years (SD 2.22). Just 17 (11%) had post-school education; of these, 
the median length of post-school education was one year (IQR, 0.35–2 years).  
   
Employment status and categories are presented in Figures 5 and 6. Most (n=110, 73%) 
were unemployed, and a further 19 (13%) were self-employed or engaged in casual 
work. Only 15 (10%) were employed in full-time positions; the remaining 6 (4%) were 
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employed part-time. According to Annexure 3 of the Employment Equity Act 55 of 1998 
(see Appendix H), of those who were employed (full-time, part-time or self-employed/ 
engaged in casual work), 17 (49%) would be classified as Category 9 (Elementary 
Occupations), a grouping defined as those occupations which require relatively low/ 
elementary levels of knowledge and experience. Examples of Category 9 occupations 
within this sample include ‘domestic worker’ (n=4) and ‘fruit and vegetable seller’ (n=3). 
The remaining participants fell into the following categories: Category 6 (Service and 
Sales Workers), 26%; Category 7 (Craft and Related Trades), 17%; Category 4 (Clerks), 
6%; Category 3 (Technicians and Associated Professionals), 2%.     
 
 
Figure 5. Employment status. 
 
 
 
Figure 6. Employment categories. 
 
Unemployed, 
73% 
Employed part-time 
4% 
Casual/ self-employment 
13% 
 
Employed full-time 
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Twenty (13%) had a disability grant (DG), and a further 68 (45%) had applied for a DG, 
and were awaiting approval1. The mean monthly income of the sample, including all 
current and expected wages and grants for the follow-up period, was R968.63 per month 
(range 0–6,000 ZAR [South African Rands]). Twenty-four patients (16%) had no current 
or expected monthly income from any source.  
 
The demographic characteristics of the sample are presented in Table 8.  
 
Characteristic N or mean/ median 
Gender 
      Female 
 
95 (63%) 
Age 
   Median (years) 
 
34 (IQR, 29–40) 
Home language  
   English 
   Southern Sotho  
   Shona    
   Sothu  
   Xhosa 
 
1 (0.67%) 
1 (0.67%) 
1 (0.67%) 
2 (1.33%) 
145 (96.67%) 
Education 
   Completed school 
   Median highest grade 
 
32 (21%) 
Grade 10 (IQR, 8–11) 
   Mean education (years) 9.47 (SD, 2.22) 
Employment 
   Full-time 
   Part-time 
   Self-employed/ casual  
   Unemployed 
 
15 (10%) 
6 (4%) 
19 (13%) 
110 (73%) 
Disability grant 
   Yes 
   Applied 
   No 
 
20 (13%) 
68 (46%) 
62 (41%) 
Expected monthly income* 
   Mean (ZAR)  
 
968.63 
 
Table 8. Demographic profile of the sample (n=150). * Includes all current and expected wages and grants 
for the follow-up period. IQR, interquartile range; ZAR, South African Rands.  
 
The study sample represented 4% of the clinic’s ever-treated population (those patients 
who had ever initiated HAART treatment at the HCTC since its inception in 2002 until the 
end of the study’s monitoring period, n=4,302), and 29% of patients who initiated 
treatment during the study enrolment period (April 2007 – January 2008, n=521). The 
sample was very similar to both populations (demographic characteristics are presented 
                                                
1
 A disability grant is a government grant provided to patients with temporary or permanent disability, generally available 
to patients with a CD4+ cell count below 200 cells/µ or WHO stage IV disease. At the time of the study, disability grants 
provided approximately R700 support per month (Cornell et al., 2009) 
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in Table 9 and biomedical characteristics in Table 12 to follow), and when the study 
sample was compared with the total who initiated treatment during the study enrolment 
period, there were no significant differences observed with regard to gender (p=.26) or 
age (p=.98).    
 
Demographic 
characteristic 
Sample (n=150) HCTC ever-treated 
population (n=4,302) 
HCTC initiated 
during study 
enrolment period 
(n=521) 
Gender 63% female 67% female 68% female 
Age (mean)  34.31 years 34.52 years 34.33 years 
 
Table 9. Comparison of study sample gender and age composition with HCTC ever-treated and initiated 
during study enrolment populations. HCTC, Hannan Crusaid Treatment Centre.   
 
 
Biomedical characteristics of the sample 
Participants’ median CD4+ cell count at the start of the study was 117 cells/!L (IQR, 54–
172 cells/!L). Thirty-two (21%) had a CD4+ cell count below 50 cells/!L, 67 (45%) below 
100 cells/!L, and 134 (89%) below 200 cells/!L. The median plasma viral load level was 
4.98 log10 RNA copies/mL (IQR, 4.62–5.46 log10 copies/mL). Seventeen (11%) patients 
had HIV RNA levels greater than 500,000 copies/mL. The staging of infection across the 
sample, according to the WHO classification, was distributed as follows: WHO stage I 
(asymptomatic and including acute HIV infection), 12%; WHO stage II (early disease), 
12%; WHO stage III (late disease), 44%; WHO stage IV (AIDS), 32%.   
 
Most patients had tested HIV-positive relatively recently: 85 (57%) had tested within the 
last 12 months. The median time since diagnosis was eight months (IQR, 3–42 months). 
 
Figure 7. Length of time since HIV-positive diagnosis.  
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Most had tested because of medical advice to do so: 81% versus the 19% who had 
tested through VCT. The reasons for medical advice to test were: personal illness other 
than TB (44%), TB (20%), pregnancy (16%), and child’s illness (1%), reflecting the 
known major entry points to care.     
 
Sixty-nine percent of patients reported currently experiencing or having experienced one 
or more physical symptoms that they ascribed to HIV. The most frequently reported 
symptoms were dermatological (n=50, 33%), followed by neurological (n=43, 29%), 
gastrointestinal (n=32, 21%) and constitutional (n=31, 21%) symptoms. Thereafter, the 
following symptoms were reported at 10% or less frequency: cardiopulmonary, ear, nose 
and throat (ENT), haematological, lymphatic, musculoskeletal, ophthalmic, psychiatric, 
respiratory and urogenital. (See Appendix I for symptom categorizations.) The most 
frequently reported individual complaint was ‘rash’ (n=22, 15%). The most frequently 
reported neurological symptom was ‘headache’ (n=15, 10%), and no cognitive 
symptoms were reported. The most frequently reported psychiatric symptom was 
‘insomnia’ (n= 2, 1%). Of those who reported one or more symptoms, 55 (53%) 
considered these symptoms severe, 29 (28%) mild and 20 (19%) moderate.  
 
Twelve (13%) of the women were pregnant. Almost half of the sample (49%) was on TB 
therapy.  
 
Four patients had a documented history of mental illness prior to initiating treatment: two 
had been treated for depression, and two for acute psychosis. Thirty-five patients (23%) 
had a documented neurological history prior to initiating treatment. Nine had had motor 
vehicle accidents with associated loss of consciousness (LOC), and a further nine 
various closed-head trauma (defined as a significant blow to the head resulting in loss of 
consciousness). Seven had had tuberculosis meningitis (TBM), two Cryptococcus 
meningitis, and one undifferentiated meningitis. Five had epilepsy or a history of single 
seizures.     
 
One hundred and thirty-six patients (91%) were naïve to previous ART. Of the 14 who 
had been exposed to previous therapy, ten had received single-dose nevirapine (sd-
NVP) as prevention of mother-to-child transmission (PMTCT), two had participated in 
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previous ART drug trials, and two had defaulted treatment and presented during the 
study period for re-initiation.    
 
On initiation, 99% of patients were placed on first-line therapy including one NNRTI (EFV 
or NVP) boosted by two NRTI’s (d4T, 3TC or AZT): 81% were on either EFV plus d4T 
and 3TC (45%) or NVP plus d4T and 3TC (36%). Eighteen percent were started on EFV 
plus AZT and 3TC (7%) or NVP plus AZT and 3TC (11%). One patient was started on 
the second-line EFV (replacing LPV/r due to resistance on genotyping) plus AZT and ddI 
(see Table 10). 
 
Antiretroviral regimen Number Percentage 
NNRTI + NRTI 
EFV + d4T + 3TC 
NVP + d4T + 3TC 
EFV + AZT + 3TC 
NVP + AZT + 3TC 
EFV + AZT + ddI 
 
68 
54 
11 
16 
1 
 
45% 
36% 
7% 
11% 
1% 
 
Table 10. ART drugs prescribed to sample. NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, 
nucleoside reverse transcriptase inhibitor; EFV, efavirenz; d4T, stavudine; 3TC, lamivudine; NVP, 
nevirapine; AZT, zidovudine; ddI, didanosine. 
 
Table 11 summarizes the biomedical characteristics of the sample.   
 
Characteristic N or median 
CD4+ cell count at initiation  
   Median (cells/!L)    
 
117 (IQR, 54–172) 
CD4+ cell count 
<50 cells/!L 
<100 cells/!L   
<200 cells/!L 
 
32 (21%) 
67 (45%) 
134 (89%) 
Log HIV RNA level at initiation  
   Median (copies/mL) 
 
4.98 (IQR, 4.62–5.46)  
HIV RNA level  
   > 500,000 copies/mL 
   < 500,000 copies/mL 
 
17 (11%) 
133 (89%) 
WHO stage  
   I 
   II 
   III 
   IV 
 
18 (12%) 
18 (12%) 
66 (44%) 
48 (32%) 
Time since diagnosis*  
   Median (years) 
 
 
0.66 (IQR, 0.24–3.45)  
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Reason for HIV test* 
   VCT 
   TB 
   Personal illness other than TB 
   Pregnancy  
   Child’s illness  
 
26 (19%) 
27 (20%) 
61 (44%) 
22 (16%) 
2 (1%) 
HIV symptoms 
  Yes 
  No 
 
103 (69%) 
47 (31%) 
Pregnant** 
  Yes 
  No 
 
12 (13%) 
83 (87%) 
Current TB therapy 
   Yes 
   No 
 
 
73 (49%) 
77 (51%) 
Psychiatric history 
   Yes 
   No 
 
4 (3%) 
146 (97%) 
Neurological history 
   Yes 
   No 
 
35 (23%) 
115 (77%) 
Naïve to previous ART 
   Yes 
   No 
 
136 (91%) 
14 (9%) 
NNRTI + NRTI  
   Yes 
   No 
 
149 (99%) 
1 (1%) 
 
Table 11. Biomedical profile of the sample (n = 150). *Data not available for 12/150 participants. 
**Percentage given of total women (n = 95) in sample. IQR, interquartile range; WHO, World Health 
Organisation; VCT, voluntary counselling and testing; TB, tuberculosis; NNRTI, nonnucleoside reverse 
transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor.   
 
The study sample was similar to HCTC’s ever-treated population and to those patients 
who initiated treatment during the study enrolment period (Table 12), and when the 
study sample was compared with the total who initiated treatment during the study 
enrolment period, there were no significant differences observed with regard to mean 
CD4+ cell count (p=.86), CD4+ cell count <200 cells/!L (p=.51), HIV RNA level 
>500,000 copies/mL (p=.90), percentage WHO stage III or IV (p=.52) and pregnancy 
(p=.86).    
 
Biomedical 
characteristic 
Sample (n=150) HCTC ever-treated 
population (n=4,302) 
HCTC initiated 
during study 
enrolment period 
(n=521) 
CD4+ cell count 
(mean)  
119 cells/!L   115 cells/!L   121 cells/!L   
CD4+ cell count <200 89% 87% 88% 
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cells//!L 
HIV RNA level 
>500,000 copies/mL 
11% 10% 11% 
WHO stage III or IV 76% 74% 69% 
Pregnant* 13% 15% 14% 
 
Table 12. Comparison of study sample CD4+ cell count, HIV RNA level, WHO stage and pregnancy rates 
with HCTC ever-treated and initiated during study enrolment populations. *Percentage given of total women. 
HCTC, Hannan Crusaid Treatment Centre; WHO, World Health Organisation.   
 
Psychological characteristics of the sample 
Sixty-four patients (43%) knew their latest CD4+ cell count test result. Only one patient 
knew their latest HIV RNA test result. While 130 patients (87%) were able to accurately 
identify the names of at least one medication of their prescribed ARV regimen, less than 
half (n=71, 47%) knew the names of all (two or three) medications in their regimen. 
When asked to list all possible consequences of nonadherence to ARV’s, almost all 
patients (n=141, 94%) spontaneously mentioned poor clinical or laboratory outcomes, 
but only 11% referred to resistance, and only 5% mentioned that resistant virus could be 
transmitted to others. Only 21 patients (14%) were able to define resistance, according 
to the a priori scoring system. One hundred and twenty-five patients (89%) knew that 
they needed to take ‘all or almost all’ (defined in the questionnaire as 95% or more) of 
their ARV regimen in order to achieve best clinical and laboratory outcomes. The 
remaining 11% thought they had to take ‘most’ (defined as 60% to 94%) (7%), ‘about 
half’ (40% to 59%) (1%), or ‘some’ (less than 40%) of their medication (1%), or didn’t 
know how much they needed to take (2%).            
 
A composite knowledge score, comprising the six knowledge questions described above 
(awareness of latest CD4+ cell count and HIV RNA test results, able to identify the 
names of their prescribed ARV’s, knew possible implications of poor adherence, 
understood meaning of resistance, and knew they needed to take all of their ARV 
regimen) was calculated. The mean score across the sample was 2.4/6, or 40% (SD 
1.03). 73% of the sample scored below 50%.   
 
One hundred and five patients (70%) considered HIV a serious disease. Twelve (8%) 
thought they could fight off the disease without ARV’s. One hundred and thirty-one 
patients (87%) believed that ARV’s were going to improve their health. Sixty-four 
patients (43%) were concerned about possible side-effects of their prescribed regimen. 
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Nine (6%) said they did not like to think about ARV’s because the medications were a 
reminder of their HIV-positive status. One hundred and thirty-nine patients (93%) felt that 
the good things about ARV’s outweighed the bad. Eighty-nine patients (59%) endorsed 
the statement ‘I know better than my doctor when to when to take my medications 
because only I know how I am feeling’.  
 
A composite ARV attitudes score, comprising five of the attitudes questions described 
above (whether they thought they could fight off the disease without ARV’s, whether they 
believed ARV’s were going to improve their health, if they were concerned about 
possible side-effects of their prescribed regimen, if they didn’t like to think about ARV’s 
because the medications were a reminder of their HIV-positive status, and whether they 
felt the good things about ARV’s outweighed the bad) was calculated. A higher score 
indicated a more positive attitude. The median score across the sample was 4.25/5 
(IQR, 4–5). 84% of the sample scored 4 or 5.  
 
Almost all patients felt ‘very confident’ (n=129, 86%) or ‘quite confident’ (n=17, 11%) that 
they would be able to take their ARV medications as directed.    
 
According to the CES-D, more than a third of the sample (n=58, 39%) had symptoms 
associated with depression. Of these, 23 patients (15%) had symptoms associated with 
mild to moderate depression, and 35 patients (23%) had symptoms associated with a 
major depressive episode. The following statements were true for more than 20% of 
patients three or more days a week: ‘I felt fearful’ (26%), ‘I have been bothered by things 
that don’t usually bother me’ (25%), ‘I could not get going during the day’ (25%), ‘I did 
not feel like eating, my appetite was poor’ (23%), ‘I felt depressed and sad’ (23%) and ‘I 
felt lonely’ (22%). The following statements were true for more than 20% of patients two 
days or less a week: ‘I enjoyed life’ (28%) and ‘I felt that I was just as good as other 
people’ (24%). All items from the CES-D are presented in Table 13. 
 
Symptom Frequency (percentage) 
 Rarely/ none 
of the time 
<1 day 
Some of the 
time 
1–2 days 
Occasionally/ 
moderately 
3–4 days 
Most/ all of the 
time 
5–7 days 
1. I was bothered by 
things that usually don’t 
bother me 
 
75 (50%) 37 (25%) 20 (13%) 18 (12%) 
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2. I did not feel like 
eating; my appetite was 
poor 
92 (62%) 23 (15%) 
 
18 (12%) 17 (11%) 
3. I felt that I could not 
shake off the blues 
(sadness) even with help 
from my family or friends 
93 (62%) 33 (22%) 13 (9%) 11 (7%) 
4. I felt that I was just as 
good as other people 
23 (15%) 13 (9%) 6 (4%) 108 (72%) 
5. I had trouble keeping 
my mind on what I was 
doing 
90 (60%) 30 (20%) 17 (11%) 13 (9%) 
6. I felt depressed  65 (43%) 51 (34%) 19 (13%) 15 (10%) 
7. I felt that everything I 
did was an effort 
76 (51%) 46 (31%) 14 (9%) 14 (9%) 
8. I felt hopeful about the 
future 
11 (7%) 14 (9%) 20 (14%) 105 (70%) 
9. I thought my life had 
been a failure 
92 (61%) 31 (21%) 8 (5%) 19 (13%) 
10. I felt fearful 78 (52%) 33 (22%) 24 (16%) 15 (10%) 
11. My sleep was 
restless 
79 (53%) 25 (17%) 20 (13%) 26 (17%) 
12. I was happy 2 (1%) 24 (16%) 44 (29%) 80 (54%) 
13. I talked less than 
usual  
96 (64%) 28 (19%) 23 (15%) 3 (2%) 
14. I felt lonely 87 (58%) 30 (20%) 21 (14%) 12 (8%) 
15. People were 
unfriendly 
110 (73%) 19 (13%) 12 (8%) 9 (6%) 
16. I enjoyed life 16 (11%) 26 (17%) 26 (17%) 82 (55%) 
17. I had crying spells 92 (61%) 40 (27%) 15 (10%) 3 (2%) 
18. I felt sad 65 (43%) 55 (37%) 18 (12%) 12 (8%) 
19. I felt that people 
disliked me 
109 (73%) 16 (11%) 17 (11%) 8 (5%) 
20. I could not get ‘going’  79 (53%) 33 (22%) 21 (14%) 17 (11%) 
 
Table 13. CES-D individual item frequencies and percentages.   
 
In Radloff’s (1977) original publication of the CES-D, 16 of the 20 items were presented 
as contributing to four factors: Depressed affect (items 3, 6, 14, 17 and 18), Positive 
Affect (4, 8, 12 and 16), Somatic and Retarded Activity (1, 2, 7, 11, 20), and 
Interpersonal (15 and 19). For this analysis, Item 1 (‘I was bothered by things that 
usually don’t bother me’) was shifted from Somatic and Retarded Activity to Depressed 
Affect, Item 14 (‘I felt lonely’) was shifted from Depressed Affect to Interpersonal, and an 
additional factor – Cognitive – was added, comprising one item (item 5). Figure 8 
compares the percentage prevalence of the sample experiencing each of the five factors 
more than 1 day per week (prevalence for the Positive Affect factor is presented as the 
absence of the positive symptom). 
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Figure 8. Comparison of depressive symptoms by factor. 
   
 
According to the AUDIT’s cut-off point of 8, 61 participants (41%) were classified as 
engaging in alcohol consumption that was hazardous or harmful. Just under one quarter 
of the sample (24%) drank seven or more drinks containing alcohol on a typical day 
when they were drinking. Nineteen percent of patients failed, at least weekly, to do what 
was normally expected of them because of drinking. Nine percent of patients needed a 
first drink in the morning, at least weekly. Nineteen percent had injured themselves or 
someone else because of their drinking. More than a third of participants (35%) had had 
a relative, friend, doctor or other health care worker concerned about their drinking, 
almost all of these (92%) within the last year. The following statements were true for 
more than 20% of patients at least weekly: ‘A feeling of guilt or remorse after drinking’ 
(29%) and ‘six or more drinks on one occasion’ (28%). All items from the AUDIT are 
presented in Table 14. 
 
Symptom Frequency (percentage) 
 Never Monthly or 
less  
2–4 times 
per month 
2–3 times 
per week  
4 or more 
times per 
week 
 
1. How often do you have 
a drink containing 
alcohol? 
 
 
 
79 (53%) 6 (4%) 21 (14%) 37 (25%) 7 (4%) 
!!!!!!"!!!!!!#!!!!!!!$!!!!!"%!!!
"&!
 Depressed Affect 
!!!'!!!!!!&!!!!!"(!!!!
"$!
Positive Affect 
!!!!!(!!!!!!!%!!!!!""!!!!()!
Somatic and 
Retarded Activity 
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Interpersonal 
!!!!!!!!!!!!!!!!*!
    Cognitive 
Factors  
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 1 or 2 3 or 4 5 or 6 7–9  10 or more 
2. How many drinks 
containing alcohol do you 
have on a typical day 
when you are drinking?  
85 (57%) 16 (11%) 12 (8%) 13 (8%) 24 (16%) 
 Never Less than 
monthly 
Monthly Weekly Daily or 
almost daily 
3. How often do you have 
six or more drinks on one 
occasion? 
100 (67%) 1 (1%) 7 (4%) 36 (24%) 6 (4%) 
4. How often during the 
last year have you found 
that you were not able to 
stop drinking once you 
had started?  
120 (80%) 2 (1%) 7 (5%) 14 (9%) 7 (5%) 
5. How often during the 
last year have you failed 
to do what was normally 
expected from you 
because you had been 
drinking? 
110 (73%) 2 (1%) 10 (7%) 25 (17%) 3 (2%) 
6. How often during the 
last year have you 
needed a first drink in the 
morning to get yourself 
going after a heavy 
drinking session? 
135 (90%) 0 (0%) 1 (1%) 11 (7%) 3 (2%) 
7. How often during the 
last year have you had a 
feeling of guilt or remorse 
after drinking? 
89 (59%) 5 (3%) 13 (9%) 32 (22%) 11 (7%) 
8. How often during the 
last year have you been 
unable to remember what 
happened the night 
before because you had 
been drinking? 
120 (80%) 2 (1%) 9 (6%) 16 (11%) 3 (2%) 
 No Yes, but not in the 
last year 
Yes, during the last 
year 
9. Have you or someone 
else been injured as a 
result of your drinking? 
121 (81%) 19 (13%) 10 (6%) 
10. Has a relative or 
friend or a doctor been 
concerned about your 
drinking or suggested 
you cut down? 
98 (65%) 4 (3%) 48 (32%) 
 
Table 14. AUDIT individual item frequencies and percentages.    
 
The AUDIT’s first three items assess the amount and frequency of alcohol consumption 
(hazardous alcohol use), items 4–6 assess alcohol dependence, and items 7–10 assess 
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the problems caused by alcohol (harmful alcohol use). Figure 9 compares the 
percentage prevalence of the sample experiencing each of the three areas of alcohol-
related problems (prevalence of each symptom was considered if the response was not 
‘never’, ‘1 or 2’ or ‘no’). 
 
 
Figure 9. Comparison of alcohol abuse symptoms by area.  
 
Ten participants (7%) had used recreational drugs in the last 12 months, all of whom had 
taken marijuana, and two of whom had taken mandrax.  
 
Neuropsychological test scores consist of primary scores which summarise overall 
performance on the task (e.g. number of correct responses or time to complete) as well 
as various process scores which characterise performance on key components or 
specific aspects of the task (e.g. contrast in performance across different trials or 
number of errors made). Mean neuropsychological test scores and standard deviations 
are reported in Appendix J.  
 
There were several relationships observed between neurolopsychological test scores 
and various disease indicators (HIV RNA level, CD4+ cell count and WHO stage). 
Unsurprisingly, in most cases (14/18), poor cognitive performance was related to 
advanced disease. All 14 of these cases were scores of production or accuracy 
(producing words or designs in the D-KEFS Verbal Fluency and Design Fluency 
subtests or remembering story units in the WMS Logical Memory subtest), meaning that 
healthier patients were able to produce more words and designs and remember more of 
!%!!!!!!!!!!!!&!!!!!!!!!!!!!+!!!!!!!!!!!!!
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           Harmful 
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          Hazardous 
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the stories read to them. All 4 of the remaining cases were error scores (repetition or set 
loss errors made in the course of producing words or designs); given healthier patients’ 
higher productivity rate, it is understandable that they would have made more errors. 
WHO was the disease indicator most frequently related to cognitive functioning, 
accounting for 15 of the 18 relationships observed. These chi-square results are 
presented in Appendix K.  
 
Table 15 summarizes the key psychological characteristics of the sample.  
 
Characteristic N  
Knowledge 
Knew latest CD4+ cell count 
  Yes 
  No  
Knew latest HIV RNA test result 
  Yes 
  No 
Knew names of "1 ARV medication 
  Yes 
  No 
Knew names of all ARV medications 
  Yes 
  No 
Knew implications of nonadherence 
  Clinical/ laboratory outcomes 
  Resistance 
  Transmitted resistance 
Able to define ‘resistance’* 
   Yes 
   No 
Reported required adherence**   
   All ("95%) 
   Most (60%–94%) 
   Half (40%–59%)  
   Some (<40%) 
   Unsure     
 
 
64 (43%) 
86 (57%) 
 
1 (1%)  
149 (99%) 
 
130 (87%) 
20 (13%) 
 
71 (47%) 
79 (53%) 
 
141 (94%) 
16 (11%) 
7 (5%) 
 
21 (14%) 
129 (86%) 
 
125 (89%) 
10 (7%) 
1 (1%) 
1 (1%) 
3 (2%) 
Attitudes 
Considered HIV a serious disease 
  Yes 
  No 
Believed could fight off HIV without ART 
  Yes 
  No 
Believed ART would improve health 
  Yes 
  No 
Concerned about side effects 
  Yes 
  No 
 
 
 
105 (70%) 
45 (30%) 
 
12 (8%) 
138 (92%) 
 
139 (87%) 
19 (13%) 
 
64 (43%) 
86 (57%) 
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Preferred not to think about ART 
  Yes 
  No 
Believed good things about ART outweighed 
bad 
  Yes 
  No 
Believed knew better than doctor when to take 
medications 
  Yes 
  No 
 
9 (6%) 
141 (94%) 
 
 
139 (93%) 
11 (7%) 
 
 
89 (59%) 
61 (41%) 
ART self-efficacy 
  Very confident 
  Quite confident 
  Quite unconfident 
  Very unconfident 
 
129 (86%) 
17 (11%) 
3 (2%) 
1 (1%) 
CES-D score 
   Mild to moderate depression 
   Major depressive episode  
   Total with depressive symptoms 
 
23 (15%) 
35 (23%) 
58 (39%) 
AUDIT score 
   Hazardous or harmful alcohol consumption  
 
61 (41%) 
Illicit drug use in last 12 months 
  Yes 
  No 
 
10 (7%) 
140 (93%) 
 
Table 15. Psychological profile of the sample (n=150). *According to the a priori scoring system. ** Data 
available for 140/150 participants. CES-D, Centre for Epidemiological Studies on Depression Scale; AUDIT, 
Alcohol Use Disorders Identification Test.    
 
Social characteristics of the sample 
Forty-nine (33%) were single, 28 (19%) married, 27 (18%) cohabiting but not married, 44 
(29%) in a relationship but not cohabiting or married, one widowed and one separated. 
The median household size was 4 (IQR, 3–6). Nine participants (6%) lived alone. Forty 
(27%) lived in a household of six or more people. Fifty-three (35%) lived with a partner, 
67 (45%) with their child(ren), 43 (29%) with a parent, and 100 (67%) with other family. 
Four were living with a friend or border. Almost all patients (96%) felt they had a strong 
emotional bond with at least one other person.   
 
One hundred and twenty-seven participants (85%) knew someone else who was HIV-
positive. The mean number of HIV-positive people that participants knew was two (IQR, 
1–4.25). Forty-five (30%) had an HIV-positive spouse or partner. Of the patients who 
were in a relationship (married, cohabiting or in a relationship but not cohabiting or 
married), 46% had an HIV-positive partner. Nine (6%) had an HIV-positive child, five 
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(3%) a positive parent, and 55 (37%) a positive family member (other than spouse, child 
or parent). Sixty-nine (46%) had a positive friend and 49 (33%) a positive neighbour.      
 
Ninety-nine patients (66%) knew someone else who was on ART. The mean number of 
people on ART that participants knew was 1 (IQR, 0–2). Fourteen (9%) of sample, 14% 
of those in a relationship) had a spouse or partner on ART. Five (3%) had a child on 
ART, four (3%) a parent on ART, and 28 (19%) a family member (other than spouse, 
child or parent) on ART. Forty (27%) had a friend on ART, and 34 (23%) a neighbour on 
ART. Twenty-seven participants (18%) were living with someone who was on ART.      
 
 
Figure 10. HIV-positive others known to sample.  
 
Almost all participants (97%) had disclosed their HIV-positive status to at least one other 
person. The mean number of people disclosed to was 3 (IQR, 2–7.25). Of the patients 
who were in a relationship (married, cohabiting or in a relationship but not cohabiting or 
married), 88% had disclosed to their partner. Of the patients who lived with their 
child(ren), 69% had disclosed to their child(ren). Sixty-five (43%) had disclosed to a 
parent, 122 (81%) a family member (other than spouse, child(ren) or parent), 57 (38%) a 
friend, and 24 (16%) a neighbour. One hundred and twenty-nine patients (86%) were 
living with someone they had disclosed to, and 99 patients (66%) had disclosed to 
everyone in their household. One hundred and fifteen patients (77%) had disclosed to 
someone who would remind them to take their ART. Seventeen patients (11%) were 
living with someone they had disclosed to and who would remind them to take their ART. 
Only seven patients had disclosed to someone who felt they should not start ART. 
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Twenty-three patients (15%) said they ‘always’ saw the same doctor at their clinic visits, 
12 (8%) ‘rarely’ and 115 (77%) ‘never’. Patients said the doctors and nurses at the clinic 
spoke to them in their home language ‘always’ (n=9, 6%), ‘sometimes’ (n=43, 29%) and 
‘never’ (n=98, 65%). One hundred and thirty-one patients (87%) felt they could talk to 
the doctors and nurses at the clinic about any problems they were having. One hundred 
and thirty-six patients (91%) said they trusted the doctors and nurses. One hundred and 
forty-five patients (97%) felt the doctors and nurses at the clinic respected them. One 
hundred and forty-five patients (97%) were satisfied with their relationship with the 
doctors and nurses at the clinic. 
 
 
Figure 11. Self-reported relationship with health care provider.   
 
A composite patient-clinic relationship score, comprising four of the questions described 
above (whether patients felt they could talk to doctors and nurses at the clinic about any 
problems they were having, whether they trust the doctors and nurses, whether they felt 
the doctors and nurses at the clinic respect them, and whether they are satisfied with 
their relationship with the doctors/ nurses at the clinic) was calculated. The median score 
across the sample was four. Seventy-eight percent of the sample scored a full four.    
 
Key social characteristics of the study participants are presented in Table 16.  
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Characteristic N or median 
Relationship status 
  Single 
  Married 
  Relationship – cohabiting 
  Relationship – non-cohabiting 
  Widowed 
  Separated 
 
49 (32%) 
28 (19%) 
27 (18%) 
44 (29%) 
1 (1%) 
1 (1%) 
Household size 
  Median 
  Living alone 
  Household "6 people  
 
4 (IQR, 3–6) 
9 (6%) 
40 (27%)  
Reported emotional bond with another 144 (96%) 
HIV-positive others 
  Knew HIV-positive other 
  Number of HIV-positive others know (median) 
  Knew other on ART  
  Number of others on ART known (median) 
 
127 (85%) 
2 (IQR, 1–4.25)  
99 (66%) 
1 (IQR, 0–2)  
Disclosure 
  Disclosed to at least one person 
  Number of people disclosed to (median) 
  Living with someone disclosed to 
  Disclosed to everyone in household 
 
145 (97%) 
3 (IQR, 2–7.25) 
129 (86%) 
 99 (66%) 
Support 
  Someone will assist with ART adherence 
  Living with someone who will assist 
  "1 person against patient taking ART 
 
115 (77%) 
17 (11%) 
7 (5%) 
Patient-provider relationship 
  Always sees same doctor at clinic 
  Provider speaks in home language 
  Can talk to provider about problems 
  Trusts provider 
  Feels provider respects him/ her 
  Satisfied with relationship with provider 
 
23 (15%) 
9 (6%) 
131 (87%) 
136 (91%) 
145 (97%) 
145 (97%) 
 
Table 16. Social characteristics of the sample (n = 150). IQR, interquartile range.  
 
 
Miscellaneous characteristics of the sample 
The adherence aid most planned for use by patients initiating treatment was a pillbox 
(n=141, 94%). Thereafter, in descending order of planned use, were: alarm clock on 
cellular telephone (n=63, 42%), television or radio programme (n=16, 11%), alarm clock 
on wrist watch (n=9, 6%), free-standing alarm clock (n=7, 5%), diary (n=7, 5%) and 
calendar (n=5, 3%). 
 
Almost all patients traveled to the clinic by taxi (n=80; 53%) or on foot (n=69; 46%). Only 
one traveled by car. The median length of time patients spent traveling to the clinic was 
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25 minutes each way (IQR, 15–30 minutes). Of the 80 (53%) patients paying for 
transportation to the clinic, 80% paid R8 for return transportation (range 7–26 ZAR). 
Fifty-nine (77%) considered this quite unaffordable or very unaffordable. When asked to 
consider both time and cost, 99 (66%) thought clinic visits were very convenient or quite 
convenient, and 51 (34%) very inconvenient or quite inconvenient.     
 
Miscellaneous characteristics of the sample are presented in Table 17.  
 
Characteristic N or mean/ median 
Planned adherence aids 
  Pillbox 
  Alarm clock on cellular telephone 
  Television or radio programme 
  Alarm clock on wrist watch 
  Free-standing alarm clock 
  Diary 
  Calendar 
 
141 (94%) 
63 (42%) 
16 (11%) 
9 (6%) 
7 (5%) 
7 (5%) 
5 (3%) 
Transport type to clinic 
  Taxi  
  On foot 
  Car 
 
80 (53%) 
69 (46%) 
1 (1%) 
Transport cost to clinic* 
  Mean (ZAR) 
  Considered transport cost unaffordable 
 
8 (range 7–26)  
59 (77%) 
Time to clinic** 
  Median  
 
25 minutes each way (IQR, 15–30 min)  
Clinic visits convenient 
  Yes 
  No 
 
99 (66%) 
51 (34%) 
 
Table 17. Miscellaneous characteristics of the sample (n=150). *Transport cost and attitudes provided for 
those patients paying for transportation to the clinic (n=80, 53%). **Time to clinic data not available for 2/150 
participants. ZAR, South African Rands; IQR, interquartile range.   
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CHAPTER 5 
Outcomes at 16 and 96 weeks: Medication adherence, virological 
suppression and retention to care  
 
 
 
As outlined in Chapter 3, medication adherence was measured and evaluated according 
to four indices: 1) early behavioural marker of medication adherence (‘early pill count 
adherence’), 2) late clinical marker of medication adherence (‘late virological 
suppression’), 3) late behavioural marker of clinical care adherence (‘retention to care’) 
and 4) a composite measure of all three (‘composite adherence success’).  
 
Patients enrolling in the study were followed for 96 weeks: their early pill count 
adherence was assessed over the first 16 weeks (weeks 0–16), and their late virological 
suppression and retention to care assessed at 96-weeks (Week 96). A study timeline of 
the measurement of the adherence indices is presented in Figure 12 and their 
definitions, measurement periods and exclusions in Table 18.           
 
 
Figure 12. Adherence indices and timeline. 
 
 
                                      Adherence indices 
 Early pill count 
adherence 
Late virological 
suppression 
Retention to 
care 
Composite adherence 
success  
Definition !90% of prescribed 
medications 
HIV RNA level <50 
copies/mL 
<90 days since 
last clinic 
appointment 
!90% of prescribed 
medications, HIV RNA 
level <50 copies/mL, and 
<90 days since last clinic 
appointment 
Week 0 Week 16 Week 96 
Early pill 
adherence 
 
Late virological 
suppression 
 
Retention to 
care 
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Measure Pill count HIV RNA test File review, 
counselor 
consult 
Pill count, HIV RNA test, 
file review and counselor 
consult 
Measurement 
period 
Week 0 – 16 Week 96 Week 96  Week 0 – 96 
Excluded 
status 
None* Died, TFO Died, TFO None* 
Final n n=149 n=133 n=133 n=149 
 
Table 18. Definitions, measurement periods and exclusions of adherence indices. *1 patient who died on 
treatment between Week 0 and Week 4 excluded as no data available. TFO, transferred out.   
 
Early pill count adherence (Week 0 – Week 16) 
Early pill count adherence was assessed over the initial 16-week period following the 
first prescription visit (Week 0–Week 16). During the early pill count adherence 
monitoring period, 3 patients died on treatment, 5 TFO to other facilities and 15 were 
LTFU. For 7 of the 8 patients who died on treatment or TFO, the sub-period for which 
they had been monitored (4, 8 or 12 weeks) was used in the analyses. Pill count data 
was unavailable for one patient who died on treatment between Week 0 and Week 4 – 
after study enrolment and treatment initiation but before the first pill count – so was 
excluded from the early pill count adherence and subsequent analyses. The 15 patients 
who were LTFU were considered throughout the 16-week monitoring period and 
assigned a value of 0% adherence from the date of their first missed scheduled 
pharmacy visit. (See Chapter 3 for definitions of death on treatment, TFO and LTFU and 
justifications for their inclusion/ exclusion and data management).    
 
Patients were defined as adherent if they had taken 90% or more of their prescribed 
drugs across the 16 weeks. According to the definition, 112 patients (75%) were defined 
as adherent and 37 patients as nonadherent. Patient outcomes from the early pill count 
adherence analysis are presented in Figure 13. 
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Figure 13. Patient outcomes in early pill count analysis (Weeks 0–16).   
 
The sample’s mean pill count adherence across the 16 weeks was 87%. The number of 
patients whose mean adherence across the 16-week monitoring period fell into each 
10% adherence band is presented in Figure 14. 
 
 
Figure 14. Number of patients falling into 10% mean adherence bands across the early pill count analysis 
(Weeks 0–16).   
 
Enrolled 
n=150  
 
Died 
n=3 
 
TFO 
n=5  
 
LTFU 
n=15 
 
 
Other 
n=127  
Excluded 
n=1  
 
Included 
n=2  
 
Included  
in early pill count 
adherence analysis 
n = x 
 
Adherent  
n=112  
75% 
 
Nonadherent  
n=37 
25%  
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Although 37 patients (25%) had a mean adherence across the 16-week monitoring 
period of less than 90%, 56 patients (38%) had a single adherence measurement of less 
than 90% during at least one of the 4-week time periods comprising the 16-week 
monitoring period. The number of patients whose lowest recorded adherence during any 
4-week time period comprising the 16-week monitoring period fell into each 10% 
adherence band is presented in Figure 15. 
 
 
Figure 15. Number of patients whose lowest recorded adherence during any 4-week time period fell into 
each 10% adherence band.   
 
When comparing the sample’s mean pill count adherence across each of the 4-week 
intervals within the 16-week monitoring period, results showed a consistent decrease in 
adherence with time. The sample’s mean adherence was 93%, 88%, 84% and 83% for 
each of the 4-week time intervals taken chronologically, and the difference was 
significant (F (4) = 3.29, p=.01). Comparisons of the 4-week time intervals within the 16-
week monitoring period are presented in Table 19 and Figure 16.   
 
 Week 0 – Week 4 Week 4 – Week 8 Week 8 – Week 12 Week 12 – Week 16 
Mean 93% 88% 84% 83% 
SD (range) 18% (0% - 100%)   26% (0% - 100%)  31% (0% - 100%) 33% (0% - 100%)  
Number 
(percentage) of 
sample with mean 
adherence !90% 
n=125 (84%*) n=116 (80%**) n=111 (77%***) n=106 (75%****) 
 
Table 19. Comparison of pill count adherence across 4-week time intervals within 16-week monitoring 
period. *1 excluded due to death. **4 excluded due to death/ TFO. ***5 excluded due to death/TFO. ****8 
excluded due to death/TFO. SD, standard deviation. 
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Figure 16. Comparison of pill count adherence across 4-week time intervals within 16-week monitoring 
period. Note: Mean adherence not cumulative.   
 
When comparing the sample’s pill count adherence to each of the five drug regimens 
across the 16-week monitoring period, results showed variations in adherence by 
regimen. The sample’s mean pill count adherence across 16 weeks to d4T/3TC/EFV 
was 88%, d4T/3TC/NVP 83%, AZT/3TC/EFV 92% and AZT/3TC/NVP 91%, and the 
single patient on AZT/ddI/EFV had an adherence of 99% and the difference between 
them was significant (F (4) = 2.47, p=.04). Comparisons of the sample’s mean pill count 
adherence to each of the five drug regimens are presented in Table 20 and Figure 17.   
 
 d4T/3TC/EFV D4T/3TC/NVP AZT/3TC/EFV AZT/3TC/NVP 
Mean 88% 83% 92% 91% 
SD (range) 25% (0% - 
100%)   
32% (0% - 
100%)  
21% (0% - 
100%)  
20% (0% - 100%)  
Number 
(percentage) on 
regimens with 
mean adherence 
!90% 
n=51 (79%*) n=40 (74%**) n=8 (73%***) n=12 (75%****) 
 
Table 20. Comparison of the sample’s pill count adherence to each of the 4 drug regimens (excluding the 
single patient on AZT/ddI/EFV). *Includes 68 patients. **Includes 54 patients. ***Includes 11 patients. 
****Includes 16 patients. SD, standard deviation.    
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Figure 17. Comparison of the sample’s pill count adherence to each of the 4 drug regimens (excluding the 
single patient on AZT/ddI/EFV). 
 
 
Late virological suppression (Week 96) 
Late virological suppression was assessed at the 96-week visit. During the study’s 96-
week monitoring period, 7 patients died on treatment, 10 TFO to other facilities and 38 
were LTFU. Patients who died on treatment and TFO before the 96 week visit were 
excluded from the late virological suppression analysis. Patients who were LTFU before 
the 96 week visit were included in the virological suppression analysis and assigned as 
unsuppressed with a maximum value of >500,000 copies/mL. For patients who had not 
died, been TFO or LTFU, where a viral load test result was unavailable for the 96 week 
visit, the closest preceding viral load measurement by date was used. Due to the 
exclusions mentioned above, 133 patients were included in the late virological 
suppression analysis. (See Chapter 3 for definitions of death on treatment, TFO and 
LTFU and justifications for their inclusion/ exclusion and data management).  
 
Patients were defined as achieving virological suppression if their viral load levels were 
undetectable (<50 copies/mL) at the 96 week clinic visit. According to the definition and 
death, TFO and LTFU inclusions/ exclusions outlined in the previous paragraph, 73 
patients (55%) were defined as achieving virological suppression and 60 patients as not 
achieving virological suppression. It should be considered that 38 of the 60 
unsuppressed patients were in fact LTFU at 96 weeks; excluding these patients would 
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lift the sample’s suppression rate from 55% to 77%. Patient outcomes from the late 
virological suppression analysis are presented in Figure 18. 
 
 
Figure 18. Patient outcomes in late virological suppression analysis (Week 96).   
 
HIV RNA level across the sample at 96 weeks ranged from undetectable (<50 
copies/mL) to greater than the assay’s ability to quantify (>500,000 copies/mL), with a 
median of <50 copies/mL (IQR, <50 – >500,000 copies/mL). The number of patients 
whose viral load at the 96-week visit fell into each viral load band is presented in Figure 
19. 
 
Enrolled 
n=150  
 
Died 
n=7 
 
TFO 
n=10  
 
LTFU 
n=38 
 
 
Other 
n=95  
Included in late 
virological 
suppression analysis 
n=133 
Virologically 
suppressed (<50) 
n=73  
55% 
 
Not virologically 
suppressed (>50) 
n=60 
45%  
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Predicting adherence to antiretroviral therapy and retention to HIV care 
 
 
113 
 
Figure 19. Number of patients falling into each viral load band at the 96-week visit.   
 
Achieving a mean pill count of !90% across the first 16 weeks of treatment was 
significantly associated with achieving virological suppression (<50 copies/mL) at 96 
weeks (p<.0001). Sixty-nine percent (n=70) of those who showed good adherence were 
virologically suppressed at 96 weeks, compared with only 10% (n=3) of those with poor 
initial adherence (see Figure 20). Similarly, 96% (n=70) of the patients who had 
undetectable viral loads at 96 weeks showed good adherence initially, compared with 
just 53% (n=32) of those with viral loads >50 copies/mL.  
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Figure 20. Comparison of number of patients achieving virological suppression to mean pill count 
adherence. 
 
Table 21 compares mean pill count adherence across the first 16 weeks of treatment to 
virological outcomes at 96 weeks.  
 
Mean pill count adherence (Week 0 – 16) Percent virologically suppressed (<50 
copies/mL) at 96 weeks 
0 – 9% (n=3) 0% 
10 – 19% (n=3) 0% 
20 – 29% (n=3) 0% 
30 – 39% (n=1) 0% 
40 – 49% (n=3) 0% 
50 – 59% (n=2) 0% 
60 – 69% (n=1) 0% 
70 – 79% (n=7) 14% 
80 – 89% (n=8) 25% 
90 – 100% (n=102) 69% 
 
Table 21. Associations between mean pill count adherence across the first 16 weeks of treatment and 
virological outcomes at 96 weeks. 
 
There was a negative correlation between lowest recorded pill count adherence during 
any 4-week interval within the first 16 weeks of treatment and HIV RNA level at 96 
weeks (r=-0.56). Only 25% of those with a lowest recorded pill count adherence during 
any 4-week interval within the first 16 weeks of treatment of <90% were suppressed at 
96 weeks.  
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Retention to care  
Retention to care was assessed at the 96-week visit. As outlined earlier, 7 patients died 
on treatment and 10 TFO to other facilities. Patients who died and TFO before the 96 
week visit were excluded from the retention to care analysis. (See Chapter 3 for 
definitions of deaths on treatment and TFO and justifications for their inclusion/ exclusion 
and data management).    
 
Patients were defined as LTFU if they had not returned to the clinic for 90 days or more 
since their last appointment. Patients who did not return to the clinic for 90 days or more 
after a clinic appointment but subsequently returned to the clinic during the 96-week 
monitoring period were not defined as LTFU. According to the definition, 95 patients 
(71%) were defined as retained in care ad 38 patients as LTFU. Patient outcomes from 
the retention to care analysis are presented in Figure 21. 
 
 
 
Figure 21. Patient outcomes in retention to care analysis (Week 96).    
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Achieving a mean pill count of !90% across the first 16 weeks of treatment was 
significantly associated with retention to care at 96 weeks ([chi]2(1) = 30.39, p<.0001). 
Eighty-three percent (n=85) of those who showed good adherence were retained in care 
at 96 weeks, compared with only 32% (n=10) of those with poor initial adherence (see 
Figure 22). Similarly, 90% (n=85) of the patients who were retained in care at 96 weeks 
showed good adherence initially, compared with just 45% (n=17) of those who were 
LTFU.  
 
Figure 22. Comparison of number of patients retained in care by mean pill count adherence. 
 
Table 22 compares mean pill count adherence across the first 16 weeks of treatment 
with retention outcomes at 96 weeks.  
 
Mean pill count adherence (Week 0 – 16) Percent retained in care at 96 weeks 
0 – 9% (n=3) 0% 
10 – 19% (n=3) 0% 
20 – 29% (n=3) 0% 
30 – 39% (n=1) 100% 
40 – 49% (n=3) 0% 
50 – 59% (n=2) 50% 
60 – 69% (n=1) 0% 
70 – 79% (n=7) 57% 
80 – 89% (n=8) 50% 
90 – 100% (n=102) 83% 
Table 22. Associations between mean pill count adherence across the first 16 weeks of treatment and 
retention outcomes at 96 weeks. 
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Similarly, the mean pill count adherence across the first 16 weeks of treatment amongst 
those retained in care at 96 weeks was 93%, compared with the mean pill count 
adherence of those LTFU at 96 weeks which was 57%, a difference that was highly 
significant (p<.0001).    
 
There was also a relationship between lowest recorded pill count adherence during any 
4-week interval within the first 16 weeks of treatment and retention in care at 96 weeks 
(p<.0001). Just 48% of those with a lowest recorded pill count adherence during any 4-
week interval within the first 16 weeks of treatment of <90% were retained in care at 96 
weeks, compared with 85% of those whose lowest recorded pill count adherence never 
fell below 90%.  
 
Composite adherence success 
The composite adherence success measure comprised th  three adherence indices 
described above: early pill count adherence, late virological suppression and retention to 
care. At the end of the study’s 96-week monitoring period, patients were defined as 
achieving composite adherence success if they had achieved !90% mean adherence 
across the first 16 weeks of treatment, achieved virological suppression at 96 weeks and 
it was <90 days since their last clinic visit. Patients were included in the analysis if there 
was any pill count, HIV RNA test or retention data recorded for them. For all patients 
who had TFO or been LTFU, and all but one of those who had died on treatment before 
the end of the 96 week follow-up period, pill count data from their first 16 week follow-up 
period was available. The single patient who had died just after Week 0 and before the 
next clinic visit had no pill count, HIV RNA test or retention data available and was 
excluded from the composite adherence success analysis, meaning that 149 patients 
were analysed.  
 
According to the above definition of composite adherence success, 80 patients (54%) 
achieved adherence success and 69 patients (46%) did not. Patient outcomes from the 
composite adherence success analysis are presented in Figure 23. 
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Figure 23. Patient outcomes in composite adherence success analysis (Week 0 – Week 96).   
 
Of the 69 patients who did not achieve adherence success, nine (13%) were assigned to 
the unsuccessful group because they had not achieved !90% mean pill count adherence 
during the first 16 weeks of treatment, twelve (18%) because they were LTFU at 96 
weeks, fifteen (22%) because they did not achieve virological suppression at the 96-
week visit, three (4%) because they had not achieved !90% mean pill count adherence 
during the first 16 weeks of treatment and were LTFU at 96 weeks, seven (10%) 
because they had not achieved !90% mean pill count adherence during the first 16 
weeks of treatment and did not achieve virological suppression at the 96-week visit, five 
(7%) because they were LTFU and did not achieve virological suppression at 96 weeks, 
and eighteen (26%) because they had not achieved !90% mean pill count adherence 
during the first 16 weeks of treatment and were LTFU and did not achieve virological 
suppression at 96 weeks. Figure 24 depicts the reasons for patients’ failure to achieve 
composite adherence success.  
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Figure 24. Reasons for failure to achieve adherence success.    
 
As discussed in Chapter 4, the study sample represented 29% of patients who initiated 
treatment during the study enrolment period (April 2007 – January 2008, n=521). 
Although pill count calculations are routinely performed at HCTC at each pharmacy visit, 
these data are only recorded in patient clinic files and so was unavailable for 
comparison. However, HIV RNA test and LTFU data are recorded on a well-maintained 
clinic database, as are death and TFO data. When the study sample was compared with 
the total who initiated treatment during the study enrolment period, there were no 
significant differences observed in regard to rates of death on treatment (p=.08), TFO 
(p=.09), virological suppression (p=.12) and retention to care (p=.08) (see Table 23). 
 
Outcome Sample (n = 150) HCTC initiated during study enrolment 
period (n = 521) 
Died on treatment 7 (5%) 38 (7%) 
TFO 10 (7%) 55 (11%) 
% Virologically 
suppressed at 96 
weeks 
88 (66%) 364 (70%) 
% Retained in care at 
96 weeks 
95 (71%) 408 (78%) 
 
Table 23. Comparison of study sample outcomes at 96 weeks with those of all patients initiating treatment at 
HCTC during the enrolment period. HCTC, Hannan Crusaid Treatment Centre; TFO, transferred out.   
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Factors associated with early pill count adherence 
Table 24 displays the factors significantly associated with early pill count adherence in 
chi-square analyses.  
 
Demographic 
Employed, p=.04 
Biomedical 
Report never having experienced haematological symptoms as a result of HIV, p=.01 
Report ever having experienced dermatological symptoms as a result of HIV, p=.01 
Psychological 
No presence of alcohol abuse on AUDIT scale, p=.0004 
Drinking alcohol less frequently, p=.0003 
Drinking fewer alcoholic drinks on a typical day of drinking, p=.008 
Drinking 6 or more drinks on one occasion no more than monthly, p=.0009 
Never being unable to remember what happened the night before because of drinking, p=.03 
Experiencing feelings of guilt or remorse after drinking less than monthly, p=.01 
Never failing to do what is expected because of drinking, p<.0001 
Score of !20 on Verbal Fluency Category Fluency: Total Correct, p=.04 
No set loss errors on the ‘animals’ semantic condition of Verbal Fluency,  p<.0001 
No repetition errors or 5 or more repetition errors across Verbal Fluency and Design Fluency, p=.04      
Social 
Knowing 3 or 4 people also on ART, p=.03   
Miscellaneous  
None 
 
Table 24. Factors significantly associated with achieving !90% mean early pill count adherence. AUDIT, 
Alcohol Use Disorders Identification Test.    
 
Demographic factors 
In bivariate analyses, employment status was the only demographic factor that was 
independently associated with achieving a mean pill count adherence of 90% or more 
during the first 16 weeks of treatment (see Figure 25). While 87% of patients who were 
employed (formally employed full-time or part-time or engaged in casual labour) at 
treatment initiation achieved a mean pill count adherence of 90% or more, only 71% of 
unemployed patients were able to do so, a difference that was statistically significant 
[[chi]
2(1) = 4.08,  p=.04].  
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Figure 25. Percentage of participants achieving mean pill count !90% by employment status.    
 
Patient gender (p=.31), age (p=.84), education (grade completed, p=.31; years of 
education, p=.86), disability grant status (p=.29) and income (p=.77) were not associated 
with early pill count adherence.  
 
Biomedical factors 
While ever having experienced one or more symptoms as a result of HIV, and the 
severity of these symptoms when they were reported, were not associated with early pill 
count adherence (p=.86 and p=.85), patients who reported ever having experienced 
haematological symptoms specifically (such as a ‘nodule in the neck’ or ‘swollen glands’) 
were significantly less likely to achieve a mean pill count adherence of 90% or more 
during the first 16 weeks of treatment: while only 46% of those who had experienced 
haematological symptoms were able to achieve early pill count adherence, 78% of those 
who had not experienced such symptoms managed to do so [[chi]
2(1) = 6.42,  p=.01] 
(see Figure 26). The relationship was confirmed in a corresponding t-test which showed 
a significant difference between the mean pill count adherence of those who had 
experienced haematological symptoms (mean pill count adherence, 73%) and the mean 
pill count adherence of those who had never experienced haematological symptoms 
(mean pill count adherence, 88%), p=.02. Conversely, patients who reported ever having 
experienced dermatological symptoms (such as ‘dandruff’ or ‘dry skin’) were significantly 
more likely to achieve !90% mean pill count adherence, with 88% of these patients 
achieving !90% adherence compared with 69% of patients not reporting dermatological 
symptoms [[chi]
2(1) = 6.20,  p=.01] (see Figure 27). Other reported symptoms were not 
significantly related to early pill count adherence, including respiratory (p=.86), urogenital 
(p=.85), cardiopulmonary (p=.80), ophthalmic (p=.15), psychiatric (p=.99), lymphatic 
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(p=.43), musculoskeletal (p=.73), neurological (p=.31), constitutional (p=.12) and 
gastrointestinal (p=.34) symptoms. (See Appendix I for symptom categorisations.)  
    
 
Figure 26. Percentage of participants with haematological symptoms achieving mean pill count !90%.    
 
Figure 27. Percentage of participants with dermatological symptoms achieving mean pill count !90%.    
 
No other investigated biomedical fac ors were associated with early pill count 
adherence, including CD4+ cell count at treatment initiation (p=.25), HIV RNA level at 
treatment initiation (p=.54), WHO stage (p=.74), time between positive HIV diagnosis 
and HAART initiation (p=.76), reason for HIV test (p=.16), pregnancy at treatment 
initiation (p=.37), TB therapy at treatment initiation (p=.74), neurological history (p=.80), 
having previously been exposed to ART (p=.10) and prescribed ARV regimen (p=.96).   
 
Psychological factors  
Scores on each of the individual knowledge questions as well as the composite 
knowledge score (p=.15) were not predictive of likelihood of achieving !90% mean pill 
count adherence across the first 16 weeks of treatment. This included awareness of 
latest CD4+ cell count result (p=.73), understanding the consequences of non-
adherence (p=.39), understanding the concept of resistance (p=.51) and knowing the 
required level of adherence (p=16). There was a trend towards a relationship between 
ability to name each of the ARV’s in the prescribed regimen and achieving !90% pill 
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count adherence, with 83% of those who could do so most likely to achieve !90% 
adherence, but this did not reach statistical significance (p=.06).  
 
Similarly, neither the attitudes towards or concerns about HIV and ART assessed at 
treatment initiation, nor the composite ARV attitudes score (p=.72) had any bearing on 
the likelihood of achieving mean pill count adherence of !90% across the first 16 weeks 
of treatment. Patients who thought HIV was not a ‘serious disease’ (p=.37), said they 
could ‘fight off HIV’ without HAART (p=.23), doubted the efficacy of the medication 
(p=.20), were concerned about ARV side-effects (p=.27), feared taking daily ARV’s 
would be an unwanted reminder of their HIV status (p=.85), and were unconvinced that 
the benefits of HAART would outweigh the drawbacks (p=.85) were equally likely to 
achieve !90% adherence as those with more positive attitudes. Patients’ degree of self-
efficacy (whether or not they believed they would be able to adhere to the extent 
required) (p=.13) and whether they ascribed primary responsibility for medication 
decision-making to themselves or to their health care provider (p=.14) were also not 
determinants of early pill count adherence.          
 
Neither the CES-D depression score (p=.14) nor any of its 20 individual questions was 
associated with early pill count adherence.  
 
Results showed strong associations between alcohol abuse at treatment initiation 
according to the AUDIT and early pill count adherence. While 87% of patients who 
scored seven or lower on the scale (indicating no presence of alcohol abuse) were able 
to achieve !90% mean pill count adherence across the first 16 weeks of treatment, just 
64% of patients who scored 8–15 and 57% of patients who scored 16 or higher 
managed to do so, a difference that was statistically significant [[chi]
2(2) = 15.60,  
p=.0004] (see Figure 28). The relationship between AUDIT score and pill count 
adherence was confirmed in corresponding t-tests which showed significant differences 
between the mean pill count adherence of those who scored seven or lower (mean pill 
count adherence, 94%), the mean pill count adherence of those who scored 16 or higher 
(mean pill count adherence, 77%), p=.0001, the mean pill count adherence of those who 
scored 8–15 (mean pill count adherence, 71%) and the mean pill count adherence of 
those who scored 16 or higher (mean pill count adherence, 77%), p=.001.  
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Figure 28. Percentage of participants achieving mean pill count !90% by AUDIT score.    
 
Six of the AUDIT’s 10 individual items independently predicted likelihood of achieving 
!90% mean pill count adherence across the first 16 weeks of treatment, including:  
1) How often an alcoholic drink is consumed (86% of those drinking monthly or less 
achieved !90% adherence compared with 76% of those drinking 2–4 times 
monthly, and 54% of those drinking twice or more weekly, p=.0003) 
2) The average number of alcoholic drinks consumed on a typical day of drinking 
(85% of those drinking one or two drinks achieved !90% adherence, compared 
with 71% of those drinking 3–6 drinks, and 56% of those drinking 7 or more 
drinks, p=.008) 
3) How often six or more drinks is consumed on one occasion (82% of those who 
did so monthly or less achieved !90% adherence, compared with just 56% of 
those who did so weekly or daily, p=.0009) 
4) How often they are unable to remember what happened the night before 
because of drinking (79% of those to whom this never happened achieved !90% 
adherence, compared with 73% of those to whom this happened monthly or less, 
and 50% of those to whom this happened weekly or daily, p=.03) 
5) How often they experience feelings of guilt or remorse after drinking (82% of 
those who did so less than monthly achieved !90% adherence, compared with 
64% of those that did so monthly, weekly or daily, p=.01) 
6) And a particularly strong association with how often they fail to do what is 
expected of them because of drinking (85% of those who never failed achieved 
!90% adherence, compared with 49% of those that did, p<.0001).  
 
Two other items (whether a friend, relative, doctor or other health care worker had been 
concerned about their drinking, and how often they could not stop drinking once they 
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had started) showed a trend towards a relationship with pill count adherence, but did not 
reach statistical significance (p=.08 and p=.09). Only two items on the AUDIT appeared 
unrelated to early pill count adherence: how often a drink was needed first thing in the 
morning after a heavy drinking session (p=.32) and whether they or someone else had 
been injured as a result of their drinking (p=.60).   
 
Marijuana use did not increase the likelihood of not achieving mean early pill count 
adherence !90% (p=.70). 
 
Three neuropsychological test scores predicted the likelihood of achieving mean pill 
count adherence !90% across the first 16 weeks of treatment. Two of these three scores 
were derived from the Verbal Fluency subtest of the D-KEFS, and one from both the 
Verbal Fluency and Design Fluency subtests. Patients who scored higher on the 
Category Fluency: Total Correct score (a combined measure of correctly generated 
animals and boys’ names within the Verbal Fluency subtest) were significantly more 
likely to achieve !90% early pill count adherence (p=.04). Specifically, 82% of those who 
could generate 20 or more correct (no set loss or repetitions) animals and boys’ names 
within the 120 seconds across the two conditions were later classified as good adherers 
according to pill count, compared with only 60% of those who could not. There was a 
particularly strong relationship between set loss (classification errors) on the animals 
semantic condition of the Verbal Fluency subtest and likelihood of achieving !90% early 
pill count adherence [[chi]
2(1) = 17.79, p<.0001]. While 79% of patients who made no set 
loss errors managed to achieve !90% early pill count adherence, only 13% of those who 
made one or more set loss errors did the same. Finally, patients who made either no 
repetition errors or many (5 or more) repetition errors across the Verbal Fluency and 
Design Fluency subtests were more often (83% versus 63%) adherent on early 
treatment, than those who made some (1–4) errors (p=.04).                  
 
Three other neuropsychological test scores from the Verbal Fluency subtest (set loss 
within the ‘A’ letter fluency trial, set loss across the two semantic fluency trials [animals 
and boys’ names], and all responses [including repetition and set loss errors] generated 
within the semantic switching trial) showed a trend towards a relationship with early pill 
count adherence, with patients who generated more responses and made less errors 
more likely to achieve !90% adherence, but did not reach statistical significance (77% 
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versus 50%, p=.06; 77% versus 56%, p=.06; and 61% versus 70%, 81% and 94%, 
p=.08 respectively).  
 
Three test scores from the D-KEFS Colour-Word Interference subtest also bordered on 
significance (self-corrected errors in the naming condition, all errors in the inhibition 
condition, and all errors across the subtest [82% versus 71% and 62%, p=.08; 94% 
versus 76% and 67%, p=.07; and 82% versus 69%, p=.08 respectively]), with patients 
who showed more errors less likely to achieve !90% adherence. One test score from the 
WMS Logical Memory subtest (combined measure of delayed recall of both units and 
themes from the second story) did the same (65% versus 77% and 86%, p=06), with 
patients who were able to recall more story units and themes more likely to achieve 
!90% adherence.  
 
No neuropsychological test scores from the D-KEFS Tower subtest or WMS Digit Span 
subtest predicted early pill count adherence.  
 
Social factors 
Only one social factor was a significant predictor of likelihood of achieving !90% 
adherence across the first 16 weeks of treatment. While knowing anyone else on ART 
(binary response) was not predictive of achieving !90% adherence (p=.57), the number 
of people patients knew who were also on ART was predictive (p=.03). Patients who 
knew three people on ART, and patients who knew four or more people on ART were 
most likely to achieve !90% adherence (100% of the first group and 92% of the second 
group managed to adhere), while patients who knew no-one, one person or two people 
were less like to achieve !90% adherence (77%, 72% and 57% from each group 
respectively managed to adhere) (see Figure 29). Patients’ relationships with those they 
knew on ART was not predictive however, with patients who had a partner or spouse on 
ART (p=.13), other family on ART (p=.64), a friend on ART (p=.38) or lived with 
someone on ART (p=.73) equally likely to achieve !90% adherence as those who did 
not.       
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Figure 29. Percentage of participants achieving mean pill count !90% by number of people also on ART 
known.    
 
Three other social factors approached significance as predictors of achieving !90% early 
pill count adherence. While 84% of patients who were not in a relationship achieved 
!90% adherence, 76% of those who were married or cohabiting, and 64% of those who 
were married but separated or in a non-cohabiting relationship managed to do so, 
although these associations did not reach significance (p=.09). For those with a partner, 
living with that partner increased the likelihood of adherence (77% compared 63% 
achieved !90% adherence, p=.05). For those with a partner, if that partner was HIV-
positive, the patient was more likely to adhere (78%) than if the partner was HIV-
negative (64%) (p=.05).       
 
No other social variables were predictive of early pill count adherence. Aside from the 
benefit just mentioned for those with a partner of living with that partner, no other 
household-related social variables influenced early pill count adherence, including 
household size (p=.83), and living with one’s child(ren) (p=.20), parent(s) (p=.86) or 
other family members (p=.17). Again, aside from the other benefit just mentioned of 
increased likelihood of achieving !90% adherence for those with a partner if that partner 
was HIV-positive, no other variables related to knowing HIV-positive others impacted on 
adherence, including knowing anyone (binary response) HIV-positive (p=.71), having an 
HIV-positive child (p=.16), family member (p=.52) or friend (p=.67), or the total number of 
HIV-positive people known (p=.41). 
 
Disclosure did not seem to affect patients’ ability to adhere. This included having 
disclosed to a partner (for those who had a partner) (p=.10), children (p=.62), parents 
(p=.14), other family members (p=.64) or friends (p=.27). Living with someone disclosed 
to (p=.16), disclosing to everyone in household (p=.81), living with someone disclosed to 
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who was also on ART and would remind them to take the ART (p=.19), attitudes towards 
ART of those disclosed to (p=.79) and the total number of people disclosed to (p=.18) 
did not affect early pill count adherence.   
 
No factors relating to the patient’s relationship with the health care provider impacted 
patients’ likelihood of achieving !90% early pill count adherence, including whether they 
saw the same doctor at clinic visits (p=.48), whether the doctors and nurses at the clinic 
spoke to them in their home language (p=.17), if they felt they could talk to  the doctors 
and nurses at the clinic about any problems they were having (p=.20) and whether they 
felt they could trust the doctors and nurses at the clinic (p=.32). The composite patient-
clinic relationship score (p=.26) was not of predictive value either.                           
 
Miscellaneous factors 
Use of material aids such as pill boxes (p=.33), cell phone alarms (p=.36) and wrist 
watch alarms (p=.85) did not impact ability to achieve !90% mean pill count adherence 
across the first 16 weeks of treatment.  
 
The mode of transport patients used to get to clinic visits (p=.14), how long it took them 
to travel to the clinic (p=.31), how much this transport cost them (p=.39) and whether or 
not they felt this cost was affordable (p=.24) did not influence the likelihood of achieving 
!90% mean pill count adherence. When asked to take both time and costs associated 
with clinic visits into account, patients who considered clinic visits convenient were no 
more likely to achieve !90% mean pill count adherence than those who did not (p=.12).     
 
In sum, several demographic, biomedical, psychological and social factors at treatment 
initiation were significantly associated with likelihood of achieving early pill count 
adherence !90% over the first 16 weeks of treatment. Patients who were employed were 
more likely to adhere (p=.04) as were patients who had never experienced 
haematological symptoms as a result of HIV (p=.01) and patients who had ever 
experienced dermatological symptoms as a result of HIV (p=.01). Patients who showed 
no presence of alcohol abuse on the AUDIT scale (p=.0004) and who reported drinking 
less frequently (p=.0003), drinking fewer alcoholic drinks on a typical day of drinking 
(p=.008), drinking six or more drinks on one occasion no more than monthly (p=.0009), 
never being unable to remember what happened the night before because of drinking 
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(p=.03), experiencing feelings of guilt or remorse after drinking less than monthly (p=.01) 
and never failing to do what is expected because of drinking (p<.0001) were most likely 
to adhere. Patients who scored !20 on the Verbal Fluency: Total Correct (p=.04), made 
no set loss errors on the ‘animals’ semantic condition of Verbal Fluency (p<.0001) and 
no repetition errors or five or more repetition errors across Verbal Fluency and Design 
Fluency (p=.04) did best. Finally, patients who knew three or four people also on ART 
(p=.03) were most likely to adhere.  
      
 
Factors associated with late virological suppression 
Table 25 displays the factors significantly associated with late virological suppression in 
chi-square analyses.  
 
Demographic 
Employed, p=.04 
No disability grant, p=.006 
Biomedical 
Reported ever having experienced urogenital symptoms as a result of HIV, p=.04 
Psychological 
No presence of alcohol abuse on AUDIT scale, p=.0001 
Drinking alcohol less frequently, p<.0001  
Drinking fewer alcoholic drinks on a typical day of drinking, p=.0005  
Drinking 6 or more drinks on one occasion no more than monthly, p=.0004 
Never being unable to remember what happened the night before because of drinking, p=.007 
Experiencing feelings of guilt or remorse after drinking less than monthly, p=.02 
Never failing to do what is expected because of drinking, p<.0001 
Never having had a friend, relative, doctor or health care worker concerned about their drinking, p=.007 
Never being unable to stop drinking once they had started, p=.003 
6 or fewer errors on Colour-Word Interference, p=.003   
2 or fewer self-corrected errors on Colour-Word Interference, p=.002 
Improving by 1-2, 3 or 4-5 points after second exposure in Logical Memory, p=.03 
Inability to recall longer number series in Digit Span, p=.04    
Social 
Living alone or with one other person, p=.007   
Miscellaneous  
Planning to use cell phone alarm as reminder, p=.0003   
 
Table 25. Factors significantly associated with achieving virological suppression. AUDIT, Alcohol Use 
Disorders Identification Test.     
 
Demographic factors 
In the bivariate analyses examining the relationships between demographic factors and 
the likelihood of achieving HIV RNA suppression (<50 copies/mL) at the 96 week visit, 
employment status at treatment initiation was again independently associated with 
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outcome. While 80% of patients who were employed achieved late virological 
suppression, just 61% of unemployed patients were able to do so, a difference that was 
statistically significant [[chi]2(1) = 4.06, p=.04] (see Figure 30).  
 
 
Figure 30. Percentage of participants achieving virological suppression by employment status.    
 
In addition, while disability grant status at treatment initiation had not been associated 
with early pill count adherence, it was independently associated with late virological 
suppression [[chi]2(2) = 10.31, p=.006]. Patients without a disability grant were most 
likely to achieve late virological suppression (82%); patients who already held a disability 
grant or had applied for one pending approval were less likely to be suppressed (65% 
and 53% respectively) (see Figure 31).   
 
 
Figure 31. Percentage of participants achieving virological suppression by disability grant status. DG, 
disability grant.   
 
Patient gender (p=.42), age (p=.17), education (grade completed, p=.31; years of 
education, p=.51) and income (p=.18) were not associated with late virological 
suppression.  
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Biomedical factors 
As with the early pill count adherence analyses, ever having experienced one or more 
symptoms as a result of HIV, and the severity of these symptoms when they were 
reported, were not associated with late virological suppression (p=.57 and p=.73). 
However, the reporting of specific symptoms was again predictive; in this analysis, 
having experienced urogenital symptoms (such as ‘discharge’ or ‘genital ulcers’) 
emerged as significantly associated with virological suppression at 96 weeks, with 100% 
of patients who reported ever having experienced urogenital symptoms suppressed 
compared with 64% of those who did not report urogenital symptoms [[chi]
2(1) = 4.35, 
p=.04] (see Figure 32).  
 
 
Figure 32. Percentage of participants achieving virological suppression by urogenital symptoms.    
 
Ophthalmic symptoms (such as ‘visual disturbances’) also approached significance 
[[chi]2(1) = 3.03, p=.08], in this case as a deterrent to achieving virological suppression, 
with only 33% of those who had experienced ophthalmic symptoms suppressed 
compared with 68% of those who had not. Other reported symptoms were not related to 
late virological suppression, including dermatological (p=.93), haematological (p=.67), 
respiratory (p=.97), cardiopulmonary (p=.71), psychiatric (p=.71), lymphatic (p=.49), 
musculoskeletal (p=.50), neurological (p=.30), constitutional (p=.69) and gastrointestinal 
(p=.61) symptoms.    
 
Although a trend towards a relationship between CD4+ cell count at treatment initiation 
and late virological suppression was clear, with patients who had lower CD4+ cell counts 
(<100 cells/"L and 100–199 cells/"L) less likely to achieve virological suppression at 96 
weeks than those with CD4+ cell count at treatment initiation >200 cells/"L (56%, 74% 
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and 75% respectively), this did not reach significance (p=.08). Another trend that also 
did not reach significance (p=.06) was seen in the relationship between having 
previously been exposed to ART and failure to virologically suppress at 96 weeks, with 
only 42% of the ART-exposed achieving suppression compared with 69% of the ART-
naïve.    
 
No other biomedical variables were predictive of late virological suppression, including 
HIV RNA level at treatment initiation (p=.44), WHO stage (p=.82), time between positive 
HIV diagnosis and HAART initiation (p=.39), reason for HIV test (p=.21), pregnancy at 
treatment initiation (p=.60), TB therapy at treatment initiation (p=.99), neurological 
history (p=.94) and prescribed ARV regimen (p=.93).   
 
Psychological factors 
As with the early pill count adherence analyses, scores on each of the individual 
knowledge questions as well as the composite knowledge score (p=.52) were not 
predictive of likelihood of achieving virological suppression at 96 weeks. This included 
awareness of latest CD4+ cell count result (p=.11), understanding the consequences of 
non-adherence (p=.43), understanding the concept of resistance (p=.77) and knowing 
the required level of adherence (p=14). In this analysis, there was no trend towards a 
relationship between ability to name each of the ARV’s in the prescribed regimen and 
achieving !90% mean pill count adherence (p=.46).  
 
Similarly, and as with the early pill count analysis, none of the attitudes towards or 
concerns about HIV and ART assessed at treatment initiation or the composite ARV 
attitudes score (p=.58) influenced late virological suppression. Patients who thought HIV 
was not a ‘serious disease’ (p=.31), said they could ‘fight off HIV’ without HAART 
(p=.79), doubted the efficacy of the medication (p=.63), were concerned about ARV 
side-effects (p=.61), feared taking daily ARV’s would be an unwanted reminder of their 
HIV status (p=.59), and were unconvinced that the benefits of HAART would outweigh 
the drawbacks (p=.45) were equally likely to achieve virological suppression as those 
with more positive attitudes. And, as with the early pill count analysis, whether patients 
ascribed primary responsibility for medication decision-making to themselves or their 
health care provider (p=.33) did not determine their likelihood of achieving virological 
suppression. While in the early pill count adherence analysis patients’ degree of self-
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efficacy for treatment adherence did not predict !90% adherence, in the late virological 
suppression analysis there was a trend towards a relationship between self-efficacy and 
likelihood of achieving virological suppression, with 69% of those who were very 
confident that they could take their ART regimen as prescribed, virologically suppressed 
at the 96 week visit, compared to just 47% of those who were quite confident, quite 
unconfident or very unconfident) (p=.06). 
 
As with the early pill count analysis, neither the overall CES-D depression score (p=.23) 
nor any of its 20 individual questions was associated with late virological suppression.  
 
Results examining the relationship between alcohol abuse at treatment initiation and late 
virological suppression at 96 weeks showed even stronger associations than those 
between alcohol abuse at treatment initiation and early pill count adherence across the 
first 16 weeks of treatment. This was true of the overall alcohol abuse score on the 
AUDIT (p=.0001 versus p=.0004), with 80% of patients who scored seven or lower 
achieving undetectable viral loads and just 47% of patients who scored eight or higher 
managing to do so (see Figure 33), and five of the AUDIT’s six items that had been 
significantly associated with early pill count adherence:  
1) How often an alcoholic drink is consumed (81% of those drinking monthly or less 
achieved virological suppression, compared with 67% of those drinking 2–4 times 
monthly, and 40% of those drinking twice or more weekly, p<.0001) 
2) The average number of alcoholic drinks consumed on a typical day of drinking 
(80% of those drinking one or two drinks achieved undetectable viraemia, 
compared with 61% of those drinking 3–6 drinks, 54% of those drinking 7–9 
drinks, and 33% of those drinking 10 or more drinks, p=.0005) 
3) How often six or more drinks is consumed on one occasion (76% of those who 
did so monthly or less achieved suppression compared with just 44% of those 
who did so weekly or daily, p=.0004) 
4) How often they were unable to remember what happened the night before 
because of drinking (73% of those who to whom this never happened achieved 
suppression, compared with 46% of those to whom this happened monthly or 
less, and 38% of those to whom this happened weekly or daily, p=.007) 
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5) How often they fail to do what is expected of them because of drinking (79% of 
those who never failed achieved suppression, compared with 34% of those that 
did, p<.0001).  
The other item that had been a significant predictor of early pill count adherence was 
also a predictor of late virological suppression: how often they experience feelings of 
guilt or remorse after drinking, with 74% of patients who did so less often than monthly 
achieving suppression, compared with 54% of those that did so monthly, weekly or daily 
(p=.02).   
 
 
Figure 33. Percentage of participants achieving virological suppression by AUDIT score.    
 
Furthermore, the two items that had been close to significance in the pill count 
adherence analyses (whether a friend, relative, doctor or other health care worker had 
been concerned about their drinking and how often they could not stop drinking once 
they had started) emerged as significant in this analysis, with 74% of those who had 
never had someone concerned achieving viral loads <50 copies/mL, compared with 51% 
of those who had, p=.007 and 74% of those who were never unable to stop drinking 
achieving suppression, compared with 44% of those who were unable to stop drinking 
monthly or less, and 38% of those who were unable to stop drinking weekly or daily, 
p=.003. One of the two items that had been unrelated to early pill count adherence (how 
often a drink was needed first thing in the morning after a heavy drinking session) 
approached significance in this analysis (p=.05), and the other remained insignificant 
(whether they or someone else had been injured as a result of their drinking, p=.13).     
 
As with the early pill count analysis, marijuana use did not increase the likelihood of 
having a detectable viral load at 96 weeks (p=.32). 
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Four neuropsychological test scores predicted the likelihood of achieving virological 
suppression at the 96 week visit. One of these four (all errors across the D-KEFS 
Colour-Word Interference subtest) had bordered on significance in the early pill count 
adherence analysis (p=.08), but reached significance in this analysis (p=.04), with 75% 
of those who made six or fewer errors achieving virological suppression, compared with 
58% of those who made seven or more errors. The other three neuropsychological test 
scores that were predictive of virological suppression at the 96 week visit had not been 
predictive of achieving !90% early pill count adherence. The first, also a marker of errors 
made across the D-KEFS Colour-Word Interference subtest but this time including only 
self-corrected errors, was highly significant (p=.002), with 83% of those who made two or 
fewer errors achieving virological suppression, compared with 61% of those who made 
three to six errors, and 49% of those who made seven or more errors. The second, from 
the WMS Logical Memory subtest, a marker of improved recall of a story after a second 
exposure to it, showed that those patients who did not improve at all, and those patients 
who improved dramatically were less likely to achieve viral suppression than those who 
improved by one–two, three, or four–five points, 66% and 50%, compared with 69%, 
74% and 82% respectively (p=.03). The fourth and final significant neuropsychological 
test score predictor of virological suppression at the 96 week visit was a marker of ability 
to accurately recall a series of numbers and repeat them back to the examiner both 
forwards and backwards from the Digit Span test. Here, the longer the series that the 
patient was able to recall, the less likely he or she was to achieve virological suppression 
(p=.04).  
 
One of the other two D-KEFS Colour-Word Interference subtests that had bordered on 
significance in the early pill count adherence analysis (self-corrected errors in the 
naming condition) continued to approach significance in this analysis (p=.09) while the 
other (all errors in the inhibition condition) did not show a trend towards significance in 
this analysis (p=.24). Another neuropsychological test score from the D-KEFS Colour-
Word Interference subtest (self-corrected errors in the inhibition condition) was close to 
significance in the late virological suppression analysis, with those patients who made 
more errors less likely to achieve virological suppression below 50 copies/mL at 96 
weeks (p=.08). Another neuropsychological test score from the WMS Logical Memory 
subtest, a combined measure of delayed recall of both units and themes from the 
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second story that had bordered on significance in the pill count analyses (p=.06), was 
not significant in this analysis (p=.61).  
 
None of the scores from the Verbal Fluency or Design Fluency subtests of the D-KEFS 
significantly predicted ability to achieve late virological suppression, including the two 
scores from the Verbal Fluency subtest that were predictive of early pill count adherence 
(a combined measure of correctly generated ‘animals’ and ‘names’, and set loss errors 
on the ‘animals’ semantic condition), the one score derived from the Verbal Fluency and 
Design Fluency subtests that was predictive of early pill count adherence (repetition 
errors) and the three scores from the Verbal Fluency subtest that showed a trend 
towards a relationship with early pill count adherence (set loss within the ‘A’ letter 
fluency trial, set loss across the two ‘animals’ and ‘boys’ names’ semantic fluency trials, 
and all responses generated within the semantic switching trial).  
 
As with the early pill count analyses, no neuropsychological test scores from the D-
KEFS Tower subtest predicted virological suppression at the 96 week visit.  
 
Social factors 
Only one social variable at treatment initiation was a significant predictor of virological 
suppression at 96 weeks. Patients who lived in smaller households (either alone or with 
one other person) were significantly more likely to achieve undetectable viral loads at 96 
weeks than those living in households of three or more people (89% versus 61%, 
p=.007) (see Figure 34). There was a trend towards a relationship between living with a 
parent and failure to achieve virological suppression, with just 55% of those living with a 
parent achieving suppression, compared to 71% of those who did not (p=.09). Although 
in the early pill count adherence analysis, for those who were in a relationship, living with 
that partner had been predictive of adherence, this was not a significant factor in the 
virological suppression analysis (p=.30). As with the early pill count analysis, living with 
one’s child(ren) (p=.70) or other family members (p=.21) did not impact virological 
suppression.  
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Figure 34. Percentage of participants achieving virological suppression against household size.    
 
While a significant predictive relationship had been observed between having an HIV-
positive partner and achieving !90% mean early pill count adherence (amongst those 
who had a partner), this relationship was not evident in the virological suppression 
analysis (p=.40). As with the early pill count adherence analyses, no other variables 
related to knowing HIV-positive others impacted virological suppression, including 
knowing anyone HIV-positive (p=.48), having an HIV-positive child (p=.15), family 
member (p=.73) or friend (p=.39), or the total number of HIV-positive people known 
(p=.71).  
 
While a significant predictive relationship had been observed between the number of 
people patients knew who were also on ART and their likelihood of achieving !90% 
mean early pill count adherence, this relationship was not evident in the virological 
suppression analysis (p=.13). As with the early pill count adherence analysis, no other 
variables related to knowing others on treatment impacted likelihood of achieving 
virological suppressio , including knowing anyone on ART (p=.13), knowing other family 
on ART (p=.83), knowing a friend on ART (p=.14) and living with someone on ART 
(p=.49). 
      
As with the early pill count adherence analysis, disclosure did not seem to affect 
patients’ likelihood of suppression. This includes having disclosed to a partner (for those 
who had a partner) (p=.13), children (p=.45), parents (p=.37), other family members 
(p=.61), total number of people disclosed to (p=.11), disclosing to everyone in household 
(p=.69), and attitudes towards ART of those disclosed to (p=.83). There was however a 
trend towards a predictive relationship between disclosing to a friend and failure to 
achieve virological suppression at 96 weeks (p=.09), and a predictive relationship 
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between living with someone disclosed to who was also on ART and had agreed to 
remind them to take the ART and success in achieving virological suppression 96 weeks 
(p=.08), with 87% of those to whom this applied achieving suppression compared with 
64% to whom this did not.   
 
Like with the early pill count adherence analysis, no factors related to the patient’s 
relationship with the health care provider impacted likelihood of achieving HIV RNA 
suppression, including whether they saw the same doctor at clinic visits (p=.62), whether 
the doctors and nurses at the clinic spoke to them in their home language (p=.35), if they 
felt they could talk to  the doctors and nurses at the clinic about any problems they were 
having (p=.89) and whether they felt they could trust the doctors and nurses at the clinic 
(p=.81). The composite patient-clinic relationship score (p=.63) was again not of 
predictive value either.                       
    
Miscellaneous factors 
Unlike the early pill count adherence analysis, use of a material aid was predictive of 
likelihood of achieving virological suppression. Specifically, 84% of patients who planned 
to use cell phone alarms were virologically suppressed at the 96 week visit, compared 
with 54% of those not planning to use them (p=.0003) (see Figure 35). Other material 
aids such as pill boxes (p=.82) and wrist watch alarms (p=.76) did not impact likelihood 
of achieving virological suppression.  
 
 
Figure 35. Percentage of participants achieving virological suppression against planned use of cell phone 
alarm as adherence reminder.    
 
As with the early pill count adherence analysis, the mode of transport patients used to 
get to clinic visits (p=.18), how long it took them to travel to the clinic (p=.65), how much 
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this transport cost them (p=.47) and whether or not they felt this was affordable (p=.11) 
did not influence the likelihood of achieving late virological suppression. And again, 
when asked to take both time and costs associated with clinic visits into account, 
patients who considered clinic visits convenient were no more likely to achieve HIV RNA 
suppression than those who did not (p=.32).     
 
In sum, several demographic, biomedical, psychological, social and miscellaneous 
factors at treatment initiation were significantly associated with likelihood of achieving 
late virological suppression at 96 weeks. Patients who were employed were more likely 
to adhere (p=.04) as were patients who did not hold and had not applied for a disability 
grant (p=.006) and patients who had ever experienced urogenital symptoms as a result 
of HIV (p=.04). Patients who showed no presence of alcohol abuse on the AUDIT scale 
(p=.0001) and who reported drinking less frequently (p<.0001), drinking fewer alcoholic 
drinks on a typical day of drinking (p=.0005), drinking six or more drinks on one occasion 
no more than monthly (p=.0004), never being unable to remember what happened the 
night before because of drinking (p=.007), experiencing feelings of guilt or remorse after 
drinking less often than monthly (p=.02), never failing to do what is expected because of 
drinking (p<.0001), never having had a friend, relative, doctor or health care worker 
concerned about their drinking (p=.007) and never being unable to stop drinking once 
they had started (p=.003) were most likely to be suppressed. Patients who made six or 
fewer total errors or two or fewer self-corrected errors on the Colour-Word Interference 
Test (p=.003 and p=.002), patients who improved by 1–2, 3 or 4–5 points after the 
second exposure in the Logical Memory Test (p=.03) and who could not recall a longer 
number series in the Digit Span test (p=.04) did best. Patients who lived alone or with 
one other person (p=.007) were most likely to achieve suppression. Finally, patients who 
planned to use a cell phone alarm as an adherence reminder (p=.0003) were most likely 
to be suppressed.   
      
 
Factors associated with retention to care 
Table 26 displays the factors significantly associated with retention to care at 96 weeks 
in chi-square analyses.  
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Demographic 
Employed, p=.009 
Biomedical 
Never having experienced ophthalmic symptoms as a result of HIV, p=.04 
Psychological 
No presence of alcohol abuse on AUDIT scale, p=.02 
Drinking alcohol less frequently, p=.02 
Drinking 6 or more drinks on one occasion no more than monthly, p=.01 
Experiencing feelings of guilt or remorse after drinking less often than monthly, p=.04 
Never failing to do what is expected because of drinking, p=.002 
Generating 7 or more words on the letter ‘A’ fluency trial of Verbal Fluency, p=.02 
Generating 16 or more words across all 3 letter fluency trials of Verbal Fluency, p=.03 
Generating 16 or more correct words across all 3 letter fluency trials of Verbal Fluency, p=.02 
Any repetition errors in the ‘animals’ semantic category of Verbal Fluency, p=.002   
More repetition errors across Verbal Fluency and Design Fluency, p=.04 
Higher proportion of original recall remembered in delayed recall in Logical Memory, p=.04    
Social 
Not living with family other than spouse, child, or parent, p=.02 
Not disclosing to family other than spouse, child, or parent, p=.03 
Not disclosing to a friend, p=.03       
Miscellaneous  
None 
 
Table 26. Factors significantly associated with retention to care at 96 weeks. AUDIT, Alcohol Use Disorders 
Identification Test.      
 
 
Demographic factors 
In the bivariate analyses examining the relationships between demographic factors and 
the likelihood of remaining in care at 96 weeks (consistent with earlier definition, patients 
not remaining in care had not returned to the clinic for 90 days or more since their last 
appointment and were not known to have transferred out to another treatment facility or 
died), employment status was once again associated with outcome, with 89% of patients 
who were employed at treatment initiation retained in care at 96 weeks compared with 
65% of unemployed patients [[chi]
2(1) = 6.84, p=.009] (see Figure 36). Disability grant 
status had been significantly associated with late virological suppression but was not 
related to retention to care (p=.18).  
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Figure 36. Percentage of participants retained in care by employment status.    
 
As with the early pill count and late virological suppression analyses, patient gender 
(p=.33), age (p=.86), education (grade completed, p=.35; years of education, p=.70), 
and income (p=.22) were not associated with retention to care.  
 
Biomedical factors 
As with the early pill count and late virological suppression analyses, ever having 
experienced one or more symptoms as a result of HIV, and the severity of these 
symptoms when they were reported, were not associated with retention to care (p=.77 
and p=.77). However, the reporting of a specific symptom was again predictive; in this 
analysis, having experienced ophthalmic symptoms (such as ‘visual disturbances’) 
(which had approached significance in the virological suppression analysis at p=.08) 
emerged as a significant barrier to retention to care, with only 33% of those who had 
experienced ophthalmic symptoms retained in care compared with 73% of those who 
had not [[chi]
2(1) = 4.47, p=.04] (see Figure 37). Other reported symptoms were not 
related to retention to care, including dermatological (p=.12), haematological (p=.41), 
respiratory (p=.34), cardiopulmonary (p=.87), psychiatric (p=.87), lymphatic (p=.34), 
musculoskeletal (p=.77), neurological (p=.27), constitutional (p=.89), urogenital (p=.82) 
and gastrointestinal (p=.41) symptoms.    
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Figure 37. Percentage of participants retained in care against ophthalmic symptoms.    
 
A trend towards a relationship between CD4+ cell count at treatment initiation and 
retention to care was seen (as had been the trend towards a relationship between CD4+ 
cell count at treatment initiation and late virological suppression), with patients who had 
the lowest CD4+ cell counts (<100 cells/"L) less likely to remain in care at 96 weeks 
than those with CD4+ cell count 100–199 cells/"L and >200 cells/"L (61%, 81% and 
75% respectively), although this did not reach significance (p=.06).  
 
No other investigated biomedical variables were predictive of retention to care, including 
HIV RNA level at treatment initiation (p=.91), WHO stage (p=.24), time between positive 
HIV diagnosis and HAART initiation (p=.59), reason for HIV test (p=.17), pregnancy at 
treatment initiation (p=.62), TB therapy at treatment initiation (p=.91), neurological 
history (p=.95), having previously been exposed to ART (p=.77) and prescribed ARV 
regimen (p=.94).   
 
Psychological factors 
As with the early pill count adherence and late virological suppression analyses, scores 
on each of the individual knowledge questions as well as the composite knowledge 
score (p=.20) were not predictive of likelihood of remaining in care at 96 weeks. This 
included awareness of latest CD4+ cell count result (p=.87), understanding the 
consequences of non-adherence (p=.80), understanding the concept of resistance 
(p=.75), ability to name each of the ARV’s in the prescribed regimen (p=.97) and 
knowing the required level of adherence (p=82).  
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As with the early pill count and late virological suppression analyses, none of the 
attitudes towards or concerns about HIV and ART assessed at treatment initiation or the 
composite ARV attitudes score (p=.35) influenced retention to care. Patients who 
thought HIV was not a ‘serious disease’ (p=.31), said they could ‘fight off HIV’ without 
HAART (p=.41), doubted the efficacy of the medication (p=.52), were concerned about 
ARV side-effects (p=.17), feared taking daily ARV’s would be an unwanted reminder of 
their HIV status (p=.30), and were unconvinced that the benefits of HAART would 
outweigh the drawbacks (p=.23) were equally likely to remain in care as those with more 
positive attitudes. Patients’ degree of self-efficacy for treatment adherence (p=.81) and 
whether they ascribed primary responsibility for medication decision-making to 
themselves or their health care provider (p=.47) were also not determinants of retention 
to care.          
 
As with the early pill count and virological suppression analyses, neither the overall 
CES-D depression score (p=.49) nor any of its 20 individual questions was associated 
with retention to care.  
 
Results showed associations between alcohol abuse at treatment initiation according to 
the AUDIT and retention to care, as they had with the previous outcomes. While 80% of 
patients who scored seven or lower on the scale remained in care, just 60% of patients 
who scored 8 or higher did so, a difference that was statistically significant (p=.02) (see 
Figure 38). 
 
 
Figure 38. Percentage of participants retained in care against AUDIT score.    
  
Four of the AUDIT’s 10 individual items independently predicted likelihood of remaining 
in care, including:  
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1) How often an alcoholic drink is consumed (79% of those drinking monthly or less 
remained in care, compared with 76% of those drinking 2–4 times monthly, and 
55% of those drinking twice or more weekly, p=.02) 
2) How often six or more drinks is consumed on one occasion (78% of those who 
did so monthly or less often remained in care, compared with just 56% of those 
who did so weekly or daily, p=.01) 
3) How often they experience feelings of guilt or remorse after drinking (78% of 
those who did so less often than monthly remained in care, compared with 62% 
of those that did so monthly, weekly or daily, p=.04) 
4) How often they fail to do what is expected of them because of drinking (79% of 
those who never failed remained in care, compared with 53% of those that did, 
p=.002).  
 
There was a trend towards a significant association between the average number of 
alcoholic drinks consumed on a typical day of drinking (p=.09), although this did not 
reach significance. The other five items appeared unrelated to retention to care: how 
often they are unable to remember what happened the night before because of drinking 
(p=.29), whether a friend, relative, doctor or other health care worker had been 
concerned about their drinking (p=.30), how often they could not stop drinking once they 
had started (p=.52), how often a drink was needed first thing in the morning after a 
heavy drinking session (p=.53) and whether they or someone else had been injured as a 
result of their drinking (p=.25).   
 
Marijuana use, as with early pill count and late virological suppression, did not increase 
the likelihood of not remaining in care at 96 weeks (p=.56). 
 
Six neuropsychological test scores predicted the likelihood of remaining in care at 96 
weeks. Four of these six scores derived from the Verbal Fluency subtest of the D-KEFS, 
one from both the Verbal Fluency and Design Fluency subtests, and one from the 
Logical Memory subtest of the WMS. Patients who were able to generate more words 
(including errors) in the ‘A’ letter fluency trial were more likely to remain in care, with 
83% of those who generated seven or more words remaining in care, compared with 
64% of those who generated six or less words [[chi]
2(1) = 5.80, p=.02]. Patients who 
were able to generate more words (including errors) across the three letter fluency trials 
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were more likely to remain in care, with 81% of those who generated 16 or more words 
remaining in care, compared with 57% of those who generated 15 or less words (p=.03). 
This was also true of correctly generated words (excluding errors) across the three letter 
fluency trials, with 76% of those who generated 16 or more words remaining in care, 
compared with 59% of those who generated 15 or less words (p=.02). Patients who 
made any repetition on the ‘animals’ semantic category trial and patients who made 
more repetition errors across the Verbal Fluency and Design Fluency subtests were 
likely (100% versus 66% and 85% versus 62% respectively) to remain in care at 96 
weeks than those who made no or fewer errors (p=.002 and p=.04). Finally, patients who 
were able to recall, after a delay, a greater proportion of the units and themes from the 
second story that they had originally recalled were more likely to remain in care, with 
88% of those who could recall all units and themes that they had originally recalled 
remaining in care, compared with 66% of those who remembered only some of the units 
and themes that they had originally recalled (p=.04). One other neuropsychological test 
score bordered on significance as a predictor of retention to care (correctly generated 
words in the ‘A’ letter fluency trial) (p=.08). 
 
No neuropsychological test scores from the D-KEFS Colour-Word Interference subtest, 
D-KEFS Tower subtest or WMS Digit Span subtest predicted retention to care.  
 
Social factors 
Three social factors were significant predictors of likelihood of remaining in care at 96 
weeks. Living with family members other than spouse, child(ren) or parent(s) was 
predictive of failure to remain in care, with 65% of those who did so remaining in care, 
compared with 84% of those who did not (p=.02) (see Figure 39). Disclosing to family 
members other than spouse, child(ren) or parent(s) was predictive of failure to remain in 
care, with 67% of those who had done so remaining in care, compared with 89% of 
those who had not (p=.03) (see Figure 40). Similarly, disclosing to friends was predictive 
of failure to remain in care, with 59% of those who had done so remaining in care, 
compared with 79% of those who had not (p=.03) (see Figure 41).The total number of 
people disclosed to approached significance as a predictor of retention to care (p=.06), 
with patients who disclosed to the smallest number of people more likely to be retained 
(87% of those who disclosed to no-one or one person, 74% of those who disclosed to 2–
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5 people, 73% of those who disclosed to 6–7 people and 55% of those who disclosed to 
8 or more people).   
 
 
Figure 39. Percentage of participants retained in care by household composition.    
 
 
Figure 40. Percentage of participants retained in care by disclosure to family.    
 
 
Figure 41. Percentage of participants retained in care by disclosure to friend(s).   
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While knowing anyone else on ART (p=.29), the number of people patients known on 
ART (p=.44), having a partner or spouse (p=.27) or friend on ART (p=.32), and living 
with someone on ART (p=.36) were not predictive of retention to care at 96 weeks, 
knowing family members other than spouse, child(ren) or parent(s) on ART approached 
significance (p=.06) as a predictor of loss to follow-up, with 56% of those who knew 
family members on ART remaining in care, compared with 75% of those who did not.  
 
Having disclosed to a partner (for those who had a partner) (p=.95), child(ren) (p=.81), or 
parent(s) (p=.91), living with someone disclosed to (p=.63), disclosing to everyone in 
household (p=.08), living with someone disclosed to who was also on ART and would 
remind them to take the ART (p=.86) and attitudes towards ART of those disclosed to 
(p=.91) were not predictive of retention to care.  
 
No factors related to the patient’s relationship with the health care provider impacted 
patients’ likelihood of remaining in care at 96 weeks, including whether they saw the 
same doctor at clinic visits (p=.45), whether the doctors and nurses at the clinic spoke to 
them in their home language (p=.33), if they felt they could talk to the doctors and nurses 
at the clinic about any problems they were having (p=.94) and whether or not they felt 
they could trust the doctors and nurses at the clinic (p=.64). The composite patient-clinic 
relationship score (p=.94) was not of predictive value either.                           
 
Aside from the relationship between living with family other than spouse, child(ren) and 
parent(s) and loss to follow-up mentioned earlier, no other household-related social 
variables influenced retention to care, including household size (p=.10), and living with 
one’s partner or spouse (p=23), child(ren) (p=.27), or parent(s) (p=.95). Again, aside 
from the relationship between knowing family other than spouse, child(ren) and parent(s) 
on ART and loss to follow-up mentioned earlier, no other variables related to knowing 
HIV-positive others impacted adherence, including knowing anyone (binary response) 
HIV-positive (p=.51), having an HIV-positive partner (p=.75), child (p=.28), other family 
member (p=.14), or friend (p=.32), or the total number of HIV-positive people known 
(p=.72).  
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Miscellaneous factors 
Use of material aids such as pill boxes (p=.82), cell phone alarms (p=.91) and wrist 
watch alarms (p=.39) did not impact retention to care at 96 weeks.  
 
As with the early pill count and virological suppression analyses, the mode of transport 
patients used to get to clinic visits (p=.70), how long it took them to travel to the clinic 
(p=.77), how much this transport cost them (p=.72) and whether or not they felt this was 
affordable (p=.66) did not influence the likelihood of remaining in care at 96 weeks. And 
again, when asked to take both time and costs associated with clinic visits into account, 
patients who considered clinic visits convenient were no more likely to remain in care 
than those who did not (p=.55).     
 
In sum, several demographic, biomedical, psychological and social factors at treatment 
initiation were significantly associated with likelihood of being retained in care at 96 
weeks. Patients who were employed were more likely to b  retained (p=.009) as were 
patients who never reported having experienced ophthalmic symptoms as a result of HIV 
(p=.04). Patients who showed no presence of alcohol abuse on the AUDIT scale (p=.02) 
and who reported drinking less frequently (p=.02), drinking six or more drinks on one 
occasion no more than monthly (p=.01), experiencing feelings of guilt or remorse after 
drinking less often than monthly (p=.04) and never failing to do what is expected 
because of drinking (p=.002) were most likely to be retained. Patients who generated 
seven or more words on the letter ‘A’ fluency trial, 16 or more words across all three 
letter fluency trials or 16 or more correct words across all three letter fluency trials of the 
Verbal Fluency Test (p=.02, p=.03 and p=.02), made any repetition errors in the 
‘animals’ semantic category of the Verbal Fluency Test (p=.002), made more repetition 
errors across the Verbal Fluency and Design Fluency Tests (p=.04) and who 
remembered, after a delay, a higher proportion of their original recall in the Logical 
Memory Test (p=.04) were more likely to remain in care. Finally, patients who did not live 
with family other than spouse, child or parent (p=.02), had not disclosed to family other 
than spouse, child or parent (p=.03) and patients who had not disclosed to a friend 
(p=.03) were most likely to be retained.   
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Factors associated with combined adherence success  
Table 27 displays the factors significantly associated with combined adherence success 
in chi-square analyses.  
 
Demographic 
Employed, p=.01 
Biomedical 
None 
Psychological 
Knowing none or all of the names of prescribed ARV’s in regimen, p=.04 
No presence of alcohol abuse on AUDIT scale, p=.02 
Drinking alcohol less frequently, p=.006 
Never failing to do what is expected because of drinking, p=.003 
No set loss errors on the ‘animals’ semantic condition of Verbal Fluency, p=.003 
Score of 20-29 on combined immediate recall of both stories on Logical Memory, p=.04 
Social 
Living with spouse or partner, p=.03    
Miscellaneous  
None 
 
Table 27. Factors significantly associated with achieving combined adherence success. AUDIT, Alcohol Use 
Disorders Identification Test.     
 
Demographic factors 
In the bivariate analyses examining the relationships between demographic factors and 
the likelihood of achieving combined adherence success over the 96-week study 
monitoring period (consistent with earlier definition, patients achieving combined 
adherence success had achieved success in each of the three adherence indices: mean 
pill count adherence of 90% or more across the first 16 weeks of treatment, retention to 
care and virological suppression at 96 weeks), employment status was once again 
associated with outcome, with 74% of patients who were employed at treatment initiation 
achieving combined adherence success compared with 46% of unemployed patients 
(p=.01) (see Figure 42). Disability grant status had been significantly associated with late 
virological suppression and bordered on significance in the combined adherence 
success analyses (p=.05), with patients without a disability grant most likely to achieve 
combined adherence success (66%); patients who already held a disability grant or had 
applied for one pending approval were less likely to achieve combined adherence 
success (50% and 44% respectively).   
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Figure 42. Percentage of participants achieving combined adherence success against employment status.   
 
As with the early pill count, late virological suppression and retention to care analyses, 
patient gender (p=.73), age (p=.53), education (grade completed, p=.34; years of 
education, p=.50) and income (p=.24) were not associated with combined adherence 
success.  
 
Biomedical factors 
As in the individual outcome analyses, ever having experienced one or more symptoms 
as a result of HIV, and the severity of these symptoms when they were reported, were 
not associated with the combined adherence success measure (p=.80 and p=.53). None 
of the specific symptoms were associated with the combined adherence success 
measure either, although there was a trend towards a relationship between having 
experienced ophthalmic symptoms (which had approached significance in the virological 
suppression analysis at p=.08 and emerged as a significant barrier in the retention to 
care analyses at p=.04), with 17% of those who had experienced ophthalmic symptoms 
achieving combined adherence success compared with 55% of those who had not 
[[chi]
2(1) = 3.45, p=.06]. Other reported symptoms were not related to combined 
adherence success, including dermatological (p=.10), haematological (p=.25), 
respiratory (p=.61), cardiopulmonary (p=.23), psychiatric (p=.88), lymphatic (p=.77), 
musculoskeletal (p=.79), neurological (p=.21), constitutional (p=.79), urogenital (p=.91) 
and gastrointestinal (p=.74) symptoms.    
 
Although a trend towards a relationship between having previously been exposed to 
ART and failure to achieve combined adherence success was seen, with only 29% of 
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the ART-exposed achieving combined adherence success compared with 56% of the 
ART-naïve, this did not reach significance (p=.05).  
 
No other biomedical variables were predictive of combined adherence success, 
including CD4+ cell count at treatment initiation (p=.62), HIV RNA level at treatment 
initiation (p=.47), WHO stage (p=.23), time between positive HIV diagnosis and HAART 
initiation (p=.53), reason for HIV test (p=.52), pregnancy at treatment initiation (p=.89), 
TB therapy at treatment initiation (p=.38), neurological history (p=.92) and prescribed 
ARV regimen (p=.73).   
 
Psychological factors 
As in the individual outcome analyses, scores on most of the individual knowledge 
questions as well as the composite knowledge score (p=.15) were not predictive of 
likelihood of achieving combined adherence success. This included awareness of latest 
CD4+ cell count result (p=.26), understanding the consequences of non-adherence 
(p=.14), understanding the concept of resistance (p=.73) and knowing the required level 
of adherence (p=.99). In this analysis however, there was a significant relationship 
between ability to name each of the ARV’s in the prescribed regimen and likelihood of 
achieving combined adherence success (p=.04), with patients who knew none or all of 
the names most likely to achieve success (65% and 62%) and patients who knew one or 
two names least likely to do so (44% and 38%) (see Figure 43). 
 
 
Figure 43. Percentage of participants achieving combined adherence success against number of ARV 
names in regimen known.   
 
As with the other outcome analyses, none of the attitudes towards or concerns about 
HIV and ART assessed at treatment initiation or the composite ARV attitudes score 
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(p=.22) influenced combined adherence success. Patients who said they could fight off 
HIV without HAART (p=.53), doubted the efficacy of the medication (p=.55), were 
concerned about ARV side-effects (p=.55), feared taking daily ARV’s would be an 
unwanted reminder of their HIV status (p=.42) and were unconvinced that the benefits of 
HAART would outweigh the drawbacks (p=.67) were equally likely to achieve combined 
adherence success as those with more positive attitudes. Patients’ degree of self-
efficacy for treatment adherence (p=.38) and whether they ascribed primary 
responsibility for medication decision-making to themselves or their health care provider 
(p=.80) were also not determinants of achieving combined adherence success. There 
was a trend towards a relationship between believing HIV was not a serious disease and 
achieving combined adherence success, with 64% of those who believed it was not a 
serious disease achieving combined adherence success across the study’s 96-week 
monitoring period, compared with 49% of those who believed it was a serious disease, 
although this did not reach significance (p=.08). 
 
As with the outcomes analyses, neither the overall CES-D depression score (p=.82) nor 
any of its 20 individual questions was significantly associated with combined adherence 
success. However, in this analysis, two of the individual items approached significance: 
the item measuring frequency of feelings of loneliness (p=.08) and the item measuring 
frequency of feelings of hope for the future (p=.05). In the negative item measuring 
loneliness, patients on both extremes (less than 3 days per week or more than 5 days 
per week) did best (58% as opposed to 37%), and in the positive item measuring hope, 
patients on both extremes did worst (52% as opposed to 63%).       
 
Results showed associations between alcohol abuse at treatment initiation according to 
the AUDIT and combined adherence success, as they had with each of the three 
individual outcomes. While 64% of patients who scored seven or lower on the scale 
achieved combined adherence success, just 38% of patients who scored 8 or higher did 
so, a difference that was statistically significant (p=.02) (see Figure 44).  
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Figure 44. Percentage of participants achieving combined adherence success by AUDIT score.   
 
Two of the AUDIT’s 10 individual items independently predicted likelihood of achieving 
combined adherence success: how often an alcoholic drink is consumed (64% of those 
drinking monthly or less frequently achieved combined adherence success, compared 
with 62% of those drinking 2–4 times monthly, and 30% of those drinking twice or more 
weekly, p=.006) and how often they fail to do what is expected of them because of 
drinking (63% of those who never failed, achieved success, compared with 53% of those 
that did, p=003). There were trends between three other items and combined adherence 
success, including: the average number of alcoholic drinks consumed on a typical day of 
drinking (p=.05), how often six or more drinks is consumed on one occasion (p=.05), and 
how often they experience feelings of guilt or remorse after drinking (p=.09). The other 
five items were not associated with combined adherence success: how often they are 
unable to remember what happened the night before because of drinking (p=.40), 
whether a friend, relative, doctor or other health care worker had been concerned about 
their drinking (p=.50), how often they could not stop drinking once they had started 
(p=.55), how often a drink was needed first thing in the morning after a heavy drinking 
session (p=.54) and whether they or someone else had been injured as a result of their 
drinking (p=.68).   
 
Marijuana use once again did not increase the likelihood of not achieving combined 
adherence success over the 96 weeks (p=.12). 
 
Two neuropsychological test scores predicted the likelihood of achieving combined 
adherence success across the 96-week study monitoring period. Set loss (classification 
errors) on the ‘animals’ semantic condition of the Verbal Fluency subtest was predictive 
(as it had been in the early pill count adherence analysis) [[chi]
2(2) = 9.80, p=.007]. The 
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number of units and thematic units immediately recalled across both stories in the WMS 
Logical Memory subtest was also predictive [[chi]2(36) = 51.86, p=.04].                     
 
No neuropsychological test scores from the D-KEFS Design Fluency subtest, D-KEFS 
Colour-Word Interference subtest, D-KEFS Tower subtest or WMS Digit Span subtest 
predicted combined adherence success.   
 
Social factors 
Only one social factor was predictive of combined adherence success. While 65% of 
patients who had a partner and who lived with that partner achieved combined 
adherence success across the study’s 96-week monitoring period, just 39% of patients 
who had a partner but did not live with that partner managed to do so (p=.03) (see 
Figure 45). Living with family other than spouse, child(ren) or parent(s) approached 
significance (p=.07), with 49% of those who lived with other family achieving combined 
adherence success, compared with 64% of those who did not. Relationship status also 
approached significance (p=.05), with 56% of patients who were not in a relationship, 
65% of those who were married or cohabiting, and 38% of those who were married but 
separated or in a non-cohabiting relationship achieving combined adherence success.  
 
 
Figure 45. Percentage of participants achieving combined adherence success against living with partner. 
Note: only participants who reported being in a relationship included in this analysis.   
 
No other social variables predicted combined adherence success, including all other 
household-related variables (household size, p=.60; living with child(ren), p=.40; living 
with parent(s), p=.10), variables related to knowing HIV-positive others (knowing anyone 
HIV-positive, p=.45; total number of HIV-positive others known, p=.25; having an HIV-
positive spouse or partner, child, other family or friend, p=.44, p=.21, p=.87 and p=.73), 
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variables related to knowing others on ART (knowing anyone on ART, p=.27; living with 
someone on ART, p=.83; total number of others on ART known, p=.29; having a spouse 
or partner, family member other than child or parent, or friend on ART, p=.12, p=.99 and 
p=.36), variables related to disclosure (total number disclosed to, p=.26; disclosure to 
partner, child)ren, parent(s), other family members, or friends, p=.59, p=.62, p=.20, 
p=.41 and p=.12; living with someone disclosed to, p=.10; disclosed to everyone in 
household, p=.33; living with someone disclosed to who was also on ART and would 
remind them to take ART, p=.14; attitudes towards ART of those disclosed to, p=.44) 
and variables related to the patient-health care provider relationship (whether they saw 
the same doctor at clinic visits, p=.93; whether the doctors and nurses at the clinic spoke 
to them in their home language, p=.41; if they felt they could talk to  the doctors and 
nurses at the clinic about any problems they were having, p=.83; whether they felt they 
could trust the doctors and nurses at the clinic, p=.95; composite patient-clinic 
relationship score, p=.46).                            
 
Miscellaneous factors 
Use of material aids such as pill boxes (p=.91), cell phone alarms (p=.12) and wrist 
watch alarms (p=.42) did not impact ability to achieve combined adherence success 
across the study’s 96-week monitoring period. 
 
The mode of transport patients used to get to clinic visits (p=.42), how much this 
transport cost them (p=.47) and whether or not they felt this was affordable (p=.34) did 
not influence the likelihood of achieving combined adherence success. When asked to 
take both time and costs associated with clinic visits into account, patients who 
considered clinic visits convenient were no more likely to achieve combined adherence 
success than those who did not (p=.33).     
 
In sum, several demographic, psychological and social factors at treatment initiation 
were significantly associated with likelihood of achieving combined adherence success 
across the first 96 weeks of treatment. Patients who were employed were more likely to 
achieve success (p=.01) as were patients who could name none or all of the names of 
the ARV medication in their regimen (p=.04). Patients who showed no presence of 
alcohol abuse on the AUDIT scale (p=.02) and who reported drinking less frequently 
(p=.006) and never failing to do what is expected because of drinking (p=.003) were 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Predicting adherence to antiretroviral therapy and retention to HIV care 
 
 
156 
most likely to succeed. Patients who made no set loss errors in the ‘animals’ semantic 
condition of the Verbal Fluency Test (p=.003) and scored 20–29 on combined immediate 
recall of both stories on the Logical Memory Test (p=.04) were more likely to achieve 
success. Finally, patients who lived with a spouse or partner (p=.03) were most likely to 
succeed.   
 
 
Multivariate analysis 
Logistic regression analysis was performed, with the combined adherence success 
measure as the dependent variable. As with the bivariate combined adherence success 
analyses, patients were included in the logistic regression analysis if there was any pill 
count, HIV RNA test or retention data recorded for them. For all patients who had TFO 
or been LTFU, and all but one of those who had died on treatment before the end of the 
96 week follow-up period, pill count data from their first 16 week follow-up period were 
available. The single patient who had died just after Week 0 and before the next clinic 
visit had no pill count, HIV RNA test or retention data available and was excluded from 
the regression analysis, meaning that 149 patients were analyzed.  
 
When the logistic regression analysis was performed, the following variables entered the 
model to predict the combined adherence success measure: number of alcoholic drinks 
consumed on a typical day of drinking (p=.002), CD4+ cell count (p=.004), relationship 
status (p=.009), proportion of original recall remembered in delayed recall of Logical 
Memory (p=.04), number of words generated on the letter ‘F’ fluency trial of Verbal 
Fluency (p=.06), planned use of cell phone alarm as reminder (p=.06), time taken to 
travel to clinic (p=.06) and age (p=.07) (see Table 28). The overall multivariate model 
had a Gini coefficient of .58 (58%).  
 
Predictor OR (95% CI) p-value 
Number of alcoholic drinks 
consumed on a typical day of 
drinking 
0.58 (0.41–0.82)  p=.002 
CD4+ cell count 0.61 (0.43–0.87) p=.004 
Relationship status 0.64 (0.44–0.92)  p=.009 
Proportion of original recall 
remembered in delayed recall 
of Logical Memory     
0.61 (0.38–0.99) p=.04 
Number of words generated 0.48 (0.24–0.95) p=.06 
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on the letter ‘F’ fluency trial of 
Verbal Fluency 
Planned use of cell phone 
alarm as reminder  
 
0.56 (0.31–1.02) p=.06 
Time taken to travel to clinic 0.41 (0.18–0.94)  p=.06 
Age 0.60 (0.38–0.94) p=.07 
 
Table 28. Predictors of combined adherence success measure in logistic regression analysis.  
 
 
RAT scorecard 
Based on the prediction model, a RAT and associated scorecard was developed for use 
in routine PHC ART clinics. The RAT was designed for use at first clinic presentation, in 
order to screen and accurately identify patients at highest risk for non-adherence and 
LTFU, so that targeted adherence support measures could be initiated.  
 
The tool consists of eight items, corresponding to the eight variables that entered the 
model to predict the combined adherence success measure. Two items are completed 
through clinic file review, four are asked directly of the patient, and two are completed 
through neuropsychological tests. Depending on the response to each item, a score is 
allocated. See Table 29 for items and associated scores.  
 
Question Score 
Clinic file review 
Age  <27 years – 4 
27 – 37 years – 14 
38 – 40 years – 32 
41 or older – 41   
Most recent CD4+ cell count result <100 cells/"L – 5 
100 – 199 cells/"L – 34 
!200 cells/"L – 44 
Interview 
How long does it take you to travel to the clinic 
(one-way)? 
<15 minutes – 34 
!15 minutes – 5  
What is your relationship status? Single – 28  
Widowed – 28 
Separated – 5  
In relationship, but not cohabiting – 5  
In a relationship and cohabiting – 40  
Married – 40   
How many drinks containing alcohol do you 
have on a typical day when you are drinking? 
0 drinks – 56  
1 – 3 drinks – 29 
4 or more drinks – 5  
Do you plan to use an alarm clock on your cell 
phone to help you to remember to take your 
Yes – 27  
No – 5  
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antiretrovirals?  
Neuropsychological assessment 
Administer Logical Memory subtest from 
Wechsler Memory Scale (WMS): 
Percent retention score 
Score <85% – 5  
Score 85% – 99% – 14 
Score 100% - 35 
Administer Verbal Fluency subtest from Delis-
Kaplan Executive Functions System (D-KEFS): 
F Total Responses 
<7 responses – 5 
7 – 10 responses – 27 
11 or more responses – 34  
 
Table 29. RAT questions and associated scores.   
 
The lowest possible achievable score is 39, and highest 311; lowest scores indicate 
highest likelihood of failing to achieve !90% mean pill count adherence across the first 
16 weeks of treatment, virological suppression and retention to care at 96 weeks.  
 
Score distributions for the sample are presented in Table 30. In order for the RAT to be 
utilised as a profiling tool and trigger for increased support, individual programmes may 
use the score distribution table to select the cut-off for advanced or diminished support 
based on resources and funding. Using the ‘Cumulative % of total’ column, an estimated 
proportion of the patient base may be selected for additional support. For instance, if the 
programme chose to offer increased support to the 25% of the overall population that is 
most likely to not achieve adherence success, a score of 146 would be selected as the 
cut-off. Selecting this cut-off would mean offering additional support to an estimated five 
patients per 150 patients who are likely to achieve adherence success (6.3% of the 
patient base who are likely to achieve adherence success) and an estimated 32 patients 
per 150 patients who are not likely to achieve adherence success (46.4% of the patient 
base who are not likely to achieve adherence success).  
 
Alternatively, using the ‘Cumulative % of those not achieving adherence success’ 
column, an estimated proportion of the patient base who are not likely to achieve 
adherence success may be selected for additional support. For instance, if the 
programme chose to offer increased support to 50% of the population that is most likely 
to not achieve adherence success, a score of 151 would be selected as the cut-off. 
Selecting this cut-off would mean offering additional support to an estimated seven 
patients per 150 patients who are likely to achieve adherence success (8.8% of the 
patient base who are likely to achieve adherence success) and an estimated 35 patients 
per 150 patients who are not likely to achieve adherence success (50.7% of the patient 
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base who are not likely to achieve adherence success).   
 
Score Cumulative 
no. of those 
achieving 
adherence 
success 
 
Cumulative
% of those 
achieving 
adherence 
success 
Cumulative 
no. of those 
not 
achieving 
adherence 
success 
Cumulative 
% of those 
not 
achieving 
adherence 
success 
Cumulative 
% of total 
Cumulative 
default rate 
 
 
 
61 0 0 1 1.4 0.7 100 
70 0 0 2 2.9 1.3 100 
71 0 0 3 4.3 2 100 
82 0 0 4 5.8 2.7 100 
95 0 0 5 7.2 3.4 100 
97 0 0 6 8.7 4 100 
102 0 0 8 11.6 5.4 100 
107 0 0 9 13 6 100 
110 0 0 10 14.5 6.7 100 
112 0 0 12 17.4 8.1 100 
114 0 0 13 18.8 8.7 100 
116 1 1.3 13 18.8 9.4 92.9 
117 1 1.3 14 20.3 10.1 93.8 
118 1 1.3 15 21.7 10.7 93.8 
121 1 1.3 16 23.2 11.4 94.1 
123 1 1.3 17 24.6 12.1 94.4 
125 2 2.5 17 24.6 12.8 89.5 
128 2 2.5 18 26.1 13.4 90 
130 3 3.8 19 27.5 14.8 86.4 
131 4 5 21 30.4 16.8 84 
132 4 5 22 31.9 17.4 84.6 
133 4 5 23 33.3 18.1 85.2 
134 4 5 24 34.8 18.8 85.7 
135 4 5 26 37.7 20.1 86.7 
142 4 5 28 40.6 21.5 87.5 
143 5 6.3 29 42 22.8 85.3 
144 5 6.3 30 43.5 23.5 85.7 
145 5 6.3 31 44.9 24.2 86.1 
146 5 6.3 32 46.4 24.8 86.5 
150 5 6.3 33 47.8 25.5 86.8 
151 7 8.8 35 50.7 28.2 83.3 
152 9 11.3 37 53.6 30.9 80.4 
153 9 11.3 38 55.1 31.5 80.9 
154 9 11.3 40 58 32.9 81.6 
156 10 12.5 40 58 33.6 80 
157 12 15 40 58 34.9 76.9 
160 13 16.3 40 58 35.6 75.5 
161 14 17.5 42 60.9 37.6 75 
163 15 18.8 42 60.9 38.3 73.7 
164 16 20 44 63.8 40.3 73.3 
165 18 22.5 45 65.2 42.3 71.4 
169 18 22.5 46 66.7 43 71.9 
170 19 23.8 47 68.1 44.3 71.2 
171 19 23.8 48 69.6 45 71.6 
172 20 25 50 72.5 47 71.4 
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173 21 26.3 50 72.5 47.7 70.4 
174 23 28.8 52 75.4 50.3 69.3 
175 24 30 52 75.4 51 68.4 
176 25 31.3 52 75.4 51.7 67.5 
177 25 31.3 53 76.8 52.3 67.9 
179 27 31.8 53 76.8 53.7 66.3 
180 28 35 53 76.8 54.4 65.4 
181 30 37.5 53 76.8 55.7 63.9 
182 33 41.3 53 76.8 57.7 61.6 
183 34 42.5 54 78.3 59.1 61.4 
184 35 43.8 55 79.7 60.4 61.1 
185 36 45 55 79.7 61.1 60.4 
186 39 48.8 55 79.7 63.1 58.5 
187 39 48.8 56 81.2 63.8 58.9 
188 40 50 57 82.6 65.1 58.8 
189 40 50 58 84.1 65.8 59.2 
191 41 51.3 58 84.1 66.4 58.6 
192 42 52.5 58 84.1 67.1 58 
194 43 53.8 58 84.1 67.8 57.4 
195 47 58.8 61 88.4 72.5 56.5 
196 48 60 61 88.4 73.2 56 
197 50 62.5 61 88.4 74.5 55 
199 50 62.5 62 89.9 75.2 54.4 
203 50 62.5 63 91.3 75.8 55.8 
204 51 63.8 64 92.8 77.2 55.7 
205 52 65 64 92.8 77.9 55.2 
207 54 67.5 64 92.8 79.2 54.2 
208 55 68.8 64 92.8 79.9 53.8 
209 57 71.3 64 92.8 81.2 52.9 
210 58 72.5 65 94.2 82.6 52.8 
211 59 73.8 66 95.7 83.9 52.8 
213 59 73.8 67 97.1 84.6 53.2 
214 60 75 67 97.1 85.2 52.8 
215 62 77.5 68 98.6 87.2 52.3 
216 64 80 68 98.6 88.6 51.5 
217 68 85 68 98.6 91.3 50 
220 69 87.3 68 98.6 91.9 49.6 
221 71 88.8 68 98.6 93.3 48.9 
222 72 90 68 98.6 94 48.6 
224 73 91.3 68 98.6 94.6 48.2 
226 75 93.8 68 98.6 96 47.6 
228 76 95 68 98.6 96.6 47.2 
230 77 96.3 68 98.6 97.3 46.9 
235 78 97.5 68 98.6 98 46.6 
239 79 98.8 68 98.6 98.7 46.3 
241 79 98.8 69 100 99.3 46.6 
245 80 100 69 100 100 46.3 
 
Table 30. Sample’s RAT score distributions   
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CHAPTER 6 
Interpretations and implications 
 
 
 
New HAART regimens for the treatment of HIV disease can dramatically reduce HIV-
related morbidity and mortality and improve patients’ clinical and immunological health 
where they are available. However, the regimens are chronic and unforgiving of even 
modest or occasional treatment lapses, which can lead to HIV viral load rebound and 
ultimately antiretroviral resistance (Catz et al., 2000). In resource-constrained, high 
prevalence settings like South Africa, transmissible drug resistant strains are a real fear 
and the consequences profound, both for individual and public health. Retention in ART 
programmes is a precursor to medication adherence and is as essential for programme 
success. Promotion of good antiretroviral adherence and retention to care is imperative.     
 
The aim of this study was to look at the role played by various demographic, biomedical, 
psychological and social factors in determining HIV outcomes in a resource-limited 
setting in Southern Africa. The study extended the research in this area by conducting 
bivariate and logistical regression analyses to determine which factors were associated 
with adherence outcomes.  
 
One of the key strengths of this study was that it captured longitudinal rather than cross-
sectional data, allowing for the determination of causal inferences rather than just 
associations. Of those studies that have included longitudinal data, most are measured 
over short periods; some only days (Spire et al., 2002; Tesoriero et al., 2003; Wagner, 
2002; Wagner et al., 2002). Because HAART requires life-long adherence to be 
beneficial, research was needed to examine predictors of long-term adherence. Another 
strength was the sample composition of mostly treatment-naïve patients (91% had never 
been exposed to previous therapy; of the 14 who had, 10 had received sd-NVP as 
PMTCT, two had participated in previous ART drug trials, and two had defaulted 
treatment and presented during the study period for re-initiation). This eliminated 
uncertainty as to the direction of the relationships found (for instance, studies showing 
relationships between depression and ART adherence in non-naïve patients cannot 
determine whether poor adherence led to depression or depression led to poor 
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adherence), and further bolstered the capacity of the study to determine causal 
inferences. Another was the choice of four different complementary methods of 
assessing, evaluating and classifying adherence: early pill count adherence, late 
virological suppression, retention to care and a composite measure of all three. The two 
medication adherence indicators (pill count and viral load) have both been repeatedly 
validated in HIV-positive populations (Bisson et al., 2006; Golin et al., 2002; Gordillo et 
al., 1999; Laniece et al., 2003; Roco et al., 1999; van Oosterhout et al., 2005; Weidle et 
al., 2006). This intensive measurement approach was designed to capture the complex 
variations in adherence from different angles and was in accordance with adherence 
editorials and reviews advocating a multi-component approach to adherence 
measurement (Chesney, 2000; Turner & Hecht, 2001; Wutoh et al., 2003). Finally, the 
study included testing of neurocognitive functioning, a factor which, although repeatedly 
identified in numerous studies investigating reported barriers to adherence (Brigado et 
al., 2001; Chesney et al., 2000; Golin et al., 2002; Murphy et al., 2000; Pienaar et al., 
2006; Roberts, 2000; Spire et al., 2002; Weidle et al., 2006), has rarely been objectively 
assessed in observational adherence research, likely due to the skill-set and associated 
expense involved in such testing. The study design and methodology allowed the 
researcher to determine valid and reliable predictors of ARV nonadherence and LTFU to 
follow-up in the South African context, and represented a significant methodological 
improvement over past studies in the field.  
 
The demographic and clinical distributions of participants enrolled in the study (n=150) 
largely reflected those of the total clinic population (n=4,302) and the population initiating 
treatment during the study enrolment period (n=521). In the sample, total clinic 
population and the population initiating treatment during the study enrolment period, 
women predominate (63%, 67% and 68% respectively) and mean age (34 years, 35 
years and 34 years), mean CD4+ cell count (119 cells/!L, 115 cells/!L and 121 
cells/!L), proportion of patients with viral loads >500,000 copies/mL (11%, 10% and 
11%), proportion of patients classified as WHO stage III/IV (76%, 74% and 69%), and 
proportion of women pregnant (13%, 15% and 14%) were very similar.  
 
The demographic and clinical characteristics of the study sample are also broadly 
representative of public-sector patients accessing ART in South Africa and even public-
sector patients accessing ART in sub-Saharan Africa. In the study sample, women 
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predominate (63%), which is also characteristic of a recent cohort analysis of 44,177 
ART patients from eight public sector programmes across South Africa (Cornell et al., 
2010) (68%), and a meta-analysis of 74,289 ART patients across 33 cohorts in 13 sub-
Saharan countries (Rosen et al., 2007) (54%). The sample’s mean age of 34 years is 
just slightly younger than the median age of the recent South African cohort analysis (35 
years), and the weighted mean age of the sub-Saharan meta-analysis at (35.5 years). 
The mean starting CD4+ cell count of 119 cells/!L is slightly higher than the median 
starting CD4+ cell count of the recent South African cohort analysis (103 cells/!L), and 
lower than the weighted mean starting CD4+ cell count of the sub-Saharan meta-
analysis (132 cells/!L). The median plasma starting viral load level of 4.98 log10 RNA 
copies/mL is slightly higher than the recent South African cohort analysis (4.9 
copies/mL). Seventy-six percent of the sample were classified as WHO stage III/IV, 
slightly less than the recent South African cohort analysis (80%). Starting viral load and 
WHO stage data was not presented for the sub-Saharan meta-analysis. 
 
The findings confirm the presence of symptoms associated with depression according to 
the CES-D in a substantial proportion of patients. Thirty-nine percent showed prominent 
depressive symtomatology: 15% had symptoms associated with mild to moderate 
depression and 23% displayed symptoms associated with a major depressive episode. 
There is a dearth of epidemiological data on the prevalence of psychiatric disorders in 
South Africa; until 2008 there had been no nationally representative data. In that year, 
Stein et al. (2008) reported results from a national household survey conducted with 
over 4,000 adult South Africans and found a lifetime prevalence of major depression of 
9.8%. This study’s sample presented with current symptomatology associated with a 
major depressive episode at more than double the lifetime prevalence of the national 
sample.  
 
HIV infection has long been identified as a risk factor for major depressive disorder 
globally (Bing et al., 2001); a systematic review and meta-analysis showed that HIV-
positive individuals have nearly double the rate of major depression as HIV-negative 
individuals (Ciesla & Roberts, 2001). Prevalence rates range widely, from 0% (Fukunishi 
et al., 1997) to 49% (Dew et al., 1997), with differences across studies likely a function of 
both methodological variations (e.g. use of structured psychiatric interviews versus self-
report symptom checklists) and differences in study populations (e.g. injection drug 
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users versus general adult populations) (Rabkin, 2008). Considering the previously 
reported association between depressive symptoms and higher mortality rates (Ickovics 
et al., 2001; Wilkie et al., 1998), these results call for early identification and treatment of 
depression in this population for the sake of both mental health and survival time. The 
latest South African Department of Health clinical guidelines for HIV/AIDS management 
(Department of Health, 2010a) do stipulate the conduct of ‘a basic psychological 
assessment to document social issues and current psychological state’ before treatment 
initiation (p.12) and that clinicians ‘treat depression and substance abuse’ (p.17). 
However there is a chronic lack of mental health human resources at PHC level. This is 
evidenced in the study’s sample: while 39% of the sample showed prominent depressive 
symptomatology, just two patients (1%) had a documented history of depression in their 
clinic files.  
 
Alcohol abuse rates were also high in this sample with 41% classified according to the 
AUDIT as engaging in alcohol consumption that was hazardous or harmful. Stein et al.’s 
(2008) national survey found a lifetime prevalence of alcohol abuse of 11.4% in the 
general population. The comparatively high rate in this sample is a strong call to 
prioritise the identification and treatment (either pharmacologically or behaviourally) of 
substance abuse in ART-initiating populations in South Africa. Previous international 
literature has already shown that a disproportionate number of HIV-infected individuals 
exhibit substance use disorders relative to the general adult population (Chander, 
Himelhoch & Moore, 2006), with prevalence rates ranging from 8% (Galvan et al., 2002) 
to 41% (Lefevre et al., 1995). This may in part be explained by the role played by 
premorbid alcohol abuse in increasing sexual risk behaviour and HIV acquisition (Fisher, 
Bang, & Kapiga, 2007; Simbayi et al., 2006), but is also likely a function of alcohol abuse 
as a behaviour adopted in dealing with HIV disease and its associated challenges.     
 
Optimal medication adherence ("90%) was achieved by 112 participants (75%) across 
the first 16 weeks of treatment, and the sample’s mean pill count adherence across the 
period was 87%. As outlined in Chapter 1, ART outcomes literature reports highly 
variable adherence rates across programmes, with mean adherence levels ranging from 
71% to 100% (Lima et al., 2009; Weidle et al., 2006). For instance, a Ugandan study 
reported 99% of patients to be adherent (Weidle et al., 2006), contrasted with a 
Canadian study in which only 129 of the 278 patients participating in the study (46%) 
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were adherent (Palepu et al., 2006). The WHO’s recommended strategy for prevention 
and assessment of HIVDR in resource-limited countries suggests a target of >90% of 
ART patients taking >90% of each of their prescribed drugs at each clinic visit. In this 
representative sample of 150 newly-initiated HAART patients, the finding that this target 
is far from being reached, with one quarter of the cohort unable to adhere to the 
regimen, is of concern. Given the importance of ARV adherence for optimal clinical 
response and the associated nonadherence risks of patient illness and death, HIV 
transmission, and single- and multi-drug resistance, it is critical that programmes be 
adapted to increase this level.  
 
In the sample, excluding deaths and TFO, 38 patients (29%) were LTFU at 96 weeks. As 
discussed, LTFU rates, like adherence levels, vary widely across reports, programmes 
and study populations. Studies in Uganda (Kabugo et al., 2005) and Cameroon (Guiard-
Schmid et al., 2004) have reported LTFU rates as high as 39.3% and 38.5%, while a 
study from Khayelitsha, South Africa (Coetzee et al., 2004) reported the extremely low 
rate of 0.3%. In the systematic review of 33 patient cohorts from sub-Saharan Africa, 
LTFU was highly variable, ranging from 15% to 54%, with a weighted mean of 40% at 24 
months, also largely due to LTFU (figure not given) (Rosen et al., 2007). In the recent 
cohort analysis of patients across 8 public sector programmes across South Africa, the 
LTFU rate was 22% at 24 months, a level that, although lower than that of this sample, 
the authors considered to be a ‘major threat’ to the national programme (Cornell et al., 
2010, p.2266). The WHO’s recommended strategy for prevention and assessment of 
HIVDR in resource-limited countries suggests a target of <20% LTFU in first year of ART 
(Bennet et al., 2008). With a LTFU rate of 29% at 96 weeks, this sample has far from 
met that target.  Since retention to clinical care is a precursor to medication adherence, 
attrition from ART programmes raises many of the same issues as described with regard 
to ART adherence. Reaching and maintaining low LTFU rates in ART programmes is 
key to ensuring continuity of treatment so that patients reap the survival benefits of ART, 
halt disease transmission and minimise both their own and society-wide resistance. 
 
The results of this study show that when deaths (n = 7), TFO (n = 10) and LTFU (n = 38) 
are excluded, 73 patients (77% of the 95 patients retained in care) were virologically 
suppressed (<50 copies/mL) at 96 weeks. This outcome compares favourably with 
international benchmarks. A meta-analysis of ART programmes in resource-poor 
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settings which included 10 observational cohorts found the weighted mean proportion of 
patients with undetectable viral loads at 24 months to be .496, although this 24-month 
estimate only included data from the 3 studies which provided long-term data - South 
Africa (Coetzee et al., 2004), Cote D’Ivoire (Seyler et al., 2003) and Kenya (Macharia et 
al., 2003) (Ivers et al., 2005). The WHO’s recommended strategy for prevention and 
assessment of HIVDR in resource-limited countries suggests a target of >70% of 
patients, who, at 12 months, had an HIV RNA level of less than the detection limit of the 
test used (Bennet et al., 2008), a target that was met in this cohort at the 96 week 
assessment.  
 
The significant association between achieving a mean pill count of "90% across the first 
16 weeks of treatment and achieving virological suppression (<50 copies/mL) at 96 
weeks (p<.0001) suggests that pill count correlates well with actual adherence in this 
study, and confirms the choice to use pill counts as a proxy measure of pill-taking 
behaviour. That finding, along with the association between achieving a mean pill count 
of "90% across the first 16 weeks of treatment and retention to care at 96 weeks 
(p<.0001), shows that patients who are unlikely to achieve optimal treatment outcomes 
and/ or leave care may be identified early on in the treatment process. The increases in 
percentage of patients who were virologically suppressed by 10% mean pill count band 
confirms that even modest deviations in pill-taking can dramatically alter long-term 
treatment outcomes.  
 
The sample’s mean pill count adherence changed significantly during the 16-week 
monitoring period, decreasing with each 4-week interval (p = .01). The percentage of 
patients achieving a mean pill count adherence of "90% also decreased appreciably 
with time. This finding is consistent with several other observational cohorts also 
reporting decreases in adherence rates with time (Carrieri et al., 2003; Liu et al., 2001; 
Parruti et al., 2006; Roco et al., 1999). These results suggest that adherence 
interventions are needed throughout the treatment course rather than just treatment 
readiness preparations at the onset.  
 
This study identified unemployed patients as being more likely to be nonadherent 
according to all four indices of adherence behaviour measured: early pill count 
adherence, late virological suppression, retention to care and the composite adherence 
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success measure. The finding is supported by two previous studies; one, a cross-
sectional study of 366 HAART patients in Spain wherein having a job was associated 
with better adherence (Gordillo et al., 1999), the other a qualitative series of interviews 
conducted with 18 clinicians at various community centers conducting ARV trials, where 
the most frequently mentioned barrier to patient recruitment, retention and adherence 
was unemployment (endorsed by 45% of clinicians) (Morse et al., 1995).  
 
Since neither education nor income was related to any of these four indices in this 
sample, it seems that the relationship was not mediated by either of these factors. 
Similarly none of the disease markers assessed in the study (CD4+ cell count, viral load 
and WHO stage) were significantly associated with any of these four indices, ruling 
severity of illness out as an explanation for both unemployment status and poor 
adherence. Other explanations could be that patients who are without employment might 
also consume more alcohol or be more cognitively impaired. It is possible that patients 
who are unemployed lead less structured lifestyles than their employed counterparts, 
with routine and schedule fluctuations that do not lend themselves to adherence to a 
daily medication regimen. It is perhaps surprising that these patients were also less likely 
to be retained in care at 96 weeks, since clinic visits should have been less challenging, 
as missing work, a factor found in previous studies (Do et al., 2010; Maskew et al., 2007; 
Weiser et al., 2003) to be a barrier to clinic attendance, would not have been a difficulty. 
It may be the case then that unemployed patients were lost to follow-up from the clinic, 
not because clinic visits themselves were difficult, but because they had struggled with 
medication adherence, and were thus less motivated to attend further visits, of which two 
of the primary focuses are dispensing of medication and adherence assessments. 
Further research is needed to clarify the exact mechanisms determining the association 
between unemployment and nonadherence and loss to follow-up. In the interim, special 
attention to this patient group in ART counseling and possible coordination of medical 
treatment with social services could increase adherence and facilitate retention to care in 
ART programmes.     
 
In this study, those patients who had already obtained or applied for a disability grant at 
initiation of HAART were less likely to be virologically suppressed at 96 weeks than 
those who did not hold a disability grant and did not plan to apply for one. Disability 
grants are awarded based upon a number of criteria, most notably a confirmation from a 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Predicting adherence to antiretroviral therapy and retention to HIV care 
 
 
 
168 
medical practitioner that the patient is unfit (physically or mentally) to work, and bank 
records indicating that the set asset and income thresholds were not exceeded in each 
case (South African Social Security Agency [SASSA], 2010).  
 
While age was not found to be an independent predictor of pill-taking behaviour, 
virological suppression or retention to care, it did enter the multivariate model to predict 
the combined adherence success measure, with a p-value of .07 and an OR of .60 (.38–
.94), with older patients most likely to achieve overall adherence success. This is in line 
with findings by others (Carrieri et al., 2006; Caluwaerts et al., 2009; Cornell et al., 2010; 
Golin et al., 2002; Gordillo et al., 1999; Hill et al., 2010; Hinkin et al., 2002; Hinkin et al., 
2004; Karcher et al., 2007; Kerr et al., 2005; Mocroft et al., 2008; Spire et al., 2002; 
Wagner, 2002) that younger patients are those with the highest risk of poor adherence 
and loss to follow-up. Possible explanations include the fact that younger patients would 
have less prior experience with medication-taking and that their lifestyles are more prone 
to fluctuations which would make a high-burden medication regime more challenging 
(Hinkin et al., 2002). In this case age-specific interventions may be necessary.       
 
In this study, as in others (Caluwaerts et al., 2009; Catz et al., 2000; Dalal et al., 2008; 
Do et al., 2010; Gebo et al., 2003; Karcher et al., 2007; Spire et al., 2002), other 
demographic factors like gender and education were not associated with any of the four 
adherence indices. As outlined in Chapter 2, some research has linked these 
demographic factors with various adherence behaviours (Gordillo et al, 1999.; Maskew 
et al, 2007.; Mocroft et al., 2008; Turner et al., 2003; Wagner, 2002; Wools-Kaloustian et 
al., 2006; Zachariah et al., 2008). But the data has been highly inconsistent across 
studies, which, given the relative lack of methodological challenge associated with 
assessing demographic profile and therefore unlikelihood of methodologically-
determined findings, points to the differential impact demographics may have in different 
countries, cultures and contexts on health-seeking behaviour.   
 
In bivariate analyses, patients with more advanced disease at treatment onset (higher 
CD4+ cell count and HIV RNA level, more advanced WHO stage) did not differ 
significantly in their adherence, virological suppression or retention to care rates 
compared with healthier patients. There was a trend towards a relationship between 
lower CD4+ cell count and less likelihood of both retention to care and achieving 
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virological suppression at 96 weeks, although neither relationship reached significance 
(p=.06 in both cases). CD4+ cell count did enter the multivariate model to predict the 
combined adherence success measure, with a p-value of .004 and an OR of .61 (.43–
.87), with patients with lower CD4+ cell counts least likely to achieve overall adherence 
success. As the national ART programme continues to expand and individuals begin to 
access HIV care earlier in their disease process (both as a result of the decreasing 
backlog of supremely ill patients and new national clinical guidelines stipulating 
treatment initiation at a CD4+ cell count of 350 cells/!L for pregnant women and patients 
with TB co-infection), the country’s treatment initiation base is expected to present with 
higher CD4+ cell counts, limiting the possible impact of severe disease on adherence 
and retention rates. Others have observed both decreased adherence (Ammassari et al., 
2004; Gordillo et al., 1999; Weidle et al., 2006) and higher LTFU (Caluwaerts et al., 
2009; Lanoy et al., 2006; Mocroft et al., 2008; Zachariah et al., 2008) in sicker patients, 
ascribing the finding to either decreased efficacy of treatment in those already very ill at 
treatment initiation, the impact of ill health on ability to attend visits and adhere to 
complex regimens or hidden mortality.  
 
The study found that the reporting of one or more symptoms the patient ascribed to HIV 
and the severity of the symptoms when they were reported, was not associated with any 
of the four adherence indices. Of note, however, the reporting of certain specific 
symptoms was predictive of either superior or inferior adherence and retention rates. In 
the case of haematological symptoms (such as ‘nodule in neck’) and ophthalmic 
symptoms (such as ‘visual disturbances’), patients who reported experiencing them were 
significantly less likely to succeed - those with haematological symptoms to achieve a 
mean pill count adherence of "90%, and those with ophthalmic symptoms to be retained 
in care at 96 weeks. Conversely, patients who reported ever having experienced 
dermatological symptoms (such as ‘dandruff’ or ‘dry skin’) or urological symptoms (such 
as ‘discharge’ or ‘genital ulcers’) were likely to fare better, in the case of dermatological 
symptoms to achieve "90% mean pill count adherence and in the case of urogenital 
symptoms to be virologically suppressed at 96 weeks. It is possible that certain 
symptoms, if bothersome but not significantly debilitating (such as ‘dandruff’ within the 
dermatological symptoms category), may motivate patients to attend visits and adhere to 
their medication in the hope of alleviating such symptoms, whilst haematological 
symptoms for instance, may be more likely to impact overall functioning and indicative of 
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more severe pathologies, might impact ability to adhere and attend visits. These results 
argue for 1) HIV symptomatology to be clearly assessed at clinic visits and symptoms 
treated aggressively in order to facilitate capacity to adhere to medication routines and 
clinic visits, and 2) patient education to focus on the critical need to take medications in 
order to minimise symptoms, using any symptoms the patient is experiencing as a 
motivator of adherence behaviour. HIV symptom status instruments like the Sign and 
Symptom Checklist for persons living with HIV disease-revised (SSC-HIV-rev) are 
available for ease of assessment (Holzemer et al., 1999).      
    
All other biomedical factors that were assessed were not predictive of adherence to ARV 
therapy, virological suppression or retention to care, including time between positive HIV 
diagnosis and HAART initiation, reason for HIV test, pregnancy at treatment initiation, 
TB therapy at treatment initiation, neurological history, having been previously exposed 
to ART and prescribed ARV regimen.   
 
Bivariate analyses demonstrated that 24 of the psychological variables and 7 of the 
social variables assessed were linked with adherence and retention outcomes. What is 
particularly noteworthy about this finding is that these data, unlike the demographic, 
laboratory and clinical data types outlined above, are not routinely collected at clinic 
visits and are therefore unlikely to be detected by health care workers like doctors and 
nurses, and therefore cannot be impacted or compensated for. Van Servellen, Johiro 
and Thichacek (2002) performed a medical record review of 146 HAART patients in four 
community-based clinics in the United States, checking for completeness of adherence 
and adherence predictor documentation, and reported that adherence issues, in both 
frequency and type, were inadequately documented, with the absence or presence of 
mental health and substance abuse problems clearly noted in just 25% and 17% of 
charts respectively. Several of these factors are potentially modifiable and highlight the 
role that psychosocial interventions may play in improving treatment adherence, 
retention to medical care and biomedical outcomes.  
 
An unexpected finding was that measures of knowledge, attitudes and beliefs related to 
HIV and ART were largely unrelated to adherence. With the exception of being able to 
correctly name the medications in one’s prescribed regimen – which bordered on 
significance as a predictor of early pill count adherence (p=.06) and was significantly 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Predicting adherence to antiretroviral therapy and retention to HIV care 
 
 
 
171 
related to the combined adherence success measure (p=.04), interestingly with patients 
who could either name none or all of their medications faring best – none of the 
knowledge variables were significantly related to early pill count adherence, late 
virological suppression or long-term retention to care. This is an important finding as 
much of the focus of the latest Department of Health clinical guidelines for HIV/AIDS 
management (Department of Health, 2010a, p.12) is on knowledge transfer as the 
means to prepare patients for treatment and facilitate adherence once they are on 
treatment. As outlined in Chapter 1, the guidelines recommend the conduct of an 
‘information and education session’ pre-treatment and that at the treatment 
commencement visit ‘the multidisciplinary team should reassess ART readiness criteria’, 
including ‘patient’s understanding of their HIV status, the need for ART, importance of 
adherence and the link to treatment outcomes, specifically virological suppression, and 
commitment to scheduled visits.’ The guidelines also propose ‘explaining the link 
between virological suppression and clinical outcome and adherence’, ‘provide ongoing 
education to patients on their disease, including any new diagnoses, unexplained 
symptoms or opportunistic infections’, and ‘spend(ing) time with the patient and 
explain(ing) the disease, the goals of therapy and why the need for adherence’ as 
longer-term adherence support strategies (p.17).     
 
The previous finding that depressed mood, as measured by self-report rating scales, 
may play a significant role in adherence behaviour (Ammassari et al., 2004; Arnsten et 
al., 2007; Carrieri et al., 2006; Catz et al., 2000; Do et al., 2010; Gardenier et al., 2010; 
Gordillo et al., 1999; Malcolm et al., 2003; Murphy et al., 2000) was not confirmed in this 
setting. In each of the three adherence outcomes analyses as well as the combined 
adherence success analysis, neither the overall CES-D depression score nor any of its 
20 individual questions was significantly associated with adherence success. This is not 
the first study to find no association between depressed mood and adherence (Spire et 
al., 2002), reflecting a differential impact of mental illness in different contexts. However, 
as outlined earlier, the high level of depressive symptomatology in the sample (with 39% 
of participants reporting prominent depressive symptomatology) suggests that 
integration of clinical and mental health services would be beneficial to ART initiators.   
 
Clearly, one of the most significant and consistent barriers to medication adherence, 
virological suppression and retention to care was alcohol abuse. These results are 
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consistent with numerous studies that have found a strong correlation between 
adherence to HAART and alcohol abuse (Chesney et al., 2000; Do et al., 2010; Golin et 
al., 2002; Spire et al., 2002). Patients who scored seven or lower on the AUDIT scale 
(indicating no presence of alcohol abuse) were more likely to achieve "90% mean pill 
count adherence across the first 16 weeks of treatment, remain in care at 96 weeks, 
achieve virological suppression at 96 weeks and achieve combined adherence success. 
Eight of the AUDIT’s ten individual items independently predicted at least one of the 
adherence outcomes: two items (how often an alcoholic drink is consumed and how 
often they fail to do what is expected of them) predicted all three outcomes and the 
combined adherence success measure, two items (how often six or more drinks is 
consumed on one occasion and how often they experience feelings of guilt or remorse 
after drinking) predicted the three outcomes and showed a trend towards a relationship 
with the combined adherence success measure, one item (the average number of 
alcoholic drinks consumed on a typical day of drinking) predicted both likelihood of 
achieving "90% mean pill count adherence and virological suppression, showed a trend 
towards a relationship with retention to care and the combined adherence success 
measure and entered the multivariate model to predict the combined adherence success 
measure, with a p-value of .002 and an OR of .58 (.41–.82), one item (how often they 
were unable to remember what happened the night before because of drinking) 
predicted both likelihood of achieving "90% mean pill count adherence and virological 
suppression and two items (how often they could not stop drinking once they had started 
and whether a friend, relative, doctor or other health care worker had been concerned 
about their drinking) predicted virological suppression and showed a trend towards a 
relationship with early pill count adherence.  
 
A probable explanation for this finding is that alcohol abuse acutely produces situations 
in which it is difficult to prioritise medication taking and more generally leads to a chaotic 
lifestyle that is adversative to the structure needed to adhere to a regular and complex 
medication regimen. The implications are dramatic – with such high alcohol abuse rates 
in treatment initiators and the observed relationship between alcohol abuse and 
adherence behaviour, this is of major concern for the country’s HIV treatment 
programme. Since alcohol use has also been repeatedly associated with increased 
sexual risk behaviour (Castilla et al., 1999; Shillington et al., 1995; Stein et al., 2005; 
Stueve & O’Donnell, 2005), patients who abuse alcohol are more likely to adhere poorly, 
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develop resistance and practice unsafe sex, transmitting drug-resistant HIV strains to 
others. Alcohol abuse is, however, potentially modifiable, with several studies showing 
successful alcohol abuse interventions in primary care settings (Cordoba et al., 1998; 
Israel et al., 1996; Maisto et al., 2001; Ockene, Adams, Jurley, Wheeler & Hebert, 1999). 
The implementation of routine alcohol abuse screening and associated interventions 
should be implemented alongside the national ARV treatment programme as a matter of 
urgency in order to facilitate successful individual clinical outcomes and manage public 
health risk.   
 
Drug use has been associated with decreased adherence to ART (Ammassari et al., 
2004; Gebo et al., 2003; Golin et al., 2002; Hinkin et al., 2004; Lanoy et al., 2006; Lima 
et al., 2009; Lima et al., 2009; Malcolm et al., 2003; Roco et al., 1999; Turner et al, 
2003); however this was not the case in this study. In this sample, adherence, virological 
suppression, retention and combined adherence success rates of patients who had used 
recreational drugs in the past 12 months were as good as the rates of patients who had 
not. This finding is perhaps attributable to the fact that just ten participants (7%) were 
categorised as drug users (having used recreational drugs in the previous 12 months), 
possibly leading to insufficient statistical power to detect a significant relationship. An 
alternative explanation is that the primary drug used was marijuana (all ten participants), 
with just two having used mandrax, reflecting a lower impact of a less psychoactive 
substance.  
 
This work has provided evidence that patients who perform poorly on certain 
neurocognitive measures are more likely to adhere poorly, be LTFU or be virologically 
unsuppressed. Overall, across the four sets of bivariate analyses and the multivariate 
analysis, 14 of the neuropsychological test scores were related to the adherence indices. 
The neuropsychological test with the most associations with adherence outcomes was 
the Verbal Fluency subtest of the D-KEFS. As outlined in Chapter 3, the test consists of 
three conditions: in the first, the examinee is required to generate as many words as 
possible that begin with a series of designated letters (‘F’, ‘A’, ‘S’) in three trials of 60 
seconds each; in the second, the examinee is required to generate as many words as 
possible that belong to designated semantic categories (‘animals’ and ‘boys’ names’) in 
two trials of 60 seconds each; and in the third, the examinee is required to use 
designated semantic categories again (‘fruit’ and ‘furniture’), this time alternating 
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between them, in one trial of 60 seconds. For this test, four types of process measures 
are recorded: 1) number of correct responses in each of the three conditions and the 
number of correct switches in the third condition, 2) contrast in performance between 
generating words in the first and second conditions and contrast in performance 
between the second and third conditions, 3) errors of repetition (same response 
generated more than once within a trial) and errors of set-loss (response generated that 
does not follow the phonemic or semantic rule of the trial) and 4) time-interval analyses 
(i.e. the number of correct words generated during each of the four 15-second intervals 
making up a trial). The test provides a measure of the examinee’s ability to generate 
words fluently in both a restricted phonemic format (letter fluency) and a restricted 
semantic format (category fluency), providing both a good indication of organised 
thinking and volitional capacity. The switching condition requires rapid shifting from one 
cognitive set to another, assessing cognitive flexibility and the ability to undertake and 
manage conflicting demands.  
 
Patients who were able to generate more words (including errors) in the letter ‘F’ fluency 
trial, the letter ‘A’ fluency trial and across all three letter fluency trials (‘F’, ‘A’ and ‘S’) 
were more likely to succeed, in the case of the letter ‘F’ fluency trial to achieve combined 
adherence success (according to the multivariate model), and in the case of the letter ‘A’ 
fluency trial and across all three letter fluency trials to be retained in care (according to 
the bivariate analyses). Further, patients who generated more correct words (excluding 
errors) across all three letter fluency trials and across both semantic categories 
(‘animals’ and ‘boys’ names’) were more likely to be retained in care and to achieve 
mean early pill count adherence "90% respectively. These results suggest first that 
patients who are able to develop effective cognitive strategies that organise their thinking 
and thereby generate more words (for instance, using the same initial consonant, 
variations on a word or theme or developing sub-categories) (Lezak, 1995) are also 
more likely to be able to organise their thinking about, and planning for, medication 
adherence and clinic attendance and second that patients who show intact motivation, 
volition and the initiation and maintenance of intentional behaviour without prompting, 
resulting in superior word output, are also more likely to exhibit more volitional capacity 
in the context of their health behaviour.  
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Further, patients who made any set loss (classification) errors on the ‘animals’ semantic 
condition trial (i.e. generating a word that could not be classified as an animal) were both 
more unlikely to achieve mean early pill count adherence "90% and combined 
adherence success. This is logical and even expected as patients who struggle to 
engage in rule-following and self-regulation are unlikely to be able to comply with 
complex pharmacologic regimens and a demanding long-term clinic attendance 
schedule.  
 
Surprisingly, at first glance, patients who made any repetition errors on the ‘animals’ 
semantic condition trial (i.e. generated the same word more than once within the trial) or 
more repetition errors across the Verbal Fluency and Design Fluency subtests of the D-
KEFS (i.e. generated the same word or design more than once within a trial) were more 
likely to be retained in care at 96 weeks (in both cases) and achieve mean early pill 
count adherence "90% (in the case of repetition errors across the Verbal Fluency and 
Design Fluency subtests only). This unexpected outcome may be explained by taking 
into account the fact that those examinees that generate more words have a greater 
base of words from which it is possible to repeat. While the relationship between 
increased errors and better adherence outcomes is worthy of further study, for the 
purposes of this study, the finding is therefore interpreted as a consequence of 
increased word generation in those with intact cognitive strategizing and volition.   
 
Two test scores from the Colour-Word Interference subtest of the D-KEFS were 
predictive of likelihood of virological suppression at 96 weeks. The test’s first condition 
requires examinees to name coloured patches, the second to read colour-words (e.g. 
‘red’) printed in black ink, and the third to name the ink colour of colour-words where the 
ink colour differs from the colour-word (e.g. the word ‘blue’ printed in red ink). For these 
conditions three types of measures are recorded: 1) number of seconds the examinee 
takes to complete each condition and the combined number of seconds the examinee 
takes to complete the first two conditions, 2) contrast in performance between seconds 
to complete the third condition versus the first condition and 3) self-corrected errors and 
uncorrected errors. The test assesses the examinee’s ability to inhibit a learned 
response (e.g. reading printed words) in order to generate a required and conflicting 
response (e.g. naming the dissonant ink colour in which the words are printed). Patients 
who made fewer total errors across the subtest and patients who made fewer self-
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corrected errors across the subtest were more likely to be virologically suppressed at 96 
weeks - again highlighting the role that rule-following and self-regulation play in 
adherence behaviour.  
 
Memory was also implicated in adherence outcomes through the Logical Memory 
subtest of the WMS. In the first condition, two short stories are presented orally to the 
examinee; the first story is presented once and the second story twice. The examinee is 
then required to retell the stories from memory. In the second condition, after a 25–35 
minute delay, the examinee is required to retell both stories. Then the examinee is 
required to answer a series of 30 yes/ no questions, 15 about each story. For this test 
four types of measures are recorded: 1) number of correctly recalled story units for each 
of the two stories and across both stories, and for each of the conditions and across both 
conditions, 2) the number of correctly recalled story themes from each story and across 
both stories, and for each of the conditions and across both conditions, 3) the 
improvement in recall after the second presentation of the second story (learning slope) 
and 4) number of correct responses to yes/ no questions. Patients who were able to 
recall a greater number of units and themes immediately across both stories were more 
likely to achieve combined adherence success. Similarly patients who were able to 
recall, after a delay, a greater proportion of the units and themes from the second story 
that they had originally recalled were both more likely to be retained in care (according to 
the bivariate analyses) and to achieve combined adherence success (according to the 
multivariate model). Finally, patients who somewhat improved (improved by between 
one and five points) their recall of a story after a second exposure to it, were more likely 
to achieve virological suppression than those who did not improve at all or those who 
improved dramatically. This finding is understandable as those patients who improved by 
six or more points would have had to have a low initial score in order for such 
improvement to take place. These results implicate both auditory immediate and auditory 
delayed recall in adherence processes. Patients who are able to store and retain a 
greater amount of information and instruction will be more likely to remember to take 
their medications as required and attend their clinic appointments as scheduled; story 
recall omissions (both individual story units and larger story themes) will mean 
medication-taking omissions and missed clinic visits.  
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Finally, one measure from the Digit Span subtest of the WMS emerged as a significant 
predictor of virological suppression. This test requires the examinee to recall a series of 
digits, increasing in length, and to repeat them back to the examiner. The test consists of 
30 items, starting at two digits in the series for both conditions, and increasing up to nine 
digits in the first condition and eight digits in the second condition. In the first condition, 
examinees are required to repeat each series as it was presented (forwards); in the 
second condition, examinees are required to repeat each series in the reverse order 
(backwards). For this test, two measures were recorded: 1) number of correctly recalled 
items in each condition and across both conditions, and 2) number of correctly recalled 
digits in each condition. Contrary to what would be reasonably expected, patients who 
were able to recall a longer series of numbers were less likely to achieve virological 
suppression. Further research is needed to clarify the relationship between this measure 
and adherence behaviour.  
 
The latest South African Department of Health guidelines (Department of Health, 2010b) 
restrict treatment in the general adult population to patients with WHO stage IV disease 
or CD4+ cell counts <200 cells/!L, based on the outdated WHO 2002 guidelines (WHO, 
2002), although pregnant women with CD4+ cell counts of less than 350 cells/!L and all 
patients co-infected with TB, regardless of CD4+ cell count, are also eligible. The 
guidelines, in addition to the late stage at which many patients in South Africa present 
for treatment (Bekker et al., 2006; Cornell et al., 2010; Lawn et al., 2006) due to poor 
VCT access, infrequent measurement of CD4+ cell counts and referral delays (Dalal et 
al., 2008; Lawn et al., 2006), means that the time of HAART initiation in South Africa is 
when patients are most likely to exhibit neuropsychological deficits. The WHO 2003 
revised guidelines (WHO, 2003; WHO 2006; WHO, 2009) recommend earlier treatment, 
as does the Southern African HIV Clinicians Society. Less stringent guidelines and 
earlier treatment initiation would help patients to initiate treatment when they are less 
likely to be cognitively impacted by the disease, and thereby lower the risk of 
nonadherence and loss to follow-up due to cognitive dysfunction. In the meantime, 
health-care providers may work with the patient to incorporate the regimen and its 
associated instructions into the patient’s daily schedule, for instance by linking it with 
certain everyday behaviours or occurrences. Mechanical reminders such as the use of 
cell phone alarms have proven successful in this sample and may be especially 
beneficial for those with disease-associated cognitive dysfunction. Finally, facilitating 
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social support in the form of an on-treatment buddy or significant other who can assist 
with medication reminders may be useful here.      
 
While studies have almost uniformly shown that increased social support (Carrieri et al., 
2006; Catz et al., 2000; Gardenier et al., 2010; Gordillo et al., 1999; Nam et al., 2008; 
Parruti et al., 2006) and disclosure (Abel & Painter, 2003; Catz et al., 2000; Do et al., 
2010; Malcolm et al., 2003; Maskew et al., 2007; Murphy et al., 2000; Nam et al., 2008; 
Ncama et al., 2008; Richard et al., 2009) positively impact adherence levels, with just a 
few exceptions (Golin et al., 2002; Wagner, 2002; Weiser et al., 2003; Zacariah et al., 
2008), the results of this study indicate a more complex picture.  
 
In terms of relationship status, it appears that single and married/ cohabiting couples 
achieve similar good levels of adherence success, whilst those patients who are married 
but separated or in a non-cohabiting couple fare worst. It seems there is little difference 
between being single or in a ‘stable’ (married or cohabiting) relationship, but that if in a 
relationship, it is better to be in a stable one. This was evidenced by the trends towards 
predictive relationships between relationship status and adherence outcomes in the 
bivariate analyses. In both the early pill count adherence and combined adherence 
success analyses, patients who were married but separated or in non-cohabiting 
relationships fared worst; in the case of the early pill count adherence analyses, those 
who were single did best, with those married or in cohabiting relationships a close 
second, while in the case of combined adherence success, those who were married or in 
cohabiting relationships did best, with those who were single a close second. In the 
multivariate model, relationship status emerged as predictive of adherence success, 
again with those who were married but separated or in non-cohabiting relationships least 
likely to succeed, and mirroring the combined adherence success bivariate analysis with 
those who were married or in cohabiting relationship faring best and those who were 
single a close second.  
 
Two additional analyses conducted within the in-relationship group showed similar 
results. In the first, for those patients who did have a partner, living with that partner 
increased their likelihood of achieving combined adherence success (there was also a 
trend towards a relationship between this factor and early pill count adherence). A 
possible explanation is that a live-in partner may be a more constant and reliable source 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Predicting adherence to antiretroviral therapy and retention to HIV care 
 
 
 
179 
of support, which studies have shown to be an important correlate of adherence (Carrieri 
et al., 2006; Catz et al., 2000; Gardenier et al., 2010; Nam et al., 2008; Spire et al., 
2002). A component of such support may include assistance with medication 
management such as personal reminders to take the antiretroviral agents, another social 
factor that has been presented in the literature as facilitating patient adherence 
behaviour (Abel & Painter, 2003; Murphy et al., 2000). In the second, a trend towards a 
relationship between (for those patients with partners) being in a seroconcordant rather 
than serodiscordant couple and achieving good ("90%) mean early pill count adherence 
was observed. Being in a seroconcordant relationship may facilitate shared disease and 
side effect burden, both factors which may negatively impact adherence motivation (Abel 
& Painter, 2003; Catz et al., 2000; Gardenier et al., 2010; Parruti et al., 2006; Spire et 
al., 2002) and decrease the likelihood of stigma, which is sadly still common in South 
Africa (Ncama et al., 2008).  
 
Perhaps surprisingly, this study found that increased levels of disclosure did not predict 
improved medication adherence or adherence to care. In fact there were four negative 
associations between level of disclosure and adherence success. There was a trend 
towards a relationship between the number of people disclosed to and likelihood of 
remaining in care at 96 weeks, with patients who had disclosed to the smallest number 
of people more likely to be retained. Similarly, disclosing to family members other than 
spouse/ partner, child(ren) or parent(s) was predictive of failure to remain in care, as was 
disclosing to friends (there was also a trend towards a relationship between disclosing to 
friends and less likelihood of achieving virological suppression).   
 
One possibility that might explain these findings is that disclosure to more people, 
especially those not in direct familial relationships with the patient, may lead to higher 
levels of stigmatisation and social rejection, making medication-taking and clinic 
attendance difficult. It may be that certain types of disclosure are in fact beneficial, but 
that those types were not directly assessed in this study. In Nam et al.’s (2008) one-to-
one interviews assessing reasons for nonadherence among on-treatment HAART 
patients, the concept of an encouraging confidante emerged strongly as a facilitator of 
medication adherence. The descriptions for such a person included someone to share 
the burden of their HIV status and promote messages of hope (hope for a relationship, 
having children and hope for a cure were mentioned). Patients initiating HAART might 
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disclose to a large number of people of varying relationship type, but if they do not have 
a particular person in whom to confide, they will not be able to access the kind of 
individualised, non-judgmental emotional support to which Nam et al.’s participants were 
referring. The present study did not directly examine this sub-concept. The items in the 
present study that most closely approximated this were the combined item for living with 
someone who is also on antiretrovirals to whom the patient has disclosed and who has 
committed to reminding him or her to adhere (there was a trend towards a relationship 
between this item and virological suppression) and number of people known who were 
also on antiretroviral therapy (there was a relationship between greater number of 
people known and greater likelihood of achieving early pill count adherence success). 
These findings should be used to strengthen existing disclosure messages administered 
by health care practitioners and counselors at patient preparedness visits, in particular 
about choosing appropriate confidantes in whom to confide and gain in-depth support. 
Furthermore, HIV programmes may need to allocate resources to enhance true and 
worthwhile social support. For instance, involvement of a close and potentially 
supportive other in clinic visits and patient education may be beneficial, as well as the 
establishment of regular support groups for patients on ART.         
  
The results of this study indicate that patients who live in households of three or more 
people (i.e. with more than one person) are less likely to achieve undetectable viral 
loads at 96 weeks than those who live alone or with one other person, and that patients 
who live with family other than spouse, parent or child are less likely to be retained in 
care at 96 weeks. Several factors related to such living conditions may be at play here; 
these include crowded living environments and lack of privacy (impacting ability to 
adhere when disclosure has not taken place) as well as lower socio-economic status 
and food insecurity (perhaps decreasing the priority status of health behaviour as 
compared with more immediate drivers). Further investigation into these relationships 
would certainly be worthwhile in future research. 
 
In contrast to earlier reports (Abel & Painter, 2003; Gardenier et al., 2010; Golin et al., 
2002; Murphy et al., 2000; Nam et al., 2008; Roberson et al., 2009; Spire et al., 2002), 
this study did not find a relationship between patient-provider relationship and 
medication adherence or retention to care. This may be because each of the relationship 
indicators was so positively skewed – 87% of patients felt they could talk to the doctors 
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and nurses at the clinic about any problems they were having, 91% said they trusted the 
doctors and nurses, 97% felt the doctors and nurses at the clinic respected them and 
97% were satisfied with their relationship with the doctors and nurses – making 
associations unlikely to be detected in this sample size. As such, the result that patient-
provider relationship does not impact adherence behaviour should be interpreted with 
caution. It may be pertinent to consider more deeply the patient-provider relationships in 
this clinic in future research as a model for successful therapeutic partnerships. Previous 
research has indicated that factors such as seeing the clinician as a confidante (Nam et 
al., 2008) and high levels of trust in the provider (Golin et al., 2002) are important to 
patients and may facilitate adherence. After a series of focus groups focusing on barriers 
to ARV adherence and strategies to overcome them, Murphy et al. (2000) advocated for 
health care providers to promote trust in their relationships with patients by encouraging 
questions, involving patients in medical decision-making, and suggesting that patients 
contact them if side effects or other problems arise.   
 
Planned use of a cell phone alarm as an adherence aid was associated with increased 
likelihood of virological suppression at 96 weeks and entered the multivariate model to 
predict the combined adherence success measure, with a p-value of .06 and an OR of 
.56 (.31–1.02), with patients planning to use cell phone alarms most likely to achieve 
combined adherence success. This finding is certainly of practical use in a clinical 
setting and advice to use this material aid should be incorporated into treatment 
preparedness. Interestingly, planned use of pill boxes, a commonly-provided tool in 
public health settings, was not related to improved adherence, although the small 
prevalence of non-users in this sample (just 6%) may have limited its ability to detect a 
relationship in this sample.  
 
Although not a significant predictor of any of the four adherence indices in bivariate 
analyses, length of time spent traveling to the clinic did enter the multivariate model to 
predict the combined adherence success measure, with a p-value of .06 and an OR of 
.41 (.18–.94), with patients who spent the least time most likely to achieve overall 
adherence success. Conducting more home visits (Mehta et al., 1997), offering flexible 
clinic hours (for instance, remaining open on certain evenings or weekends), providing 
free or discounted transportation and offering child care services during clinic visits 
(Battaglioli-DeNero, 2007) are possible solutions to removing this barrier.   
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Predicting adherence to antiretroviral therapy and retention to HIV care 
 
 
 
182 
 
In sum, this work has provided evidence that both short- and long-term adherence can 
be reliably predicted based on patient characteristics at treatment initiation, and 
therefore that assessing patients’ a priori biopsychosocial status would be beneficial in 
identifying patients at risk of poor adherence and defaulting. Reasons for nonadherence 
are multifactorial, requiring targeted interventions. Factors associated with 
nonadherence, nonsuppression and/ or loss to follow-up were younger age, 
unemployment, holding/ having applied for a disability grant, lower CD4+ cell count, 
haematological or ophthalmic but not dermatological or urological symptoms, ability to 
name just some of the medications in the prescribed regimen, alcohol abuse, poor 
neurocognitive performance, unmarried or in non-cohabiting relationship, disclosure to 
broader family or friends, less people known on antiretrovirals, living in households of 
three or more, no planned use of cell phone alarm as adherence aid and greater length 
of time spent traveling to the clinic. High depression and alcohol abuse rates call for 
early identification and treatment of mental health disorders in this population. Special 
attention should be paid to younger and unemployed patient groups in adherence 
counseling. HIV symtomatology should be assessed and symptoms managed 
aggressively. Adaptation of treatment guidelines for earlier treatment initiation would 
minimise cognitive compromise in initiating populations. Mechanical reminders like cell 
phone alarms have proven successful in this sample and may be especially beneficial to 
those with cognitive dysfunction. Patients should be counseled to choose appropriate 
confidantes for disclosure and supportive relationships should be encouraged. Clinic visit 
burden should be minimised through home visits, flexible clinic hours and discounted 
transportation.    
   
 
Limitations  
Certain limitations of this study deserve mention and should be considered in 
interpreting the study results. Although the sample is broadly demographically and 
clinically representative of adult ART patients in this setting, and as part of the 
government ART roll-out programme, likely to be demographically and clinically 
generalisable to other ART programmes in South Africa (since 80% of the population 
rely on the public sector for health services [Barron & Roma-Reardon, 2008]), the true 
generalisability of these results is unclear due to the fact that the sample was a single-
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center cohort and also in part to the specific center chosen. While the sample may have 
been demographically and clinically similar to broader populations, since psychological 
and social data is not routinely collected in public-sector biomedical settings (as 
evidenced in this study by the disparity between a 39% prevalence of prominent 
depressive symptomatology on investigation versus a 1% documentation of depression 
in clinic files), it is not known how concordant the sample’s psychological and social 
profiles are with other South African settings or even the total clinic population at this 
center. Although referrals for participation included all patients initiating treatment during 
the study enrolment period whose clinic visits fell within the times when the interviewer 
was present at the clinic, patients who agreed to participate were ultimately volunteers 
who self-selected to take part. We have little information on those patients who refused 
to participate; we do know that gender, age, starting CD4+ cell count, starting HIV RNA 
level, WHO stage and pregnancy rates did not differ between the study sample and the 
total who initiated treatment during the study enrolment period. However, these patients 
may have differed in meaningful psychological or social ways from those that did not 
agree to take part, ways that were unable to be assessed as it was not available for 
comparison. For instance, study participants may conceivably have been more or less 
satisfied with their relationship with the clinic (more willing to spend extra time at the 
clinic, or wanting a space to air complaints) or more or less depressed (drawn to a 
private session where psychological issues would be discussed, or more motivated to 
engage in a new task like study participation). It is also unknown whether they differed 
behaviourally in terms of pill count adherence, as this data – unlike the virological 
suppression and adherence to care data – was unavailable for all patients. For instance, 
patients who are able to set and keep a study appointment visit may be more motivated 
or able to adhere to an antiretroviral regimen than the average patient.   
 
Moreover, although the clinic is part of the government ARV programme, it works in 
partnership with an NGO linked to a major academic institution and thus may have 
impacted patient outcomes in positive ways unavailable to clinics without such support. 
However, in a comprehensive comparative analysis of five diverse ART clinics in the 
Western Cape that included the Hannan Crusaid Treatment Centre among them, 
Pienaar et al. (2006) found that despite different settings, support networks, staff 
profiles, patient education programmes, adherence systems and opening hours, there 
were no significant differences in the proportion of patients retained in care at six months 
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or rates of virological suppression. That said, the findings in this study require further 
investigation in other settings.   
 
Partly due to the necessarily labour-intensive interview schedule and its associated 
running time of three hours, which is unlike the larger observational cohorts described in 
Chapter 2, an appropriate but modest sample size of 150 was chosen. Because of this 
sample size the study may not have detected some weaker associations between 
certain factors and outcomes owing to insufficient statistical power. It is for this reason 
that relationship trends were also presented in Chapter 5. Contrarily, because this study 
set out to undertake a comprehensive assessment of demographic, biomedical, 
psychological and social factors, a large number of bivariate analyses were carried out, 
wherein some significant (p#.05) relationships could have occurred due to chance alone. 
To address this issue, all significant associations were assessed for plausibility and 
discarded from the regression model where necessary.         
 
Although almost all participants were Xhosa-speaking, the D-KEFS and WMS are only 
available in English and were administered by a tester who spoke English to the 
participant. Although reliable translators were available, and utilized in 33% of cases, 
with translation, the reliability and validity of tests may have been weakened. Further, 
although precautions were taken to adapt the neuropsychological administration to a 
local population, including the use of adapted measures (see Chapter 3 for wording 
modifications), translators where necessary, and raw scores rather than developed-
world norms, the administration may have been challenging for participants with a low 
educational background (only 21% of the sample had completed high school) and 
neither the D-KEFS not the WMS allow for factors like educational background or social 
circumstances to be taken into consideration when scoring.  
 
The depression survey instrument used in this study, the CES-D, provides an 
assessment of symptoms associated with depression. Unlike a full psychiatric 
assessment, it cannot be utilised as a diagnostic tool, but rather a screening instrument 
to identify individuals with depressive symptoms. As such, this study is limited in its 
ability to make conclusions about the prevalence of verified mood disorders. Given the 
study aims (to formulate a screening assessment for adherence risk to be administered 
at lay counselor level) and context (a naturalistic study carried out in a busy primary 
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health care clinic), such rating scales are appropriate, and have been utilised in similar 
work in almost all cases (Ammassari et al., 2004; Arnsten et al., 2007; Carrieri et al., 
2006; Catz et al., 2000; Do et al., 2010; Gordillo et al., 1999; Spire et al., 2002).     
 
Furthermore, although the interview was conducted by a researcher unknown to the 
patient base, in an outbuilding separate from the clinic building, and confidentiality of 
responses was assured during the consent process, it cannot be excluded that answers 
might have been biased by social desirability. With the emphasis on things like 
decreased alcohol intake and disclosure at this relatively-resourced clinic, visible to 
patients in treatment readiness sessions and on-treatment adherence, participants may 
have under-reported alcohol use and over-reported disclosure.    
 
In addition, pill counts, while widely used and repeatedly validated (Golin et al., 2002; 
Gordillo et al., 1999; Laniece et al., 2003; Weidle et al., 2006), have well-known 
limitations. The concept of measuring returned medicine as a proxy for consumed 
medicine poses particular challenges - the phenomenon of ‘pill dumping’, where patients 
dispose of surplus medications, has been reported. In order to mitigate this problem all 
adherence scores of greater than 100% were capped at 100%; however, this did not 
deal with those cases of non-adherence which were increased up to 100% due to pill-
dumping. Nevertheless, the significant association between pill count adherence and 
virological suppression in the present study and in others (Bangsberg et al., 2000; Liu et 
al., 2001) suggests that pill count correlates well with actual adherence and confirms the 
choice to use pill counts as a proxy measure of pill-taking behaviour. Moreover, even if 
an overestimate of pill-taking behaviour did occur through reliance on pill counts as the 
index, this is not likely to have impacted the observed associations between medication 
adherence and the predictors examined.  
 
Since this study set out to observe and statistically assess predictors of adherence 
behaviour, quantitative methodology was used. Because of this, a structured interview 
schedule was utilised. As such, the depth of insight and thorough exploration of 
relationships between various predictors gained through qualitative methodologies like 
in-depth interviews or focus groups could not be gained.  
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One of the strengths of this study was in its assessment at HAART initiation, rather than 
when patients were already on treatment. However this meant that other factors (factors 
that by definition could only have occurred once treatment had begun – for instance real 
or perceived rather than anticipated side effects) were unable to be assessed. In the 
same way, many of the factors that were assessed at treatment initiation in this study 
are not static, but adapt and transition due to changing external (e.g. new disclosures) 
and internal (e.g. negative ART experiences) circumstances throughout the course of 
treatment. Conducting a baseline assessment only meant that these changes were not 
picked up and their impact not assessed.  
 
The above-mentioned potential limitations may impact the interpretation of the results. 
Notwithstanding the interpretive cautions noted above, the findings from this study 
showing significant relationships between certain demographic, biomedical, 
psychological and social factors and various adherence behaviours remain important, 
given the significance of medication adherence and retention to care for individual 
clinical outcomes and public health.  
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CHAPTER 7 
The final word: Conclusions, recommendations and next steps 
 
 
 
The results of this study have profound implications for the practical delivery of 
comprehensive HIV/AIDS care services in under-resourced settings. It is important to 
note that the intention of this research has not been to provide justifications or 
rationalisations for delaying or denying HAART provision to at-risk patients. Predictions 
about specific risk profiles do not apply to all persons fitting such profiles. Instead and as 
initially described, this work sets out to inform the delivery of targeted treatment 
readiness and on-treatment support programmes. The results of this study have clearly 
shown that no ‘silver bullet’ treatment readiness or adherence support intervention will 
be possible; there are too many and too varied a group of factors associated with 
adherence behaviour. Instead, what will be necessary is a multidimensional, 
interdisciplinary approach, applying several methods of promoting adherence 
simultaneously.  
 
This study identified younger, unemployed and disability grant-holding patients as more 
likely to be nonadherent or LTFU; accordingly, special attention should be paid to these 
patient groups in adherence counseling. Patients with lower starting CD4+ cell counts 
also fared poorly, likely because of the impact of poor health on their ability to attend 
clinic visits and adhere to complex regimens. Relaxing treatment guidelines to include 
patients with higher CD4+ cell counts and encouraging earlier patient presentation will 
reduce the impact of severe illness on adherence and retention rates. Patients reporting 
haematological or ophthalmic symptoms were less likely to adhere (in the case of 
haematological symptoms) and remain in care (in the case of ophthalmic symptoms), 
while patients with dermatological or urogenital symptoms did better than others. It 
seems that certain symptoms may motivate patients to adhere and attend visits in the 
hope of alleviating them, while others are actually prohibitive. In this case, HIV 
symtomatology should be assessed at each clinic visit, so that symptoms may be 
managed and also used as a stimulus for adherence behaviour. With the exception of 
being able to name some of the medications in the prescribed regimen, none of the 
measures of knowledge levels, attitudes or beliefs related to HIV and ART were related 
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to adherence behaviour, which is a noteworthy finding given the focus of many treatment 
readiness and on-treatment adherence programmes on knowledge transfer.  
 
Alcohol abuse was a significant and consistent barrier to each of the adherence 
outcomes, and especially important given the high prevalence rate in the sample. 
Initiating routine alcohol abuse screening and targeted interventions should be 
prioritised. Support may be offered directly through multi-disciplinary clinics or health 
care workers who develop skills in both HIV care and psychosocial interventions. 
Alternatively, substance abuse issues may be identified at primary health care level for 
referral to other professionals for case management (e.g. psychologists or social 
workers). 
                       
The relationships found between executive functioning and adherence behaviour points 
to the need for interventions that assist patients in setting and organising their 
medication-taking routines at the outset, planning and problem-solving how they will 
manage medication-taking in the context of other competing life circumstances. The 
associations between memory performance and adherence emphasise the need for 
interventions that help patients to make complex regimens easier to recall. 
Neuropsychological dysfunction should be compensated for through adaptation of 
national treatment guidelines for earlier treatment initiation and advising patients to use 
mechanical reminders like cell phone alarms.  
 
The finding that unmarried patients, patients in non-cohabiting relationships, patients 
who had disclosed to broader family or friends and patients who lived in households of 
three or more were least likely to succeed argues against the uniform giving of advice to 
disclose as widely as possible. Instead, patients should be encouraged to identify 
appropriate confidantes within their environments and develop supportive relationships 
as far as possible. Finally, greater length of time spent traveling to the clinic was a 
barrier to achieving combined adherence success and could be mediated through home 
visits, longer refill periods, flexible clinic hours and free or discounted clinic 
transportation. 
 
Some of these results also have implications for the structure of treatment readiness and 
on-treatment adherence programmes. For instance, the fact that mean pill count 
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adherence and percentage of patients achieving a mean pill count adherence of !90% 
decreased with each 4-week interval suggests that adherence is not static, but a ‘moving 
target’. Patients who adhere well initially may not maintain high levels of adherence due 
to treatment fatigue, the emergence of side effects, and other setbacks. This means that 
ongoing programmes are needed throughout the treatment course, rather than just at 
initiation, in order to facilitate durable adherence. Further, the finding that greater length 
of time traveling to the clinic was a barrier to achieving combined adherence success 
implies that interventions should either be home-based or integrated as far as possible 
into existing clinic visits, rather than requiring additional clinic attendance. Lastly, the 
significant relationship between patients knowing more people also on ART and the 
greater likelihood of achieving early pill count adherence success suggests that group, 
rather than one-on-one programmes, should be the chosen modality for message 
delivery.    
 
This study set out to develop a RAT to predict treatment success, suitable for routine 
clinical use by lay counselors in resource-limited settings, in order to facilitate the 
detection of those patients at high risk for nonadherence and LTFU and in need of 
increased adherence support. The tool was successfully developed and should now be 
pilot-tested for its feasibility, acceptability and efficacy in a community clinic setting and 
in a more diverse set of environments. It is expected that data obtained from this pilot 
will provide sufficient evidence for wider implementation. The feasibility analysis should 
include the following: assessment of lay counselors’ ability to administer the tool, 
integration of its administration within routine clinical activities and the time and costs 
associated with its administration. The time and costs involved in effecting the 
intervention should be weighed against the gains of preserving first-line regimens, 
decreasing hospitalisations and health care system burden, decreasing LTFU and 
therefore LTFU tracing. The acceptability analysis should be conducted with both clinic 
staff and patients, and examine ease of use (usability) and perceived effectiveness 
(utility). Finally, the efficacy analysis should include sufficient orientation and training 
with lay community counselors on tool administration and subsequent administration to a 
powered sample of patients presenting for ART initiation. The tool should be validated 
through comparisons with pill count, virological suppression and LTFU data as proxy 
objective measures. Interim analysis of the data should be performed with final analysis 
at the end of the pilot. To establish the tool’s usefulness in other settings (for instance, 
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its usefulness in other groups with HIV such as those with higher education levels or 
higher CD4+ counts), samples from various primary health care settings should be used, 
focusing on a comparison of feasibility, acceptability and efficacy outcomes. Finally, 
changes resulting from the implementation of this tool should be evaluated and reported.  
 
The above-mentioned steps are necessary to validate the tool before it may function as 
an important component of effective HIV care delivery to the growing millions who need 
it in resource-limited settings. The tool, if implemented, could make possible stratified 
retention and adherence support, so that rather than all patients receiving modest levels 
of support, those patients who would gain the most from increased and directed support 
would receive it. This implementation would make the best use of our health system’s 
limited resources and human capital, and in so doing, minimize the risk of society-wide 
resistance associated with this growing pandemic.  
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APPENDIX A 
Biopsychosocial Questionnaire 
 
 
 
Biopsychosocial Questionnaire 
Version 1.1, July 2007 
Participant Number  
Date / /  
DEMOGRAPHICS 
1. What is your gender? 
Male 
Female 
2. What is your date of birth?  / /  
3. What language do you speak at home?  
Xhosa 
English 
Afrikaans 
Other: _______________ 
4. What is the highest level of education you have 
completed?  
Grade: __________ 
 
If participant has completed Grade 12, ask: 
 
4a. Have you completed any tertiary education? 
Yes. Number of years: __________ 
No 
5. How would you describe the work that you do?   
Permanent part- or full-time  
Self-employed or engaged in casual work. If so, nature 
of work: ____________________ 
Unemployed with disability grant  
Unemployed without disability grant 
Applied for disability grant  
Other: ____________________ 
6. What is your total monthly income (including all 
wages and grants)? 
R __________ 
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PERCEIVED HIV SYMPTOMATOLOGY 
7. Have you experienced any symptoms from HIV? 
Yes: _______________________________________ 
____________________________________________ 
No 
 
If participant has experienced symptoms, ask: 
 
7a. How would you describe these symptoms? 
Mild 
Moderate 
Severe 
KNOWLEDGE 
8. What is your most recent CD4+ cell count? 
  
 
CD4+ cell count according to patient: __________  
Unsure  
 
Check clinic file for patient’s degree of accuracy.  
CD4+ cell count in file: __________ 
Patient correct/ incorrect/1  
9. What is your most recent viral load test result? 
Viral load according to patient: __________  
Unsure 
 
Check clinic file for patient’s degree of accuracy.  
Viral load in file: __________ 
Patient correct/ incorrect/1 
10. What are the names of the antiretroviral 
medications that have been prescribed for you?  
 
Medications according to patient:  
1. _______________ 
2. _______________ 
3. _______________  
Unsure 
 
Check clinic file for patient’s degree of accuracy.  
Medications according to file: 
1. _______________ 
2. _______________ 
3. _______________ 
Patient correct/ incorrect/3 
11. If patients do not take all of their prescribed 
antiretroviral medications, what are all of the 
possible consequences?  
No prompt.  
Tick all that apply.  
The virus may not be adequately suppressed/ their 
viral load test result will be above the limits of detection 
Their immune functions may not improve/ their CD4+ 
cell count will remain high  
Their HIV may become ‘resistant’ to antiretrovirals 
This resistant HIV may be passed on to others 
Unsure  
12. In HIV medicine, when we talk about 
‘resistance’ what do we mean? 
 No prompt.  
_____________________________________________ 
_____________________________________________ 
 
A score of 1 is recorded if the participant mentions that 
incomplete adherence may lead to medication not 
working/ not working as well. 
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Patient correct/ incorrect/1 
13. How much of your antiretroviral medications 
do you need to take correctly in order for them to 
be most effective? 
All or almost all  (95% or greater)   
Most (60 - 94%) 
About half (40 – 59%) 
Some (less than 40%) 
Unsure  
ATTITUDES, SEFL-EFFICACY 
Please indicate whether or not you agree with the statements below. 
14. HIV is a serious disease.  
Agree 
Disagree 
 
15. I can fight off HIV without the antiretrovirals.  
Agree 
Disagree 
 
16. Antiretrovirals will improve my health.  
Agree 
Disagree 
 
17. I am concerned about the possible side effects of my prescribed regimen.    
Agree 
Disagree 
 
18. I don’t like to think about antiretrovirals because they remind me that I have HIV. 
Agree 
Disagree 
 
19. The good things about antiretrovirals outweigh the bad.   
Agree 
Disagree 
 
20. I know better than my doctor when I know better than my doctor when to take my medications because 
only I know how I am feeling. 
Agree 
Disagree 
21. How confident do you feel that you will be able 
to take your antiretroviral medications as directed? 
Very confident   
Quite confident 
Quite unconfident 
Very unconfident 
DRUG USE 
22. Have you used any illicit drugs in the past 12 
months?  
Yes 
No 
 
If participant has used illicit drugs, ask: 
 
22a. Please specify which drug(s) you have taken. 
Tick all that apply.   
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Marijuana (intsango, weed, dope, ganja) 
Cocaine (crack, speedball) 
Inhalants (glue, poppers, laughing gas) 
Narcotics (heroin, morphine, opium) 
Stimulants (speed, rush, ecstasy) 
Other: _______________ 
SUPPORT SYSTEMS AND DISCLOSURE  
23. What is your relationship status? 
Single 
In a relationship, but not cohabiting or married 
In a relationship, cohabiting  
Married 
Divorced 
Widowed 
Separated 
24. How many people (adults and children, including 
you) live in your household?  
Number: __________ 
25. With whom do you live?  
Tick all that apply. 
Spouse or partner   
Child(ren)  
Parent(s) 
Other family member(s) 
Other: _______________ 
26. Do you feel a strong emotional bond with at least 
one other person?  
Yes   
No 
27. Do you know anyone else who has HIV? 
Yes   
No 
 
If participant does know anyone, ask: 
 
27a. Who is this person? Tick all that apply. 
Spouse or partner   
Child(ren)  
Parent(s) 
Other family member(s) 
Friend(s) 
Colleague(s) 
Other: _______________ 
 
27b. Total number of people known: _____ 
28. Do you know anyone else who is also on 
antiretrovirals? 
Yes   
No 
 
If participant does know anyone, ask: 
 
28a. Who is this person? Tick all that apply. 
Spouse or partner   
Child(ren)  
Parent(s) 
Other family member(s) 
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Friend(s) 
Colleague(s) 
Other: _______________ 
 
28b. Total number of people known: _____ 
29. Have you told anyone you are HIV-positive?  
Yes   
No 
 
If participant has told anyone, ask: 
 
29a. Who have you disclosed to? List: ____________ 
___________________________________________ 
 
29b. Total number of people disclosed to: _____ 
 
29c. How do you think this person/ these people feel 
about you starting antiretrovirals? 
They feel I should take antiretrovirals    
They feel I should not take antiretrovirals  
They do not know I am scheduled to start 
antiretrovirals  
Other: _______________ 
 
29d. Do you think this person/ these people will help 
you to take your antiretrovirals (e.g. remind you at 
dosing times or come with you to the clinic)? 
Yes  
No  
RELATIONSHIP WITH HEALTH CARE PROVIDER 
30. How often do you see the same doctor at your 
clinic visits?  
Always   
Usually  
Rarely  
Never  
31. Do the doctors and nurses at your clinic speak 
with you in your home language?   
Always   
Usually  
Rarely  
Never 
32. Are you able to talk to the doctors and nurses at 
your clinic about any problems you are having?  
Yes  
No 
33. Do you trust the doctors and nurses at your clinic?  
Yes  
No 
34. Do you feel the doctors and nurses at your clinic 
respect you?  
Yes  
No 
35. Are you satisfied with your relationship with the 
doctors and nurses at your clinic?  
Yes  
No 
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ADHERENCE AIDS 
36. Do you plan to use any of the following to help 
you to take your antiretrovirals? 
Tick all that apply. 
Pill box   
Free-standing alarm clock  
Alarm clock on wrist watch 
Alarm clock on cell phone    
Diary  
Calendar   
Other: _______________ 
CLINIC VISITS 
37. How do you travel to the clinic?  
 
Taxi  
Bus 
Train 
Car 
Foot 
38. How long does it take you to get to the clinic?  
Hours: _____ 
Minutes: _____ 
39. How much does it cost you to come to the clinic? 
 
Nothing  
R __________ 
 
If participant spends R1 or more, ask: 
 
69a. How affordable is this for you?  
Very affordable 
Quite affordable 
Quite unaffordable 
Very unaffordable 
40. Considering both time and costs, how convenient 
are clinic visits for you?  
Very convenient  
Quite convenient 
Quite inconvenient 
Very inconvenient 
 
Thank you for your time. 
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APPENDIX B 
Centre for Epidemiological Studies in Depression Scale (CES-D)  
 
 
 
CENTRE FOR EPIDEMIOLOGICAL STUDIES IN DEPRESSION SCALE (CES-D) (Radloff, 1977) 
Circle the number for each statement that best describes how often the participant felt or behaved in this way 
during the past week. 
1. I was bothered by things that 
usually don’t bother me 
Rarely/ none of 
the time 
<1 day 
Some of the time 
1–2 days 
Occasionally/ 
moderately 
3–4 days 
Most/ all of 
the time 
5–7 days 
2. I did not feel like eating; my 
appetite was poor 
Rarely/ none of 
the time 
<1 day 
Some of the time 
1–2 days 
Occasionally/ 
moderately 
3–4 days 
Most/ all of 
the time 
5–7 days 
3. I felt that I could not shake off 
the blues (sadness) even with 
help from my family or friends 
Rarely/ none of 
the time 
<1 day 
Some of the time 
1–2 days 
Occasionally/ 
moderately 
3–4 days 
Most/ all of 
the time 
5–7 days 
4. I felt that I was just as good as 
other people 
Rarely/ none of 
the time 
<1 day 
Some of the time 
1–2 days 
Occasionally/ 
moderately 
3–4 days 
Most/ all of 
the time 
5–7 days 
5. I had trouble keeping my mind 
on what I was doing 
Rarely/ none of 
the time 
<1 day 
Some of the time 
1–2 days 
Occasionally/ 
moderately 
3–4 days 
Most/ all of 
the time 
5–7 days 
6. I felt depressed 
Rarely/ none of 
the time 
<1 day 
Some of the time 
1–2 days 
Occasionally/ 
moderately 
3–4 days 
Most/ all of 
the time 
5–7 days 
7. I felt that everything I did was 
an effort 
Rarely/ none of 
the time 
<1 day 
Some of the time 
1–2 days 
Occasionally/ 
moderately 
3–4 days 
Most/ all of 
the time 
5–7 days 
8. I felt hopeful about the future 
Rarely/ none of 
the time 
<1 day 
Some of the time 
1–2 days 
Occasionally/ 
moderately 
3–4 days 
Most/ all of 
the time 
5–7 days 
9. I thought my life had been a 
failure 
Rarely/ none of 
the time 
<1 day 
Some of the time 
1–2 days 
Occasionally/ 
moderately 
3–4 days 
Most/ all of 
the time 
5–7 days 
10. I felt fearful 
Rarely/ none of 
the time 
<1 day 
Some of the time 
1–2 days 
Occasionally/ 
moderately 
3–4 days 
Most/ all of 
the time 
5–7 days 
11. My sleep was restless 
Rarely/ none of 
the time 
<1 day 
Some of the time 
1–2 days 
Occasionally/ 
moderately 
3–4 days 
Most/ all of 
the time 
5–7 days 
12. I was happy 
Rarely/ none of 
the time 
<1 day 
Some of the time 
1–2 days 
Occasionally/ 
moderately 
3–4 days 
Most/ all of 
the time 
5–7 days 
13. I talked less than usual 
Rarely/ none of 
the time 
<1 day 
Some of the time 
1–2 days 
Occasionally/ 
moderately 
3–4 days 
Most/ all of 
the time 
5–7 days 
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14. I felt lonely 
Rarely/ none of 
the time 
<1 day 
Some of the time 
1–2 days 
Occasionally/ 
moderately 
3–4 days 
Most/ all of 
the time 
5–7 days 
15. People were unfriendly 
Rarely/ none of 
the time 
<1 day 
Some of the time 
1–2 days 
Occasionally/ 
moderately 
3–4 days 
Most/ all of 
the time 
5–7 days 
16. I enjoyed life 
Rarely/ none of 
the time 
<1 day 
Some of the time 
1–2 days 
Occasionally/ 
moderately 
3–4 days 
Most/ all of 
the time 
5–7 days 
17. I had crying spells 
Rarely/ none of 
the time 
<1 day 
Some of the time 
1–2 days 
Occasionally/ 
moderately 
3–4 days 
Most/ all of 
the time 
5–7 days 
18. I felt sad 
Rarely/ none of 
the time 
<1 day 
Some of the time 
1–2 days 
Occasionally/ 
moderately 
3–4 days 
Most/ all of 
the time 
5–7 days 
19. I felt that people disliked me 
Rarely/ none of 
the time 
<1 day 
Some of the time 
1–2 days 
Occasionally/ 
moderately 
3–4 days 
Most/ all of 
the time 
5–7 days 
20. I could not get ‘going’ 
Rarely/ none of 
the time 
<1 day 
Some of the time 
1–2 days 
Occasionally/ 
moderately 
3–4 days 
Most/ all of 
the time 
5–7 days 
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APPENDIX C 
Alcohol Use Disorders Identification Test (AUDIT) 
 
 
ALCOHOL USE DISORDERS IDENTIFICATION TEST (AUDIT) (WHO, 1992) 
Choose the answer that best fits your behaviour or experiences over the past year.  
1. How often do you have a 
drink containing alcohol? 
Never 
Monthly or 
less 
2–4 times per 
month 
2–3 times per 
week 
4 or more 
times per 
week 
2. How many drinks 
containing alcohol do you 
have on a typical day when 
you are drinking? 
1 or 2 3 or 4 5 or 6 7–9 10 or more 
3. How often do you have six 
or more drinks on one 
occasion? 
Never 
Less than 
monthly 
Monthly Weekly 
Daily or 
almost daily 
4. How often during the last 
year have you found that you 
were not able to stop drinking 
once you had started? 
Never 
Less than 
monthly 
Monthly Weekly 
Daily or 
almost daily 
5. How often during the last 
year have you failed to do 
what was normally expected 
from you because you had 
been drinking? 
Never 
Less than 
monthly 
Monthly Weekly 
Daily or 
almost daily 
6. How often during the last 
year have you needed a first 
drink in the morning to get 
yourself going after a heavy 
drinking session? 
Never 
Less than 
monthly 
Monthly Weekly 
Daily or 
almost daily 
7. How often during the last 
year have you had a feeling of 
guilt or remorse after 
drinking? 
Never 
Less than 
monthly 
Monthly Weekly 
Daily or 
almost daily 
8. How often during the last 
year have you been unable to 
remember what happened the 
night before because you had 
been drinking? 
Never 
Less than 
monthly 
Monthly Weekly 
Daily or 
almost daily 
9. Have you or someone else 
been injured as a result of 
your drinking? 
No 
Yes, but not in the last 
year 
Yes, during the last year 
10. Has a relative or friend or 
a doctor been concerned 
about your drinking or 
suggested you cut down? 
No 
Yes, but not in the last 
year 
Yes, during the last year 
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APPENDIX D 
Receipt of Travel Reimbursement Form 
 
 
RECEIPT OF TRAVEL REIMBURSEMENT FORM 
STUDY: Predicting adherence to antiretroviral therapy and retention to HIV care: 
Effects of baseline biopsychosocial status and neuropsychological functioning 
 
Participant Number  
I, (name and surname of participant) ____________________________ have received R50 
travel reimbursement for participation in this study.  
 
Signature: ____________________ 
 
Date: / /    
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APPENDIX E 
Variables excluded   
 
 
 
Variables excluded from bivariate analyses and regression model as one response set !90%  
• Home language  
• Psychiatric history  
• Knowing own HIV RNA test result  
• Knowing that resistant virus can be transmitted to others  
• Not liking to think about ARV’s because the medications are a reminder of HIV-positive 
status  
• Use of cocaine, inhalants, narcotics or stimulants  
• Having a strong emotional bond with at least one other person  
• Having an HIV-positive child, parent or colleague  
• Having a child, parent or colleague on ART 
• Having disclosed to at least one other person  
• Having disclosed to a colleague  
• Feeling the doctors and nurses at the clinic respect them  
• Planned use of wrist watch alarm, free-standing alarm, diary or calendar as reminder aid  
 
Variables excluded from regression model due high correlations  
• Employment status  
• Disability grant status 
• AUDIT total score  
• Having failed to do what was expected because of drinking 
• Having had a relative, friend or doctor concerned about their drinking 
• Disclosed to partner, child, parent, extended family or friend 
• Disclosed to everyone in the home 
• Whether someone disclosed to would assist with adherence  
• Convenience of clinic visits 
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APPENDIX F 
Information sheet and consent form (English) 
 
 
 
  
 
INFORMATION SHEET  
STUDY: PREDICTING ADHERENCE TO ANTIRETROVIRAL THERAPY AND 
RETENTION TO HIV CARE: EFFECTS OF BASELINE BIOPSYCHOSOCIAL 
STATUS AND NEUROPSYCHOLOGICAL FUNCTIONING 
 
Why are we doing this study? 
Antiretroviral medications have helped people with HIV to live longer healthier lives. But in 
order for these medications to work well, the people taking them need to take them almost 100% 
correctly and come to all their clinic visits. We want to find out what makes people take 
antiretrovirals correctly and come to their clinic visits and what stops them from being able to do 
so. This will help us in the future to find ways of supporting people before they start treatment 
and while they are on treatment.       
 
Who will be in this study? 
This study will invite people who are 18 years or older, who have HIV, who are soon going to 
start antiretroviral treatment, who are not inpatients in a hospital, and who are able to agree to 
take part in this study. By the end of the study, we will have 150 people like this in the study. 
 
How will you consent to take part in this study?  
This information sheet explaining the study will be given to you to read, or read to you if you are 
unable to read. Please feel free to ask the researcher any questions you have about the study. 
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If you choose to take part in the study, you will sign your name on two copies of the consent form 
at the back of this information sheet.  One copy is for you to keep and the other will be kept by the 
researcher in a secure place.  If you do not want to keep your copy, the researcher will keep it in a 
secure place for you. If you would like the researcher to, she will give information about the study 
to your family and/ or partner(s).  
 
It is important that you know the following: 
• Your participation is voluntary. You do not have to take part in this study.  
• You can decide to stop participating in this study at any time. 
• If you do not take part, or if you decide to stop taking part, none of your rights will 
be compromised, and you will not lose any benefits to which you would otherwise 
be entitled. 
 
How long is your participation in this study? 
Taking part in this study will involve a two-hour assessment. This assessment will take place at 
your clinic before or after the clinic appointment at which you are first prescribed antiretrovirals or 
within a few days of that appointment. The researcher will examine your clinic file for relevant 
information at the time of the assessment. Then, four to six months after the assessment, the 
researcher will look at your clinic file again to see if you have managed to take the medications 
correctly. Then, 24 to 26 months after the assessment, the researcher will look in your clinic file a 
final time to see your latest viral load test result and to see if you managed to stay at the clinic. If 
necessary, the researcher might also talk to your counselor at this time to see if you stayed at the 
clinic, and if not, what the reason was.   
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What will happen at the study visit?  
First, the researcher will ask you some questions about: who you are, what HIV symptoms you 
have, what you know about HIV and antiretrovirals, what you believe about antiretrovirals, how 
confident you feel about taking antiretrovirals, whether you have people to support you, whether 
you have told anyone you are HIV-positive, how you feel about your doctors and nurses, how 
easy it is for you to attend the clinic, whether you have any symptoms of depression and how 
much alcohol you drink. Then, the researcher will ask you to perform a few small tasks. These 
tasks involve reading, writing and speaking. The questions and tasks will each take about two 
hours.    
 
What are the risks of taking part in this study? 
We will not be giving you any extra medications in this study or taking any extra blood from you. 
When you are answering questions in the study, such as those about whether you have told 
anyone you are HIV-positive, whether you have any symptoms of depression or how much 
alcohol you drink, you might become sad, afraid or embarrassed. The researcher will do her best 
to help you if you feel this way. If necessary, she will refer you to a social worker. 
 
What are the benefits of taking part in this study? 
While you will not benefit directly from this study in terms of health benefits, you or others may 
benefit in the future from facts learned in this study. The facts that we gain from this study may 
help with HIV research, treatment and support. 
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Can you withdraw from this study? 
You can withdraw from the study at any time.  You do not have to give a reason for 
withdrawing.  If you choose to withdraw, you will not suffer any penalty or loss of benefits that 
you would otherwise have been entitled to receive. Withdrawing from the study will not affect 
any current or future medical care you may need. You may be removed from the study without 
your consent if the study is stopped or cancelled, or for other administrative reasons. 
 
Are your results confidential? 
All facts collected about you - including your medical information, the answers you give to the 
questions, and your performance on the small tasks - will be private and not available to anyone 
other than the study staff. None of these facts will be passed on without your permission. Except 
for your consent form (which will be kept secure) you will be identified only by your special 
study number, which will be known only to you and the researcher. Your identity will not be 
disclosed in any publication or presentation of this study. 
 
Whom can you contact about the study? 
If you have a problem related to being in the study, please call Daniella Mark at (021) 650 
6987 or 083 462 9542. 
If you have any questions about your rights as a research participant, please call Dr Blockman, 
the Chair of the University of Cape Town’s Research Ethics Committee at (021) 406 6492.  
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CONSENT FORM 
STUDY: PREDICTING ADHERENCE TO ANTIRETROVIRAL THERAPY AND RETENTION 
TO HIV CARE: EFFECTS OF BASELINE BIOPSYCHOSOCIAL STATUS AND 
NEUROPSYCHOLOGICAL FUNCTIONING 
 
Participant 
I, _________________________________ (name of participant), agree to participate in the research study 
entitled: Predicting adherence to antiretroviral therapy and retention to HIV care: Effects of baseline 
biopsychosocial status and neuropsychological functioning. 
 
I give permission for the researcher to access my clinic file for the next 24 months and to talk to my 
counselor during this time. I have been told in detail about the study and read the information sheet (or had it 
read to me) and know what participation will involve. I understand that my consent is entirely voluntary and 
that I may withdraw from the study at any time and for any reason and this will not affect the rights I may 
otherwise have. 
 
Signature:  ____________________ 
Date: |__|__|/|__|__|__|/|__|__|__|__|   
 
Researcher: 
I have explained the nature, demands and foreseeable risks of this study to the above participant. 
 
Print Name:  ___________________________________    
Signature:  ____________________ 
Date: |__|__|/|__|__|__|/|__|__|__|__|  
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APPENDIX G 
Information sheet and consent form (Xhosa) 
 
 
 
INCWADANA YENKCAZELO   
 
PHANDO: UQIKELELO LOKULANDELA UNYANGO LWA MACHIZA 
ATHOMALALISA INTHSOLONGWANE KAGAWULAYO: UBUNJANI 
BENTSHOLONGWANE KAGAWULAYO OKUNXULUMENE NOKUNGASEBENZI 
KOBUME BOMZIMBA NEMPILO 
 
(Predicting adherence to antiretroviral therapy and retention to HIV care: Effects of baseline 
biopsychosocial status and neuropsychological functioning) 
 
 
Kutheni sisenza olu phando?  
Amachiza athomalalisa intsholongwane kagawulayo (HIV) ancede abantu abane ntsholongwane 
kagawulayo (HIV) ukuba baphile ubomi obude nobunempilo. Kodwa ke ukuze lamachiza 
asebenze kakuhle, abantu abawasebenzisayo kufuneka bawasebenzise kakuhle. Sifuna ukwazi 
ukuba yintoni ebangela abantu ukuba bawathathe kakuhle lamachiza athomalalisa 
intsholongwane kagawulayo kwaye iyintoni ebangela ukuba bawayeke ukuwathatha. Oku kuza 
kusinceda kwixa elizayo ukuba sigqibe ekubeni ngubani okulungeleyo ukuthatha lamachiza 
kwanokufumana iindlela zokuxhasa abantu xa bethe baqalisa ukuba kolu nyango.  
 
Ngubani oza kuba kolu phando?  
Olu phando lumema abantu abane 18 yeminyaka nangaphezulu, abane HIV, kwanabaza kuqalisa 
unyango lwamachiza athomalalisa iHIV, kwaye abangazange balufumane ngaphambili, 
abangezozigulana zesibhedlele, abakwaziyo ukuthetha isingesi, abangazanga baba naso isigulo 
sengqondo esinxulumene neHIV kwaye abathi bakuvume ukuthatha inxaxheba kolu phando. 
Ekupheleni kolu phando, siza kuba nabantu abayi 150 abanjengaba kolu phando. 
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Uza kuvuma njani ukuthatha inxaxheba kolu phando?   
Le ncwadana yenkcazelo echaza uphando uza kuyinikwa ukuba uyifune. Nceda ukhululeke ukubuza 
nayi phina imibuzo onayo malunga nolu phando.  
 
Ukuba ufuna ukuthatha inxaxheba kolu phando, uza kusayina igama lakho kumaphepha amabini 
afanayo ale ncwadana yesivumelwano kwiphepha elingemva lale ncwadana. Enye ikopi uza 
kuyigcina kuwe, kwaye enye iza kugcinwa sithi kwindawo ekhuselekileyo. Ukuba awufuni 
ukuyigcina le kopi yakho, siza kukugcinela kwindawo ekhuselekileyo. Ukuba uyathanda, singathi 
sinike inkcazelo yolu phando kusapho okanye amaqabane akho. 
 
Kubalulekile ukuba wazi oku kulandelayo: 
• Ukuthatha inxaxheba kolu phando kungokuzithandela. Awunyanzelekanga ukuba 
uthathe inxaxheba kolu phando.   
• Ungathi ugqibe ukuba ufuna ukuyeka kuthatha inxaxheba kolu phando nangaliphi na 
ixesha 
• Ukuba awuthathi nxaxheba, okanye ugqiba ekubeni uyeke ukuthatha inxaxheba, 
amalungelo akho awasayi kuchaphazeleka, kwaye awuyi kulahlekelwa nazo naziphina 
iinzuzo obe kufanele uzifumane 
 
Luza kuba kangakani ixesha lam lokuthatha inxaxheba kolu phando?  
Ukuthatha inxaxheba kolu phando kuza kuquka iyure yokuhlalutywa. Olu hlalutyo luza kwenzeka 
kwiklinikhi yakho ngaphambi okanye emva kolunye lotyelelo lwakho eklinikhi. Umntu omela iqela 
lophando uza kujonga ingxelo yakho yase klinikhi ukukhangela iinkcukacha ezingqamene nolu 
phando. Kwiinyanga ezine ukuya kwezi ntandathu emva koku jongwa kwale ngxelo, umntu osuka 
kuphando lwethu uza kujonga ingxelo yakho yase klinikhi  ukuza ajonge ukuba uwathatha ngendlela 
eyiyo na amachiza akho.  
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Kuza kwenzeka ntoni kutyelelo lo phando?  
Okokuqala siza kukubuza imibuzo emalunga: nokuba ungubani, zeziphi iimpawu ze HIV onazo, 
kulula kangakanani ukuba ukuba ufikelele eklinikhi, oko ukwaziyo nge HIV kwakunye 
namachiza athomalalisa iHIV, oko ukukholelwayo malunga nalamachiza athomalalisa iHIV, 
uzithembe kangakanani ekuthatheni la machiza, ukuba ukhe waxelela nabani na ukuba uneHIV, 
ukuba unabo na abantu abakuxhasayo, uvakalelwa njani na ngoogqirha kwanoonesi bakho, kuba 
unazo na iimpawu zokuxinzeleleka kwanokuba bungakanani na utywala obuselayo. Siza kuthi 
futhi sikucele ukuba wenze nje izinto ezimbalwa. Ezi zinto ziquka ukufunda, ukubhala 
kwanokuthetha. Imibuzo kwanezi zinto ziza kuthatha malunga nesiqingatha seyure. 
 
Yeyiphi imingcipheko ngokuthatha inxaxheba kolu phando?  
Asizokukunika mayeza kwaye asizokukutsala gazi kolu phando. Xa uphendula imibuzo kolu phando 
emalunga nokuba ukhona na umntu omxeleleyo ukuba uneHIV, okanye zikhona na iimpawo 
zoxinzeleleko onazo okanye bungakanani na utywala obuselayo, ungathi ube neetlloni okanye 
udakumbe. Siza kwenza kangangoko sinakho ukuba sikuncede xa uthi uvakalelwe ngolu hlobo. 
Ukuba kuthu kube yimfuneko, siza kuthi sikugqithisele kunontlalo-ntle.  
 
Zeziphi iinzuzo ngokuthatha inxaxheba kolu phando?  
Ngoxa ungazokuthi uzuze ngokungqalileyo kolu phando ngokwasempilweni, wena okanye abanye 
ningathi nizuze kwixa elizayo ngolwazi oluzakube lufumaneke kolu phando. Oko sikuzuzayo kolu 
phando kungathi kuncede uphando lweHIV, unyango kwanenkxaso.  
 
Ingaba ungayeka ukuthatha inxaxheba kolu phando? 
Ungathi uyeke ukuthatha inxaxheba kolu phando nangaliphi na ixesha. Awunyanzelekanga ukuba 
unike isizathu sokurhoxa kwakho. Ukuba ukhetha ukurhoxa, awuzokuthi uchaphazeleke okanye 
ulahlekelwe nazizo naziphi na iingenelo obunokuba kanti uyazifumana. Ukurhoxa kolu phando 
akusayi kuchaphazela naluphi uncedo lezonyago olufumanayo okanye onokuthi ulufune kwixa 
elizayo.  
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Ungathi ukhutshwe kolu phando ngaphandle kwemvume yakho ukhuba luthi olu phando luyekwe 
okhanye lurho xiswe, okanye nangaso nasiphina esinye isizathu. 
 
Iingaba iingxelo zakho zikhuselekile?  
Zonke iinkcukacha eziqokelelweyo malunga nawe, kuquka iingxelo zonyango, iimpendulo 
ozinikileyo kwimibuzo yethu, kwakunye nendlela owenze ngayo kwezinye izinto ezimbalwa 
obucelwe ukuba uzenze, ziza kuba yimfihlo kwaye azisayi kufumaneka nakubani na ngaphandle 
kwabasebenzi bophando.  Akukho nanye kwezingxelo eya kwaziswa ngaphandle kwemvume 
yakho. Ngaphandle kwencadwana yesivumelwano (eyakuthi igcinwe kwindawo ekhuselekileyo) 
uza kwaziswa kuphela ngenombolo ekhethekileyo, eyakuthi yaziwe kuphela nguwe kwakunye 
nabasebenzi bophando. Ubuwena bakho abusayi kwaziswa kuyo nayiphina ingxelo okanye 
impapasho yolu phando.  
 
Ungaqhagamshelana nabani malunga nolu phando?  
Ukuba unengxaki enxulumene nokuba kolu phando, nceda utsalele uDaniella Mark kwa 
(021) 650 6987 okanye 083 462 9542. 
Ukuba unemibuzo malunga namalungelo akho njengomntu othatha inxaxheba kuphando, tsalela 
uDr Blockman, usihlalo wekomiti yamalungelo ezophando kwa (021) 406 6338.  
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IFOMU YESIVUMELWANO    
 
PHANDO: UQIKELELO LOKULANDELA UNYANGO  LWA MACHIZA ATHOMALALISA 
INTHSOLONGWANE KAGAWULAYO: UBUNJANI BENTSHOLONGWANE KAGAWULAYO 
OKUNXULUMENE NOKUNGASEBENZI KOBUME BOMZIMBA NEMPILO 
 
 
Umthathi-nxaxheba 
Mna, _____________________________________________ (igama lomthathi-nxaxheba), Ndiyavuma 
ukuthatha inxaxheba kuphando olu sisihloko: PHANDO: UQIKELELO LOKULANDELA UNYANGO  
LWA MACHIZA ATHOMALALISA INTHSOLONGWANE KAGAWULAYO: UBUNJANI 
BENTSHOLONGWANE KAGAWULAYO OKUNXULUMENE NOKUNGASEBENZI KOBUME 
BOMZIMBA NEMPILO. 
 
Ndinika imvume kubasebenzi bophando ukuba bajonge ingxelo yam ngoxa ndifumana unyango kangangee 
nyanga ezintandathu. Ndiye ndaxelelwa ngokuzeleyo malunga nolu phando kwaye ndiyazi ukuba ukuthatha 
inxaxheba kuza kuquka ntoni. Ndiyaqonda ukuba ukuthatha kwam inxaxheba kungokuzithandela 
ngokupheleleyo kwaye ndingathi ndirhoxe kolu phando nangaliphi na ixesha kwaye nangasiphina isizathu 
kwaye oku akusayi kuwachaphazela amalungelo am asemthethweni endingathi ndibe nawo. 
 
Umsayino: __________________ 
Umhla: |__|__|/|__|__|__|/|__|__|__|__| 
 
Umntu ofumana isivumelwano: 
Ndilucacisile uhlobo lolu phando, oko kufunekayo kwanemingcipheko enokuthi ibe khona kolu phando kweli 
volontiya lingentla.  
 
Igama ngokucacileyo:  ____________________________  
Umsayino: __________________ 
Umhla: |__|__|/|__|__|__|/|__|__|__|__| 
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APPENDIX H 
Annexure 3 of the Regulations to the Employment Equity Act 
 
 
 
Annexure 3 of the Regulations to the Employment Equity Act                                                                         EEA 10 
ANNEXURE 3: Occupational Categories        
Employment Equity Act 55 of 1998 
 
WHAT IS THE PURPOSE OF THIS ANNEXURE? 
This annexure provides a summary of definitions for occupational categories which may be used by employers when 
completing forms EEA 2 and 
EEA 4. 
 
INSTRUCTIONS 
Each occupational category contains a description and illustrative list of occupations that may be included in that 
category. The complete guideline to occupational categories may be obtained from Statistics SA. 
 
1. Legislators, Senior Officials and managers 
This group includes occupations whose main tasks consist of determining and formulating policy and 
strategic planning, or planning, directing and co-ordinating the policies and activities of the organisation in 
the private and public sectors, determining and formulating l ws and for directing and controlling the 
functions of the organisation. Includes: chief executive officer; president; vice president; chief operating 
officers; general managers and divisional heads, managers who provide the direction of a critical technical 
function; postmaster; superintendent; dean and school principal etc.                                          
 
2. Professionals 
This group includes occupations whose main tasks require a high level of professional knowledge and 
experience in the fields of physical and life sciences, or social sciences and humanities. The main tasks 
consist of increasing the existing stock of knowledge, applying scientific and artistic concepts and theories 
to the solution of problems, and teaching about the foregoing in a systematic manner. Includes: engineers 
(civil, mechanical, chemical, electrical, petroleum, nuclear, aerospace, etc.); architects; lawyers; 
biologists; geologists; psychologists; accountants;  physicists, system analysts; assayers; valuators; town 
and traffic planners etc. 
 
3. Technicians and Associate Professionals 
This group includes occupations whose main tasks require technical knowledge and experience in one or 
more fields of the physical and life sciences, or the social sciences and humanities. The main tasks consist 
of carrying out technical work connected with the application of concepts and operational methods in the 
abovementioned fields and in teaching at certain educational levels. Includes: computer programmers; 
nurses; physio-and-occupational therapists; draftsmen/women; musicians; actors; photographers; 
illustrating artists; product designers; radio and television announcers; translators and interpreters; writers 
and editors; specialised inspectors and testers of electronic, electrical, mechanical, etc. products; 
vocational instructors; technicians (medical, engineering, architectural, dental, physical science, life 
science, library, etc.); pilot; broker; designer; quality inspector etc. 
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4. Clerks  
This group includes occupations whose main tasks require the knowledge and experience necessary to 
organise, store, compute and retrieve information. The main tasks consist of performing secretarial duties, 
operating word processors and other office machines, recording and computing numerical data, and 
performing a number of customer orientated clerical duties, mostly in connection with mail services, money-
handling operations and appointments. Includes all clerical work, regardless of difficulty, in which the 
activities are predominantly non-manual. Includes: bookkeepers; tellers; cashiers; collectors (bills and 
accounts); messengers and office helpers; office machine operators; mail clerks; typists; telephone operators; 
electronic data processing equipment operators; clerks (production, shipping and receiving, stock, 
scheduling, ticket, freight, library, reception, travel, hotel, personnel, statistical, general office); secretaries 
etc. 
 
5. Service and Sales Workers 
This group includes occupations whose main tasks require the knowledge and experience necessary to 
provide personal and protective services and to sell goods in shops or markets. The main tasks consist of 
providing services related to travel, housekeeping, catering, personal care, protection of individuals and 
property, and maintaining law and order, or selling goods in shops or markets. Includes: attendants (hospital 
and other institutions, including nurses’ aides and orderlies); barbers; bartenders; guides; food and beverage 
serving occupations; housekeepers; childcare occupations; 
conductors; fire-fighters; police offices; advertising agents; real estate agents; sales workers and sales clerks; 
shop attendants; stock brokers; insurance brokers; travel agents; sales people of technical and business 
services; etc. 
 
6. Skilled Agricultural and Fishery Workers 
This group includes occupations whose main tasks require the knowledge and experience necessary to 
produce farm, forestry and fishery products. The main tasks consist of growing crops, breeding or hunting 
animals, catching or cultivating fish, conserving and working forests, and selling agricultural and fishery 
products to purchasers. Includes: farmers; growers; planter; viticulturists; winemakers; skilled horticultural 
workers; greenkeepers; skilled fishermen/women etc. 
 
7. Craft and Related Trades 
This group includes occupations whose main tasks require the knowledge and experience of skilled trades 
and handicrafts which, among other things, involve an understanding of materials and tools to be used, as 
well as all stages of the production process, including the characteristics and the intended use of the final 
product. They are frequently journeymen/women who have received an extensive period of training The 
main tasks consist of extracting raw materials, constructing buildings and other structures and making 
various products, as well as handicraft goods. Includes: miners; quarriers; stoneworkers; bricklayers; 
stonemasons; carpenters; shopfitters; plasterers; plumbers; electricians; painters; mechanics; glass-makers; 
locksmiths; sheet metal workers; etc. 
 
8. Plant and Machine Operators and Assemblers 
This group includes occupations whose main tasks require the knowledge and experience necessary to 
operate and monitor large-scale and often highly automated industrial machinery and equipment. The main 
tasks consist of operating and monitoring of mining, processing, and production machinery and equipment, 
as well as driving vehicles and driving and operating mobile plant, or assembling products from components. 
Includes: truck and tractor drivers; bus drivers; paving, surfacing and related occupations; roofers; 
photographic processors; sound and video recording equipment operators; those in apprenticeship training; 
textile workers; production machine workers etc. 
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EEA 10 
9. Elementary Occupations 
This group covers occupations which require relatively low/elementary levels of knowledge and 
experience necessary to perform mostly simple and routine tasks, involving the use of hand held tools 
and in some cases considerable physical effort, and, with few exceptions, limited personal initiative and 
judgement. The main tasks consist of selling goods in streets, door-keeping and property watching, as 
well as cleaning, washing, pressing, and working as labourers in the fields of mining, agriculture and 
fishing, construction and manufacturing. Includes: news and other vendors; garage attendants; car 
washers and greasers; gardeners; farm labourers; unskilled railway track workers; labourers performing 
lifting, digging, mixing, loading, and pulling operations; garbage collectors; stevedores; sweepers; 
charworkers etc. 
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APPENDIX I 
Symptom and system characterizations 
 
 
 
SYMPTOM SYSTEM 
Abscess in perineum Urogenital 
Arm pain Musculoskeletal 
Arthralgia Musculoskeletal 
Back pain Musculoskeletal 
Bad dreams Psychiatric 
Chest pain Musculoskeletal; Cardiopulmonary 
Cough Respiratory  
Cramps in fingers and feet Musculoskeletal; Constitutional 
Dandruff Dermatological  
Depression Psychiatric 
Diarrhea Gastrointestinal; Constitutional 
Discharge Urogenital  
Dizzy Neurological; Constitutional 
Dry eyes Ophthalmic 
Dry skin Dermatological  
Ears 'leaking' ENT 
Eczema Dermatological 
Eye pain Ophthalmic 
Fatigue Constitutional; Heamatological  
Feeling cold  Constitutional  
Feeling hot Constitutional  
Feet burning Neurological 
Fever Constitutional  
Flu Constitutional 
Foot pain Musculoskeletal; Neurological 
General pain Musculoskeletal; Constitutional 
Genital ulcers Urogenital  
Gets sick often Constitutional  
Headache Neurological 
Heart pain Musculoskeletal; Cardiopulmonary 
Heart palpitations Cardiopulmonary 
Herpes Urogenital  
Insomnia Psychiatric; Constitutional 
Itchy Dermatological 
Itchy eyes Ophthalmic; Dermatological 
Itchy tongue ENT; Dermatological 
Itchy vagina  Urogenital; Dermatological 
Knee pain Musculoskeletal 
Leg pain Musculoskeletal 
Lip sores Dermatological 
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Loss of appetite Constitutional; Gastrointestinal 
Loss of weight Constitutional; Gastrointestinal 
Meningitis Neurological 
Mouth sores Gastrointestinal; Constitutional 
Mouth ulcers Gastrointestinal; Constitutional 
Neck pain Musculoskeletal; Neurological 
Night sweats Constitutional  
No interest in sex Psychiatric 
Nodule in neck Haematological; Lymphatic  
Noise in ears ENT 
Oral thrush Gastrointestinal; Dermatological 
Pain in kidneys Urogenital; Musculoskeletal 
Pain in lungs Cardiopulmonary; Musculoskeletal 
Pain on sides Musculoskeletal 
Painful urination Urogenital 
PCP Cardiopulmonary 
Photophobia Neurological; Ophthalmic 
Pimples Dermatological 
Pins and needles  Neurological; Musculoskeletal 
Problem balancing on feet Neurological; Musculoskeletal 
Rash Dermatological 
Rash - PPE Dermatological 
Rash in vagina Urogenital 
Red eyes Ophthalmic 
Ringworm Dermatological; Gastrointestinal 
Rotten nails Dermatological 
Shakiness Constitutional; Neurological 
Shingles Dermatological 
Shortness of breath Cardiopulmonary 
Sores Dermatological 
Stomach pain Gastrointestinal 
Sweating Constitutional  
Swollen glands Constitutional; Haematological; Lymphatic 
Swollen gums Gastrointestinal 
Swollen legs/ feet/ ankles Lymphatic; Cardiopulmonary; Musculoskeletal; 
Haematological 
TB Respiratory; Gastrointestinal; Neurological; Respiratory 
Thrush Gastrointestinal; Urogenital; Constitutional 
Vaginal sores Urogenital 
Visual disturbances Ophthalmic; Neurological 
Vomiting Gastrointestinal 
Weakness Constitutional; Neurological; Musculoskeletal; 
Haematological 
White tongue Gastrointestinal 
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APPENDIX J 
 
 
Test Score Name Score 
Type 
 
Mean Standard 
Deviation 
D-KEFS 
Verbal Fluency 
Test 
F Total Correct Responses  
F Total Set-Loss Errors  
F Total Repetition Errors  
A Total Correct Responses  
A Total Set-Loss Errors  
A Total Repetition Errors  
S Total Correct Responses  
S Total Set-Loss Errors  
S Total Repetition Errors   
Letter Fluency: Total Correct  
Letter Fluency: Total Responses 
Animals Total Correct Responses  
Animals Total Set-Loss Errors  
Animals Total Repetition Errors  
Boys’ Names Total Correct Responses  
Boys’ Names Total Set-Loss Errors  
Boys’ Names Total Repetition Errors  
Category Fluency: Total Correct  
Category Fluency: Total Responses   
Category Switching: Total Correct Responses  
Category Switching: Total Switching Accuracy   
Category Switching: Total Set-Loss Errors  
Category Switching: Total Repetition Errors  
Category Switching: Total Responses  
Conditions 1–3 Combined Set-Loss Errors  
Conditions 1–3 Combined Repetition Errors  
Conditions 1–3 Combined Total Responses  
Accuracy 
Error 
Error 
Accuracy 
Error 
Error 
Accuracy 
Error 
Error 
Accuracy 
Attempt 
Accuracy 
Error 
Error 
Accuracy 
Error 
Error 
Accuracy 
Attempt 
Accuracy 
Accuracy 
Error 
Error 
Attempt 
Error 
Error 
Attempt 
8.20  
0.27 
0.25 
5.60 
0.40 
0.10 
8.22 
0.20 
0.15 
22.01 
23.26 
9.81  
0.06  
0.19  
13.58  
0.08  
0.19  
23.39  
23.9  
9.32  
8.42  
0.62  
0.49  
10.15  
1.60 
1.35 
57.38 
3.59 
0.69 
0.56 
3.25 
0.82 
0.32 
3.92 
0.51 
0.45 
9.58 
9.54 
3.13 
0.27 
0.48 
4.46 
0.38 
0.58 
6.40 
6.4 
2.58 
2.59 
1.10 
1.57 
2.18 
1.96 
2.15 
15.28 
D-KEFS Design 
Fluency Test 
  
Filled Dots: Attempted Designs  
Filled Dots: Total Correct  
Filled Dots: Set-Loss Designs  
Filled Dots: Repeated Designs  
Empty Dots Only: Attempted Designs  
Empty Dots Only: Total Correct  
Empty Dots Only: Set-Loss Designs  
Empty Dots Only: Repeated Designs  
Combined Filled + Empty Dots: Total Correct  
Switching: Attempted Designs  
Switching: Total Correct  
Switching: Set-Loss Designs  
Switching: Repeated Designs  
Category Fluency: Attempted Designs   
Design Fluency: Total Correct  
Total Set-Loss Designs  
Total Repeated Designs 
Attempt 
Accuracy 
Error 
Error 
Attempt 
Accuracy 
Error 
Error 
Accuracy 
Attempt 
Accuracy 
Error 
Error 
Attempt 
Accuracy 
Error 
Error 
6.47  
5.54  
0.13  
0.79  
7.39  
5.80  
0.14  
1.45  
11.34  
7.30  
5.30 
0.64  
1.43  
21.77  
17.27  
0.91  
4.33 
2.64 
2.18 
0.66 
1.16 
2.89 
2.13 
0.42 
1.83 
3.90 
2.79 
2.30 
0.99 
1.87 
10.73 
9.53 
1.35 
8.92 
D-KEFS Colour-
Word 
Colour Naming Completion-Time  
Uncorrected Colour Naming Errors 
Time 
Error 
45.92  
1.37 
89.66 
2.69 
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Appendix J. Neuropsychological test score means and standard deviations. D-KEFS, Delis-Kaplan 
Executive Functions System; WMS, Wechsler Memory Scale.  
 
 
D-KEFS Colour-
Word 
Interference Test 
  
Colour Naming Completion-Time  
Uncorrected Colour Naming Errors 
Corrected Colour Naming Errors 
Total Colour Naming Errors 
Word Reading Completion-Time  
Uncorrected Word Reading Errors  
Corrected Word Reading Errors  
Total Word Reading Errors  
Combined Naming+Reading Completion-Time  
Inhibition Completion-Time  
Uncorrected Inhibition Errors 
Corrected Inhibition Errors   
Total Inhibition Errors  
Inhibition Real Errors 
Time 
Error 
Error 
Error 
Time 
Error 
Error 
Error 
Time 
Time 
Error 
Error 
Error 
Error 
45.92  
1.37 
1.46 
2.76 
33.87 
0.38 
0.48 
0.86 
85.05 
95.15 
2.97 
2.68 
6.96 
3.40 
89.66 
2.69 
1.47 
3.01 
11.81 
0.91 
0.91 
1.45 
26.00 
36.35 
5.42 
2.29 
16.94 
16.97 
D-KEFS Tower 
Test 
Total Achievement Score  
Rule-Violations-Per-Item Ratio 
Accuracy 
Error 
11.38  
0.69 
4.13 
0.75 
WMS 
WMS Logical 
Memory 
 
LMI Story A Recall Unit Score  
LMI Story B 1
st
 Recall Unit Score  
1
st
 Recall Total Score  
LM Story B 2
nd
 Recall Unit Score  
Learning Slope 
Recall Total Score   
LMII Story A Recall Unit Score  
LMII Story B Recall Unit Score  
LMII Recall Total Score 
Percent Retention  
Recognition Total Score 
Accuracy 
Accuracy 
Accuracy 
Accuracy 
Accuracy 
Accuracy 
Accuracy 
Accuracy 
Accuracy 
Accuracy 
Accuracy 
11.52  
7.07  
18.59  
9.28  
2.16  
28.02  
9.71  
7.95  
17.67  
83.20  
22.64 
4.16 
3.31 
6.72 
3.90 
2.62 
9.99 
4.58 
3.70 
7.56 
22.24 
3.42 
WMS Digit Span 
 
Digits Forward  
Digits Backward  
Total Score 
Accuracy 
Accuracy 
Accuracy 
6.83  
3.69  
10.53 
2.02 
1.64 
3.11 
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APPENDIX K 
 
 
Test and score types Viral load 
 
CD4+ cell 
count 
WHO stage 
D-KEFS 
D-KEFS Verbal Fluency Test 
F Total Correct Responses  
F Total Set-Loss Errors  
F Total Repetition Errors  
A Total Correct Responses  
A Total Set-Loss Errors  
A Total Repetition Errors  
S Total Correct Responses  
S Total Set-Loss Errors  
S Total Repetition Errors   
Letter Fluency: Total Correct  
Letter Fluency: Total Responses 
Animals Total Correct Responses  
Animals Total Set-Loss Errors  
Animals Total Repetition Errors  
Boy’s Names Total Correct Responses  
Boy’s Names Total Set-Loss Errors  
Boy’s Names Total Repetition Errors  
Category Fluency: Total Correct  
Category Fluency: Total Responses   
Category Switching: Total Correct Responses  
Category Switching: Total Switching Accuracy   
Category Switching: Total Set-Loss Errors  
Category Switching: Total Repetition Errors  
Category Switching: Total Responses  
Conditions 1–3 Combined Set-Loss Errors  
Conditions 1–3 Combined Repetition Errors  
Conditions 1–3 Combined Total Responses  
 
 0.79 
 0.29 
 0.85 
 0.45 
 0.24 
 0.16 
 0.17 
 0.25 
 0.11 
 0.31 
 0.39 
 0.95 
 0.92 
 0.78 
 0.54 
 0.30 
 0.58 
 0.45 
 0.40 
 0.77 
 0.84 
 0.06 
 0.75 
 0.82 
 0.48 
 0.62 
 0.98 
 
 0.46 
 0.33 
 0.54 
 0.13 
 0.26 
 0.17 
 0.36 
 0.62 
 0.95 
 0.55 
 0.64 
 0.28 
 0.32 
 0.26 
 0.85 
 0.32 
*0.03 
 0.66 
 0.09 
 0.28 
 0.14 
 0.69 
 0.95 
 0.32 
 0.93 
 0.56 
 0.65 
 
*0.04 
 0.74 
 0.15 
 0.24 
 0.28 
 0.81 
 0.25 
 0.42 
 0.69 
 0.25 
 0.33 
 0.14 
 0.95 
 0.18 
 0.05 
 0.95 
 0.22 
*0.0009 
*0.0008 
*0.002 
*0.0009 
 0.54 
 0.46 
*0.009 
 0.46 
 0.96 
*0.009 
D-KEFS Design Fluency Test 
Filled Dots: Attempted Des gns  
Filled Dots: Total Correct  
Filled Dots: Repeated Designs  
Empty Dots Only: Attempted Designs  
Empty Dots Only: Total Correct  
Empty Dots Only: Repeated Designs  
Combined Filled + Empty Dots: Total Correct  
Switching: Attempted Designs  
Switching: Total Correct  
Switching: Set-Loss Designs  
Category Fluency: Attempted Designs   
Design Fluency: Total Correct  
Total Set-Loss Designs  
Total Repeated Designs  
 
 0.33 
*0.02 
 0.62 
 0.15 
 0.47 
 0.32 
 0.57 
 0.22 
 0.77 
 0.44 
 0.19 
 0.56 
 0.50 
 0.16 
 
 0.79 
 0.36 
 0.30 
 0.48 
*0.02 
 0.63 
 0.43 
 0.85 
 0.67 
 0.24 
 0.65 
 0.43 
 0.56 
 0.50 
 
*0.01 
 0.41 
 0.25 
 0.05 
 0.07 
 0.57 
 0.33 
 0.27 
 0.47 
 0.05 
 0.60 
 0.38 
*0.03 
*0.04 
D-KEFS Colour-Word Interference Test 
Colour Naming Completion-Time  
Uncorrected Colour Naming Errors 
Corrected Colour Naming Errors 
 
 0.70 
 0.13 
 0.52 
 
 0.29 
 0.17 
 0.63 
 
 0.19 
*0.03 
 0.13 
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Total Colour Naming Errors 
Uncorrected Word Reading Errors  
Corrected Word Reading Errors  
Total Word Reading Errors  
Combined Naming + Reading Completion-Time  
Inhibition Completion-Time  
Uncorrected Inhibition Errors 
Corrected Inhibition Errors   
Total Inhibition Errors  
Inhibition Real Errors  
 0.99 
 0.37 
 0.58 
 0.96 
 0.16 
 0.15 
 0.32 
 0.10 
 0.48 
 0.32 
 0.71 
 0.61 
 0.46 
 0.63 
 0.78 
 0.74 
 0.23 
 0.89 
 0.94 
 0.72  
 0.64 
 0.75 
 0.08 
 0.40 
 0.15 
 0.82 
 0.74 
 0.33 
 0.56 
 0.71 
D-KEFS Tower Test 
Total Achievement Score  
Rule-Violations-Per-Item Ratio  
 
 0.53 
 0.65 
 
 0.95 
 0.86 
 
 0.07  
 0.98 
WMS 
WMS Logical Memory 
LMI Story A Recall Unit Score  
LMI Story B 1
st
 Recall Unit Score  
1
st
 Recall Total Score  
LM Story B 2
nd
 Recall Unit Score  
Learning Slope 
Recall Total Score   
LMII Story A Recall Unit Score  
LMII Story B Recall Unit Score  
LMII Recall Total Score 
Percent Retention  
Recognition Total Score 
 
 0.61 
 0.70 
 0.15 
 0.18 
 0.12 
 0.25 
 0.43 
 0.78 
 0.34 
 0.95 
 0.07 
 
 0.29 
 0.16 
 0.92 
 0.42 
 0.58 
 0.21 
 0.71 
 0.67 
 0.65 
 0.35 
 0.25 
 
*0.006 
 0.28 
*0.004 
 0.06 
 0.15 
 0.19 
*0.03 
 0.23 
 0.10 
*0.04 
 0.07 
WMS Digit Span 
Digits Forward  
Digits Backward  
Total Score 
 
 0.18 
 0.21 
 0.30 
 
 0.51 
 0.10 
 0.81 
 
 0.70 
 0.36 
 0.50 
 
Appendix K. Neuropsychological test score relationships with disease markers. * Indicates significant 
relationships. WHO; World Health Organisation; D-KEFS, Delis-Kaplan Executive Functions System; WMS, 
Wechsler Memory Scale.  
